Hartford Hospital Research Program

Welcome to the latest edition of the Hartford 

Hospital Research Program’s biannual report. 

is report highlights our recent achievements, 

provides a financial summary, and presents research 

accomplishments by department. I am proud to 

recognize the achievements of our many researchers 

and I thank them for their interest and involvement. 

I would also like to recognize the staff of Research 

Administration whose hard work has contributed to 

the growth of research at Hartford Hospital. Special 

thanks goes to Tara McLaughlin and Tiffany Rowe 

Hubbard for their collaboration in producing this 

report. 

I hope you find this information to be of interest, and 

to be reflective of each department’s many research 

accomplishments. 

Sincerely, 

Laurine Bow, PhD 

Vice President for Research 

Photo credits 

Joy Miller: Cover 

Kevin Hagan: pages 9 and 57

Welcome to the latest edition of the Hartford 

Hospital Research Program’s biannual report. 

is report highlights our recent achievements, 

provides a financial summary, and presents research 

accomplishments by department. I am proud to 

recognize the achievements of our many researchers 

and I thank them for their interest and involvement. 

I would also like to recognize the staff of Research 

Administration whose hard work has contributed to 

the growth of research at Hartford Hospital. Special 

thanks goes to Tara McLaughlin and Tiffany Rowe 

Hubbard for their collaboration in producing this 

report. 

I hope you find this information to be of interest, and 

to be reflective of each department’s many research 

accomplishments. 

Sincerely, 

Laurine Bow, PhD 

Vice President for Research 

Photo credits 

Joy Miller: Cover 

Kevin Hagan: pages 9 and 57

is report presents the research accomplishments of 2006 and 2007. During this 

period, Research Administration staff processed 419 new projects, tracked 808 active 

studies involving human participants, assisted in the submission of 126 federal and 

foundation grant applications and supported the Institutional Review Board in 179 

expedited and 104 full reviews. 

 

Hartford Hospital’s Division of Cardiology 

and Departments of Pharmacy and Research 

Administration have collaborated with 

the University of Connecticut (UCONN) 

Schools of Pharmacy and Business to create a 

health outcomes and policy conglomerate. 

e Agency for Healthcare Research and Quality (AHRQ) 

has selected this group as an Evidence-based Practice Center 

(EPC). e team includes Hartford Hospital researchers Jeffrey 

Kluger, MD, Jeffrey Mather, MS, and Robert Quercia, MS, 

and UCONN faculty members C. Michael White, PharmD, 

and Craig Coleman, PharmD, and invovles Hartford Hospital 

practice sites. 

AHRQ has only designated 14 EPCs in North America. EPCs 

use a scholarly modality of systematic review that includes 

reviewing and summarizing current data, performing metaanalyses 

and simulation studies, and applying cost-effectiveness 

or health policy models to translate the results to the healthcare 

environment. EPCs are invaluable resources for Medicaid, 

Medicare, other federal agencies, medical organizations, and 

payors as they make evidence-based policy decisions. 

e Heart Rhythm Service has developed an extensive 

patient care database. Drs Kluger, Coleman, and White 

have recently harnessed this database to answer important 

patient care questions. ey have determined that statins can 

reduce mortality in patients with Implantable Cardioverter 

Defibrillators (ICDs) and can improve the safety of the devices 

by reducing inappropriate shocks. In a meta-analysis, they 

determined that women might not benefit to the same extent as 

men when given an ICD, a finding that opens up new areas for 

future investigation. 

 

e National Institute of General Medical 

Sciences (NIGMS) recently awarded Dr. 

Gualberto Ruano, President & CEO of 

Genomas, a $1.2 million Fast-Track Phase 

I-II Small Business Innovation Research 

(SBIR) Grant, “DNA Diagnostic System for 

Statin Safety and Efficacy.” 

Statins are the most effective medications for managing elevated 

low-density lipoprotein cholesterol concentrations. ese drugs 

offer effective strategies to reduce cardiovascular disease and 

improve survival. Statin-induced neuromyopathy (SINM), 

presenting as a constellation of nerve and muscle side effects, 

is the drug’s main clinically relevant safety risk. SINM is more 

frequent at the higher doses required for treating advanced heart 

disease, varies in extent between individual statins, and varies 

from patient to patient. ese side effects are disabling for 10% 

of patients. 

Genomas is partnering with Hartford Hospital’s Division of 

Cardiology to develop a DNA-guided clinical management 

system to predict and compare SINM risk for patients taking 

atorvastatin, simvastatin and rosuvastatin. PhyzioType 

Clinical Management Systems are an ensemble of inherited 

DNA markers genotyped by arrays and interpreted by a 

biomathematical algorithm. A PhyzioType informs a 

physician of his or her patients’ predicted side effect risks for the 

three drugs. 

Genomas has secured $3.1 million in NIH SBIR funding for 

PhyzioType product development. ese programs have 

been anchored by the Genomas-Hartford Hospital partnership 

established in 2004 for translating DNA-guided medicine into 

clinical practice.

e Research Program is committed to the administrative and scientific support of 

researchers at Hartford Hospital as they continue to explore questions that will help 

shape the future of health care. 

 

 

Hartford Hospital and its Center for Eliminating Health 

Disparities among Latinos (CEHDL) Program sponsored 

three outstanding University of Connecticut undergraduate 

students during the summer of 2007 to study health disparities 

in the Latino community. Sandra Ruiz, Stacy Botex, and 

Gabriela Bautista completed a comprehensive program 

that included rotations in several Hartford Hospital areas: 

Research Administration, Clinical Research, Primary Care, 

the HIV Clinic, Inpatient Medicine, Social Work, Nutrition, 

Emergency Medicine, and Women’s Health. e Brownstone 

Clinic, which primarily serves the Latino community, was 

the primary site. Students reviewed the literature on health 

disparities and addressed health disparity-related patient issues 

with the healthcare and research teams. 

e interns received crosscultural 

training from 

experts at the Hispanic 

Health Council. e 

interns participated in an 

active research project in 

the Women’s Life Center 

at Hartford Hospital. 

e interns gave a final 

presentation, reporting their 

study findings to scientists 

and healthcare profesionals 

from Hartford Hospital, the 

University of Connecticut, 

Charter Oak Health Center, 

Manchester Community 

College, and STRONG-CT 

Community College Initiative program. 

 

“We must continue to increase the awareness of health disparities 

because just reading the statistics is not enough to understand the 

scope of the problem.” —CEHDL Intern 

e Helen & Harry Gray Cancer Center at Hartford Hospital 

has been chosen to participate in a three-year pilot project for 

the National Cancer Institute’s (NCI) National Community 

Cancer Centers Program (NCCCP) under Dr. Andrew Salner, 

Principal Investigator and Gray Cancer Center Director. Once 

fully implemented, the program will help bring state-of-the-art 

cancer care to patients in community hospitals across the United 

States. Hartford Hospital is one of the 14 sites nationwide, and 

the only New England facility chosen to participate in the pilot. 

Hartford Hospital’s selection for this 

extremely competitive program was 

based on the hospital’s leadership 

role and excellence in care delivery, 

its clinical research programs, its 

outreach efforts and its cancer 

information systems. 

e program will encourage collaboration with private-practice 

physicians and includes an important research component. It 

will explore new and enhanced ways to assist, educate, and treat 

the needs of underserved populations—including elderly, rural, 

inner-city and low-income patients—as well as racial and ethnic 

groups with unusually high cancer rates. e pilot program 

will allow Hartford Hospital to offer earlierphase 

(Phase I and Phase II) cancer research 

studies in addition to Phase III studies. ese 

earlier-phase studies will explore the use of new 

drug molecules, gathering data on toxicity and 

effectiveness for different types of tumors. 

e NCCCP takes an innovative approach to 

cancer research including prevention, detection, 

treatment and survivorship. Hartford Hospital’s 

participation in the NCCCP signifies the 

degree to which NCI recognizes its expertise 

in diagnosis, care and support for patients and 

families. It will enhance the comprehensiveness 

of the programs that are available to patients 

and will further strengthen the hospital’s 

leadership role in cancer care in the region and 

in Connecticut.

e external funds received are derived from the September accounting statement. 

All calculations are based on the fiscal cycle of October 1—September 30. 

 

Cardiology $1,648,000 $1,918,000 

CAIRD* $1,617,000 $1,231,000 

Community $102,000 

Collaborative $411,000 $244,000 

Traumatology $127,000 $114,000 

Medicine $135,000 $432,000 

Neurology $246,000 $304,000 

Oncology $511,000 $584,000 

Orthopedics $156,000 $174,000 

Pharmacy $20,000 

Pre-Clinical 

Laboratory $176,000 $492,000 

Psychiatry $3,539,000 $3,297,000 

Radiology $71,000 $12,000 

Surgery $40,000 $42,000 

Women’s Health $37,000 $42,000 

Intellectual Property $28,000 $50,000 

Other $218,000 $149,400 

*Center for Anti-Infective Research and Development

Fiscal Year 2006: October 1, 2005—September 30, 2006 

Federal, Foundation and State figures are funds expended. 

All other figures represent new initial total awards. 

Fiscal Year 2007: October 1, 2006—September 30, 2007 

Federal, Foundation and State figures are the annual award. 

All other figures represent new initial total awards. 

 

Cardiology $253,994 $1,105,985 

Medicine $146,140 $211,862 

Neurology $1,276 $187,230 

Oncology $406,879 $991,083 

Psychiatry $2,533,894 $4,222,482 

Surgery $10,997 $35,722 

Traumatology $31,177 

Women’s Health $25,508 

 

 

 

Cardiology $133,113 

Collaborative $450,894 

Medicine $9,675 

Oncology $25,000 

Psychiatry $14,000 $200,730 

Research $46,803 



 

 

Community $81,500 

Medicine $1,500 

Psychiatry $68,250 $938 


 

 

 

Cardiology $167,643 $276,385 

Medicine $294 $13,181 

Psychiatry $211,670 $285,588 


Traumatology $99,000 $98,000 

 

 

 

CAIRD* $1,111,359 $1,401,267 

Cardiology $947,214 $711,370 

Medicine $176,333 $119,445 

Neurology $439,629 $804,547 

Oncology $326,263 $93,600 

Orthopedics $85,913 $341,685 

Preclinical 

Laboratory $123,896 $451,032 

Psychiatry $609,256 $71,950 

Radiology $274,963 $47,200 

Surgery $8,300 $123,000 


Women’s Health $49,688 $30,031

e Research Committee, Institutional Review Board and Institutional Animal Care and 

Use Committee are responsible for the scientific review of projects or the ethical involvement 

of research subjects. 

 

 

e responsibilities of the Research Committee are four-fold. 

e Committee reviews the scientific merit of research projects 

and awards internal research funding. It also investigates any 

allegations of research misconduct and evaluates potential 

conflicts of interest. 

Members 

Laurine Bow, PhD, Chair 

Jaber Aslanzadeh, MD 

James Bowers, JD 

Karyl Burns, PhD 

Erika Cappelutti, MD 

William Crombleholme, MD 

Ellen Dornelas, PhD 

John Goethe, MD 

Gary Heller, MD , PhD 

Kevin Keating. MD 

Jeffrey Kluger, MD 

Joseph Kuti, PharmD 

Jeffrey Mather, MS 

Godfrey Pearlson, MD 

Joanne Roy, RN, PhD 

Ilene Staff, PhD 

Cunegundo Vergara MD 

C. Michael White, PharmD 

Les Wolfson, MD 

 

 

 

e Institutional Review board is charged with the ethical 

oversight of research projects involving human research 

subjects at Hartford Hospital. It conducts risk/benefit 

analyses of potential research studies and monitors ongoing 

studies for safety. 

Members 

Robert D. Siegel, MD, Chair 

George Perdrizet, MD, PhD, Vice Chair 

Christopher Clyne, MD 

Alexandra Flowers, MD 

John Goethe, MD 

Benjamin Goldfarb 

Debra Hein, CNM 

Gary V. Heller, MD, PhD 

Tiffany R. Hubbard 

Rev. James Ibekwe, PhD 

Jacqueline Lyon, MD 

Leslie Lothstein, MD 

Joseph Nesta, MD 

David O’Sullivan, MS 

Joanne Roy, PhD 

Richard M. Shulman, PhD 

James Rancourt, PharmD 

 

e Research Program would like to thank those individuals 

who completed their committee tenure during this report 

period. 

Research Committee: 

W. Jeffrey Baker, MD 

Mark Dailey, MD 

Sheryl Horowitz, PhD 

Michael Ivy, MD 

Frederick Knauft, MD 

Isaac Silverman, MD 

Richard Simon, MD 

Joel Sorosky, MD 

IRB: 

Michael Lindberg, MD (Vice 

Chair) 

Neil Asthana, MD 

Lynn Deasy, RN 

Kenneth Freedman, MD 

Karl Hebert 

Jeffrey Hirst, MD 

Paul ompson, MD 

Jo Clare Wilson, Rev. 

 

 

 

e Institutional Animal Care and Use Committee is 

charged with the ethical oversight of research projects 

involving animal research subjects.

Medical Staff Supported Awards 

e following projects received awards cosponsored 

by the Medical Staff and the Hartford 

Hospital Research Endowment Fund: 

Sleep Dependent Consolidation of 

Spatial Memory, $7,750. 

Practicing Out Loud and the Role 

of Nursing in a Hospital Setting, $10,775. 

e Impact of Oral Magnesium 

L-Lactate on Occurrence of Ventricular Arrhythmias and Patient 

Perceived Quality of Life Among Patients with Implantable 

Cardioverter-Defibrillators: e Adjuvant Magnesium (AdMag) Trial 

Cost-Utility Analysis, $9,952. 

Long-term Psychological 

Adjustment in Patients with Implantable Cardioverter Defibrillators, 

$7,559. 

Detection of Triamcinolone Acetonide 

in Human Intraocular Fluids, $9,900. 

e Utility of Transesophageal 

Echocardiography in the Diagnosis of Infective Endocarditis, $7,875. 

Characterizing the Dyslexia Phenotype 

Using Genetics and MR Morphology, $9,722. 

e Impact of Automated Testing on 

the Clinical Outcomes and Economics of Infections Due to Extended 

Spectrum Beta-Lactamase Producing Enterobacteriaceae, $9,390. 

Clinical and Quality of Life Outcomes 

Following Diagnosis of Prostate Adenocarcinoma. Supported through 

Departmental ($27,000) and Medical Staff funds ($10, 762). 

Late-Pregnancy Fears of Labor 

and Delivery in Nulliparous Pregnant Women: A Survey, $8,840. 

Trends in Renal Cancer Surgery: e 

Hartford Hospital Experience, $1,280. 

Analysis of CT Perfusion and Salvageable 

Penumbra as a Function of Time in Acute Stroke, $10,000. 

Antepartum Depression 

Inventory: A Comparative Analysis of Performance with e Beck 

Depression Inventory, $9,966. 

Prospective Follow-up Study of 

the Effects of Locus-of-Control and Life Stressors on Long-Term 

Outcome of Treatment for Major Depressive Disorder, $9,723. 

Open Competition Awards 

e following projects received funding through 

the Open Competition program in fiscal years 

2006 and 2007: 

e Cognitive-Enhancing Effects 

of D-Cycloserine among Non-Demented Elderly, $74,923. 

A Preliminary Study of Statin- 

Associated Cognitive Impairment, $34,588. 

e Utility of Routine Cytochrome P450 

Genotyping in the Selection of Type and Dosage of Antidepressant 

Medication, $74,797. 

White Matter Changes in Normal Aging: 

Impact on Everyday Functioning, $16,563. 

e Role of Cardiac PET Perfusion 

Imaging in the Diagnosis of Coronary Disease in Patients with 

Diabetes Mellitus, $48,394. 

Does Exercise Training Alter Hippocampal 

Size and Function in Humans: A Preliminary Study, $56,317. 

e Use of Magnesium to Improve 

Hemodynamics, Cholesterol and Glucose Control: A Substudy of 

AdMag, $47,000. 

Clonal Outbreak of Clostridium 

Difficile-Associated Disease with High Morbidity and Mortality, 

$58,500. 

A Comparison of Hormonal 

erapy Tapering Regimens for Mediating Hot Flashes, $56,623. 

Neuropsychological Functioning in 

Compulsive Hoarding, $74,898. 

Virtual Reality Exposure Treatment for 

Combat-Related Posttraumatic Stress Disorder in Operation Iraqi 

Freedom and Operation Enduring Freedom Veterans, $73,894. 

e Research Program extends its appreciation 

to the Medical Staff for its continued support 

of research at Hartford Hospital

Research Administration provides administrative oversight for all research activities at Hartford 

Hospital. e Research Program supports the research activities of the Hospital through 

a centralized infrastructure including Grants Administration, Human Research Protections, 

Database Design and Development, and Proposal Design and Statistical Analysis. In addition, 

the Clinical Research Center and the Preclinical Research Facility support research 

activities under the auspices of Research Administration. Research Administration carries out 

its mission to support the hospital’s research activities under the direction of Laurine Bow, 

PhD, Vice President for Research. 

 

 

e Grants & Contracts division provides financial oversight 

on research projects, assistance with contract negotiation, 

administrative guidance for external grant submissions, 

assistance with budget preparation and accounting 

procedures. is division is charged with ensuring that grants 

and contracts are prepared according to the appropriate 

regulations and policies and that accounting procedures for 

research studies are followed correctly. 

 

 

e Human Research Protections Program provides oversight 

for the protection of human research subjects in accordance 

with federal regulations and hospital policies. It provides 

administrative support to the Institutional Review Board and 

Institutional Animal Care and Use Committee, and provides 

on-going study monitoring. 

 

 

e Database Design and Development division creates 

custom databases and Teleform instruments and provides 

technical support. Staff are experienced with many platforms, 

including Microsoft Access, SQL Server, Web Development, 

Teleform Design and ADT/Lab/HL7 Interfacing. 

 

 

e Proposal Design and Statistical Analysis division provides 

assistance with scientific study design and statistical analysis. 

Its Senior Scientists have years of medical research experience 

in Cardiology, Medicine, Transplant, Surgery and Women’s 

Health, as well as public health and program evaluation. 

 

e Research Program has recently added a Grant Writing 

position. e Grant Writer is a resource for the medical 

staff in their external research funding pursuits. Services 

offered include background development, literature review, 

scientific writing and funding opportunities exploration. 

e grantwriter works closely with the divisions of Research 

Administration to support the development of external grant 

applications. 

 

e First Annual Research Day 

was November 8, 2007. Its 

goal was to raise community 

awareness of Hartford Hospital 

research. e theme was 

“Hartford Hospital research: 

Locally grown, globally known,” 

illustrating Hartford Hospital’s 

nationally and internationally 

presented research. 

is event was aimed at both 

the community and employees. 

Over 125 previously presented 

research posters were on 

display. ere were also educational tables, games, prizes, 

and refreshments (including bottled water donated by Crystal 

Rock). e posters were judged by Research Day patrons and 

the three presenters with the greatest number of votes for the 

best posters were awarded prizes. A vote for poster favorites 

entered participants into a raffle for prizes donated by the 

Hospital and by the Hospital’s Auxiliary. Two huge maps 

of the Unites States and the World were used to illustrate 

the global reach of research conducted at Hartford Hospital 

with research projects being presented at venues as far away as 

Japan and as close as West Hartford.

e Clinical Research Center (CRC) is an invaluable resource 

for clinicians interested in conducting research initiatives at 

Hartford Hospital. e CRC provides administrative and 

research coordinator support for research activities of the 

institution’s medical staff. Support is provided for both 

investigator- initiated studies as well as industry-funded 

trials sponsored by pharmaceutical and medical device 

companies. While the CRC staff supports many experienced 

investigators they are also able to assist new investigators. As 

part of Research Administration, the CRC interacts with 

a multidisciplinary staff with expertise in areas of clinical 

research design, grantwriting, contract negotiation and 

budget review, IRB document preparation, database design 

and data analysis. 

e administrative office of the CRC is located in Research 

Administration on the 2nd floor of the Education and 

Resource Center (ERC) Building. Additionally, satellite 

offices are located throughout the hospital including offices 

in the Stroke Center and the Division of Cardiology. An 

outpatient clinical trials office is located in the medical 

building to facilitate studies being conducted by our private 

physician groups. 

 

e Study Center is located on the 6th floor of the ERC 

building and is available to investigators by reservation 

to support Phase I – IV studies requiring overnight 

accommodations. e Center has a suite of 24 private sleep 

rooms with bathroom and shower facilities for each group of 

4 rooms. Each room includes a bed with bedding, dresser, 

closet and desk as well as a wall-mounted television. e 

Center also has a shared lounge area with television, DVD 

player, couches and chairs. e kitchen facility includes a 

large refrigerator, microwaves, toaster ovens and storage 

cabinet areas. An area for clinical assessments is available 

with an exam table, scale, blood pressure monitor and 

medical supplies. A specimen processing laboratory includes 

a centrifuge, refrigerator/freezer, sink and phlebotomy chair. 

e facility is alarmed and can be used to monitor patients 

and ensure subject compliance. Trained medical personnel 

with clinical trial experience are available to staff the Study 

Center. Additional staffing and supplies are available to meet 

the needs of individual studies. 

Services provided by the CRC include: 

marketing services to potential study sponsors 

and referrals to our physician investigators 

marketing of trial opportunities to potential 

subjects 

study initiation and regulatory maintenance 

contract and budget preparation 

regulatory documentation preparation and 

maintenance including IRB submission and 

continuing review 

coordinator study support 

patient screening, enrollment, randomization 

coordination of all study procedures (i.e., study 

visits, study drug administration, study-related 

interventions per study protocol) 

availability for all sponsor monitoring visits 

and audits 

data management 

completion of case report forms, query 

resolution 

reporting adverse events and other regulatory 

requirements to the IRB 

data entry

e CRC has supported the clinical research activity of hospital 

investigators since 1993. e staff has grown to include 19 

research professionals committed to providing excellence in 

clinical research. A Director and Study Center Coordinator 

provide management of the operational and financial areas 

of the department. A Research Pharmacy Technician is 

part of the CRC staff and assumes accountability for all 

investigational drug use at the institution. e CRC study 

coordination staff includes 14 Clinical Research Associates 

with clinical research experience ranging from four to twelve 

years. Included in this group are eight RNs and LPNs. Ten 

of the coordinators hold clinical research certification through 

the Society of Clinical Research Associates (SOCRA) or the 

Association of Clinical Research Professionals (ACRP). 

Two of the coordinators also have experience in basic science 

research. e CRC is also staffed by two clinical research 

assistants who support to the study coordinators and provide 

other assistance with research tasks as needed. 

 

e CRC continues to support clinical research in General 

Surgery, Cardiovascular Surgery, Orthopaedic Surgery, 

Preventive Cardiology, Infectious Disease, Neurology, 

Pulmonary Medicine, Traumatology/Emergency Medicine, 

Radiology, Urogynecology and Women’s Health. We were 

pleased to provide study coordination services to three 

additional hospital divisions this past year. 

e CRC and study physicians are pleased to offer these new 

study therapies to our Hartford Hospital patients. 

 

 

 

 

 

e CRC is supporting the trials 

conducted in the Gastroenterology 

division under the direction of Dr. 

Joseph Cappa and the physicians from 

Connecticut GI. Trials in this area 

are investigating new medications and 

dosing regimens for patients suffering 

from Ulcerative Colitis, Crohn’s 

Disease and Irritable Bowel Disease. 

 

e CRC also provides support for 

all research studies conducted by 

Dr. Detlef Wencker who joined the 

Cardiology division as Director of the 

Heart Failure Services and Cardiac 

Transplantation during the Summer of 

2007. Dr. Wencker will study several 

investigational drugs and implantable 

devices aimed at improving the 

prognosis of heart failure patients. 

 

e CRC staff assumed the clinical 

trial work conducted by Drs. Kluger 

and Clyne in the Arrhythmia Center. 

ese studies investigate ways to 

optimize pacemaker settings to achieve 

optimal patient outcomes and also 

evaluate new devices for patients with 

heart arrhythmias.

Hartford Hospital’s preclinical research facility was 

established in 1952, and has provided support for numerous 

surgical specialties. Innovative research and training has 

resulted in many significant developments for the hospital, 

such as open-heart surgery, heart and liver transplants, and 

intra-coronary drug delivery via balloon catheters. 

e facility performs preclinical contract work and 

biocompatibility testing, both Good Laboratory Practices 

(GLP) and non-GLP. Additionally, three surgical suites are 

available for testing, training or research. 

 

 

 

 

 

 

e facility is licensed by the United States Department of 

Agriculture (USDA) and Accredited by the Association for 

Assessment and Accreditation of Laboratory Animal Care, 

International (AAALAC). 

 

Facility Capabilities 

In Vivo Medical Device Testing 

In Vivo Biocompatibility Testing 

Surgical Research & Development 

Surgical Training Courses 

GLP and non-GLP studies 

Quality Assurance Program

Gualberto Ruaño, MD, PhD 

Director of Genetics Research, Hartford Hospital 

President, Genomas 

One of the promises of the Human Genome Project 

is individualization of patient care based on highly 

heterogeneous innate metabolic factors determined by DNA 

typing of gene polymorphisms. e practice of DNA-guided 

medicine requires the translation of such gene polymorphism 

into clinical decision support for personalized healthcare. 

Pharmacogenetics serves as the foundation for the most 

clinically advanced application of DNA-guided medicine. 

 

 

Located at Hartford Hospital, the Laboratory of Personalized 

Health (LPH, Division of Genomas), performs clinical DNA 

typing for pharmacogenetic case referrals. Operational since 

October 2005, LPH has already diagnosed drug metabolism 

capacities for 500 patients referred by physicians at Hartford 

Hospital and throughout Connecticut. LPH is licensed by 

the Connecticut Department of Public Health and certified 

by Centers for Medicare and Medicaid Services as a highcomplexity 

clinical molecular laboratory. 

 

 

e hepatic cytochrome P450 (CYP450) isoenzymes 

CYP2D6, CYP2C9, and CYP2C19 metabolize and inactivate 

many drugs including antidepressants, antipsychotics, 

anticoagulants, and analgesics. ey also metabolize selective 

pro-drugs into their active metabolites. ese isoenzymes are 

highly polymorphic in gene sequence and protein structure. 

eir resultant variable biochemical properties substantially 

alter individual patient drug response. By means of DNA 

typing, the innate drug metabolism capacity of the patient 

can be predicted and diagnosed simply from a blood sample. 

LPH has analyzed the frequency of CYP450 polymorphisms 

in Hartford Hospital populations and determined that 

approximately 50% of patients are carriers of a deficient or 

null polymorphism for CYP2D6, and approximately 25% for 

CYP2C9 or CYP2C19. 

 

 

Many psychotropics (including Selective Serotonin Reuptake 

Inhibitors, Atypical Antipsychotics, Tricyclic Antidepressants 

and Attention Deficit Hyperactivity Disorder agents) are 

metabolized by the CYP450 isoenzymes. Inherited common 

variations in DNA result in extremes of enzymatic activity 

with resultant highly deficient or ultra rapid drug metabolism. 

DNA typing is valuable in the diagnosis of patients refractive 

to psychotropic therapy or prone to recurrent side effects. In 

a case report from the Institute of Living, a patient with a 

6-year history of adverse effects to 18 psychotropics was 

diagnosed as profoundly deficient in drug metabolism by 

DNA typing at LPH of CYP2D6, CYP2C9, and CYP2C19 

genes. DNA typing is also relevant to the management of 

psychotropic prescription for highly vulnerable populations 

such as children and adolescent patients. erapy can be 

directed toward drugs whose primary metabolic pathway are 

least deficient or normal in an individual patient. 

 

 

Warfarin (Coumadin®) is widely prescribed for management 

of atrial fibrillation, cardiac valve surgery, orthopedic 

procedures, pulmonary embolism and deep vein thrombosis. 

Yet warfarin management presents a clinical conundrum. 

ere is a broad range of maintenance doses within the 

population to obtain therapeutic anticoagulation. e drug 

label carries a black box warning for bleeding which is common 

despite periodic INR monitoring. Warfarin is metabolized 

by the CYP2C9 isoenzyme and exerts its anticoagulant 

effect through inhibition of Vitamin K Epoxide Reductase 

(VKOR), which reduces Vitamin K for activation of various 

clotting factors. Patients who are carriers of both CYP2C9 

and VKOR polymorphisms have a significantly higher rate of 

bleeding complications. New dosage guidelines are available 

from dosing algorithms now significantly enhanced with 

CYP2C9 and VKOR gene polymorphisms. In August 2007, 

the FDA revised the drug label for Coumadin® to reflect this 

new gene-based prescription guidance. 

 

 

Tamoxifen (Nolvadex®) and codeine are examples of prodrug 

activation by the CYP2D6 isoenzyme. Tamoxifen 

is metabolized to the biologically active intracellular 

metabolite endoxifen. Breast cancer patients with deficient 

or null CYP2D6 polymorphisms experience less benefit 

from tamoxifen and have higher recurrence rates and deaths. 

Codeine is metabolized to its active metabolite morphine. If 

given standard codeine doses, patients deficient or null for 

CYP2D6 metabolism may not experience analgesia while 

ultra-rapid metabolizers may experience apnea or even 

respiratory arrest.

Patients can be referred to LPH through the Clinical 

Laboratory Partners network throughout Connecticut. 

Multi-gene physiogenomic systems identifying patients at 

risk of statin-induced neuromyopathy, glitazone-related 

edema, and psychotropic-induced metabolic syndrome are 

under development. 

 

 

 

Antidepressants, 

Antipsychotics 

Warfarin (Coumadin®) 

Tamoxifen (Nolvadex®), Codeine 

CYP2D6, CYP2C9, CYP2C19 

CYP2C9, VKOR 

CYP2D6 

 

 

and null alleles of CYP2 genes in a major USA hospital: Implications for 

personalized drug safety. Personalized Medicine, 3(2), 131-137, 2006. 

Ruaño G, Bower B. e pharmacogenomics of Warfarin (Coumadin) 

administration. Connecticut Medicine, 70(4), 251-252, 2006. 

Holford TR, Windemuth A, Ruaño G. Designing physiogenomic studies. 

Pharmacogenomics, 7(2): 157-158, 2006. 

Ruaño G, Seip RL, Bilbie C, Zöllner S, Miles M, Zoeller R, Visich P, 

Gordon P, Angelopoulos T J, Pescatello L, Moyna N, Tsongalis GJ, Otvos 

J, Ordovas JM, ompson PD. A common promoter polymorphism of the 

Apolipoprotein A1 gene affects exercise-induced changes in cholesterol 

distribution among HDL subfractions. Atherosclerosis 185: 65-69, 2006. 

Ruaño G, Zöllner S, Goethe JW. Drug-induced metabolic syndrome (DIMS) 

in psychiatry: a diagnostic need uniquely suited to pharmacogenomics. In: 

Wong SHY, Linder MW, Valdes R Jr, eds. Pharmacogenomics and proteomics: 

enabling the practice of personalized medicine. Washington, DC: AACC Press, 

2006; 277–82. 

Ruaño G, Windemuth A, Holford T. Physiogenomics: Integrating systems 

engineering and nanotechnology for personalized health. In e Biomedical 

Engineering Handbook, 3rd Edition, Joseph D. Bronzino, editor, CRC Press 

Taylor and Francis, 28-1-28-9, 2006. 

Ruaño G, ompson PD, Windemuth A, Smith A, Kocherla M, Holford 

TR, Seip R, Wu AHB. Physiogenomic analysis links serum creatine kinase 

activities during statin therapy to vascular smooth muscle homeostasis. 

Pharmacogenomics Vol. 6, No. 8 (December), pp. 865-872, 2005. 

 

 

 

Genetic Modulation of Lipid Metabolic Response to Aerobic 

Exercise. Hartford Hospital Research Endowment Funds, $50,000. 

 

Relationship of Muscle Injury to Muscle Hypertrophy. Hartford 

Hospital Research Endowment Funds, $35,488. 

 

Ruaño G, ompson PD, Windemuth A, Seip RL, Dande A, Sarokin A, 

Kocherla M, Smith A, Holford TR, Wu AH. Physiogenomic association of 

statin-related myalgia to serotonin receptors. Muscle & Nerve, 36: 329-335, 

2007. 

Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, 

Windemuth A, de Leon J. Physiogenomic comparison of weight profiles 

of Olanzapine- and Risperidone-treated patients. Molecular Psychiatry, 12: 

474- 482, 2007. 

Ruaño G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman 

Y, Pearlson G, Goethe JW, Schwartz HI. Somatic complications of 

psychotropic medications in a patient with multiple CYP2 drug metabolism 

deficiencies. Connecticut Medicine, 71: 197-200, 2007. 

Ruaño G, Windemuth A, Kocherla M, Holford TR, Fernandez ML, 

Forsythe CE, Wood RJ, Kraemer WJ, Volek JS. Physiogenomic analysis 

of weight loss induced by dietary carbohydrate restriction. Nutrition and 

Metabolism, 3: 20-30, 2006. 

Ruaño G, Makowski G, Windemuth A, Kocherla M, Weiss S, Goethe JW, 

Bower B, Wu AHB, ompson PD. High carrier prevalence of deficient

Paul D. ompson, MD • Alan Ahlberg, MA • Jeremy Barbagallo, MA • Cherie Bilbie, MS • Jill Cloutier 

RN • Christopher Clyne, MD • Giselle Cyr, RN • Marcin Dada, MD • Ellen Dornelas, PhD • Edward 

Fischer, PhD • Brenda Foxen, RN • Daniel Fram, MD • Danette Guertin, APRN • Deborah Katten, RN • 

Jeffery Kluger, MD •Gary Heller, MD • Jeffrey Hirst, MD • Francis Kiernan, MD • Justin Lundbye, MD 

• Raymond McKay, MD • Roger Mennett, MS • Joseph Mitchel, DO • Deborah Murphy, RN • Charles 

Primiano, MD • David Silverman, MD • Marilyn Siwy, RN • Detlef Wencker, MD • Charles White, 

PharmD • Ravi Yarlagadda, MD 

 

e Division of Cardiology and Henry Low Heart Center’s 

mission is to deliver excellent patient care by applying 

therapeutic treatments derived from rigorous scientific study. 

We are a leader in cardiovascular research including: heart 

failure, prevention, nuclear imaging, diagnosis and treatment 

of complex arrhythmias and cardiac catheterization. In 

FY07 e Division of Cardiology obtained new research 

funds of $3,007,870 (federal), $722,870 (industry), $74,583 

(foundation) and $105,991 in research endowment awards. 

 

is active research program employs PET (Positron 

Emission Tomography) and SPECT (Photon Emission 

Computed Tomography) imaging techniques. Dr. Gary 

V. Heller directs both Nuclear Cardiology and Hartford 

Hospital’s Cardiology Fellowship. Under his direction, the 

cardiology fellows are active in conducting and publishing 

scientific studies. In 2007, Kirkeith Lertsburapa M.D., 

competed in the national American Society of Nuclear 

Cardiology Young Investigators Award Program. Under 

Dr. Heller’s leadership, Hartford Hospital has also been the 

recipient of a $3 million grant for the WOMEN Study: What 

is the Optimal Evaluation of Ischemia in Women. is 

prospective, randomized trial completed enrollment of 826 

women with intermediate to high likelihood of coronary artery 

disease. Drs. Heller, Shaw, Mieres and Hendel are principal 

investigators and Deborah Katten is study coordinator for 

26 recruiting centers. New research will focus on the role of 

cardiac PET perfusion imaging in obtaining early diagnoses 

of coronary disease in people with diabetes, who are at high 

risk for the development of this disorder. 

 

 

Dr. Jeffrey Kluger leads an active research program focusing 

on new technologies to diagnose and treat problems of the 

electrical conduction system of the heart. Drs. Kluger, Clyne 

and Yarlagadda have spear-headed a series of clinical research 

studies examining pharmacologic methods of preventing 

atrial fibrillation following cardiac surgery, new implantable 

cardioverter defibrillator technologies for the primary 

prevention of sudden cardiac death and utilization of catheter 

ablation for atrial fibrillation. Working collaboratively with 

Dr. Mike White at the University of Connecticut School of 

Pharmacy, the team received a prestigious grant from the 

Agency for Health Care Research and Quality to establish an 

Evidence-Based Practice Center. 

 

 

Directed by Detlef Wencker, M.D., this dividsion is rapidly 

developing a center of excellence in congestive heart failure 

research. Dr. Wencker has received funding from NIH to 

study Myocyte Apoptosis. He is also the principal investigator 

on a multicenter study that investigates new treatments for 

patients with acute heart failure who are hospitalized for 

volume overload and require intravenous diuretic therapy. 

Hartford Hospital also participates in the ASCEND-HF 

Study: Acute Study of Clinical Effectiveness of Nesiritide 

in Decompensated Heart Failure under Dr. Wencker’s 

leadership. is is a large, national trial to assess the safety 

and effectiveness of Nesiritide in people with advanced heart 

failure. 

 

 

is research program focuses on the development and testing 

of new interventional and cardiac imaging techniques, on the 

assessment of adjunctive interventional pharmacology, and 

on the maintenance and analysis of a comprehensive research 

database. Previous research has included the development 

of balloon aortic and mitral valvuloplasty, catheter-based 

local drug delivery, radiofrequency coronary angioplasty, 

and intra-cardiac ultrasound. Major contributions have also 

been made in the assessment of drug-coated stents, primary 

percutanaeous intervention for acute myocardial infarction, 

directional coronary atherectomy, catheter-based femoral 

arteriotomy closure, catheter-based thrombectomy, multiple 

new intracoronary stents, intracoronary brachytherapy, and 

left ventricular assist devices. In addition, catheterization 

physicians have served as principal investigators for over 

30 multi-center, national trials over the last five years. 

Dr. Raymond McKay is the principal investigator on the 

TITAN, IC TITAN, TRITON, TRILOGY ACS, RA 

–TIMI 50, BRACCO, and PLATO trials. Dr. Francis

Kiernan is principal investigator on SWAT and CORDIS 

ELITE. Drs. Raymond G. McKay and Isaac Silverman are 

principal investigators on CLOSURE 1. 

Maintenance and analysis of the laboratory’s interventional 

database is an important focus of this program. Currently, 

the database encompasses in-hospital and 9-month clinical 

outcomes on over 6700 consecutive patients treated with 

percutaneous intervention. Over the last 5 years, 55 abstracts 

have been presented at the annual scientific sessions of the 

American Heart Association, the American College of 

Cardiology and the Society for Cardiac Angiography and 

Intervention. 

 

Paul D. ompson, M.D. directs this research program 

focused on the effect of cholesterol-lowering medication 

(specifically statins) on skeletal muscle function. In 2007 he 

received a grant from the National Heart Lung and Blood 

Institute to study this phenomenon. e research has identified 

DNA polymorphisms predictive of statin neuromuscular side 

effects and exercise response. Cardiovascular genetics has also 

been advanced at Hartford Hospital. Under the direction 

of Gualberto Ruaño, M.D., Ph.D., Director of Genetics 

Research, studies of statin and exercise physiogenomics are 

underway. Working together with the Olin Neuropsychiatry 

Research Center, Dr. ompson’s team also has begun to 

utilize functional magnetic resonance imaging to examine 

the impact of exercise on brain function. Dr. ompson has 

published extensively on heart problems in marathon runners 

and was the lead author on the 2007 consensus statement 

about the risks of acute cardiovascular events in elite athletes 

from the American Heart Association Council on Nutrition, 

Physical Activity, and Metabolism and the Council on 

Clinical Cardiology. Psychologist Ellen Dornelas, PhD 

leads an active research program focused on behavioral and 

pharmacologic interventions for smoking cessation. 

 

 

 

e Effect of Statins on Skeletal Muscle Function. National Institutes 

of Health, $3,007,870. 

 

 

Diabetes, Depression, and Coronary Heart Disease Risk in Post- 

Menopausal Women. American Diabetes Association subcontract 

through the University of Connecticut,$28,860. 

 

e Impact of Short-Term High Intensity Statin erapy Versus 

Low Intensity Statin erapy on Inflammatory Mediators in 

Cardiothoracic Surgery Patients: e Atrial Fibrillation Suppression 

Trial IV (AFIST IV) Pilot Study. Gustavus and Louise Pfeifer 

Research Foundation, $74,583. 

 

 

Meta-Analyses of the Impact of Appropriate Antibiotic erapy on 

Mortality in Patients with Ventilator-Associated Pneumonia and 

Blood Stream Infections. AstraZeneca, $20,625. 

Meta-Analysis of erapies for Treatment of Early- and Late- 

Stage Parkinson’s Disease. Boehringher-Ingelheim Pharmaceuticals, 

$17,500. 

 

e OMNI Study. Medtronic, Inc., $66,927.00 . 

Response of Cardiac Resynchronization erapy Optimization with 

V-V Timing in Heart Failure Patients (RESPONSE HF). St. Jude 

Medical, $34,247. 

 

A 12 Week, Double-Blind, Placebo-Controlled, Multicenter Study 

with a 40 Week Follow-up Evaluating the Safety and Efficacy of 

Varenicline Tartrate 1 MG BID for Smoking Cessation in Subjects 

with Cardiovascular Disease. Pfizer, $160,327.

An Open-Label Multi-Center, Phase 3 Study Evaluating the 

Prognostic Usefulness of I123-mIBG Scintigraphy for Identifying 

Subjects with Heart Failure who will Experience an Adverse Cardiac 

Event ( Protocol PC MBG311 CPR). GE Healthcare, $157,500. 

Development of a Normal Database and Criteria for Abnormality 

for ß-Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid (Iodofiltic 

Acid I 123) for Quantitative Imaging (Protocol MIP-BP22). 

Molecular Insight Pharmaceuticals, $50,094. 

SPARC: Study of Myocardial Perfusion and Coronary Anatomy 

Imaging Roles in CAD. Brigham & Women’s Hospital 

$50,375. 

Open-Label, Phase 2 Study of the Safety and Efficacy of ß-Methylp-[123I]-Iodophenyl-Pentadecanoic 

Acid (Iodofiltic Acid I 123) 

for Identification of Ischemic Myocardium Using Single Photon 

Emission Computed Tomography (SPECT) in Adults with 

Symptoms Consistent with Acute Coronary Syndrome (ACS). 

Molecular Insight Pharmaceuticals, $56,445. 

e Prognostic Value of Left Ventricular Ejection Fraction From 

Cardiac PET Myocardial Perfusion Imaging in Patients with 

Known or Suspected Coronary Artery Disease. BRACCO, $78,738. 

Evaluation of Astonish Processing Phase II. Phillips Medical Systems, 

$139,583. 

 

A Randomized, Controlled Trial to Evaluate the Safety and Efficacy 

of the Zomaxx Drug Eluting Coronary Stent System as Compared to 

the TAXUS Express Paclitaxel-Eluting Stent in de novo Coronary 

Artery Lesion. Abbott Vascular, $300,956. 

 

A Single-Center Registry to Investigate the Long-Term Safety and 

Efficacy of the Sirolimus-Eluting CYPHER Intracoronary Stent. 

Cordis, $140,410. 

A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and 

Safety Study of AZD6140 Compared to Clopidogrel for Prevention 

of Vascular Events in Patients with Non-ST or ST Elevation Acute 

Coronary Syndromes (ACS) - PLATO. AstraZeneca, $182,265. 

 

A Randomized, Placebo Controlled, Parallel Group, Double-Blind 

Study of the Efficacy and Safety of Rimonabant in Abdominally 

Obese Subjects with Multiple Cardiovascular and Metabolic Risk 

Factors and with LDL-Cholesterol at NCEP ATP III Treatment 

Goal (Protocol Number: L-0137). Sanofi-aventis US, ICON Clinical 

Research, $77,967. 

Lipid Treatment Assessment Project 2 (L-TAP 2) Protocol 

#NRA5090005. Pfizer, $6,250. 

A Randomized Multicenter Crossover FUTURA Trial to 

Compare the Performance of the Plasmat® Futura Heparin 

Induced Extracorporeal LDL Precipitation (H.E.L.P.) Apheresis 

System to the Approved Plasmat® Secura H.E.L.P. Apheresis 

System in the Reduction of LDL Cholesterol in Subjects with 

Hypercholesterolemia Refractory to Current Conventional 

Treatment. HELP Inc. c/o Spencer Trask Specialty Group, LLC, 

$91,875. 

A Multicenter, Randomized, Double-Blind, Titration Study to 

Evaluate and Compare the Efficacy and Safety of Ezetimibe Added 

On to Atorvastatin 40 mg Versus Up Titration to Atorvastatin 80 

mg in Hypercholesterolemic Patients at High Risk for Coronary 

Heart Disease Not Adequately Controlled on Atorvastatin 40 mg. 

(Protocol 090-03/EZT578). Merck & Co., Inc., $26,500. 

 

 

e Impact of Oral Magnesium L-Lactate on Occurrence of 

Ventricular Arrhythmias and Patient Perceived Quality of Life 

Among Patients with Implantable Cardioverter-Defibrillators: e 

Adjuvant Magnesium (AdMag) Trial Cost-Utility Analysis. New 

Investigator, $9,952. 

 

A Preliminary Study of Statin-Associated Cognitive Impairment. 

Open Competition, $34,588. 

 

e Utility of Transesophageal Echocardiography in the Diagnosis 

of Infective Endocarditis. Small Grant, $7,875. 

 

e Role of Cardiac PET Perfusion Imaging in the Diagnosis 

of Coronary Disease in Patients with Diabetes Mellitus. Open 

Competition, $48,394. 

 

Does Exercise Training Alter Hippocampal Size and Function in 

Humans: A Preliminary Study. Open Competition, $56,317. 

 

e Use of Magnesium to Improve Hemodynamics, Cholesterol 

and Glucose Control: A Substudy of AdMag. Open Competition, 

$47,000. 

Comparison of Rates of Successful Termination and Recurrence of 

Atrial Fibrillation as well as the Incidence of Torsades de Pointes 

in Patients Treated with Ibutilide Alone to ose Treated with 

Ibutilide and Magnesium: e Hartford Hospital Experience from 

the TIME Trial and beyond (TIME II). Statistical analysis supported 

through Hartford Hospital Small Grant. 

 

 

Novel Suture-Based Arteriotomy Closure Device Feasibility Study, 

$105. 

 

 

Is Cardiac Memory Blocked by Calcium Channel Blockers and 

Amiodarone? 

 

Interventional Electrophysiology Outcomes Protocol. Statistical 

analysis supported through Hartford Hospital Small Grant. 

Impact of Corticosteroids on Immediate Postoperative Recurrence 

of Atrial Tachyarrhythmias after Radiofrequency Catheter Ablation 

of Atrial Fibrillation. 

 

REACTS: Retrospective Evaluation of Aprotinin in Cardiothoracic 

Surgery. 

Can HMG-CoA Reductase Inhibitors Decrease Atrial Fibrillation 

Following Cardiothoracic Surgery? A Retrospective Cohort

Evaluation. 

 

Effect of Season, City Size, and Recruitment Source on Latinos’ 

Participation in a Statewide Smoking Cessation Program. 

 

Oxygen Mapping of the Peri-sternal Chest Wall in Post-Operative 

Open Heart Surgery Patients. 

 

Comparison of Left Ventricular Apical Linear Dimension 

Between Real Time ree Dimensional Echocardiography and 

the Conventional Standard Two Dimensional Echocardiography. 

Statistical analysis supported through Hartford Hospital Small Grant 

 

An Economic and Safety Evaluation of the Use of Intravenous 

Protamine to Rapidly Reverse Anticoagulation in Patients Receiving 

Radiofrequency Catheter Ablation of Atrial and Ventricular 

Arrhythmias. 

 

Follow up of Patients with Coronary Artery Disease who have 

Undergone Rapid Aspirin Desensitization Before or After 

Percutaneous Coronary Intervention. 

 

Echocardiographic Features of the Cardiomyopathy Associated 

with Alstrom Syndrome: A Retrospective Review. 

 

Percutaneous Coronary Intervention Clinical Outcomes. 

e Role of Glycemic Control During Cardiac Catheterization 

Procedures and Cardiac Events. 

Clinical Outcomes Blanket Protocol of Get-With-the-Guidelines 

- Heart Failure (SWTG-HF) Database. 

 

Pulmonary Venous Catheter Ablation and its Effect on P-Wave 

Dispersion in Patients with Atrial Fibrillation. 

e Effects of Statin erapy on the Development of Early Recurrent 

Atrial Fibrillation after Catheter-Based Pulmonary Vein Ablation. 

Statistical analysis supported through Hartford Hospital Small Grant. 

 

Effect of Heart Rate on Ventricular Dyssynchrony. 

 

Molecular Changes in Human Muscle with Unloading/Reloading. 

 

 

Upper Arm Muscle Injury, Soreness, and Strength Changes 

Associated with Two Bouts of Resistance Exercise. Hartford 


 

CHARISMA: Clopidogrel for High Atherothrombotic Risk 

and Ischemic Stabilization, Management and Avoidance. Sanofi- 

Synthelabo Research, $201,250. 

Ischemia-Guided Percutaneous Coronary Intervention in Stable 

Multi-Vessel Disease: e Role for Stress Tc-99m Sestamibi Gated 

SPECT Imaging. 

H8D-MC-EMBB PPAR Alpha (LY518674): A phase 2 Dosefinding 

and Safety Study for Atherogenic Dyslipidemia. e 

Cleveland Clinic Foundation/Eli Lilly and Company, $80,138. 

 

Use of Gated Blood Pool Imaging to Predict Improvement with 

Bi-Ventricular Pacing - A Pilot Study. Hartford Hospital Research 

Endowment Funds, $9,295. 

Acute Hemodynamic Effects of Atrio-Biventricular Pacing in 

Postoperative Coronary Bypass Patients. Hartford Hospital Research 


Swine Ischemia Model-Voltage and Flow Mapping. Hartford 


Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in 

ICDs (INTRINSIC RV). Guidant, $77,625. 

e Impact of Intravenous Magnesium on Atrial Vulnerability in 

Patients Receiving Radiofrequency Catheter Ablation for Atrial 

Fibrillation. Hartford Hospital Research Endowment Funds, $40,894. 

OPTION CRT/Atx (Cardiac Resynchronization erapy & Atrial 

erapy). BIOTRONIK Inc., $59,698. 

Multicenter Automatic Defibrillator Implantation Cardiac 

Resynchronization erapy (MADIT-CRT). University of 

Rochester/Guidant Corporation, $133,793. 

 

Pharmacoeconomic Considerations of Utilizing the AFIST 

Prophylactic Amiodarone Dosing Regimens in Everyday Practice. 

Drug Assistance Program to Reduce Disparities in Health. 

Efficacy and Cost-Effectiveness of Facilitated Percutaneous 

Coronary Intervention (PCI) Compared with Primary PCI in 

Patients with ST-Segment Elevation Myocardial Infarction 

Transferred from Community Hospitals. 

 

e Anterior Fat Stripe Sign: A CT Marker for Cervical Injury. 

 

CRUSADE: Can Rapid Risk Stratification of Unstable Angina 

Patients Suppress Adverse Outcomes with Early Implementation of 

the ACC/AHA Guidelines? Millennium Pharm. & Schering Plough 

Pharm., $20,000. 

 

Intensive Counseling for Pregnant Smokers. Hartford Hospital 

Research Endowment Funds, $50,000. 

An Internet-Based Information and Support Program for Reduction 

of Depressive Symptoms and Service Utilization After Myocardial 

Infarction. Hartford Hospital Research Endowment Funds, 

$53,599. 

Nicotine Replacement Treatment for Pregnant Smokers. University 

of Connecticut, $527,683. 

Genetic and Psychosocial Predictors of Mood Change Following 

Acute Coronary Syndrome. 

SAD-Moms: Study of treatment for Antepartum Depression 

in expecting Mothers. Hartford Hospital Research Endowment

Funds,$73,000. 

 

Clinical Utility of Attenuation Correction of Pharmacologic Stress 

Tc-99 Sestamibi SPECT Myocardial Perfusion Imaging in Patients 

with Known or Suspected Coronary Artery Disease. 

 

Determinanats of Functional Tricuspid Regurgitation and its 

Correlations with Pulmonary Artery Pressure as Measured Directly 

with Swan-Ganz Catheter. 

A Phase 3, International, Multicenter, Open-Label, Dual-Injection, 

Echocardiographic Imaging and Safety Study of AI-700 in Patients 

with Suspected Ischemic Heart Disease Undergoing Single-Photon 

Emission Computed Technology (IND 57288). Acusphere Inc., 

$93,500. 

Investigational Ultrasound System and Investigational Transducers 

Project. 

 

A Comparison of Dipyridamole, Adenosine and Dobutamine in 

Evaluating the Severity and Reversibility of Defects Using Tc- 

99m Sestamibi SPECT Imaging in Patients with Coronary Artery 

Disease. Bristol-Myers Squibb, $15,000; Hartford Hospital Research 


Detection of Ischemia in Asymptomatic Diabetics (DiaD). Yale 

University School of Medicine, $289,843. 

Stress Technetium-99m Sestamibi Gated SPECT Imaging in the 

Detection of Coronary Artery Disease in Patients with Dilated 

Cardiomyopathy. Hartford Hospital Research Endowment Funds, 

$50,000. 

Nuclear Substudy II: Short-Term Effects of Medical and Surgical 

erapy on Ischemic Burden as Determined by Myocardial 

Perfusion SPECT Imaging in Patients Enrolled in the COURAGE 

Trial. Cedars-Sinai Medical Center, $7,500. 

Comparison Between Dipyridamole and Adenosine Tc-99m 

Sestamibi SPECT Myocardial Perfusion Imaging in Patients with 

Known or Suspected Coronary Artery Disease. Hartford Hospital 


Impact of Moderate Intensity Aerobic Exercise Training on 

Myocardial Contractile Reserve in Patients with Ischemic 

Cardiomyopathy. Hartford Hospital Research Endowment Funds, 

$67,000. 

Comparison of Imaging Characteristics Between Upright Solid 

State Imaging and Supine Anger-Camera Imaging in Patients 

Undergoing Stress Tc-99m Sestamibi SPECT Myocardial 

Perfusion Imaging. Digirad Corporation, $13,750. 

Screening for Asymptomatic Ischemia: Health Outcomes (Factors 

Associated with Control of Diabetes and Silent Heart Disease). 

Assessment of Myocardial Perfusion and Left Ventricular Function 

from Stress and Rest Tc-99m Sestamibi Gated SPECT Imaging for 

the Prediction of Future Cardiac Events in Patients with Known 

or Suspected Coronary Artery Disease. Hartford Hospital Research 


Progression of Coronary Artery Disease in Diabetic and Non- 

Diabetic Individuals as Measured by Serial Gated Myocardial 

Perfusion Imaging. Hartford Hospital Research Endowment Funds, 

$10,074. 

e Impact of Race on the Utility of Rest/Stress Tc-99m Sestamibi 

Myocardial Perfusion Imaging Among Hispanics, Blacks and 

White. 

Nuclear Imaging Database Research Project. Bristol Meyers Squibb 

Imaging Inc., $95,000. 

Impact of Stress Modality Upon Diagnosis and Risk Stratification in 

Patients with Left Bundle Branch Block (LBBB). 

Clinical Utility of Attenuation Correction of Pharmacologic Stress 

Tc-99 Sestamibi SPECT Myocardial Perfusion Imaging in Patients 

with Known or Suspected Coronary Artery Disease. 

e WOMEN Study: What is the Optimal Method for Ischemia 

Evaluation in Women? Cardiovascular Clinical Studies Inc., $28,146. 

Open-Label, Phase 2B Study of the Safety and Efficacy of 

Methyl-P-Iodophenyl-Pentadecanoic Acid ([123 I] - BMIPP) 

for Identification of Ischemic Myocardium Using Single Photon 

Emission Computed Tomography (SPECT) in Adults Admitted 

to the Emergency Department. Molecular Insight Pharmaceuticals 

Inc., $72,471. 

Attenuation Correction with the CardioMD Camera: Validation by 

Comparison with Attenuation Correction with the Vertex Cardio 

60 Camera. Nuclear Medicine Division, Philips Med. System, 

$100,632. 

ECG-Gated Dobutamine Stress Technetium-99m Sestamibi Single 

Photon Emission Tomographic Imaging: Risk Stratification Using 

Combined Assessment of Myocardial Perfusion And Function. 

A Phase IV Open-Label, Randomized, Multi-Center Trial to 

Evaluate the Ability of Technetium Tc99m Sestamibi Stress 

Myocardial Perfusion Imaging to Detect Asymptomatic Restenosis 

in Diabetic Patients who have Undergone Percutaneous Coronary 

Intervention. Bristol-Myers Squibb Company, $67,625. 

A Prospective Comparison of Gated, Rest/Stress Rubidium-82 

Positron Emission Computed Tomography (PET) vs. Gated, Rest/ 

Stress Technetium 99-M SPECT: A Pilot Study. Bracco Diagnostics 

Inc., $285,802. 

Identification of Hibernating Myocardium using Dobutamine 

Stress Rubidium-82 Myocardial Perfusion Positron Emission 

Tomography: Pilot Study of a Novel Technique for Assessment of 

Myocardial Viability. Hartford Hospital Research Endowment Funds, 

$57,209. 

Nuclear Cardiology Imaging Clinical Outcomes. Statistical analysis 

supported through Hartford Hospital Small Grant . 

An Open-Label, Multicentre, Phase 3 Study Evaluating the 

Prognostic Utility of Technetium-99m Tetrofosmin SPECT 

Myocardial Perfusion Imaging for Identifying Subjects that will 

Experience an Ischemic Cardiac Event. GEHealthcare, $11,000. 

 

Protocol P00-6302: A Multicenter, Randomized, Double Blind 

Study of the SIROLIMUS-Coated BX Velocity Balloon Expandable 

Stent in the Treatment of Patients with De Novo Native Coronary 

Artery Lesions. Cordis Inc., $102,000.

COURAGE: CSP-424 Clinical Outcomes Utilizing 

Revascularization and Aggressive Drug Evaluation. Department of 

Veterans Affairs, $378,000. 

Humanitarian Use Device - JOSTENT Coronary Stent Graft. 

e-CYPHER Post Market Surveillance Registry. Cordis Corporation, 

New Jersey, $11,620. 

ARRIVE - Taxus Peri-Approval Registry: A Multi-Center Safety 

Surveillance Program. Boston Scientific Corporation, $114,410. 

 

AFIST III- e Impact of Retaining the Aortic Fat Pad on 

Post-Cardiothoracic Surgery Atrial Fibrillation Incidence Versus 

Standard of Care: e Atrial Fibrillation Suppression Trial III. 

Hartford Hospital Research Endowment Funds, $49,950; Donaghue 

Medical Research Foundation,$100,368. 

MASTER: Microwave T Wave Alternans Testing for Risk 

Stratification of Post MI Patients. Medtronics, $120,023. 

CAPTURE: Complete Automatic Pacing reshold Utilization 

Recorded by EnPulse. Medtronics, $49,125. 

Optimal SVC Coil Usage in ICD Patients. St. Jude Medical, 

$9,500. 

ASSIST - Atrial Tachyarrhythmia Suppression Strategy in ICD 

Subjects Trial. St. Jude Medical, Scientific Studies Organization, 

$9,000. 

Outcomes of ICD Patients with Primary versus Secondary 

Prevention Indications. 

e Adjuvant Magnesium Trial (AdMag): Assessment of the 

Impact of Oral Magnesium on ICD Firing and Quality of Life. 

Donaghue Medical Research Foundation, $162,175. 

 

Exercise Training and Endothelial Vasomotor Function in 

Patients with Coronary Artery Disease. Hartford Hospital Research 


 

e Utility of Tc-99m Gated SPECT in Women with an 

Intermediate to High Llikelihood of Coronary Artery Disease 

Referred for Exercise Stress Myocardial Perfusion Imaging. 

 

Comparison of Angiographic and In-Hospital Outcomes in Patients 

with ST-Segment Elevation Myocardial Infarction (STEM) Treated 

with Percutaneous Coronary Intervention (PCI) with (Facilitated 

PCI) or without (Primary PCI) Adjunctive Pharmacotherapy. 

TITAN: Time to Integrilin erapy in Acute Myocardial Infarction 

- TIMI 34 Trial. Millennium, $40,000. 

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute 

Coronary Syndrome Subjects Who Are to Undergo Percutaneous 

Coronary Intervention/TRITON-TIMI 38. Quintiles Inc., 

$143,022. 

CARE (Visipaque 320 and Isovue-370 in Cardiac Angiography in 

Renally Impaired Patients). Bracco Diagnostics Inc., $88,194. 

 

Impact of Acute Regional LV Dysfunction on Mitral Closure 

Geometry: A Human Study Employing Angioplasty as a Model of 

Acute Ischemia. 

 

e Effect of Exogenous Testosterone on Endothelial Function. 

NIH, $73,900; Hartford Hospital Research Endowment Funds, 

$49,425. 

FAMUSS: Functional SNP’s associated with Human Muscle Size 

and Strength. NIH/NIAMS, $567,424. 

B. Braun Medical Inc. Patient Registry for the H.E.L.P. System. 

HF-ACTION: Heart Failure and A Controlled Trial Investigating 

Outcomes of Exercise TraiNing: Ancillary Study - Investigation of 

the Role of Genetic Variation in the Clinical Expression of Heart 

Failure. National Heart, Lung & Blood Institute (NHLBI) and Duke 

University, $685,000. 

Determining the Reliability and Reproducibility of Brachial Artery 

Reactivity. Hartford Hospital Research Endowment Funds, $13,125. 

Comparison of Administering Daily to Alternate Day Atorvastatin 

on Hyperlipidemia. Hartford Hospital Research Endowment Funds, 

$9,375.. 

ASTEROID: A 104-Week, Open-label, Multi-Center, Phase IIIb 

Study Evaluating the Effect of Treatment with Rosuvastatin 40 mg 

on Atherosclerotic Disease as Measured by Intravascular Ultrasound 

and Quantitative Coronary Angiography in Subjects Undergoing 

Coronary Angiography who have Coronary Artery Disease. 

AstraZeneca Pharmaceuticals, L.P., $110,487. 

Effect of Atorvastatin on Skeletal Muscle Gene Expression and 

Exercise. Hartford Hospital Research Endowment Funds, $50,000. 

Gene Expression Profiling and the Repeated Bout Effect: A Pilot 

Study. 

JUPITER: A Randomized, Double-Blind, Placebo-Controlled, 

Multicenter, Phase III Study of Rosuvastatin (Crestor\200) 20 

mg in the Primary Prevention of Cardiovascular Events Among 

Subjects with Low Levels of LDL-Cholesterol and Elevated Levels 

of C-Reactive Protein. PPD Development, LP, $102,250. 

Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, 

Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic 

Efficacy, Safety, and Tolerability of Fixed Combination CP- 

529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 

24 Months Compared with Atorvastatin Alone, in Subjects with 

Mixed Lipodemia. Pfizer, Inc., $540,531. 

Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, 

Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic 

Efficacy, Safety, and Tolerability, of Fixed Combination CP- 

529,414/ Atorvastatin, Administered Orally, Once Daily (QD) 

for 24 Months Compared with Maximally Tolerated Atorvastatin 

erapy Alone, in Subjects with Heterozygous Familial 

Hypercholesterolemia. Pfizer, Inc., $1,455,625. 

Skeletal Muscle Gene Expression in Patients with Statin-Induced 

Myalgia. Donaghue Medical Research Foundation, $239,996. 

LUNAR: A 12-Week, Randomized, Open-Label, 3-Arm, Paralleled 

Group, Multicenter, Phase IIIb Study Comparing the Efficacy and 

Safety of Rosuvastatin 20 mg and 40-mg with that of Atorvastatin 

80mg in Subjects with Acute Coronary Syndromes (Protocol No: 

4522). AstraZeneca, ICIB Clinical Research, Inc., $54,039.

Early Changes in Muscle Gene Expression Following 

Immobilization. 

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group 

Evaluation of the Fixed Combination Torcetrapib/Atorvastatin, 

Administered Orally, Once Daily (QD), Compared with 

Atorvastatin Alone, on the Occurrence of Major Cardiovascular 

Events in Subjects with Coronary Heart Disease or Risk Equivalents. 

Pfizer, Inc., $347,000. 

A Randomized, Double-Blind and Placebo-Controlled 2-Way 

Crossover Study of Statin-Induced Myalgia in Hypercholesterolemia 

Patients. Pfizer, $68,678. 

Effects of Low and High Dose Atorvastatin On Exercise-Induced 

Muscle Injury. Merck & Co., Inc., $408,227. 

 

Electrocardiographic (ECG) Evaluation of Transmural Dispersion 

of Repolarization and QT Prolongation in Patients Receiving 

Amiodarone or Pure Blockers of the Rapid Component of the 

Delayed Rectifier Potassium Channel (Sotalol or Dofetilide). 

 

Alkotob ML, Soltani P, Sheatt MA, Katsetos MC, Rothfield N, Hager 

WD, Foley RJ, Silverman DI. Reduced exercise capacity and stress induced 

pulmonary hypertension in patients with scleroderma. Chest; 2006: 130: 

176–181. 

Angelopoulos TJ, Sivo SA, Kyriazis GA, Caplan JD, Zoeller RF, Lowndes 

J, Seip RL, ompson PD. Do age and baseline LDL cholesterol levels 

determine the effect of regular exercise on plasma lipoprotein cholesterol and 

apolipoprotein B levels? Eur J Appl Physiol. 2007 Nov;101(5):621-8. 

Anglade MW, Kluger J, White CM, Aberle J, Coleman CI. iazolidinedione 

use and postoperative atrial fibrillation: a US nested case-control study. Curr 

Med Res Opin. 2007 Oct 4. 

Baker WL, Gutierrez-Williams G, White CM, Kluger J, Coleman CI. e 

effect of cinnamon on glucose control and lipid parameters. Diabetes Care. 

2007 Oct 1. 

Baker WL, White CM, Kluger J, Denowitz A, Konecny CP, Coleman 

CI. Effect of perioperative corticosteroid use on the incidence of 

postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm. 

2007 Apr;4(4):461-8. 

Bateman T, Heller GV, McGhie I, Friedman J, Case J, Bryngelson J, 

Hertenstein G, Moutray K, Reid K, Cullom SJ. Diagnostic accuracy of rest/ 

stress ECG-gated Rubidium-82 myocardial perfusion PET: Comparison 

with ECG-gated Tc-99m-Sestamibi SPECT. J Nucl Cardiol 2006;12:24- 

33. 

Baggish AL, ompson PD. e Athlete’s Heart 2007: Diseases of the 

Coronary Circulation. Cardiol Clin. 2007 Aug;25(3):431-40. 

Baghdasarian SB, Heller GV. e role of myocardial perfusion imaging in 

the diagnosis of patients with coronary artery disease: developments over the 

past year. Curr Opin Cardiol. 2005 20:369-374. 

Baghdasarian SB, ompson PD. How safe are very low LDL cholesterol 

levels? Nat Clin Pract Cardiovasc Med. 2006 Jun;3(6):306-7. 

Blanchard BE, Tsongalis GJ, Guidry MA, LaBelle LA, Poulin M, Taylor 

AL, Maresh CM, Devaney J, ompson PD, Pescatello LS. RAAS 

polymorphisms alter the acute blood pressure response to aerobic exercise 

among men with hypertension. Eur J Appl PhysioI. 2006 May;97(1):26-33. 

Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, 

Knutson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, 

Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates 

ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE 

Trial Research Group. Optimal medical therapy with or without PCI for 

stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. 

Boden WE, O’Rourke RA, Teo KK , Hartigan PM, Maron DJ, Kostuk 

W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, 

Chaitman BR, Mancini J, Berman DS, Gau G, Weintraub WS, on behalf of 

the COURAGE Trial Co-Principal Investigators and Study Coordinators. 

e evolving pattern of symptomatic coronary artery disease in the United 

States and Canada: Baseline characteristics of the Clinical Outcomes 

Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) 

Trial. Am Heart J. 2006 Jun;151(6):1173-9. 

Caron MF, Dore DD, Min B, Kluger J, Boguk I, White CM. 

Electrocardiographic and blood pressure effects of the ephedracontaining 

TrimSpa thermogenic herbal compound in healthy volunteers. 

Pharmacotherapy. 2006 Sep;26(9):1241-6. 

Chyun DA, Melkus GD, Katten DM, Price WJ, Davey JA, Grey N, Heller 

GV, Wackers FJ. e association of psychological factors, physical 

activity, neuropathy, and quality of life in type 2 diabetes. Biological Research 

for Nursing 2006, 7 (4):279-288. 

Clarkson PM, Kearns AK, Rouzier P, Rubin R, ompson PD. Serum 

creatine kinase levels and renal function measures in exertional muscle 

damage. Med Sci Sports Exerc. 2006 pr;38(4):623-7. 

Clyne CA, Shah A, Yarlagadda R, Migeed M, Kluger J. Catheter ablation 

for atrial fibrillation: Hartford Hospital experience. Conn Med. 2007 

Feb;71(2):69-76. 

Coleman CI, Rigali VT, Hammond J, Kluger J, Jeleniowski KW, White 

CM. Evaluating the safety implications of aprotinin use: the Retrospective 

Evaluation of Aprotinin in Cardio oracic Surgery (REACTS). J orac 

Cardiovasc Surg. 2007 Jun;133(6):1547-52. 

Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensinconverting 

enzyme inhibitors or angiotensin receptor blockers on the 

frequency of post-cardiothoracic surgery atrial fibrillation.Ann Pharmacother. 

2007 Mar;41(3):433-7. 

Coleman CI, McKay RG, Boden WE, Mather JF, White CM. Effectiveness 

and cost-effectiveness of facilitated percutaneous coronary intervention 

compared with primary percutaneous coronary intervention in patients with 

ST-segment elevation myocardial infarction transferred from community 

hospitals. Clin er. 2006 Jul;28(7):1054-62. 

Cosio-Lima LM, ompson PD, Reynolds KL, Headley SA, Winter CR, 

Manos T, Lagasse MA, Todorovich JR, Germain M. e acute effect of 

aerobic exercise on brachial artery endothelial function in renal transplant 

recipients. Prev CardioL 2006;9:211-4. 

Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade 

de pointes. Ann Pharmacother. 2007 Feb;41(2):336-40. 

Dale KM, White CM, Henyan NN, Kluger J, Coleman CI. Impact of 

statin dosing intensity on transaminase and creatine kinase. Am J Med. 2007 

Aug;120(8):706-12. 

Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J, White CM. Impact 

of gender on statin efficacy. Curr Med Res Opin. 2007 Mar;23(3):565-74. 

Review. 

Dale KM, Coleman CI, Henyan N, Kluger J, White CM. Statins and 

Cancer. JAMA 2006;295:74-80. 

Dornelas, E.A., Fischer, E.H., Stepnowski, R.R., ompson, P.D. Urban 

ethnic minority women’s attendance at health clinic vs. church-based exercise 

programs. Journal of Cross Cultural Gerontology. 2007 22:129-136. 

Dornelas, EA, Magnavita, J.J., Beazoglou, T., Fischer, E.H. Oncken, c., 

Lando, H., Greene, J., Barbagallo, J., Stepnowski, R., Gregonis, E. Efficacy 

and cost-effectiveness of a clinic-based counseling intervention tested in 

an ethnically diverse sample of pregnant smokers. Patient Education and 

Counseling, 2006 64, 342-349. 

Dornelas, E.A., Patten, c., Fischer, E.H., Decker, P.A., Offord, K., 

Barbagallo, J., Pingree, S., Croghan, I., Ahluwalia, J.S. Ethnic variation 

in socioenvironmental factors that influence adolescent smoking, Journal of 

Adolescent Health, 2005 36 (3),170-177.

Dornelas, E.A. and Fischer, E.H. Effect of season, city size and recruitment 

source on Latinos’ participation in a statewide smoking cessation program. 

Journal of Smoking Cessation, 2007, 2, 1-5. 

Dornelas, E.A. & ompson, P.D. Smoking cessation for cardiac patients. 

Preventive Cardiology, 2007 Suppl.1, 21-33. 

Dornelas, E.A. and Burg, M. Behavioral Cardiology in E. Topel (Editor) 

P. ompson (Section Editor for Preventive Cardiology) Textbook of 

Cardiovascular Medicine, ird Edition, Philadelphia, PA: Lippincott 

Williams & Wilkins, 2007. 

Elkoustaf R, Mamkin I, Manolios M, Siraj Y, Mather J, Boden W, Kiernan 

FJ, McKay RG. e impact of pretreatment with eptifibitide compared with 

abciximab on in-hospital outcomes in patients with ST-segement elevation 

myocardial infarction treated with facilitated percutaneous coronary 

intervention. Cath Cardio Inteven 2006; 67(5): p 757. 

Elkoustaf RA, Mamkin I, Mather JF, Murphy D, Hirst JA, Kiernan FJ, 

McKay RG. Comparison of results of percutaneous coronary intervention for 

non-ST-elevation acute myocardial infarction or unstable angina pectoris in 

men versus women. Am J Cardiol. 2006 Jul 15;98(2):182-6. 

Fernández A, Sorokin A, ompson PD. Corneal arcus as coronary artery 

disease risk factor. Atherosclerosis. 2007 Aug;193(2):235-40. 

Foley RJ, Katsetos M, Silverman D, Rothfield N, Alkotob L, Hager W. 

Etiology of dyspnea in systemic sclerosis. Arthritis & Rheumatism 2005. 

Gadarla MR, Pullatt RC, ompson PD. Role of cardiac rehabilitation after 

acute coronary syndromes. Acute Coronary Syndromes. 8:49-55, 2007. 

Gillespie EL, Gryskiewicz A, White CM, Kluger J, Humphrey C, Horowitz 

S, Coleman CI. Effect of aprotinin on the frequency of postoperative atrial 

fibrillation or flutter. Am J Health-System Pharmacy 2005;62:1370-74. 

Gillespie EL, Perkerson KA, White CM, Kluger J, Coleman CI. Effect 

of Aprotinin on the incidence of postoperative atrial fibrillation after 

cardiothoracic surgery. American Journal of Health-System Pharmacy 2005;62: 

1370-4. 

Gillespie E, White CM, Kluger J, Rancourt JA, Gallagher R, Coleman CI. 

Cost effectiveness of amiodarone for prephylaxis of atrial fibrillation after 

cardiothoracic surgery. Pharmacotherapy 2006;26:499-504. 

Gryskiewicz K, Gillespie E, White CM, Kluger J, Gallagher R, Coleman CI. 

Impact of Hispanic Ethnicity on the Likeliness of Developing Postoperative 

Atrial Fibrillation. Connecticut Medicine 2006;70:77-80. 

Guidry MA, Blanchard BE, ompson PD, Maresh CM, Seip RL, Taylor 

AL, Pescatello LS. e influence of short and long duration on the blood 

pressure response to an acute bout of dynamic exercise. Am Heart J. 2006 

Jun;15l(6):1322.e5-12. 

Guertin D, Faheem O, Ling T, Pelletier G, McComas D, Yarlagadda RK, 

Clyne C, Kluger J. Electromagnetic Interference (EMI) and arrhythmic 

events in ICD patients undergoing gastrointestinal procedures. Pacing Clin 

Electrophysiol. 2007 Jun;30(6):734-9. 

Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera 

CA, Heath GW, ompson PD, Bauman A. Physical activity and public 

health: Updated recommendation for adults from the American College of 

Sports Medicine and the American Heart Association. Circulation. 2007 

Aug 1. 

Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera 

CA, Heath GW, ompson PD, Bauman A. Physical activity and public 

health: updated recommendation for adults from the American College of 

Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 

2007 Aug;39(8):1423-34. 

Henyan N, Gillespie EL, White CM, Kluger J, Coleman CI. e impact of 

intravenous Magnesium on post-cardiothoracic surgery atrial fibrillation and 

length of hospital stay: A meta-analysis. Annals of oracic Surgery 2005; 80: 

2402-2406. 

Henyan NN, White CM, Gillespie EL, Smith K, Coleman CI, Kluger J. e 

impact of gender on survival amongst patients with implantable cardioverter 

defibrillators for primary prevention against sudden cardiac death. J Intern 

Med. 2006 Nov;260(5):467-73. 

Hubal Mj, Gordish-Dressman H, ompson PD, Price TB, Hoffman £P, 

Angelopulos n, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller 

RF, Seip RL, Clarkson PM. Variability in muscle size and strength gain after 

unilateral resistance training. Med Sci Sports Exer. 2005, 37 (6): 964-72. 

Iwai S, Cantillon DJ, Kim Rj, Markowitz SM, Mittal S, Stein KM, Shah BK, 

Yarlagadda RK, Cheung lW, Tan YR, Lerman BB. Right and left ventricular 

outflow tract tachycardias: evidence for a common electrophysiologic 

mechanism. J Cardiovasc Electrophysiol. 2006 Oct; 17(10):1052-8. 

Juszczyk MA, Seip RL, ompson PD. Decreasing LDL cholesterol and 

medication cost with every-other-day statin therapy. Prev Cardiol. 2005 

Fall;8(4):197-9. 

John S, Sorokin AV, ompson PD. Phytosterols and vascular disease. Curr 

Opin Lipidol. (1):35-40, 2007. 

Kalaga RV, Malik A, ompson PD. Exercise-related spontaneous coronary 

artery dissection: Case report and literature review. Medicine & Science in 

Sports & Exercise. 39(8):1218-1220, 2007. 

Kalus J, White M, Caron M, Guertin D, McBride BF, Kluger J. e impact 

of catecholarnines on defibrillation threshold in patients with implanted 

cardioverter defibrillators. Pacing Clinical Electrophysiol. 2005;28(11):1147- 

1156. 

Kalus JS, White CM, Caron MF, Guertin D, McBride BF, Kluger J. 

e impact of elevations in catecholamine concentrations on defibrillation 

threshold in patients with implanted cardioverter defibrillators. e 

Defibrillation reshold Effects of Catecholarnines Trial (DTECT). Pace, 

2005;28:1147-56. 

Kapetanopoulous A, Peckham G, Kiernan F, Clyne C, Kluger, J, Migeed 

MA. Implantation of a biventricular pacing and defibrillator device via a 

persistent left superior vena cava. J Cardiovasc Med 2006 7;430-433. 

Kapetanopoulos A, Katsetos MC, Kluger J. Intraoperative hypothermia 

increased defibrillation energy requirements. J Cardiovasc Med (Hagerstown). 

2007 Sep;8(9):741-3. 

Kapetanopoulos A, Zambuto DA, Primiano CA. Congenital left main 

atresia in an adult diagnosed with multidetector computed tomography. Eur 

Heart J 2007 Sep;28(17):2093. 

Kimmelstiel CD, Clyne CA: Cardiology techniques: A case-based approach. 

Chapter in Electrophysiologic Testing, Kimmelstiel, Hendel, (eds). Springer 

Publishing Co. 2006. 

Kostek MA, Pescatello LS, Seip RL, Angelopoulos TJ, Clarkson PM, 

Gordon PM, Moyna NM, Visich PS, Zoeller RF, ompson PD, Hoffman 

EP, Price TB. Subcutaneous fat alterations resulting from an upper-body 

resistance training program. Med Sci Sports Exerc. 2007 Jul;39(7):1177-85. 

Leaf A, Albert C, Josephson M, Steinhaus D, Kluger J, Kang J, Cox B, 

Zhang H, Schoenfeld D. Prevention of fatal arrhythmias in high-risk 

subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112:2762-2768. 

Leon AS, Franklin BA, Costa, F, Balady G, Berra KA, Stewart Kj, 

ompson PD, WilliamsMA, Lauer MS. AHA scientific statement: 

Cardiac rehabilitation and secondary prevention of coronary heart disease. 

Circulation. 2005;111:369-376. 

Lertsburapa K, Shah A, Clyne CA. e impact of cardiac resynchronization 

therapy on atrial tachyarrhythrnia incidence in congestive heart failure 

patients. Circulation, 2006, October, 114 (18): II-616. 

Levine BD, Pelliccia A, ompspn PD, Douglas PS, Fu Q, DiPaolo F, 

Kiernan F, Zasadil M. e cardiovascular evaluation of women athletes. Med 

Sci Sports Exerc. 2005, 37 (8): 1431-2. 

Mamkin I, Elkoustaf RA, Zhang Q, Mather JF, Kiernan FJ, McKay RG. 

Drug-eluting stent implantation results in effective treatment of small 

coronary artery disease (DESIRE Small CAD). Conn Med. 2007 Oct;71(9): 

517-22. 

Mamkin I, Mather JF, Kiernan FJ, McKay RG. More studies are needed 

on gender-based outcomes in percutaneous coronary intervention with drug-

eluting stents. Am J Cardiol. 2007 Aug 1;100(3):560-1. 

Marcoff L, ompson PD. e role of coenzyme Q10 in statin-associated 

myopathy: a systematic review. J Am Coll Cardiol. 49(23):2231-7, 2007. 

Marcoff L, ompson PD. Reply. J Am Coll Cardiol. 2007 Nov 6;50(19): 

1911. 

Maron BJ, Douglas, PS, Graham TP, Nishimura RA, ompson PD. Task 

force I: preparticipation screening and diagnosis of cardiovascular disease in 

athletes. J Am Coll Cariol. 2005, 45 (8): 1322-6. 

Maron BJ, ompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, 

Dimeff R, Douglas PS, Glover DW, Hutter AM Jr, Krauss MD, Maron MS, 

Mitten MJ, Roberts WO, Puffer JC, American Heart Association Council 

on Nutrition, Physical Activity, and Metabolism. Recommendations and 

considerations related to preparticipation screening for cardiovascular 

abnormalities in competitive athletes, 2007 update: A scientific statement 

from the American Heart Association Council on Nutrition, Physical 

Activity, and Metabolism: Endorsed by the American College of Cardiology 

Foundation. Circulation. 115(12):1643-455, 2007. 

Madias JE, Song J, White CM, Kalus JS, Kluger J. Response of the ECG 

to short term diuresis in patients with heart failure. Annals of Noninvasive 

Electrocardiology, 2005; 62:288-96 . 

McBride BF, Min B, Guertin D, Kluger J, Henyan N, Coleman cr, Silver 

B, White CM. An evaulation of the impact of oral magnesium lactate on the 

corrected QTc interval of patients peceiving Sotalol or Dofetilide to prevent 

atrial or ventricular tachyarrhythrnia recurrence. Annals of Noninvasive 

Electrocardiology 2006;11:163-9. 

Mc Bride BF, Kalus JS, Guertin DC, Dale KM, Kluger J, White CM. 

Impact of catecholamines on the QTc interval in patients at high risk of 

sudden death. Conn Med. 2007 Sep;71(8):465-8. 

McKenney JM, Davidson MH, Saponaro J, ompson PD, Bays HE. Use 

of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. 

J Cardiovasc Pharmacol. 2005 Nov;46(5):594-9. 

Mena, C., Wencker, D., Krumholz, H., McNamara, R. (2006) Detection 

of heart transplant rejection in adults by echocardiographic diastolic indices: 

A quality review of the literature, J Am Soc Echocardiogr. 2006 Oct;19(10): 

1295-300. 

Min B, Kalus J, Kluger J, Guertin D, McBride BF, White CM. e 

impact of catecholamines in patients with or without beta-blockers on 

ventricular fibrillation cycle length and variability. Annals of Noninvasive 

Electrocardiology, 2005;10:305-11. 

Min B, McBride BF, Ismali, Kardas MI, Sinha V, Kluger J, White CM. 

e hemodynamic effects of an Ephedra free multicomponent weight 

loss supplement in healthy volunteers. American Journal of Health-System 

Pharmacy, 2005;62:1582-5. 

Min B, McBride BF, Kardas MJ, Ismall A. Sinha V, Kluger J, White, CM. 

Electrocardiographic effects of an Ephedra free multicomponent weight loss 

supplement in healthy volunteers. Pharmacotherapy 2005;25:654-9. 

Morasco, B.J., Dornelas, E.A., Fischer, E.H., Oncken, C, Lando, H. 

Spontaneous smoking cessation during pregnancy among ethnic minority 

women: A preliminary investigation. Addictive Behaviors, 2006. (31), 203- 

210. 

Navare SM, Katten D, Johnson LJ, Mather JF, Fowler MS, Ahlberg AW, 

Miele N, Heller G. Risk stratification with ECG-gated Dobutamine stress 

technetium-99rn sestamibi single photon emission tomographic imaging: 

Value of heart rate response and assessment of LV function. JACC 2006;47: 

781-8. 

Ouyang P, Tardif JC, Herrington DM, Stewart KJ, ompson PD, Walsh 

MN, Bennett SK, Heldman AW, Tayback MA, Wang NY; for the Estrogen 

And Graft Atherosclerosis Research (EAGAR) investigators. Randomized 

trial of hormone therapy in women after coronary bypass surgery. Evidence 

of differential effect of hormone therapy on angiographic progression of 

disease in saphenous vein grafts and native coronary arteries. Atherosclerosis 

2006; 189 (2): 375-86. 

Papaioannou GI, Kasapis, C, Seip RL, Grey NJ, Katten D, Wackers 

FJ, Inzucchi SE, Engel S, Taylor A, Young LH, Chyun DA, Davey JA, 

Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller GV. Value of 

peripheral vascular endothelial function in the detection of relative myocardial 

ischemia in asymptomatic type 2 diabetic patients who underwent myocardial 

perfusion imaging. J Nucl Cardiol 2006;13:362-8. 

Patel AA, Clyne CA, Henyan NN, White CM, Zembrowski BF, Migeed 

M, Yarlagadda R, Kluger J, Coleman CI. e use of protamine after 

radiofrequency catheter ablation: a pilot study. J Interv Card Electrophysiol. 

2007 Mar;18(2):155-8. 

Patel AA, White CM, Shah SA, Dale KM, Kluger J, Coleman CI. e 

relationship between statin use and atrial fibrillation.Curr Med Res Opin. 

2007 May;23(5):1177-85. 

Patel AA, White CM, Gillespie EL, Kluger j, Coleman CI. Safety of 

Amiodarone in the prevention of postoperative atrial fibrillation: A metaanalysis. 

American Journal of Health System Pharmacists 2006;63:829-37. 

Patel MD, ompson PD. Phytosterols and vascular disease. Atherosclerosis. 

2006 May;186(l):12-9. 

Patten, C.A., Rock, E., Meis, T.M., Decker, P.A., Colligan, R.C., Pingree, 

S., Dornelas, E.A., Offord, K.P., Boberg, E.W., Gustafson, D.H. (2007). 

Frequency and type of use of a home-based, internet intervention for 

adolescent smoking cessation. Journal of Adolescent Health, 41, 437-443. 

Patten, CA., Croghan, LT., Meis, T.M., Decker, PA, Pingree, S., Colligan, 

R.C, Dornelas, E.A., Offord, K.P., Boberg, E.W., Baumberger, R.K., Hurt, 

R.D., Gustafson, D.H. (2006). Randomized clinical trial of an internetbased 

versus brief office intervention for adolescent smoking cessation. 

Patient Education and Counseling, 64, 249-258. 

Perkerson K, Gillespie E, White CM, Kluger J, Takata H, Coleman CI. 

e impact of prophylactic Amiodarone on length of stay and stroke after 

cardiothoracic surgery. Pharmacotherapy 2005; 25:320-4. 

Pescatello LS, Kostek MA, Gordish-Dressman H, ompson PD, Seip 

RL, Price TB, Angelopoulos N, Clarkson PM, Gordon PM, Moyna NM, 

Visich PS, Zoeller RF, Devaney JM, Hoffman LP. ACE ID genotype and 

the muscle strength and size response to unilateral resistance training. Med 

Sci Sports Exerc. 2006 Jun;38(6):1074-81. 

Pescatello LS, Blanchard BE, Tsongalis GJ, Maresh CM, O’Connell A, 

ompson PD. e alpha-adducin Gly460Trp polymorphism and the 

antihypertensive effects of exercise among men with high blood pressure. 

Clin Sci (Lond). 2007 Sep;113(5):251-8. 

Pescatello LS, Kelsey BK, Price TB, Seip RL, Angelopoulos TJ, Clarkson 

PM,Gordon PM, Moyna NM, Visich PS, Zoeller RF, Gordish-Dressman 

HA, Bilbie SM, ompson PD, Hoffman EP. e muscle strength and size 

response to upper arm, unilateral resistance training among adults who are 

overweight and obese. J Strength Cond Res. 2007 May;21(2):307-13. 

Pescatello LS, Turner D, Rodriguez N, Blanchard BE, Tsongalis GJ, Maresh 

CM, Duffy V, ompson PD. Dietary calcium intake and renin angiotensin 

system polymorphisms alter the blood pressure response to aerobic exercise: a 

randomized control design. Nutr Metab (Lond). 2007 Jan 4;4:1. 

Pistilli EE, Gordish-Dressman H, Seip RL, Devaney JM, ompson PD, 

Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, 

Visich PS, Zoeller RF,Hoffman EP, Gordon PM. Resistin polymorphisms 

are associated with muscle, bone, and fat phenotypes in white men and 

women. Obesity (Silver Spring). 2007 Feb;15(2):392-402. 

Porter IT, Schneider KA, Maksoud A, Joseph RD, Lebourveau PA, Meyers 

DG: Audibility of the Fourth Heart Sound Correlates with the Level of Left 

Ventricular Diastolic Function. Circulation 2006; 14 (18):II-816. 

Pullatt RC, Gadarla MR, Karas RH, Alsheikh-Ali AA, ompson PD. 

Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol. 

100(1):152-3, 2007. 

Kalaga RV, Rubin F, Heller GV, and Lundbye JB. Images of Prinzmetal’s 

Angina: A case report. J Nucl Cardiol 2007; 14(3):408-411. 

Kalaga RV, Malik A, and ompson PD. Exercise-related spontaneous

coronary artery dissection: Case report and literature review. Med.Sci.Sports 

Exerc.2007; 39(8):1218-1220. 

Roberts BH, ompson PD. Is there evidence for the evidence-based 

guidelines for cardiovascular disease prevention in women? Gend Med. 2006 

Mar;3(l):5-12. 

Ruaño G, ompson PD, Windemuth A, Smith A, Kocherla M, Holford 

TR, Seip R, Wu AH. Physiogenomic analysis links serum creatine kinase 

activities during statin therapy to vascular smooth muscle homeostasis. 

Pharmacogenomics. 2005 Dec;6(8):865-72. 

Ruaño G, Seip RL, Windemuth A, zollner S, Tsongalis Gj, Ordovas j, 

Otvos j, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos n, 

Pescatello L, Moyna N, ompson PD. Apolipoprotein Al genotype affects 

the change in high density lipoprotein cholesterol subfractions with exercise 

training. Atherosclerosis. 2006 Mar;185(l):65-9. 

Ruaño G, ompson PD, Windemuth A, Seip RL, Dande A, Sorokin A, 

Kocherla M, Smith A, Holford TR, Wu AH. Physiogenomic association of 

statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3): 

329-35. 

Ruffin R, ompson PD. Can exercise prevent the common cold? Am J 

Med. 2006 Nov;119(11):909. 

Navare S, Katten D, Johnson L, Mather J, Fowler M,Ahlberg A, Miele 

N, Heller G. Risk stratification with ECG-gated Dobutamine stress 

technetium-99m sestamibi single photon emission tomographic imaging: 

Value of heart rate response and assessment of LV function. JACC 2006;47: 

781-8. 

Sander S, Coleman CI, Patel AA, Kluger J, White CM. e impact of 

coenzyme Q10 on systolic function in patients with chronic heart failure. J 

Card Fail. 2006 Aug;12(6):464-72. 

Sander S, Coleman CI, Gillespie EL, Kluger J, White CM. Comparison 

of the efficacy and safety of Urokinase and Alteplase for peripheral arterial 

occlusion: A meta-analysis. Pharmacotherapy 2006;26:51-60. 

Seip RL, Otvos J, Bilbie C, Tsongalis GJ, Miles M, Zoeller R, Visich P, 

Gordon P, Angelopoulos N, Pescatello L, Moyna N, ompson PD. e 

effect of apolipoprotein E genotype on serum lipoprotein particle response to 

exercise. Atherosclerosis. 2006 Sep;188(l):126-33. 

Sewright KA, Clarkson PM, ompson PD. Statin myopathy: Incidence, 

risk factors, and pathophysiology. Curr Atheroscler Rep. 2007 Nov;9(5):389- 

96. 

Shah SA, Kluger J, White CM. Monotherapy versus combination therapy 

with class III antiarrhythmic agents to attenuate transmural dispersion of 

repolarization: a potential risk factor for torsade de pointes. Pharmacotherapy. 

2007 Sep;27(9):1297-305. 

Shah SA, Schlesselman L, Cios D, Lipeika J, Patel AA, Kluger J, White 

CM. Effects of echinacea on electrocardiographic and blood pressure 

measurements. Am J Health Syst Pharm. 2007 Aug 1;64(15):1615-8. 

Shah SA, Sander S, Cios D, Lipeika J, Kluger J, White CM. 

Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy 

individuals: a double-blind, randomized controlled trial. Ann Pharmacother. 

2007 Mar;41(3):420-5. 

Shah AR, Athar H, Mamkin I, Siraj Y, Angampally R, Manolios M, 

Maloney K, Jarvis-Cloutier J, Mennett R, Mather J, Primiano CA, Kiernan 

FJ, Boden WE, McKay RG. Blood transfusion is an independent predictor 

of long-term mortality in anemic patients undergoing percutaneous coronary 

intervention. Cath Cardio Intervent 2006; 67(5): p 780. 

Shah AR, Athar H, Mamkin I, Manolios M, Angampally R, Siraj V, Jarvis- 

Cloutier J, Maloney K, Mather J, Mennett R, Fram DB, Kiernan FJ, Boden 

WE, McKay RG. Comparison of invasive sealant and suture-mediated 

arteriotomy closure devices in patients undergoing percutaneous coronary 

intervention. Cath Cardio Intervent 2006; 67(5): p825. 

Shah AR, Tandon H, Navare S, Maksoud A, Mirza Z, Mather J, Mennet R, 

Kiernan FJ, McKay RG. Long-term follow-up of patients with ST-segment 

elevation myocardial infarction treated with sirolimus-eluting stents. J Am 

Coll Cardiol 2007; 49 (9): 243A. 

Shaw LJ, Heller GV, Casperson P, Miranda-Peats R, Slomka P, Friedman 

J, Hayes SW, Schwartz R, Weintraub WS, Maron DJ, Dada M, King 

S, Teo K, Hartigan P, Boden WE, O’Rourke RA, Berman DS. Gated 

myocardial perfusion single photon emission computed tomography in the 

clinical outcomes utilizing revascularization and aggressive drug evaluation 

(COURAGE) trial, Veterans Administration Cooperative study no. 424. J 

Nucl Cardiol 2006;13:685-98. 

Silverman DI, Cirullo L, Damato K, DeMartinis NA, DeMeo M, 

Fernandez GA, Glynn L, Hegde U, Leger R, Khamis Abu-Hasaballah K, 

Caron JM. Systematic identification and classification of adverse events in 

human research. Contemporary Clinical Trials 2006;27:295-303. 

Singh B, Bateman TM, Case JA, Heller G. Attenuation artifact, attenuatoin 

correction, and the future of myocardial perfusion SPECT. J Nucl Cardiol 

2007 Apr 14(2):153-64. 

Sorokin A, Brown JL, ompson PD. Primary biliary cirrhosis, 

hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis. 

2007 Jan 19. 

Sorokin AV, Duncan B, Panetta R, ompson PD. Rhabdomyolysis 

associated with pomegranate juice consumption. Am J Cardiol. 2006 Sep 

1;98(5):705-6. 

Steinmark, A., Dornelas, E.A. and Fischer, E. (2006). Determinants and 

barriers to participation in an Internet-based recovery program for cardiac 

patients. Journal of Clinical Psychology in Medical Settings, 13(4),353-357. 

Syme AN, Blanchard BE, Guidry MA, Taylor AW, Vanheest JL, Hasson 

S, ompson PD, Pescatello LS. Peak systolic blood pressure on a graded 

maximal exercise test and the blood pressure response to an acute bout of 

submaximal exercise. Am J Cardiol. 2006;98:938-43. 

omas JE, Lee N, ompson PD. Statins provoking MELAS syndrome. 

A case report. Eur Neurol. 57(4):232-235, 2007. 

ompson PD, Clarkson PM, Rosenson RS, e National Lipid Association 

Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin 

safety by muscle experts. Am J Cardiol. 2006 Apr 17;97(8A):69C-76C. 

ompson PD, Kiernan F. Prevention of heart disease in female athletes. 

Med. Sci. Sports. Exerc. 2005;37(9):1440-1443. 

ompson PD, Tsongalis GJ, Ordovas JM, Seip RL, Bilbie C, Miles M, 

Zoeller R, Visich P, Gordon P, Angelopoulos n, Pescatello L, Moyna N. 

Angiotensin-converting enzyme genotype and adherence to aerobic exercise 

training. Prev Cardiol. 2006 Winter;9(1):21-4. 

ompson PD, Tsongalis GJ, Ordovas JM, Seip RL, Bilbie C, Miles M, 

Zoeller R, Visich P, Gordon P, Angelopoulos N, Pescatello L, Moyna N. 

Angiotensin-converting enzyme genotype and adherence to aerobic exercise 

training. Prev Cardiol. 2006, 9(1 ):21-4. 

ompson PD, Estes III NAM. e athlete’s heart. In Textbook of 

Cariovascular Medicine 3rd Edition ed. EJ Topol. Lippincott-Raven 686- 

697, 889-901, 2007. 

ompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 

3rd, Fulton JE, Gordon NF, Haskell WL, Link MS, Maron BJ, Mittleman 

MA, Pelliccia A, Wenger NK, Willich SN, Costa F, American Heart 

Association Council on Nutrition, Physical Activity, and Metabolism; 

American Heart Association Council on Clinical Cardiology; American 

College of Sports Medicine. Exercise and acute cardiovascular events placing 

the risks into perspective: a scientific statement from the American Heart 

Association Council on Nutrition, Physical Activity, and Metabolism and 

the Council on Clinical Cardiology. Circulation. 115(17):2358-68, 2007. 

ompson PD. Cardiovascular adaptations to marathon running : the 

marathoner’s heart. Sports Med. 37(4-5):444-7, 2007. 

ompson RC, Heller GV, Johnson LL, Case JA, Cullom SJ, Garcia EV, 

Jones PG, Moutray KL, Bateman TM. Value of attenuation correction on 

ECG-gated SPECT myocardial perfusion imaging related to body mass 

index. J Nucl CardioI 2005;12:195-202. 

ompson PD, Apple FS, Wu A. Marathoner’s heart? Circulation. 2006

Nov 28;114(22):2306-8. 

ompson PD, Levine BD. Protecting athletes from sudden cardiac death. 

JAMA. 2006 Oct 4;296(13):1648-50. 

Urso ML, Scrimgeour AG, Chen YW, ompson PD, Clarkson PM. 

Analysis of human skeletal muscle after 48h immobilization reveals 

alterations in mRNA and protein for extracellular matrix components. J Appl 

Physiol. 2006 JUll 8 . 

Uthurralt J, Gordish-Dressman H, Bradbury M, Tesi-Rocha C, Devaney 

J, Harmon B, Reeves EK, Brandoli C, Hansen BC, Seip RL, ompson 

PD, Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, 

Visich PS, Zoeller RF, Gordon PM, Hoffman EP. PPARalpha L162V 

underlies variation in serum triglycerides and subcutaneous fat volume in 

young males. BMC Med Genet. 2007 Aug 16;8:55. 

Wencker, D., Acute Cardio-Renal Syndrome: (2007) Progression from 

Congestive Heart Failure to Congestive Kidney Failure, Current Heart 

Failure Reports, 2007; 4(3), 134-138. 

White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI. Effect of 

preoperative angiotensin converting enzyme inhibitor or angiotensin receptor 

blocker use on the frequency of atrial fibrillation after cardiac surgery: a 

cohort study from the atrial fibrillation suppression trials II and III. Eur J 

Cardiothorac Surg. 2007 May;31(5):817-20. 

White CM, Sander S, Coleman CI, Gallagher R, Takata H, Humphrey 

C, Henyan N, Gillespie EL, Kluger J. Impact of epicardial anterior fat 

pad retention on postcardiothoracic surgery atrial fibrillation incidence: the 

AFIST-III Study. J Am Coll Cardiol. 2007 Jan 23;49(3):298-303. Epub 2007 

Jan 8. 

Williams PT, ompson PD. Dose-dependent effects of training and 

detraining on weight in 6406 runners during 7.4 years. Obesity (Silver 

Spring). 2006 ov;14(11):1975-84. 

Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung 

JW, Tan V, Lerman BB, Mittal S. Reversal of cardiomyopathy in patients 

with repetitive monomorphic ventricular ectopy originating from the right 

ventricular outflow tract. Circulation. 2005 ;112(8):1092-7. 

Zoeller RF, Ryan ED, Gordish-Dressman H, Price TB, Seip RL, 

Angelopoulos TJ, Moyna NM, Gordon PM, ompson PD, Hoffman EP. 

Allometric scaling of biceps strength before and after resistance training in 

men. Med Sci Sports Exerc. 2007 Jun;39(6):1013-9. 

 

 

Ahmed S, Kalaga RV, Kadakia HH, Ruffin RT, Kokkirala AR, Kiernan 

FJ, Lundbye JH, Dada M, Murphy D, Mather J, McKay RG. Mortality 

following percutaneous coronary intervention for cardiogenic shock: Is it fair 

to publicly report outcomes? J Am Coll Cardiol 2007; 49 (9); 206A. 

Angampally R, Satish S, Vishal G, Siraj Y, Manolios M, Athar H, Mather 

J, Kierna FJ, McKay RG. Impact of diabetes mellitus on clinical outcomes in 

drug-eluting stent era. Cath Cardio Intervent 2006; 67(5): p. 776. 

Angampally R, Satish S, Vishal G, Kiernan FJ, McKay RG, Shaw RE. 

In-hospital outcomes for saphenous vein graft interventions in in-stent 

restenosis without distal embolic protection. Cath Cardio Intervent 2006; 

67(5): p. 824. 

Athar H, Mamkin I, Shah A, Dada M, Siraj Y, Manolios M, Rajeev A, 

Mather J, Mennett J, Jarvis-Cloutier J, Kiernan F, Boden W, McKay R. 

In-hospital outcomes for patients with ST-segment elevation myocardial 

infarction undergoing pharmacoinvasive therapy: Is benefit of facilitated PCI 

limited to prolonged door-to-balloon time? AHA 2006. 

Athar H, Shah AR, Mamkin I, Siraj Y, Manolios M, Angampally R, 

Elkoustaf RA, Mather J, Mennett R, Jarvis-Cloutier J, Kiernan FJ, Boden 

WE, McKay RG. Pharmacoinvasive for patients with St-segment elevation 

myocardial infraction presenting to community hospitals – Can we extent 

optimal door-to-balloon time?. Cath Cardio Intervent 2006; 67(5): p 756. 

Athar H, Mamkin I, Shah AR, Papaioannou GI, Dada MR, Siraj Y, Faheem 

O, Manolios M, Angampally R, Mather J, Mennet R, Jarvis-Cloutier J, Jierna 

FJ, Boden WE, McKay RG. Decreased in-hospital mortality of patients with 

ST-segment elevation myocardial infarction treated with pharmoacoinvasive 

therapy: Is benefit of facilitated PCI limited to prolonged door-to-balloon 

time? Circulation 2006; 114(18); II-347. 

Bilkoo P, Katsetos M, Foley R, Silverman D, Rothfield N, Hagerd. Diastolic 

dysfunction in systemic sclerosis seerely limits exercise performance. J Cardiac 

Failure 2005;11;S100. 

Bilkoo P, Aclatya S, Soltani P, Silverman D, Rothfield N, Hager D. 

Diastolic dysfunction and systemic sclerosis with normal left ventricular 

mass. J Am Coll Cardiol 2006 JACC 2006; 47:48A. 

Boden WE, Elkoustaf RA, Dada M, Roe MT, Peterson ED, Newby 

LK, Lytle BL, Milford-Beland S, Redberg R, Hochman JS, Diercks DB, 

Gibler WB, Ohman EM. Gender-related differences in clinical outcomes 

among high-risk NSTE ACS patients undergoing percutaneous coronary 

intervention: Results from the CRUSADE quality improvement initiative. 

AHA 2005. 

Boden WE, Dada M, Lundbye J, Roe MT, Peterson ED, Newby LK, Lytle 

BL, Redberg R, Hochman JS, Diercks DB, Gibler WB, Ohman EM. An 

early invasive strategy within 48 hours for women who present with high-risk 

NSTE ACS is associated with more aggressive pharmacotherapy and better 

in-hospital outcomes: Results from the CRUSADE quality improvement 

initiative. AHA 2005. 

Boden WE, Baghdasarian SB, Dada M, Roe MT, Peterson ED, Lytle 

BL, Milford-Beland S, Gibler WB, Ohman EM. Striking benefit of early, 

aggressive ase of ACC/AHA class I therapies in reducing in-hospital mortality 

in high-risk acute coronary syndrome: Results from e CRUSADE Quality 

Improvement Initiative of 105,606 patients. AHA 2005. 

Dada M, O’Rourke RA, Teo KK, Hartigan PM, Knudtson M, Kostuk W, 

Maron DJ, Casperson P, Weintraub WS, Boden WE, Hartford Hospital, 

Hartford. Long-term adherence to the ACC/AHA Class I post-discharge 

medications and recommendations using optimal medical therapy in 2,287 

patients with established coronary heart disease: ACC 2007. 

Dada M, O’Rourke RA, Teo KK, Hartigan PM, Knudtson M, Kostuk 

W, Maron DJ, Casperson P, Weintraub WS, Boden WE. Long-term 

adherence to the ACC/AHA Class I post-discharge medications and 

recommendations using optimal medical therapy in 2,287 patients with 

established coronary heart disease: Interim data from the Clinical Outcomes 

Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) 

Trial. AHA 2006. 

Dada M, O’Rourke RA, Teo KK, Hartigan PM, Knudtson M, Kostuk 

W, Maron DJ, Casperson P, Weintraub WS, Boden WE. Long-term 

adherence to the ACC/AHA Class I post-discharge medications and 

recommendations using multifaceted medical therapy in 2287 patients with 

established coronary heart disease: interim data from the Clinical Outcomes 


Trial. J Am Coll Cardiol 2006;47:209A. 

Dada M, O’Rourke RA, Teo KK, Hartigan PM, Knudtson M, Kostuk W, 

Maron DJ, Casperson P, Weintraub WS, Boden WE. Long-term adherence 

to treatment targets using multifaceted medical therapy in 2287 patients with 

established coronary heart disease: interim data from the Clinical Outcomes 


Trial. Circulation 2005;112:II-445. 

Dada M, Veledar E, Lewis C, Zhang Z, Boden WE, Weintraub WS. 

Quality of life in patients with established coronary heart disease and 

diabetes: Experience from a large North American multicenter randomized 

controlled trial. AHA 2005. 

Dada M, O’Rourke RA, Teo KK, McMaster, Hartigan PM, Knudtson 

M, Kostuk W, Maron DJ, Casperson P, Weintraub WS, Boden WE, on 

behalf of the COURAGE Trial Investigators and Coordinators. Longterm 

adherence to treatment targets using multifaceted medical therapy in 

2287 patients with established coronary heart disease: Interim data from 

the Clinical Outcomes Utilizing Revascularization and Aggressive Drug 

Evaluation (COURAGE). AHA 2005. 

Dornelas, E.A., Stepnowski, R., Ferrand, J., Barbagallo, J., McCullough,

L.. Affect-focused psychotherapy for antepartum depression. Society for 

Behavioral Medicine 2007 Annals of Behavioral Medicine, 33, S024. 

Dornelas, E.A. Latino No Fumes: Protégé tu Salud. A smoking cessation 

program for Hispanics. Society for Behavioral Medicine 2006 Annals of 

Behavioral Medicine, 30, S153. 

Elkoustaf R, Mamkin I, Mather J, Manolios M, Siraj Y, Hirst JA, Boden W, 

Kiernan FJ, McKay RG. e routine early invasive strategy in women with 

non-ST-segment elevation acute coronary syndrome: Is it time for a paradign 

shift? Cath Cardio Interven 2006; 67(5): p 738. 

Elkoustaf R, Mamkin I, Manolios M, Siraj Y, Mather J, Jarvis-Cloutier 

J, Hirst JA, Boden W, Kiernan FJ, McKay RG. Active infection is an 

independent predictor for increased in-hospital and 9-months adverse 

clinical outcomes in patients undergoing percutaneous coronary intervention. 

Cath Cardio Interven 2006; 67(5): p 758. 

Elkoustaf R, Mamkin I, Manolios M, Siraj Y, Mather J, Jarvis-Cloutier J, 

Hirst JA, Boden W, Kiernan FJ, McKay RG. e impact of diabetes on inhospital 

clinical outcomes in patients with ST-segment elevation myocardial 

infarction treated with primary percutaneous coronary intervention. Cath 

Cardio Interven 2006; 67(5): p 758. 

Elkoustaf R, Mamkin I, Manolios M, Siraj Y, Mather J, Jarvis-Cloutier J, 

Hirst JA, Boden W, Kiernan FJ, McKay RG. Body-mass index, in-hospital 

and 9-months outcomes in patients undergoing percutaneous coronary 

intervention: e heavier the better? Cath Cardio Interven 2006; 67(5): p 

759. 

Elkoustaf R, Mamkin I, Manolios M, Siraj Y, Mather J, Boden W, Kiernan 

FJ, McKay RG. e impact of pretreatment with eptifibitide compared with 

abciximab on in-hospital outcomes in patients with ST-segement elevation 

myocardial infarction treated with facilitated percutaneous coronary 

intervention. Cath Cardio Interven 2006; 67(5): p 757. 

Kalaga R, Mirza ZA, Shafeeq A, Kadakia HH, Ruffin F, Kokkirala AR, 

Kiernan FJ, Lundbye JB, Malik M, Murphy D, Mather J, McKay RG. 

Incidence of late angiographic stent thrombosis of Sirolimus-eluting stents. 

American College of Cardiology (March 2007). 

Maksoud A, Lertsburapa K, Mirza Z, Navar, S, Mather J, Hirst JA, McKay 

RG: A comparison of Sirolimus-eluting stents with bare-metal stents in 

saphenous vein graft lesions: A nine-month follow-up. Abstract presented at 

the 2007 SCAI Scientific Sessions. 

Maksoud A, Kapetanopoulos A, Cunningham M, Meyers DG, McKay RG, 

Vacek, JL. Cardiovascular risk factors may predict oral antiplatelet therapy 

resistance. Abstract presented at the 2007 SCAI Scientific Sessions. 

Mamkin I, Elkoustaf RA, Athar H, Baghdasarian SB, Shah A, Campbell 

P, Mather J, Maloney K, Kiernan FJ, Boden WE, McKay RG. Clinical 

outcomes of patients undergoing percutaneous coronary intervention on 

weekends as compared with weekdays. J Am Coll Cardiol 2006;47(4); p 

254A. 

Mamkin I, Elkoustaf RA, Athar H, Shah AR, Siraj Y, Manolios M, 

Angampally R, Mather J, Mennett R, Boden WE, Kiernan FJ, McKay RG. 

Is there a relationship between time of day, day of week and clinical outcomes 

for patients with acute ST-elevation myocardial infarction undergoing 

percutaneous coronary intervention? Cath Cardio Intervent 2006; 67(5): p 

744. 

Mamkin I, Elkoustaf RA, Athar H, Shah AR, Siraj Y, Manolios M, 

Angampally R, Mather J, Mennett R, Boden WE, Kiernan FJ, McKay RG. 

e impact of transient no reflow on in-hospital and long term outcomes 

following percutaneous coronary intervention for non-ST-elevation acute 

coronary syndrome? Cath Cardio Intervent 2006; 67(5): p 745. 

Mamkin I, Elkoustaf RA, Athar H, Shah AR, Mather J, Siraj Y, Manolios 

M, Angampally R, Maloney K, Mennett R, Boden WE, Kiernan FJ, McKay 

RG. e relationship between body-surface area, gender and bleeding 

complications following percutaneous coronary intervention Cath Cardio 

Intervent 2006; 67(5): p 756. 

Porter IT, Schneider KA, Maksoud A, Joseph RD, Lebourveau PA, Meyers 

DG. Audibility of the fourth heart sound correlates with the level of left 

ventricular diastolic function. Circulation 2006; 14 (18):II-816. 

Rosamond T L., Wetzel L H., Wiley M A, Tadros P N, Maksoud A., 

Brown S: Multi-slice Coronary CTA: Analysis of Clinical Outcomes in Patients 

with Abnormal Studies. 2006. 

Shah AR, Tandon H, Navare S, Maksoud A, Mirza Z, Mather J, Mennet R, 

Kiernan FJ, McKay RG. Long-term follow-up of patients with ST-segment 

elevation myocardial infarction treated with sirolimus-eluting stents. Am J 

Cardiol 2007; 49 (9): 243A. 

Shah AR, Athar H, Mamkin I, Siraj Y, Manolios M, Angapally R, Mather 

J, Mennet R, Jarvis-Clouyeir J, Maloney K, Kiernan FJ, Boden WE, McKay 

RG. Increased in-hospital and long-term morbidity and mortality in patients 

with gastrointestinal bleeding following percutaneous coronary intervention. 

J Am Coll Cardiol 2006; 47(4); p 216A. 

Shah AR, Athar H, Mamkin I, Angmapally R, Manolios M, Siraj Y, Jarvis- 

Cloutier J, Maloney K, Mather J, Mennet R, Fram DB, Boden WE, Kiernan 

FJ, McKay RG. Independent predictors of mortality in non-ST-elevation 

myocardial infarction-acute coronary syndrome patients undergoing 

percutaneous coronary intervention. Cath Cardio Intervent 2006; 67(5): p 

753. 

Shah AR, Athar H, Mamkin I, Siraj Y, Angampally R, Manolios M, 

Maloney K, Jarvis-Cloutier J, Mennett R, Mather J, Primiano CA, Kiernan 

FJ, Boden We, McKay RG. Independent predictors of re-infarction in 

non-ST-elevation myocardial infarction-acute coronary syndrome patients 

undergoing percutaneous coronary intervention. Cath Cardio Intervent 2006; 

67(5): p 754. 

Shah A, Athar H, Mamkin I, Dada M, Mather J, Mennett R, Kiernan F, 

McKay R. Impact of creatine kinase-MB elevation following percutaneous 

coronary intervention for non-ST-elevation acute coronary syndromes on inhospital 

and nine-month clinical outcomes. TCT 2006. 


McKay R. Drug-eluting stents in elderly - How is it different? TCT 2006. 


McKay R. Peripheral vascular disease - An indepdent predictor of mortality 

in patients undergoing percutaneous coronary intervention. TCT 2006. 


McKay R. Drug eluting stents in in patients with non-ST-segment elevation 

acute coronary syndromes - Where do we stand? TCT 2006. 

Shen JB, Silverman D, Schulman P, Azrin M, Hager D, Hammond 

J, Pappano P, Liang B. Cardiac P2X4 receptors: A physiologic role in 

mediating atp-evoked current and regulation in human atrial fibrillation. J 

Am Coll Cardiol 2006, 47: A. 

Zubrow ME, Siraj Y, Kierna FJ, McKay RG, Silverman I, Horowitz S, 

Gillam LD, Mangion JR. Atrial septal aneurysm predicts persistent residual 

shunt following PFO closure with CardioSEAL/STARflex Occluder device. 

J Am Coll Cardiol 2006; 47(4); p 152A.

David Nicolau, PharmD • Charles Nightingale, PhD 

Joseph L. Kuti, PharmD • Kathryn J. Eagye, MPH • Mary Banevicius, BS • Pamela Tessier, 

MS, • Christina Sutherland, BS • Debora Santini, BS • Lindsay Tuttle, BS • Henry 

Christensen, BS • Jennifer Hull, BS • Andrew Deryke, PharmD • Heather Sun, PharmD • 

Su Lee, PharmD • Somvadee Laohavaleeson, PharmD • Aryun Kim, PharmD • Anthony 

Nicasio, PharmD • Jared Crandon, PharmD • Visiting Scholars: Ionnis Kioumis, MD, and 

Pashalina Konto, MD, essaloniki, Greece • Lauro Santos Filho,PhD, Paraiba, Brazil 

 

e Center for Anti-Infective Research and Development 

continues to focus its efforts on discovering the most clinically 

as well as cost-effective method of administering antibiotics. 

Studies on new antibiotics not yet commercially available 

continue to be a high priority. Many large pharmaceutical 

companies are devoting their resources to the development 

of drugs to treat chronic illnesses. While this is still in a 

transition state, the development of new antibiotics, especially 

ones that are active against resistant bacteria, are increasingly 

being developed by smaller firms. During the past year efforts 

have been undertaken to establish new relationships with 

small to midsize biotech companies both within and outside 

the United States for the purposes of drug development of 

novel compounds. 

In addition, the group has recently embarked on the provision 

of analytical services for both investigator-sponsored studies 

and industry-sponsored investigations throughout the 

United States. e Center for Anti-Infective Research 

and Development at Hartford Hospital has a national and 

international reputation for being on the leading edge of 

Infectious Disease research and its clinical application. 

roughout the course of the year, members of the group 

have given numerous presentations involving both clinical 

practice and research-related presentations at local, national 

and international meetings. 

 

 

 

Identification of Heteroresistant Vancomycin Intermediate 

Staphylococcus aureus (hVISA) in Patients with Ventilator 

Associated Pneumonia. Pfizer, $10,000. 

Pharmacoeconomics of Antifungals in the Treatment of Invasive 

Aspergillosis with a Focus on the Polyenes. Enzon Pharmaceuticals, 

$118,250. 

 

Ertapenem Utilization And Resistance Emergence Among 

Collateral Antimicrobials (EURECA) Survey 307A1-102053. 

Merck & Co., Inc./ Clinical Development, $69,375. 

A Time Motion Study to Determine Differences in Workload 

Attributed to Preparation of a Novel Enhanced Formulation of 

Piperacillin/Tazobactam (Zosyn) with its Original Formulation. 

Wyeth, $34,318. 

A Time Motion Study to Determine Differences in Workload 

Attributed to Preparation of a Novel Reformulation of Piperacillin/ 

tazobactam (Zosyn) with its Original Formulation. Wyeth Research, 

$11,366. 

Risk Factors for Infection with Meropenem High-level Resistant 

Pseudomonas Aeruginosa and Impact on Mortality and Hospital 

Costs. AstraZeneca, $62,188. 

Tigecycline Concentration Determinations. Wyeth Pharmaceuticals, 

$35,000. 

Evaluation of the Pharmacodynamic Profile of Novel Vertex 

Pharmaceuticals Compounds in Murine Models of Infection. Vertex 

Pharmaceuticals, Inc., $52,186. 

Provision and Reporting of Susceptibility Testing for Hospital 

Based Anti-Infectives. AstraZeneca Pharmaceuticals, L.P., $399,375. 

Trends in MIC Distributions of Several Antibiotics Against 

Pseudomonas aeruginosa over a 5-Year Period at a Large Urban 

Teaching Hospital. Wyeth Pharmaceuticals, $56,250. 

Evaluation of the Impact of Inadequate Empirical erapy Against 

Pathogens Causing Complicated Skin & Soft Tissue Infections. 

Wyeth Pharmaceuticals, $81,413. 

Evaluation of Ceftobiprole Against Staphylococcus aureus in a 

Murine Pneumonia Model. Johnson&Johnson Pharmaceuticals, 

$110,494. 

Evaluation of Polymedix Inc. Novel Antimicrobials Against 

Staphylococcus aureus in a Murine igh Model. PolyMedix, Inc.,

$92,542. 

Evaluation of the Bactericidal Activity of Doripenem Human 

Simulated Exposures Against Pseudomonas aeruginosa in a 

Neutropenic Mouse igh Model. Johnson & Johnson Pharmaceutical 

R&D, $169,040. 

Evaluation of Novexecel Inc. Novel Antimicrobials Against 

Staphylococcus aureus in a Murine igh Model. Novexel, Inc., 

$125,231. 

Identification of the MexXY-OprN Efflux System in Cefepime 

Resistant, Ceftazidime Susceptible Pseudomonas aeruginosa 

Among Clinical Isolates from Hartford Hospital. 

AstraZeneca Pharmaceuticals, L.P., $11,250. 

Clinical and Economic Implication of Antibiotic Prophylaxis Failure 

in Elective Colorectal Surgery. Merck & Co., Inc., $57,505. 

Efficacy Evaluation of Affinium Pharmaceuticals Novel Systemic 

Antibacterials in the Murine Staphylococcus Aureus Pneumonia 

Model. Affinium Pharmaceuticals, $86,288. 

Evaluation of Destiny Pharma’s Novel Antimicrobials Against 

Staphylococcus Aureus in a Murine igh Model. Destiny 

Pharmaceuticals, $59,635. 

Pharmacodynamic Evaluation of Tigecycline Against Phenotypically 

Diverse S. Aureus and E. Coli in a Murine igh Model. Wyeth, 

$235,823. 

Evaluation of Novexel Inc. Novel Antimicrobials against 

Staphylococcus aureus in a Murine Pneumonia Model. Novexel, 

$111,010. 

Pharmacokinetics of Daptomycin in Patients Receiving 

Continuous Veno-Venous Hemodiafiltration (CVVHDF). 

Cubist Pharmaceuticals, $99,599. 

Pharmacodynamic Evaluation of Tigecycline Against Staphylococcus 

Aureus and Acinetobacter Baumannii in a Murine Pneumonia 

Model. Wyeth Pharmaceuticals, $218,328. 

Tissue Penetration and Pharmacokinetics of Daptomycin in 

Healthy and Diabetic Volunteers by In Vivo Microdialysis. Cubist 


OPTAMA: Evaluating in vivo Potency Against Important Gram- 

Negative Rods over the Period of 2002 to 2006. AstraZeneca 


Pharmacodynamic Modeling of Antimicrobials in the Treatment 

of Hospital Acquired Pneumonia: Comparison with 2003 

OPTAMA Report and Agreement with ATS/IDSA Guidelines 

for the Management of Hospital Acquired Pneumonia. AstraZeneca 


 

 

e Impact of Automated Testing on the Clinical Outcomes and 

Economics of Infections Due to Extended Spectrum Beta-lactamase 

Producing Enterobacteriaceae. Small Grant, $9,390. 

 

 

Clinical Outcomes and Costs Associated with a Ventilator 

Associated Pneumonia Clinical Pathway in Intensive Care Units. 

 

Clinical Pharmacodynamics of Beta-Lactam Antibiotics in Patients 

with Pseudomonas Aeruginosa Infections. 

 

 

A Multicenter, Open-Label, Randomized Comparative Study 

of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for 

the Treatment of Hospitalized Subjects with Complicated Intraabdominal 

Infection. Wyeth Pharmaceuticals, Global Medical Affairs, 

$93,313. 

Clinical Outcomes of Patients with Ventilator-Associated 

Pneumonia at Hartford Hospital. AstraZeneca, $79,106. 

Cost-Effectiveness of Telavancin Versus Vancomycin in the 

Treatment of Complicated Gram-Positive Skin and Skin Structure 

Infections. eravance, Inc. $102,375. 

Pharmacoeconomic Implications of Penicillin Resistance in 

Community-Acquired Pneumonia Caused by Streptococcus 

pneumoniae. Hartford Hospital Research Endowment Funds, 

$35,310. 

Serum Bactericidal Activity of High-Dose Daptomycin When Co- 

Administered with Gentamicin Against Isolates of Enterococcus 

Species and Staphylococcus Aureus. Cubist Pharmaceuticals, Inc. 

$99,991. 

 

Efficacy Evaluation of Vertex Pharmaceuticals Systemic Antibacterials 

in the Rat igh Infection Model. Vertex Pharmaceuticals, Inc. $29,814. 


Antibacterials in the Murine Model of Staphylococcus Aureus 

Intra-Abdominal Sepsis. Affinium Pharmaceuticals; Zimmerman & 

Assoc., Drug Development Consulting, $34,045. 

Assessment of the Pharmacodynamic Breakpoint for Meropenem 

Using a Population Pharmacokinetic Approach in Adult Patients 

with Pneumonia, Intra-Abdominal Infections, Skin and Skin 

Structure Infection, and Severe Sepsis. AstraZeneca Pharmaceuticals, 

L.P. , $253,125. 

Assessment of the pharmacodynamic breakpoint for meropenem 

using a population pharmacokinetic approach in pediatric patients 

with meningitis and general infections. AstraZeneca Pharmaceuticals, 

L.P., $158,125. 

Bioanalytical Validation and Sample Analysis of Aztreonam in 

Human Plasma by HPLC for the Telavancin Clinical Program. 

eravance, $28,000. 

Efficacy Evaluation of Activbiotics Novel Systemic Antibacterials 

in the Murine Pneumococcal Pneumonia Model. ActivBiotics, 

$45,323. 


Antibacterials in the Murine Staphylococcus Aureus igh 

Infection Model. Affinium Pharmaceuticals - Zimmerman & 

Associates, $40,030. 

Efficacy Evaluation of Anadys Pharmaceuticals Novel Systemic 

Antibacterials in the Murine Model of Pseudomonas Aeruginosa 

Intra-Abdominal Sepsis. Anadys Pharmaceuticals, Inc., $17,788.

Evaluation of the Pharmacodynamic Profile of BAY-737388/PTK- 

0796 in a Murine Pneumonia Model. Paratek Pharmaceuticals, 

$69,924. 

Evaluation of the Pharmacodynamic Profile of Novel Oxazolidinone 

L-001177279 in a Murine Pneumococcal Pneumonia Model. 

Merck & Co. Inc, $159,826. 

Efficacy Evaluation of Vertex Pharmaceuticals Novel Systemic 

Antibacterials in the Mouse S. aureus igh Infection Model. Vertex 


Efficacy Evaluation of Achillion Pharmaceuticals Novel Systemic 

Antibacterials in the Murine Model of S.aureus Intra-Abdominal 

Sepsis. Achillion Pharmaceuticals, $19,623. 

Efficacy Evaluation of Vertex Pharmaceuticals Novel Systemic 

Antibacterials in the Murine (Mouse) Model of Intra-Abdominal 

Sepsis. Vertex Pharmaceuticals, Inc., $16,706. 

Efficacy of Pulsatile Amoxicillin/Clarithromycin Dosing in a 

Murine Pneumococcal Pneumonia Model. Advancis Pharmaceuticals, 

$81,186. 

Efficacy of Replidyne Inc. Novel Systemic Antibacterials in the 

Murine Model of S. aureus Intra-Abdominal Sepsis. Replidyne, Inc., 

$17,475. 

Efficacy of Vertex Pharmaceuticals Novel Systemic Antibacterials in 

the Murine (Rat) Model of Pneumococcal Intra-Abdominal Sepsis. 

Vertex Pharmaceuticals, Inc., $38,889. 

Bronchopulmonary Pharmacokinetic and Pharmacodynamic Profiles 

of Leofloxacin 750mg in Adults Undergoing Treatment of Acute 

Exacerbaction of Chronic Bronchitis. Orth-McNeil Pharmaceuticals, 

$211,341. 

Clinical Outcomes and Pharmacodynamic Comparison of 

Intravenous Antimicrobials Against Pseudomonas Aeruginosa in 

Hungarian Hospitals. AstraZeneca Pharmaceuticals, L.P., 

$66,250. 

Determination of Gatifloxacin Concentrations in Biological 

Matrixes. Armed Forces Radiobiology Research Institute .$6,300. 

. 

Determination of Piperacillin and Tazobactam in Biological 

Matrixes. Wyeth Pharmaceuticals, $35,000. 

Development of Rat Pneumonia Model -Pilot/feasibility study 

Departmental Funds, $54,522. 

Efficacy of Wyeth Pharmaceuticals Novel Systemic Antibacterials in 

the Murine Model of Intra-abdominal Sepsis. Wyeth Pharmaceuticals, 

$11,225. 

Evaluation of Array BioPharma, Inc. Novel Compounds against 

Staphylococcus aureus in a Murine igh Model. Array BioPharma, 

Inc., $52,306. 

Evaluation of Bacterial Kill When Modeling the Bronchopulmonary 

Pharmacokinetic Profile of Moxifloxacin and Levofloxacin Against 

Parc and Gyra Containing Isolatyes of S. Pneumoniae. Bayer 


Evaluation of Replidyne Pharmaceuticals Novel Compounds against 

Staphylococcus aureus in a Murine igh Model. Replidyne, Inc., 

$54,348. 

Evaluation of the Bactericidal Activity of Meropenum and 

Ertapenum Against Extended Spectrum Beta-Lactamase Producing 

Klebsielle Pneumoniae and Escherichia Coli in a Neutropenic 

Mouse Model. AstraZeneca, $120,923. 

HPLC Analysis - An Open-Label, Multicenter, Non-Comparative 

Sinus Puncture Study of Levofloxacin in the Treatment of 

Acute Maxillary Rhinosinusitis. Cognigen Corp./OrthoMcNeil 

Pharmacutical, $78,750. 

HPLC anaylsis of Daptomycin in Human Serum. Cubist 


Murine (Rat) Staphylococcus Aureus Intra-Abdominal Sepsis 

Model: Efficacy of Affinium Pharmaceuticals Novel Systemic 

Antibacterials. Affinium Pharmaceuticals, $18,625. 

Murine (RAT) igh Infection Model: Efficacy Evaluation of 

Affinium Pharmaceuticals Systemic Antibacterials. Affinium 


Optimizing Pharmacodynamic Target Attainment Using the 

MYSTIC Antibiogram: Nosocomial Pathogens of Concern in the 

United States during 2004. AstraZeneca Pharmaceuticals, L.P. 

$58,125. 

Pharmacodynamic Comparison of Antimicrobials Against 

Streptococcus Pneumoniae, Enterobactyeriaceae and Pseudomonas 

Aeruginosa in Pediatric Patients: OPTAMA\205 Pediatric 

Program. AstraZeneca Pharmaceuticals, L.P., $72,500. 

Pharmacodynamic Comparison of Antimicrobials in the Treatment 

of Meningitis Using Monte Carlo Simulation. AstraZeneca 

Pharmaceuticals, L.P., $76,875. 

Pharmacodynamic Comparison of Antimicrobials in the Treatment 

of Severe Sepsis in the Intensive Care Unit: A Report from 

the OPTAMA Program. AstraZeneca Pharmaceuticals, L.P. 

$60,625. 

Pharmacodynamic Comparison of the Carbapenems against 

Extended-Spectrum Beta-Lactamases from the MYSTIC 

Surveillance Program. AstraZeneca, $51,875. 

Pharmacodynamic Comparison of Tigecycline Versus other 

Intravenous Antimicrobials in the Treatment of Serious Nosocomial 

Infections #3074A1-102039. Wyeth Pharmaceuticals/Global Medical 

Afff, $195,625. 

Pharmacodynamic Modeling of Antimicrobials in the Treatment 

of Complicated Skin and Skin Structure Infections. AstraZeneca 

Pharmaceuticals, L.P., $39,375. 

Pharmacodynamic Modeling of Antimicrobials in the Treatment of 

Intra-abdominal Infections. AstraZeneca Pharmaceuticals, L.P. 

$51,875. 

Urea Determination in Human Plasma and Bronchial Alveolar 

Lavage Fluid by a Colorimetric Method for the Telavancin Clinical 

Program. eravance, $10,000. 

 

Silver Elution Study (TMP04-005). Medex Inc., $17,975. 

 

Berenholtz SM, Pronovost PJ, Ngo K, Barie PS, Hitt J, Kuti JL, Septimus 

E, Lawler N, Schilling L, Dorman T, Core Sepsis Measurement Team.

Developing quality measures for sepsis care in the ICU. Jt Comm J Qual 

Patient Saf., Sep;33(9):559-68, 2007. 

Brook I, Giraldo DE, Germana A, Nicolau DP, Jackson WE, Elliott TB, 

akar JH, Shoemaker MO, Ledney DG. Comparison of Clarithromycin 

and Ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice 

with or without 60Co gamma-irradiation. Journal of Medical Microbiology, 

54:1157-1162, 2005. 

DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. Evaluation of the 

bactericidal activity of Meropenem and Ertapenem against extendedspectrum 

beta-lactamase producing Escherichia coli and klebsiella 

pneumoniae in a neutropenic mouse thigh model. Antimicrobial Agents & 

Chemotherapy, 51(4):1481-1486, 2007. 

DeRyke CA, Du X, Nicolau DP. Evaluation of bacterial kill when modeling 

the bronchopulmonary pharmacokinetic profile of Moxifloxacin and 

Levofloxacin against parC containing isolates of S. pneumoniae. Journal of 

Antimicrobial Chemotherapy, 58:601-609, 2006. 

DeRyke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP. 

Pharmacoeconomics of continuous versus intermittent infusion Piperacillin/ 

Tazobactam for the treatment of hospitalized patients with complicated 

intra-abdominal infection. American Journal of Health-System Pharmacy, 63: 

750-755, 2006. 

DeRyke CA, Kuti JL, Nicolau DP. Changes in pharmacodynamic target 

attainment for antimicrobials over a 2-year period: Results of the 2004 

OPTAMA Program in North America. Infectious Diseases in Clinical Practice, 

15(1):26-34, 2007. 

DeRyke CA, Kuti JL, Nicolau DP. Cumulative fraction of response as a 

surrogate marker for antibiotic efficacy in incremental cost-effectiveness 

analyses. Formulary, 42:252-260, 2007. 

DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of 

six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, 

Acinetobacter baumannii, Escherichia coli, and Klebsiella Species collected 

from United States intensive care units in 2004. Pharmacotherapy, 27(3): 

333-342, 2007. 

DeRyke CA, Kuti JL, Nicolau DP. Re-evaluation of current susceptibility 

breakpoints for gram-negative rods based on pharmacodynamic assessment. 

Diagnostic Microbiology and Infectious Disease, 58:337-344, 2007. 

DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies 

utilising pharmacodynamic principles: Impact on the development of 

resistance. Drugs, 66(1):1-14, 2006. 

DeRyke CA, Nicolau DP. Is all free time above the minimum inhibitory 

concentration the same: Implications for beta-lactam In vivo Modeling. 

International Journal of Antimicrobial Agents, 29:341-343, 2007. 

DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum 

bactericidal activity of high-dose Daptomycin with and without coadministration 

of Gentamicin against isolates of Staphylococcus aureus 

and Enterococcus species. Antimicrobial Agents & Chemotherapy, 50(11): 

3529-3534, 2006. 

Du X, Li C, Kuti JK, Nightingale CH, Nicolau DP. Population 

pharmacokinetics and pharmacodynamics of Meropenem in pediatric 

patients. Journal of Clinical Pharmacology, 46:69-75, 2006. 

Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy for secondary 

peritonitis: A pharmacodynamic analysis of Cefepime, Ceftazidime, 

Ceftriaxone, Imipenem, Levofloxacin, Piperacillin/Tazobactam, and 

Tigecycline using Monte Carlo simulation. Clinical erapeutics, 29(5):889- 

899, 2007. 

Eagye KJ, Kuti JL, Nicolau DP. Evaluating empiric treatment options for 

secondary peritonitis using pharmacodynamic profiling. Surgical Infections, 

8(2):215-226, 2007. 

Eagye KJ, Kuti JL, Nicolau DP. Pharmacodynamic comparison of the 

Carbapenems against E. coli and Klebsiella spp. containing extended 

spectrum beta-lactamases. American Journal of Infectious Diseases, 1(3):149- 

155, 2005. 

Eagye KJ, Nicolau DP, Lockhart S, Quinn JP, Doern GV, Gallagher 

G, Abramson MA. A pharmacodynamic analysis of resistance trends 

in pathogens from patients with infection in intensive care units in the 

United States between 1993 and 2004. Annals of Clinical Microbiology and 

Antimicrobials, 6(11):1-6, 2007. 

Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic evaluation of Meropenem 

(MER) and Cefotaxime (CTX) for pediatric meningitis – A report from the 

OPTAMA Program. Pediatric Drugs, 8(2):131-138, 2006. 

Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess 

the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa 

infections in children: A report from the OPTAMA program. Clinical 

erapeutics, 27(11):1820-1830, 2005. 

Farr GE, Nicolau DP. Respiratory tract infections: Focus on efficacy and 

safety of current treatment options. Advanced Studies in Pharmacy, 2(6):210- 

211, 2005. 

Gerbino PP, Brixner D, Sbarbaro J, Nicolau D. Appropriate initial antibiotic 

therapy in the treatment of community-acquired respiratory tract infections. 

Managed Care Interface, 18(12):41-48, 2005. 

Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. 

Pharmacokinetics of Clarithromycin Extended-Release (ER) Formulation 

in patients with AIDS. HIV Clinical Trials, 6(5):246-253, 2005. 

Kiffer CR, Kuti J, Mendes CMF, Oplustil CP, Amarante JB; Biancalana 

ML, Xavier N, Nicolau DP. Monte Carlo simulation model to optimize the 

initial empiric antimicrobial therapy for gram-negative bacterial infections 

in an adult intensive care unit of a tertiary care hospital in Brazil. Brazilian 

Journal of Infectious Disease, 11(2):183-185, 2007. 

Kiffer CRV, Mendes C, Eagye KJ, Kuti JL, Nicolau DP. Pharmacodynamic 

comparison of three carbapenems against extended spectrum beta-lactamase 

producing Escherichia coli and Klebsiella spp from the MYSTIC Program in 

Brazil. International Journal of Antimicrobial Agents, 28:340-344, 2006. 

Kim A, Kuti JL, Nicolau DP. Review of Dalbavancin, the novel semisynthetic 

lipoglycopeptide. Expert Opinion on Investigational Drugs, 16(5): 

717-733, 2007. 

Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of 

Piperacillin-Tazobactam for the treatment of Pseudomonas aeruginosa 

infections: Prolonged or continuous infusion? Pharmacotherapy, 27(11): 

1490-1497, 2007. 

Kim MK, Nicolau DP. Aminoglycoside pharmacodynamics. In Nightingale 

CH, Ambrose PG, Drusano GL, Murakawa T. (eds). Antimicrobial 

Pharmacodynamics in eory and Clinical Practice. New York, NY: Marcel 

Dekker, 147-175, 2007. 

Kim SW, Kuti JL, Nicolau DP. Intracellular penetration of antibiotics. 

Antibiotics for Clinicians, Oct-Dec: 369-373, 2006. 

Kioumis IP, Kuti JL, Nicolau DP. Intra-abdominal infections: 

Considerations for the use of the Carbapenems. Expert Opinion on 

Pharmacotherapy, 8(2):167-182, 2007. 

Kioumis IP, Nicolau DP. Antimicrobial efficacy review. Pharmacy Practice 

News. 2006;33(9) :29-32 ; and in Infectious Disease Special Edition, 67-70. 

McMahon Publishing Group, 2006. 

Kotapati S, Kuti JL, Nicolau DP. Pharmacodynamic modeling of ß-lactam 

antibiotics for the empiric treatment of secondary peritonitis: A report from 

the OPTAMA Program. Surgical Infections, 6(3):297-304, 2005. 

Kuti JL, Nicolau DP. Making the most of surveillance studies: Summary of 

the OPTAMA program. Diagnostic Microbiology and Infectious Disease, 53: 

281-287, 2005. 

Kuti JL, Ong C, Lo M, Melnick M, Soto N, Nicolau DP. Comparison of 

pharmacodynamic target attainment calculated by Monte Carlo simulation 

with microbiological response for two Carbapenems in the treatment of 

complicated skin and skin structure infections. International Journal of 

Antimicrobial Agents, 28:62-68, 2006. 

Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin - a new lipoglycopeptide 

for resistant gram-positive infections. Expert Opinion on Investigational

Drugs, 16(3):347-357, 2007. 

Lau W, Mercer D, Itani K, Nicolau D, Kuti J, Mansfield D, Dana A. A 

randomized, open-label, comparative study of Piperacillin/Tazobactam 

administered by continuous infusion vs. intermittent infusion for the 

treatment of hospitalized patients with complicated intra-abdominal 

infection. Antimicrobial Agents & Chemotherapy, 50(11):3556-3561, 2006. 

Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on Daptomycin: e first 

approved lipopeptide antibiotic. Expert Opinion on Pharmacotherapy, 7(10): 

1381-1397, 2006. 

Lee SY, Fan HW, Sutherland C, DeRyke CA, Nicolau DP. Antibacterial 

effects of Moxifloxacin and Levofloxacin simulating epithelial lining 

fluid concentrations against Community-Acquired Methicillin-Resistant 

Staphylococcus aureus (CA-MRSA). Drugs in Research & Development, 8(2): 

69-77, 2007. 

Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of 

extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella 

species on hospital costs: A matched cohort study. Infection Control and 

Hospital Epidemiology, 27(11):1226-1232, 2006. 

Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated 

skin and skin structure infections in the era of emerging resistance. Surgical 

Infections, 6(3):283-295, 2005. 

Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients 

with extended epectrum beta-lactamases (ESBL) and non-ESBL infections. 

Journal of Infection, 54:463-468, 2007. 

Lee SY, Kuti JL, Nicolau DP. Empiric pharmacodynamic performance of 

nine antimicrobials against pathogens implicated in the cause of complicated 

skin and soft tissue infections: A report from the OPTAMA Program. 

Infectious Diseases in Clinical Practice, 14:289-295, 2006. 

Lee SY, Kuti JL, Nicolau DP. Polymyxins: Older antibiotics for a new threat. 

Connecticut Medicine, 70(1):25-28, 2006. 

Lee SY, Tessier PR, Murphy CK, Nicolau DP. Bactericidal efficacy of ABI- 

0043, a novel Rifamycin, in a murine Pneumococcal Pneumonia model. 

Journal of Antibiotics, 59(12):804-807, 2006. 

Li C, Kuti JL, Nightingale CH, Nicolau DP. Clinical pharmacodynamics 

of Meropenem in patients with lower respiratory tract infections and intraabdominal 

infections. Antimicrobial Agents & Chemotherapy, 51(5):1725- 

1730, 2007. 

Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic 

analysis and dosing regimen optimization of Meropenem in adult patients. 

Journal of Clinical Pharmacology, 46:1171-1178, 2006. 

Ludwig E, Konkoly ege M, Kuti JL, Nicolau DP. Optimizing antibiotic 

dosing regimens based on pharmacodynamic target attainment against 

Pseudomonas aeruginosa collected in Hungarian hospitals. International 

Journal of Antimicrobial Agents, 28:433-438, 2006. 

Newman D, Scheetz MH, AdeyemiO, Montevecchi M, Nicolau DP, Noskin 

GA, Postelnick MJ. Serum Piperacillin-Tazobactam pharmacokinetics in a 

morbidly obese individual: One size fits all? Annals of Pharmacotherapy, 

41(10):1734-9, 2007. 

Nicasio AM, Kuti JL, Nicolau DP, Quintiliani R. Treatment of infective 

endocarditis with oral antibiotics: If the gut works use it? Antibiotics for 

Clinicians, Jan-Mar: 396-401, 2007. 

Nicasio AM, Quintiliani R Jr, DeRyke CA, Kuti JL, Nicolau DP. Treatment 

of serratia marcescens meningitis with prolong infused Meropenem. Annals 

of Pharmacotherapy, 41(6):1077-81, 2007. 

Nicolau DP. Case study: A 64-year-old man with “collateral damage”. 

Advanced Studies in Pharmacy, 2(6):241-244, 2005. 

Nicolau DP. Optimizing the use of Carbapenems in the face of increasing 

gram-negative resistance. Supplement Editor. Formulary, July Supplement: 

1-15, 2007. 

Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics 

of Dalbavancin in plasma and skin blister fluid. Journal of Antimicrobial 

Chemotherapy, 60:681-684, 2007. 

Nicolau DP, Sutherland CA, Arguedas A, Dagan R, Pichichero ME. 

Pharmacokinetics of Cefprozil in plasma and middle ear fluid of children 

undergoing treatment for acute otitis media. Pediatric Drugs, 9(2):119-123, 

2007. 

Nicolau DP, Tessier PR, Rubinstein I, Nightingale CH. In vivo 

immunomodulatory profile of Telithromycin in a murine pneumococcal 

infection model. Pharmazie, 61:343-347, 2006. 

Ong C, Kuti JL, Nicolau DP. Pharmacodynamic modeling of Imipenem- 

Cilastatin, Meropenem, and Piperacillin-Tazobactam for empiric therapy 

of skin and soft tissue infections: A report from the OPTAMA Program. 

Surgical Infections, 6(4):419-426, 2006. 

Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in 

vivo efficacy of Meropenem, Imipenem, and Cefepime against Pseudomonas 

aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagnostic 

Microbiology and Infectious Disease, 57:153-161, 2007. 

Quintiliani R Jr., Nicolau DP, Potoski BA. Aminoglycosides. In: Yu VL, 

Edwards G, McKinnon PS, Peloquin C, Morse GD, eds. Antimicrobial 

erapy and Vaccines. Volume II: Antimicrobial Agents. Second Edition. 

Pittsburgh, PA: ESun Technologies, 21-44, 2005. 

Sahni JK, Kuti JL, Nicolau DP. A time motion study to determine 

differences in pharmacy tchnician workload attributed to preparation of a 

novel reformulation of Piperacillin/Tazobactam (ZosynÒ) with its original 

formulation. Pharmacy Technology, 23:203-206, 2007. 

Santos FL, Eagye KJ, Kuti JL, Nicolau DP. Addressing resistance evolution 

in Pseudomonas aeruginosa using pharmacodynamic modeling: Application 

to Meropenem dosage and combination therapy. Clinical Microbiology & 

Infection, 13:579-585, 2007. 

Santos FL, Kuti JL, Nicolau DP. Employing pharmacokinetic and 

pharmacodynamic principles to optimize antimicrobial treatment in the face 

of emerging resistance. Brazilian Journal of Microbiology, 38:183-193, 2007. 

Sbarbaro J, Nicolau DP, Asche C. Management of community-acquired 

respiratory tract infections in an era of increasing antibiotic resistance. 

Pharmacy and erapeutics, 31(2):106-111, 2006. 

Scheetz MH, Reddy P, Nicolau DP, Noskin GA, Postelnick MJ, Stosor 

V, Zembower TR. Peritoneal fluid penetration of Tigecycline. Annals of 

Pharmacotherapy, 40(11):2064-7, 2006. 

Sun HK, Du X, DeRyke CA, Doern GV, Nicolau DP. ParE mutations in 

Streptococcus Pneumoniae may reduce bactericidal activity of respiratory 

fluoroquinolones. International Journal of Antimicrobial Agents, 29(2):230- 

232, 2007. 

Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. 

Tissue penetration of Telavancin after intravenous administration in healthy 

subjects. Antimicrobial Agents & Chemotherapy, 50(2):788-790, 2006. 

Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted 

to a large urban hospital with community-acquired pneumonia caused by 

Streptococcus pneumoniae. Chest, 130:807-814, 2006. 

Sutherland C, Nicolau DP. Development of an HPLC method for the 

determination of Doripenem in human and mouse serum. Journal of 

Chromatography B, 853:123-126, 2007. 

Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. 

Pharmacodynamic target attainment of seven antimicrobials against gramnegative 

bacteria collected from China in 2003 and 2004. International 

Journal of Antimicrobial Agents, 452-457, 2007. 

Xuan D, Nightingale CH, Hull D, Nicolau DP. Population pharmacokinetic 

analysis of the microemulsion formulation of Cyclosporin A in renal 

transplant patients. erapy, 3(2):259-264, 2006.

Banevicius MA, Deryke CA, Kaplan N, Vaughn D, Nicolau DP. In vivo 

pharmacodynamic profiling of API-1252 against Staphylococcus aureus in a 

murine thigh model. (Abstract No. D0703). 46th Interscience Conference on 

Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 

2006. 

Banevicius MA, Kaplan N., Nicolau DP. Comparative dose studies of 

API-1252 and Linezolid against community-acquired methicillin-resistant 

Staphylococcus aureus in a murine pneumonia model. (Abstract No. F1- 

930). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, 

Chicago, IL, September 17-20, 2007. 

Banevicius MA, Kaplan N, Vaughan D, Nicolau DP. Comparative Dose 

Studies of API-1252 and Linezolid against hospital-acquired (HA) and 

community-acquired (CA) methicillin-resistant staphylococcus aureus 

(MRSA) in a murine thigh model. (Abstract No. O455). 17th European 

Congress of Clinical Microbiology and Infectious Diseases - 25th International 

Congress of Chemotherapy, Munich, Germany, March 31 – April 3, 2007. 

Deryke CA, Fan HW, Banevicius MA, Nicolau DP. In vivo efficacy of 

human simulated exposures of Ertapenem (ERT) and Meropenem (MEM) 

against extended-spectrum beta-lactamase (ESBL) producing Klebsiella 

pneumoniae (KP) and Escherichia coli (EC). (Abstract No. A0011). 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San 

Francisco, CA, September 27-30, 2006. 

DeRyke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP. 

Pharmacoeconomics of continuous versus intermittent infusion Piperacillin/ 

tazobactam for the treatment of hospitalized patients with complicated 

intra-abdominal infection (Abstract No. RP76). American Society of Hospital 

Pharmacists, 40th Annual Midyear Clinical Meeting, Las Vegas, Nevada, 

December 2005. 

Deryke CA, Kuti JL, Nicolau DP. Is re-evaluation of current susceptibility 

breakpoints for gram-negative rods (GNR) based on pharmacodynamic 

(PD) assessment. (Abstract No. D0703). 46th Interscience Conference on 


2006. 

Deryke CA, Kuti JL, Nicolau DP. Pharmacodynamic (PD) target attainment 

(TA) as a surrogate marker for antibiotic efficacy in cost-effectiveness analyses 

(CEA). (Abstract No. O1465). 46th Interscience Conference on Antimicrobial 

Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006. 

Deryke CA, Nicolau DP. Is all time above the mnimum inhibitory 

concentration (MIC) the same: Implications for In Vivo modeling. (Abstract 

No. A0005). 46th Interscience Conference on Antimicrobial Agents and 

Chemotherapy, San Francisco, CA, September 27-30, 2006. 

Deryke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Pharmacokinetics 

(PK) and serum bactericidal activity of high-dose Daptomycin (DAP) 

with and without co-administration of Gentamicin against isolates of 

Staphylococcus aureus and Enterococcus species. (Abstract No. A0629). 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San 

Francisco, CA, September 27-30, 2006. 

DeRyke CA, Xu D, Nicolau DP. Evaluation of bacterial kill when modeling 

the bronchopulmonary pharmacokinetic profile of Moxifloxacin (MOX) 

and Levofloxacin (LVX) against parC containing isolates of S. pneumoniae 

(SPN) (Abstract No. 185E). American College of Clinical Pharmacy, 2005 

Annual Meeting, San Francisco, CA, October 23-26, 2005. 

Eagye KJ, Kim A, Laohavaleeson S, Kuti JK, Nicolau DP. Impact of 

inadequate antibiotic therapy (IAT) on hospital length of stay (LOS) 

in patients with complicated skin and skin structure infections (cSSSI). 

(Abstract No. K-1256). 47th Interscience Conference on Antimicrobial Agents 

and Chemotherapy, Chicago, IL, September 17-20, 2007. 

Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic evaluation 

of seven antibiotics recommended for secondary peritonitis, including the 

novel agent Tigecycline using global resistance data. (Abstract No. O421). 

17th European Congress of Clinical Microbiology and Infectious Diseases - 25th 

International Congress of Chemotherapy, Munich, Germany, March 31 – April 

3, 2007. 

Eagye KJ, Nicolau DP. Incidence of infection and impact on hospital length 

of stay (LOS) and costs in patients undergoing elective colorectal surgery 

(ECS). (Abstract No. K-1127). 47th Interscience Conference on Antimicrobial 

Agents and Chemotherapy, Chicago, IL, September 17-20, 2007. 

Eagye KJ, Nicolau DP, Heilmann K, Quinn J, Doern GV, Gallagher G, 

Abramson M. A pharmacodynamic analysis of resistance trends in pathogens 

from patients with infection in intensive care units in the United States 

between 1993 and 2004. (Abstract No. P1813). 17th European Congress of 

Clinical Microbiology and Infectious Diseases - 25th International Congress of 

Chemotherapy, Munich, Germany, March 31 – April 3, 2007. 

Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection (SI) on hospital 

length of stay (LOS) and costs in patients with ventilator-associated 

pneumonia (VAP). (Abstract No. K0286). 46th Interscience Conference on 


2006. 

Eagye KJ, Shore E, Dobkin E, Palter M, Nicolau DP, Kuti JL. Differing 

epidemiology and resistance patterns of respiratory isolates (RI) from 

three intensive care units (ICUs) within the same institution. (Abstract 

No. K0259). 46th Interscience Conference on Antimicrobial Agents and 

Chemotherapy, San Francisco, CA, September 27-30, 2006. 

Kiffer C, Kuti J, Mendes C, Sinto S, Koga P, Nicolau D. Pharmacodynamic 

comparison of linezolid, teicoplanin, and vancomycin against clinical isolates 

of Staphylococcus aureus and coagulase negative staphylococci collected 

from hospitals in Brazil. (Abstract No. P1375). 17th European Congress of 



Kiffer CRV, Mendes C, Eagye KJ, Kuti JL, Nicolau DP. Pharmacodynamic 

comparison of three carbapenems against extended spectrum beta-lactamase 

(ESBL) producing Escherichia coli and Klebsiella spp from the MYSTIC 

Program in Brazil. (Abstract No. P1550). 16TH European Congress of 

Clinical Microbiology and Infectious Diseases, Nice, France, April 2006. 

Kim A, Banevicius MA, Nicolau DP. In vivo efficacy of Doripenem human 

simulated exposures against Pseudomonas aeruginosa. (Abstract No. A- 



Kim A, Sutherland C, Kuti JL, Nicolau DP. Optimal Piperacillin/ 

Tazobactam dosing against Pseudomonas aeruginosa: Prolonged or 

continuous infusion? (Abstract No. P1372). 17th European Congress of 



Kuti JL, Dowzicky M, Nicolau DP. A pharmacodynamic (PD) model to 

assess Tigecycline (TG) predicted efficacy compared with other antibiotics 

for hospital-acquired pneumonia (HAP). (Abstract No. 213) 44th Annual 

Meeting of Infectious Diseases Society of America, Toronto, Canada, October 12- 

15, 2006. 

Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic (PD) performance 

of Tigecycline (TG) compared with other antibiotics for complicated skin 

and soft tissue infections (SSTI). (Abstract No. P1-020). 10th Western 

Pacific Congress on Chemotherapy and Infectious Diseases, Fukuoka International 

Congress Center, Fukuoka, Japan, December 3-6, 2006. 

Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JK. Cost-effectiveness 

of Telavancin (TLV) versus Vancomycin (VAN) for the treatment of 

complicated skin and skin structure infections (cSSSI). (Abstract No. O- 



Laohavaleeson S, Lolans K, Quinn JP, Kuti JK, Nicolau DP. Identification 

of the MexXY-OprM efflux system in Cefepime resistant-Ceftazidime 

susceptible Pseudomonas aeruginosa among clinical isolates from a 

US hospital. (Abstract No. C2-1501). 47th Interscience Conference on 

Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007. 

Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic 

characterization of Ceftobiprole in pneumonia caused by phenotypically 

diverse Staphylococcus aureus. (Abstract No. A-38). 47th Interscience 

Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September

17-20, 2007. 

Lee SY, Fan HW, Nicolau DP. Antibacterial effects of Moxifloxacin 

and Levofloxacin simulating epithelial lining fluid concentrations 

against community-acquired methicillin-resistant staphylococcus aureus 

(CA-MRSA). (Abstract No. P2-027). 10th Western Pacific Congress on 

Chemotherapy and Infectious Diseases, Fukuoka International Congress Center, 

Fukuoka, Japan, December 3-6, 2006. 

Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of 

extended spectrum beta-lactamase (ESBL) producing bacteria on initial 

antibiotic therapy: A case controlled study. (Abstract No. 274E). American 

College of Clinical Pharmacy, 2005 Annual Meeting, San Francisco, CA, October 

23-26, 2005. 

Nicolau DP, Sutherland C, Winget D, Baughman RP. Bronchopulmonary 

pharmacokinetics of Levofloxacin 750 mg once-daily in patients with acute 

exacerbation of chronic bronchitis. (Abstract No. A0332). 46th Interscience 

Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 

September 27-30, 2006. 

St. Germain RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. 

Pharmacodynamic target attainment of oral beta-lactams for the empiric 

treatment of acute otitis media in children (Abstract No. 642, S07). 16th 

Pediatric Pharmacy Conference and Annual Meeting, Portsmouth, Virginia, 

September 2007. 

 

Stein GE, Schooley S, Nicolau DP. Urinary bactericidal activity of 

Levofloxacin (750mg) against fluoroquinolone-resistant uropathogens. 

(Abstract No. P1533). 16th European Congress of Clinical Microbiology and 

Infectious Diseases, Nice, France, April 2006. 

Sun HK, Nicolau DP, Kuti JL. Resource utilization and outcomes of adults 

admitted to a tertiary hospital with community acquired pneumonia (CAP) 

caused by Streptococcus pneumoniae (SP) (Abstract No. 271). American 

College of Clinical Pharmacy, 2005 Annual Meeting, San Francisco, CA, October 

23-26, 2005. 

Tessier PR, Fan HW, Tanaka SK, Nicolau DP. Pharmacokinetic/ 

pharmacodynamic profile of PTK0796 against S. pneumoniae in a murine 

pneumonia model. (Abstract No. F1-1973). 46th Interscience Conference on 


2006. 

Wong SL, Shaw JP, Nicolau DP, Barrierre S, Kitt M, Goldberg M. 

Pharmacokinetic modeling of Telavancin penetration into skin blister fluid 

(Abstract No. A2786). 46th Interscience Conference on Antimicrobial Agents 

and Chemotherapy, San Francisco, CA, September 27-30, 2006. 

Zhanel GG, Baudry TJ, Laing M, Decorby M, Nored A, Nicolau DP. 

Pharmacodynamic activity of Tigecycline vs. molecularly characterized 

multi-drug resistant extended spectrum beta-lactamase (ESBL) producing 

E. coli using an in vitro model. (Abstract No. A1679). 46th Interscience 

Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 

September 27-30, 2006.

Impact of Type 2 Diabetes Peer Counseling on Behavioral, 

Metabolic and Health Outcomes Among Latinos. NIH subcontract 

through the University of Connecticut, $1,081,928. 

 

A Multi-Center, Longitudinal Study of Drug- and CAM-Induced 

Liver Injury (Version 2.2). NIDDK subcontract through the University 

of Connecticut,$10,000. 

 

 

Hemodynamic Responses to Dialysate Sodium Individualization in 

Hemodialysis. Satellite Research Foundation subcontract through Yale 


 

 

A Randomized, Double-Blind, Placebo-Controlled, Parallel- 

Group, Multicenter Study to Evaluate the Efficacy and Safety of 

DNK333 25mg B.I.D. Given Orally for 4 Weeks in Female Patients 

with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). 

Novartis Pharmaceuticals, $12,300. 

A Double-Blind, Randomized, 6-week, Parallel-Group Clinical 

Trial to Assess the Safety and Efficacy of Asacol® 4.8 g/day (800 mg 

mesalamine tablet) versus Asacol® 2.4 g/day (400 mg mesalamine 

tablet) for the Treatment of Moderately Active Ulcerative Colitis 

(ASCEND III). Proctor and Gamble Pharmaceuticals, $58,700. 

 

Sham Hyperinflation vs. Acapella Use in Patients with Artificial 

Airways. Smiths Medical ASD, Inc., $2,820. 

 

A Prospective Observational Study of the Psychometric Validation 

of a Patient-Reported Questionnaire in Acute Exacerbation 

of Chronic Obstructive Pulmonary Disease (AECOPD). 

GlaxoSmithKline, $37,450. 

A Phase 3, Open-label, Multisite, Randomized, Parallel Group Study 

of the Efficacy, and Safety of the Fixed Combination Torcetrapib/ 

Atorvastatin Administered Once Daily (QD) Compared to 

Simvastatin for 6 Weeks in Subjects with Hypercholesterolemia. 

Pfizer, Inc., $31,500. 

Psychometric Validation of a Subject-Administered Questionnaire 

to Assess Cough and Sputum in Patients with COPD Associated 

with Chronic Bronchitis and Chronic Bronchitis (Not Obstructed). 

Boehringer Ingelheim, $32,563. 

 

Evaluation of Multiple Bioassays in Serum and Pleural Fluid to 

Estimate the Probability of Cancer in Patients Presenting with 

Undiagnosed Pleural Effusion. Fujirebio Diagnostic, Inc., $72,000. 

A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess 

Safety of Tobramycin Inhalation Powder Compared to TOBI® in 

Cystic Fibrosis Subjects. Novartis Pharmaceuticals, $47,845. 

 

Roche Integrin Antagonist Follow-up for Undetected PML. 

Roche,$600. 

 

 

Examining the Use of the Safety Screen to Predict Risk of Hospital 

Falls. Statistical analysis supported through Hartford Hospital Small 

Grant. 

 

Clonal Outbreak of Clostridium Difficile-Associated Disease with 

High Morbidity and Mortality. Open Competition, $58,500. 

 

 

Internal Medicine Clinical Assessment Program (CAP). 

 

Participation in the Cystic Fibrosis Patient Registry. 

 

Ventilator Associate Pneumonia and Constant Endotracheal Tube 

Cuff Pressures. 

 

PO2095 Open-Label, Limited Access Protocol of Posaconazole in 

Invasive Fungal Infections. 

Prevalence of Nasal Carriage of MRSA at Hartford Hospital. 

 

Incidence of Positive Screening Gastric Biopsies for Helicobacter 

Pylori in Clinic Patients at Hartford Hospital: Comparison with 

Chinese Patients at Shandung University Hospital. 

 

A Comparison of Symptoms of Acute Coronary Syndrome and 

Length of Time to Seeking Treatment Based on Gender and Race. 

 

Improving Awareness of Advanced Directives in Primarily Hispanic 

Outpatient Clinics. 

 

 

 

A Pilot Study for Increasing Osteoporosis Awareness in Internal 

Medicine Residency Clinics. 

 

Hypertension Compliance and the Factors that Affect the Health 

Status and Behaviors of Hispanics in the Ambulatory Care Setting. 

Using Preoperative Electrocardiograms as a Predictive Marker for 

Perioperative Adverse Outcomes in Hispanic Patients Undergoing 

Elective Non-Cardiac Surgery.

Self Reported Provider Adherence to NAEPP Guidelines for 

Control of Factors Contributing to Asthma Severity. Statistical 


 

 

A Phase 3, Multi-center, Randomized, Double-blind, Placebocontrolled, 

Parallel-arm Study of the Efficacy and Safety of OPC- 

6535 Tablets in the Treatment of Subjects with Active Ulcerative 

Colitis. Otsuka Pharmaceuticals, $44,093. 

A Phase 3, Multi-Center, 52-Week, Open-Label, Rollover Study 

of the Safety and Efficacy of 25 mg or 50 mg of OPC-6535 Oral 

Tablets in the Treatment of Subjects with Ulcerative Colitis. Otsuka 


 

 

Osteoporosis in Kidney Transplant Recipients: Outcome Research 

and Quality Improvement Project. Hartford Hospital Small Grant 

(statistical analysis). 

Evaluating Glomerular Filteration Rate by MDRD(Modified Diet 

in Renal Disease) formula in Hispanic Patients with Diabetes 

Mellitus. Hartford Hospital Small Grant (statistical analysis). 

Differences in Management of Heart Disease in a Sample of 

Hispanic Men and Women. 

 

 

A Randomized, Double-Blind, Placebo-Controlled, Study to Assess 

Changes in Physical Function in Elderly Patients with Idiopathic 

Anemia of Aging (IAA) Receiving PROCRIT (Epoetin Alfa). 

Ortho Biotech, $43,663. 

A Randomized, Double-Blinded, Placebo-Controlled, Study to 

Assess Changes in Physical Function in Elderly Patients with 

Anemia of Chronic Disease (ACD) Receiving PROCRIT (Epoetin 

Alfa). Ortho Biotech,$43,663. 

 

Identification of Patients with Dementia in the Emergency 

Department. 

 

 

Evaluation of Initial and Long-Term Response to Hepatitis B 

Vaccination Among Chronic Renal Failure Patients. 

A Randomized Trial of Hypertonic Saline/Heparin Flush Solution 

in the Prevention of Hemodialysis Catheter-Related Bloodstream 

Infection. Hartford Hospital Research Endowment Funds, $48,000. 

Epidemiologic and Microbiologic Characteristics of Community- 

Acquired Methicillin-Resistant Staphylococcus Aureus Infections 

in Central Connecticut, 2005. Statistical analysis supported through 

Hartford Hospital Small Grant. 

 

Linezolid in the Treatment of Subjects with Complicated Skin and 

Soft Tissue Infections Proven to Be Due to Methicillin-Resistant 

Staphylococcus Aureus. Covance Inc.,$63,556. 

 

 

A Randomized, Double-blind, Placebo-controlled Study to Assess 

the Efficacy and Safety of Cincacalcet HCl in Chronic Kidney 

Disease Subjects with Secondary Hyperparathyroidism Not 

Receiving Dialysis. Amgen, Inc., $51,674. 

An Open-Label, Single-arm Study to Assess the Safety of 

Darbepoetin alfa Manufactured by a Serum Free Bioreactor 

Technology in Subjects with Chronic Kidney Disease. Amgen, Inc., 

$82,875. 

 

 

Clinical Evaluation of a Non-Invasive Cardiac Output (NICO2) 

and Respiratory Profile Monitor. 

Clinical Investigation of the Norvametrix 521 Pulse Oximeter. 

Respironics Novametric, $1,000. 

Clinical Evaluation of the Respironics Capnostat 5 CO2 Sensor. 

Respironics, Inc.,$4,500. 

NICO Non-Invasive Cardiac Output/Respiratory Profile Monitor 

with Software for Spontaneous Breathing. Respironics, Inc., $7,000. 

 

A Study to Evaluate the Utility of Pedometer Activity Measurement 

as an Outcome for Pulmonary Rehabilitation. 

 

 

Huebner CI, Shaw S, Vivian J, Vergara C, Armin J, Orzech K. Preliminary 

findings of cultural health beliefs and practices that shape health literacy and 

chronic illness outcomes in four populations. 135th Annual Meeting of the 

American Public Health Association, November 7, 2007. 

Kuti J, Shore ET, Dobkin E, Palter M, Nicolau DP, Kuti JL. Differing 

epidemiology and resistance patters of respiratory isolates from three 

intensive care units within the same institution (Abstract K-0259). 46th 

Interscience Conference on Antimicrobial Agents and Chemotherapy, San 

Francisco, CA, Sept 27, 2006. 

Salerno E, Wolf S, Banever A, Horowitz S, Troy P, Metersky M and 

Shore ET. e use of emergency department discharge interventions in the 

treatment of asthma; A retrospective look. Am J. Resp. and Crit. Care Med. 

Vol 2, p. A254, 2005. 

Scheinberg P, Shore ET. A pilot study of the safety and efficacy of 

Tobramycin solution for inhalation in patients with severe bronchiectasis. 

Chest, Vol 127 (4), pp 120-126, 2005. 

Shore ET, Lacey J, Russomanno J, Mahoney L, Scheinblum A, Naum J and 

Walden-El D. Impact of culture changes on outcomes in a medical intensive 

care unit participating in transformation of ICU project. Am. J. Resp. and 

Crit. Care Med. Vol 2, p A596, 2005. 

Shore ET, Pylant RT, Russomanno J, Mahoney, L, Fancella C. e Loss of 

airway protective endotracheal cuff pressures over time in intubated MICU 

patients. Am J. of Resp and Crit Care Med, Vol 175 Abstracts Issue, Apr 

2007. 

Shore ET, Russomanno J, Madison DD. Improvement in outcomes after 

transfer of control of a medical stepdown unit to a multidisciplinary MICU 

team lead by rounding intensivists. Abstract in Proceedings of the American 

oracic Society.Vol 3, Apr 2006. 

Troy P, Clark R, Kakarala S, Burns J, Silverman I and Shore ET. Cerebral 

edema during treatment of diabetic ketoacidosis in an adult with new onset 

diabetes. Neurocritical Care, Vol 5 (2) 55-558, 2005.

e Department of Neurology continues to receive NIH 

grants, foundation grants, drug studies and internal grant 

support exceeding one million dollars. e department 

continues its commitment to research through ongoing and 

new protocols, research programs, publications, education 

and other activities highlighted below. 

e Balance and Gait Enhancement Laboratory (BAGEL), 

led by Dr. Leslie Wolfson, has entered its seventeenth year. 

Supported by NIH funding, the lab is currently engaged 

in a 5-year longitudinal study to define vascular disease 

risk factors leading to ischemic white matter lesions that 

compromise mobility, cognitive and urinary function. MR 

imaging for this study is performed at the IOL’s Olin Center 

with Dr. Godfrey Pearlson, Director of the Olin Center, 

as a collaborator. A number of manuscripts presenting the 

baseline data are nearing completion. 

Dr. Neer Zeevi, a 2006 graduating neurology resident, 

discussed his research, ‘Acute Stroke Management in the 

Elderly’ at the International Stroke Conference in February 

2006, and his manuscript based on Stroke Center data has 

been published in the journal, Cerebrovascular Diseases. 

Dr. Louise McCullough (Research Director of the Stroke 

Center) has been awarded two NIH R01 grants addressing 

ischemic mechanisms of cell death. Dr. Christine Turtzo, 

currently a research fellow in Dr. McCullough’s lab, will be 

joining the clinical program as a stroke fellow in the near 

future. 

e clinical neuroscience database, NERVLINE, continues 

to be updated at Hartford Hospital by Dr. Pasquale Finelli. 

It has been available on CD-ROM since 1995 and has been 

available for the Pocket PC and PALM handheld devices 

since 2002. During 2007 NERVLINE.net became available 

on-line. 

 

Faculty in the Neurology Department continue their strong 

participation in clinical trials. Dr. Mohamed Hassan 

continues to serve as the site principal investigator on two 

clinical trials addressing new treatments for Parkinson’s 

Disease. Dr Alexandra Flowers continues as the site PI for 

a clinical trial focusing on the treatment of brain metastases. 

Dr. Tanya Bilchik continues to serve as the PI on several 

clinical trials addressing new treatments for migraines. Dr. 

Joao Gomes serves as the PI on the CLEAR IVH study, 

the NEST 2 study and on a Phase I study of Intravenous 

rombolysis plus Hypothermia for Acute Treatment of 

Ischemic Stroke. Dr. Isaac Silverman serves as the PI on a 

Phase II-b study of the safety and efficacy of SUN N4057 

in subjects with Acute Ischemic Stroke and Measurable 

Penumbra on MRI. 

 

e Stroke Center has been involved in a number of acute 

and secondary stroke prevention trials during 2005-2006 and 

2006–2007. It was the top enrolling site in the US for the 

FAST trial and was the third highest enrolling site on the 

Multi-MERCI trial. e Stroke Center was the only trial site 

for this study in all of Connecticut and western Massachusetts 

from 2004 - 2006. In addition to these studies, the Stroke 

Center also actively recruited for four other acute trials. 

ICTuS-L (Intravascular Cooling in the Treatment of Stroke) 

investigates the use of hypothermia induced by endovascular 

catheter in treating stroke patients. IMS III (Interventional 

Management of Stroke) compares IV tPA plus additional 

interventional therapy to IV tPA alone in patients who 

present with acute ischemic stroke. Penumbra investigates 

the safety and effectiveness of the Penumbra system in the 

revascularization of patients presenting with acute ischemic 

stroke. NEST-2 (Neuroera Effectiveness and Safety Trial) 

investigates the use of a transcranial infrared laser in patients 

presenting with acute ischemic stroke. 

e Stroke Center was also a leading enroller among US 

sites on three Secondary Prevention Trials, IRIS, PRoFESS, 

CLOSURE I. IRIS (Insulin Resistance Intervention after 

Stroke) investigates the use of pioglitazone in patients with 

insulin resistance in reducing the risk of further vascular 

events. PRoFESS (Prevention Regimen for Effectively 

avoiding Second Strokes) compares Aggrenox versus Plavix 

with or without Micardis in the prevention of recurrent 

strokes in patients over the age of 55. Closure I investigates 

the use of the StarFlex device in closing patent foramen ovales 

to reduce the risk of recurrent stroke in patients who suffered 

a stroke or TIA. 

In addition to these trials, e Stroke Center is a participating 

site in the SWISS (Siblings With Ischemic Stroke Study) 

study, investigating genetic markers in patients and their 

siblings who have suffered an ischemic stroke. 

 

 

 

Phase I Study of Intravenous rombolysis plus Hypothermia for 

Acute Treatment of Ischemic Stroke. NINDA subcontract through 

UCSD, $25,000. 

 

SWISS: Siblings With Ischemic Stroke. NIH / NINDS, $34,320. 

 

 

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, 

Cross-Over Study to Determine the Consistency of Response

for Trexima (sumatriptan 85mg/naproxen sodium 500 mg) 

Administered During the Mild Pain Phase for the Acute Treatment 

of Multiple Migraine Attacks. Glaxo Smith Kline, $41,594. 

363-08-05: Topiramate Intervention to Prevent Transformation of 

Episodic Migraine: e Topiramate INTREPID Study CAPSS- 

381. Ortho-McNeil Pharmaceuticals, $56,600. 

AMDC-001-202: A Multi-Center, Randomized, Double-Blind, 

Placebo-Controlled, Single Dose, Efficacy & Safety Outpatient 

Study of Staccato Prochlorperazine for Inhalation in Patients with 

Migraine Headaches. Alexza Pharmaceuticals, Inc., $41,400. 

191622-080-00: A Multicenter Study Evaluating the Efficacy & 

Safety of Botox (Botulinum Toxin Type A) Purified Neurotoxin 

Complex as Headache Prophylaxis in Migraine Patients with 15 or 

more Headache Days per 4-Week Period in a 24-Week, Double- 

Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 

Followed by a 32-Week Open-Label Extension Phase. Allergan, 

$551,297. 

TRX106573: A Study of Combination Product (Sumitriptan 

Succinate and Naproxen Sodium) in Migraine Subjects Who Report 

Poor Response or Intolerance to Eletriptan (Study 1 of 2). Glaxo/ 

Smith/Kline Pharmaceuticals, $40,000. 

 

NOVARTIS EPO906: An Open-Label, Multi-Center, Phase II 

Study to Evaluate the Activity of Patupilone (EPO906), in the 

Treatment of Recurrent or Progressive Brain Metastases in Patients 

with Non-Small Cell Lung Cancer. Novartis Pharmaceuticals, 

$180,339. 

 

A Randomized, Double-Blind, Placebo Controlled, Multi- 

Center, Parallel Groups Confirmatory Efficacy and Safety Trial of 

Activated Recombinant Factor VII (NovoSeven/Niastase) in Acute 

Intracerebral Haemorrhage. Novo Nordisk A/S, Denmark, $77,000. 

Neuroera Effectiveness and Safety Trial - 2 (NEST-2): A Double 

Blind, Randomized, Controlled, Parallel Group, Multicenter, 

Pivotal Study to Assess the Safety and Effectiveness of the Treatment 

of Acute Ischemic Stroke with the Neuroera Laser System within 

24 Hours from Stroke Onset. Parexel International, $16,130. 

 

A Multi-Center, Randomized, Double-Blind Placebo-Controlled, 

Parallel Group of the Efficacy, Safety, & Tolerability of E2007 

in Levodopa Treated Parkinson’s Disease Patients with Motor 

Fluctuations. Quintiles, Inc., $84,435. 

A Multi-center, Open label Extension Study to Evaluate the Longterm 

Safety, Tolerability and Efficacy of E2007 as an Adjunctive 

erapy in Levodopa Treated Parkinson’s Disease Patients with 

Motor Fluctuations. Eisai Medical Research Inc., $16,781. 

 

A Phase IIb Randomized, Double Blind, Placebo-Controlled, 

Group-Sequential, Multi-Center, Dose Finding Study of the Safety 

and Efficacy of SUN N4057 (Piclozotan) Administered for 72 

Hours by Continuous Intravenous Infusion in Subjects with Acute 

Ischemic Stroke and Measurable Penumbra on MRI (Protocol 

Number: SPI-103). Daiichi Asubio Pharmaceut, $116,100. 

 

Evaluation of the Penumbra Stroke System in the Revascularization 

of Patients with Acute Ischemic Stroke Secondary to Intracranial 

Large Vessel Occlusive Disease. Penumbra, Inc., $22,500. 

 

 

Cerebral Venous rombosis: e Hartford Hospital Experience. 

 

Wingspan Stent System with Gateway PTA Balloon Catheter, a 

Humanitarian Use Device HUD #03-0101 HDE #H050001. 

Active projects 

 

Evaluation of Outcomes of Patients with Stroke Across the 

Continuum. Hartford Hospital Research Endowment Funds, 

$118,900. 

 

Pilot Study of Combination Temozolamide and 6-ioguanine 

Chemotherapy for Patients with Recurrent Malignant Gliomas. 

Schering-Plough, $52,500. 

A Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) 

Injection for the Treatment of Brain Metastases in Patients with 

Non Small Cell Lung Cancer Undergoing Whole Brain Radiation 

erapy. Pharmacyclics, $275,400. 

 

Clot Lysis: Evaluation Accelerated Resolution of Intraventricular 

Hemorrhage (CLEAR IVH). Genetech, $7,000; Johns Hopkins 


 

Variability in Stroke Outcomes Across the Population. 

 

Humanitarian Use Device (HDE #990011) - Transcatheterdelivered, 

Permanent Implant Designed to Close Intracardiac 

Defects - CardioSEAL Septal Occlusion System. 

Multicenter, Randomized Controlled Trial to Evaluate the Safety 

and Efficacy of the STARFlex Septal Closure System Versus 

Best Medical erapy in Patients with Stroke and/or Transient 

Ischemic Attack Due to Presumed Paradoxical Embolism rough 

a Patent Foramen Ovale (CLOSURE I Trial). NMT Medical, Inc., 

$120,000. 

PRoFESS: Prevention Regimen For Effectively Avoiding Second 

Strokes: A Double-Blind, Active and Placebo Controlled Study of 

Aggrenox vs. Clopidogrel, With and Without Micardis. Boehringer 

Ingelheim, $149,994. 

MULTI-MERCI: A Multinational Controlled Registry to Evaluate 

the Concentric MERCI Retriever System. Concentric Medical Inc., 

$187,500. 

IRIS: Insulin Resistance Intervention After Stroke. Yale University 

Medical Center, $328,591. 

 

Brain Changes and Risk Factors Causing Impaired Mobility. 

NIH subcontract through the University of Connecticut Health Center, 

$185,805.

Bertoni JM, Arlette JP, Fernandez HH, Frei K, Gordon MF, Hassan MN, 

Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton 

JP and Wolf JE Jr. Parkinson’s disease and melanoma: An epidemiologic 

evaluation. Annals of Neurology 60 (10): S71-72, 2006. 

Finelli PF, DiMario FJ. Prognosis of hypoxic-ischemic leukoencephalopathy: 

An MR imaging study. NeuroCritical Care 4: 119-126, 2006. 

Finelli PF, Gupta F, Zeevi N. Neuroimaging of bilateral caudate infarction 

manifesting as parkinsonian gait disorder. Conn Med 71: 149-150; 2007. 

 

Zeevi N., Lee NS, Chhabra J., Silverman IE, McCullough LD. Acute stroke 

management in the elderly. American Heart Association International Stroke 

Conference, 2006. 

Flowers A, Kamradt J. Sequential intra-Ommaya chemotherapy and 

systemic Tarceva prolong survival in a patient with brain and leptomeningeal 

metastases from lung adenocarcinoma. J Neuro-Oncology, 8 (4), p 345 

(Abstract P129), 2006. 

Finelli PF, Naik K, DiGuiseppe JA, Prasad A. Primary lymphoma of CNS, 

Mycophenolate Mofetil and Lupus. Lupus 15: 886-888, 2006. 

Finelli PF. Multiple simultaneous intracerebral hemorrhages: A diagnostic 

approach. NeuroCritical Care 4: 267-271, 2006. 

Finelli PF. NERVLINE, A Microcomputer Information Retrieval System 

in the Clinical Neurosciences, CD-ROM (PC/PDA). Nervline, Inc. 2006 

Finelli PF. NERVLINE, A Microcomputer Information Retrieval System 

in the Clinical Neurosciences, CD-ROM (PC/PDA). Nervline, Inc. 2007 

Finelli PF. NERVLINE.net, On-line Clinical Neurology Database, 

Nervline, Inc. 2007. 

Hassan, MN. Safety of rasagiline in elderly patients with parkinson’s disease. 

Neurology 66: 1427-1429, 2006. 

Patel KC and Finelli PF. Nonaneurysmal convexity subarachnoid 

hemorrhage. NeuroCritical Care 4: 229-233, 2006. 

Poulopoulos M and Finelli PF. Neurologic complications of sphenoid 

sinusitis: A surgical emergency. Neuro-Critical Care 7: 169-171; 2007. 

 

Silverman IE, Beland DK, J Chhabra J, McCullough LD. e Drip-and- 

Ship Approach: Starting IV t-PA for acute ischemic stroke at outside 

hospitals, prior to transfer to a regional Stroke Center. Connecticut Medicine, 

69:613-20, 2005. 

Smith WS, Budzik R, Duckwiler G, Frei D, Gobin P, Grobelny T, 

Higashida RT, Hellinger F, Huddle D, Kidwell CS, Koroshez W, 

Liebeskind D, Lutsep HL, Marks MP, Nesbit GM, Rymer M, Saver JL, 

Silverman IE, Starkman S, Sung S. Multi-MERCI Writing Committee for 

the Multi-MERCI Investigators. Safety of mechanical thrombectomy and 

intravenous t-PA in acute ischemic stroke. Results of the Multi-MERCI 

Trial, Phase I. AJNR (Am J Neuroradiol), 27: 1177-82, 2006. 

Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin P, Lutsep 

HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, 

Budzik RF, Marks MP, for the MERCI Trial Investigators. Safety and 

efficacy of mechanical embolectomy in acute ischemic stroke: results of the 

MERCI Trial. Stroke, 36:1432-40, 2005. 

omas J, Lee N. Statins provoking MELAS Syndrome: A case report. Eur 

Neurol, 57: 232-235, 2007. 

Troy PJ, Clark RP, Kakaral SG, Burns J, Silverman IE, Shore E. Diffuse 

cerebral edema as a complication of adult diabetic ketoacidosis [case report]. 

Neurocritical Care, 2:55-8, 2005. 

Zeevi N., Chhabra J., Silverman IE, Lee NS, McCullough LD. Acute stroke 

management in the elderly. Cerebrovasc Dis, 965: 1-5, 2007.

On Friday, October 12, 2007, the Institute for Healthcare 

Education and the Connecticut Nursing Research Alliance 

held its 11th Annual Conference at Hartford Hospital. 

Over 300 nurses and nursing students attended from 

across Connecticut and neighboring states. e theme: 

“Evidence-Based Practice: e Essence of Nursing” united 

present knowledge and technological advances impacting 

professional nursing practice today with the rich historical 

roots upon which our nursing profession was founded. A 

display case and photo board depicting historical nursing 

artifacts enhanced the historical theme. Among the exhibits 

displayed by Steve Lytle, Hartford Hospital Archivist, was a 

student nurse’s “Materia Medica Test” from the early 20th 

century, one of four historical artifacts donated to Hartford 

Hospital Archives by an RN benefactor, Sharon Gustafson, 

and her husband Donald of Westfield, MA. Members of the 

planning committee also dressed in vintage Hartford Hospital 

School of Nursing Uniforms representing time periods from 

1898 – 1962. 

In keeping with the conference theme, speakers addressed 

a variety of topics with implications for direct patient care, 

nursing history and nursing research. John Nelson, RN 

MS presented an impressive keynote address titled: “e 

Essentials and Impact of Relationship-Based Care”. e 

afternoon plenary session by Cindy Connolly, PhD, RN, 

PNP reflected upon “e DNA of Nursing: Knowing 

Nursing’s History”. In addition to the keynote and plenary 

by Bonnie Wesorick, RN MSN CEO of Clinical Practice 

Model Resource Center; “How to Read a Meta-Analysis” by 

David O’Sullivan, Senior Scientist, Research Administration 

Hartford Hospital; “Searching the Research Literature” by 

Arlene Freed, MLS, AHIP Manager, Web-Based Resources 

and Lisa Carter, MSLIS, Clinical Librarian for Nursing 

at Health Science Libraries of Hartford Hospital and 

“Translating Evidence into Practice” by Joanne Roy, RN, 

PhD and graduates of the premiere RN Evidence-Based 

Practice Fellowship Program of Hartford Hospital. 

Several prizes were awarded in order to recognize excellence 

in nursing research and in implementation of evidence based 

practice. First, second and third place awards were bestowed 

upon the three posters judged by conference participants to 

be of the highest quality. First place was awarded to Candi 

Lincoln RN, PCCN and Heather Marica, RNPD, from 

Middlesex Hospital for their poster entitled “Development 

of an Evidence-Based Practice Guideline: e Use of Music 

erapy to Reduce Anxiety in CCU patients”. Second 

place was awarded to Terri Savino, BSN, RN, CPHQ and 

Elizabeth Molle, MS RN from Middlesex Hospital for their 

poster, “Rapid Response Team-Excellence in Evidence- 

Based Practice”. ird place was awarded to Michele 

Murdza RN, BSN, Megan O. Schimpf, MD and Christine 

LaSala, MD from Hartford Hospital for their poster “Does 

Smelly, Cloudy Urine Call for Antibiotics?” e Excellence 

in Evidence-Based Practice Award for 2007 was accepted by 

speakers, conference participants were given the opportunity 

to choose from a variety of oral abstract presentations and 

four skill-building sessions. e skill-building sessions 

included “Advancing Interdisciplinary Professional Practice 

through Evidence-Based Tools and Automation” presented 

Susan Mullin, RN and Wioletta Chrostowski, RN on behalf 

of the nursing staff of Bliss 10I for their 100% compliance 

with existing Fall Prevention Protocols, which led to 

significant reductions in patient falls in the Cardiac Intensive 

Care Unit at Hartford Hospital.

Door prizes and decorations enhanced the conference 

experience. Numerous attendees received a variety of door 

prizes including books and CDs generously donated by 

Eclipsys, Lippincott Publishing and Lynn Alchin, RN PhD 

from the University of Connecticut School of Nursing. 

Beautiful vases, floral arrangements and decorations created 

by Ellen Mendes and her staff at Creations at Work graced 

each table. e food service, provided by Wayne Oden 

and his staff from Hartford Hospital’s Food & Nutrition 

Department, was superb. 

We give special thanks to our sponsors, the Hartford Hospital 

Research Program (for an Educational Grant) and Eclipsys. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In order to highlight the growing leadership roles of nurses 

in research, the following list of projects includes those that 

involve nurses as either principal or co-investigators. Many of 

these are also listed in this report under other divisions. 

 

 

 

Breastfeeding Education and Support Trial for Obese Women: 

Early Dyad Dynamics (BESTOW:EDD). CDC subcontract through 

the University of Connecticut, $16,796. 

 

 

Perspectives of Clinicians and Social Service Personnel on the Needs 

of Older Adults With HIV/AIDS. University of Connecticut, $750. 

 

 

Assessment of the Prevalence of Delirium in ree Unique 

Populations of Hospitalized Persons. Pauline A. Toner Fund, 

UCONN School of Nursing, $1,500. 

 

 

Practicing Out Loud and the Role of Nursing in a Hospital Setting. 

Small Grant, $10,775. 

 

Examination of Interventions within Hartford Hospital’s Keeping 

In Touch Program. Statistical analysis supported through Hartford 

Hospital Small Grant. 

 

 

Inpatient Psychiatric Unit Medications and Falls Outcomes.

Transition from Student to Graduate Nurse. 

 

Caring for the Dying: A Qualitative Research Proposal. 

 

Nurses’ Experience in Caring for Patients with Substance Abuse. 

 

Evaluation of Dialysis/Transplant Nurses Knowledge and Self- 

Efficacy Regarding Advance Directives. 

 

National Database of Nursing Quality Indicators. 

 

A National Survey of Nurses’ Awareness of the Tobacco-Free 

Nurses Website. 

RN Evidence Based Practice Fellowship Program: Prospective and 

Systematic Evaluation of an Organizational-Level Evidence Based 

Practice Initiative. 

 

Geriatric Resource Nurse Program Evaluation. 

 

 

Evaluation of Application of Evidence Based Practice Project at 

Hartford Hospital 1998-December 2004. 

 

Do Nurses In An Acute Care Setting Know About Alternative 

erapies, Especially Reiki? 

 

Flight Team Management of Cardiac Patients. 

Rest Patterns Prior to Night Shift Work in Rotor Wing Flight 

Programs. 

Body Temperature Preservation in Patients Transported by Air 

Medical Helicopter. 

Rest Patterns of 24-Hour Shift Workers in Rotor Wing Flight 


Compliance with Safety Behavior in Rotor Wing Air Medical 

Transport. 

Evaluation of a Process Improvement Plan for Managing Cardiac 

Chest Pain. 

Flight Nurse Administration of Analgesic and Amnestic Medications 

to Patients Receiving Neuromuscular Blocking Agents. 

Evaluation of Trauma Analgesia in Patients Transported by Air 


Actual Work Time Totals for Air Medical Crew Members. 

 

Oral Health and its Implications During Pregnancy. 

 

Reiki: What are Its effects for Patients During Hemodialysis? 

Hartford Hospital Research Endowment Funds, $9,963. 

 

Development of a Prenatal Nutrition Guide for Puerto Rican 

Women. 

Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy 

Outcomes Among Low-Income Latinas. 

 

Assessment, Management and Treatment of Delirium in 

Hospitalized Older Adults: Identifying Related Outcomes. 

 

Nursing Orientees Baseline Knowledge of Palliative Care 

Concepts. 

 

Breastfeeding Education and Support Trial for Obese Women 

(BESTOW). Donaghue Medical Research Foundation subcontract 

through the University of Connecticut, $20,590. 

 

 

Beekman K and Strycharz C. Integration strategies associated with 

evidence- based recommendations concerning effective pain management. 

11th Annual Research Conference. Evidence Based Practice: e Essence of 

Nursing, Hartford CT, Oct. 2007. 

Blair E and Gruman C. Falls in an inpatient geriatric psychiatric population. 

Journal of the American Psychiatric Nurses Association, 11(6), 351-354, 2006. 

Caramanica L and Roy J. Evidence based practice: Creating the environment 

for practice excellence. Nurse Leader, 4(6), 38-41, 2006. 

Caramanica L, Horowitz S, Bafundo N, and Roy JF. Practicing out loud 

(POL) and the role of nursing: To what extent if any is the public’s 

understanding of nursing affected when the nurse “practices out loud”. 10th 

Annual Nursing Research Conference, October, 2006. 

Ericson J, Montano J, Johnson S and Strong A. Integration strategies 

associated with evidence-based recommendations concerning use of safe 

patient handling guidelines. 11th Annual Research Conference: Evidence based 

Practice: e Essence of Nursing, Hartford, CT October, 2007. 

Hagstrom A. Perceived barriers to implementation of a successful sharps 

safety program. AORN Journal, 83 (2), pp.391-397, 2006. 

Roy JF , Beekman K, Ericson J, Montano J and Strycharz C. RN Evidencebased 

practice fellowship program: Prospective and systematic evaluation of 

an organizational-level EBP initiative. Presented at the 6th Annual Summer 

Institute on Evidence-based practice: Quality and Safety. San Antonio TX, 

2007. 

Stetler C.B and Caramanica L. Evaluation of an evidence-based practice 

initiative: Outcomes, strengths and limitations of a retrospective, 

conceptually-based approach. Worldviews on Evidence-Based Nursing, 4(4), 

187-199, 2007.

e Cancer Clinical Research Office (CCRO) is an active 

participant in a variety of national cooperative group research 

studies and several industry-supported trials. Hartford 

Hospital’s affiliation with Dana Farber Partners/Cancer 

 

Care has provided the CCRO with the opportunity to open 

additional cancer clinical trials. e CCRO supports multiple 

National Cancer Institute (NCI) protocols sponsored by the 

Cancer and Leukemia Group B (CALGB), the Gynecologic 

Oncology Group (GOG), the National Surgical Adjuvant 

Breast and Bowel Project (NSABP) and the Radiation 

Oncology erapy Group (RTOG). 

e NSABP has recently opened several new breast cancer 

treatment trials. NSABP B-40 is a trial which involves 

chemotherapy before surgery for women with palpable breast 

masses with half of the women receiving bevacizumab, a 

drug which blocks a tumor’s blood supply, after surgery. 

NSABP B-42 is a trial for post-menopausal ER+/PR+ 

women diagnosed with invasive breast cancer to determine 

if five years of additional Letrozole will improve survival. 

NSABP B-39/RTOG 413 compares radiation therapy 

techniques for early stage breast cancer. e PACCT-1 trial 

will assign treatment regimens based on pathology specimens 

of women with ER+/PR+ node negative breast cancer. Dr. 

Patricia DeFusco is the principal investigator for the NSABP 

treatment and prevention trials at Hartford Hospital. Edith 

Clark, RN, OCN is the NSABP trial coordinator at Hartford 

Hospital. 

e GOG continues to sponsor cutting edge chemotherapy 

trials for the treatment of gynecologic cancers. GOG # 

212 is focused on tumor recurrence in women who have 

recently received chemotherapy for ovarian cancer. is trial 

compares tumor recurrence among participants 

who receive additional chemotherapy 

(either standard of care Taxol or Xyotax, an 

experimental drug which can be delivered over 

a shorter period of time) to those who receive 

standard of care physician observation. GOG # 

218 is an ovarian cancer treatment trial in which 

women are randomized to receive bevacizumab 

in addition to standard chemotherapy. e 

GOG trials continue to recruit gynecologic 

oncology patients at Hartford Hospital under 

principal investigators Dr. Stacy Nerenstone 

and Dr. Amy Brown. Susan Zahorodni, RN 

has joined the team this year as the GOG trial 

coordinator. 

e CCRO has participated in a series of 

influential trials involving Dana Farber Partners 

and the NCI CALGB. One Dana Farber 

trial for metastatic breast cancer led to FDA 

approval of a new drug, epothilone. Several 

CALGB trials are ongoing. e CALGB 

40101 trial compares Cytoxan and Adriamcyin 

chemotherapy versus Taxol in women with 

node negative breast cancer. CALGB 70301, a quality of life 

and employment study, was opened this year as a companion 

study to CALGB 40101. CALGB 79803 is an early stage 

lung cancer trial, the goal of which is to determine whether 

selenium is effective in preventing the recurrence of lung 

cancer and to collect blood samples for the development of 

biomarkers. Trials are also ongoing for cancers of the colon, 

gastric tract, kidney, and for lymphomas. Dr. Robert Siegel is 

the principal investigator for the Dana Farber and CALGB 

trials. Karen Burnham, RN coordinates the CALGB trials. 

Hartford Hospital continues as an affiliate site for trials 

sponsored by the NCI Radiation erapy Oncology Group 

(RTOG). Dr. Kenneth Leopold is the principal investigator 

for the RTOG trials at Hartford Hospital and Diane Neri, 

RN, OCN coordinates the RTOG trials as well as industrysponsored 

cancer clinical trials. e EXPLORE trial, an 

industry-sponsored trial, collected blood samples from

participants diagnosed with bone marrow failure disorders 

with the goal of developing biomarkers for paroxysmal 

nocturnal hemoglobinuria, a rare blood disorder. Another 

industry-sponsored trial, conducted for patients diagnosed 

with non-small cell lung cancer who received previous 

treatment, gave patients an opportunity to receive VEGF 

trap, a drug that blocks the tumor’s blood supply. 

Finally, the best “treatment” for cancer is prevention or early 

detection. Since 1995, the CCRO has been involved in the 

Connecticut Breast & Cervical Cancer Early Detection 

Program (CBCCEDP), a state sponsored outreach program 

that provides clinical breast examinations, mammograms and 

cervical cancer screening to the underserved and underinsured 

 

 

women of the greater Hartford area. e program has 

detected cancer in a totoal of 61 women since its inception. 

ese outreach efforts are funded by the Centers for Disease 

Control and Prevention (CDC) and organized by the State 

of Connecticut Department of Public Health. Dr. Merwood 

Jones serves as medical director, Maria Palomares is the 

case manager, and Maria Furlow is the outreach educator. 

e CCRO is in its seventh year of support through the 

CDC-funded WISEWOMAN grant, which offers glucose 

and cholesterol screening and interventions such as nutrition 

counseling, cooking and exercise demonstrations for women 

over 40 years old. e CBCCEDP has partnered with the 

American Heart Association to offer women under age 40 

who are enrolled in the CBCCEDP, an opportunity for 

free cholesterol screenings and cardiovascular educational 

materials. e AVON Foundation Breast Care Fund grant 

supports outreach activities such as the distribution of breast 

cancer education materials in the community targeting 

underserved and underinsured women. 

ese are intriguing times in cancer research and treatment. 

e CCRO remains committed to our patients and families 

through education, screening, and clinical trials. 

 

 

 

CHESS (Comprehensive Health Enhancement Support 

System) is an Internet-based information and support 

system for patients with breast or prostate cancer. ese 

patients often have difficulty finding good information, are 

hesitant or unable to attend support group meetings, and 

often feel pressured to make difficult decisions with little 

information. e CHESS program helps patients and their 

families become more actively involved in their treatment 

and recovery. It makes high quality information and social 

support easily accessible and helps patients make choices and 

decisions based on their individual needs. 

In partnership with the University of Wisconsin, 

Hartford Hospital has been offering CHESS to its 

patients for more than 10 years and has reached over 

1200 women with breast cancer and 373 men with 

prostate cancer. anks to our generous donors, we 

own 62 laptop computers and loan them to patients 

who do not have computers. We also continue to 

collaborate with Windham Hospital to offer CHESS 

to patients in the Eastern part of the state. is year 

we completed enrollment in two innovative NCIsponsored 

studies, “Centers of Excellence in Cancer 

Communication: Mentor Integration Project” and 

“Centers of Excellence in Cancer Communication: 

Component and Couple Analysis of Cancer 

Communication.” Enrollment for these projects 

was completed in May of 2007 with 215 newly 

diagnosed women. We expect that these studies will 

provide valuable information about ways in which the 

Internet and other communication tools may be used 

to improve the quality of life for all cancer patients. 

Additionally, the University of Wisconsin has 

received one of 4 NCI Communications “Centers” 

grants, and Hartford Hospital is a primary collaborator 

along with MD Anderson Cancer Center. Our newest 

CHESS research project focuses on men newly diagnosed 

with prostate cancer and is titled: Human and Computer 

Mentors for Prostate Cancer Patients. is study, funded by 

the National Cancer Institute, aims to determine if a Human 

Cancer Mentor, CHESS, or a combination of CHESS 

and the Human Cancer Mentor improve quality of life for 

men with prostate cancer. e study began enrollment in 

August and will recruit 120 patients from Hartford Hospital 

over the next year. e study’s primary outcome measure is 

Patient Quality of Life with secondary outcomes of patient 

preparedness for interactions with clinicians and mentors, 

self-efficacy, health care use, decision satisfaction, and 

considerations of treatment alternatives. is study will help 

us learn how a human cancer mentor might affect a prostate 

cancer patient’s quality of life. 

We are also collaborating with the University of Connecticut- 

Storrs Departments of Psychology and Family Studies on 

two other innovative Quality of Life studies. One study will 

address the experiences of colorectal cancer patients and will

examine their levels of psychological stress, health related 

quality of life and need for psychosocial intervention. In 

addition, it will identify factors that may place them at higher 

risk for poorer psychosocial outcomes. We will partner with 

Connecticut Surgical Group to recruit approximately 200 

eligible patients and their spouses/partners over the next 

year. 

e second study will focus on breast cancer. e study will 

examine differences in treatment decision-making between 

African-American, Hispanic and Caucasian women with 

breast cancer at two time points post-surgery to address 

how different socio-cultural, psychosocial factors and coping 

strategies may influence treatment decision-making. is 

study will provide valuable information how these factors 

may contribute to health disparities among minority breast 

cancer patients and will inform the development of further 

interventions in this area. Our participation in these studies 

underscores our ongoing commitment to providing the very 

best in care to all of our cancer patients. 

 

 

 

 

e Cancer Registry database at Hartford Hospital was 

established in 1928 and contains over 85,000 cancer cases. 

It submits over 2,500 new cancer cases to the Connecticut 

Tumor Registry, accounting for approximately 15% of all 

cancers reported statewide. All Connecticut hospitals and 

labs are required by Connecticut state statute to report all 

diagnoses of cancer to the Connecticut State Tumor Registry 

at the Department of Health, the oldest and most widely 

used central registry in the nation. e information housed 

in the Hartford Hospital system allows us to access valuable 

information on patient demographics and cancer incidence. 

ese data have been used to support presentations, research, 

certificates of need and grant applications. In addition, they 

have been used to identify areas for further improvements in 

patient care. 

 

 

Directed by Andrew Salner MD, Hartford Hospital’s Gray 

Cancer Center received a 2 year grant from the CDC in 2005 

to develop and disseminate a program to raise awareness 

of prostate cancer among urban African-American men 

utilizing trained barbers as lay health advisors. Following the 

collaborative development of educational materials, Hartford 

Hospital’s existing barbershop program was extended to New 

Haven and Bridgeport, CT with the collaboration of Yale 

New Haven Hospital and St. Vincent’s Hospital. Results of 

this successful project were presented at numerous meetings 

including the NCI Disparities Summit and the CDC Cancer 

Disparities meeting. 

 

 

 

A Phase II Study Of Fludarabine + Rituximab Induction Followed 

by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) 

Consolidation in Untreated Patients with Beta-Cell Chronic 

Lymphocytic Leukemia. CALGB/Dana-Farber, $8,400. 

 

GOG 209: Randomized Phase III Trial of Doxorubicin / Cisplatin 

/ Paclitaxel and G-CSF Versus Carboplatin / Paclitaxel in Patients 

with Stage III & IV or Recurrent Endometrial Cancer. G O G , 

$6,313. 

GOG 219: A Phase III, Randomized Trial of Weekly Cisplatin and 

Radiation Versus Cisplatin and Tirapazamine (IND #46525) and 

Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma 

Limited to the Pelvis. GOG, $6,601. 

GOG 215: A Phase II Randomized Study of the Effect of 

Zoledronic Acid (Zometa) versus Observation on Bone Mineral 

Density of the Lumbar Spine in Women who Elect to Undergo 

Risk-Reducing Surgery that Results in Removal of Both Ovaries. 

GOG,$3,960. 

GOG 0170K: A Phase II Evaluation of Mifepristone in the 

Treatment of Recurrent or Persistent Ovarian or Primary Peritoneal 

Cancer. GOG, $6,313. 

 

NSABP PROTOCOL FB-AX-003: A Phase 2 Study of 

Neoadjuvant Chemotherapy with Sequential Weekly Nanoparticle 

Albumin Bound Paclitaxel (Abraxane) Followed by 5 Fluorouracil, 

Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast 

Cancer. NSABP, $17,500. 

NSABP B-42: A Clinical Trial to Determine the Efficacy of Five 

Years of Letrozole Compared to Placebo in Patients Completing 

Five Years of Hormonal erapy Consisting of an Aromatase 

Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging 

Disease-Free Survival in Postmenopausal Women with Hormone 

Receptor Positive Breast Cancer. NSABP, $23,100. 

A Randomized Phase III Trial of Neoadjuvant erapy in 

Patients with Palpable and Operable Breast Cancer Evaluating 

the Effect on Pathological Complete Response (pCR) of Adding 

Capecitabine or Gemcitabine to Docetaxel when Administered 

Before AC (Adriamycin - Cytoxan ) with or without Bevacizumab 

and Correlative Science Studies Attempting to Identify Predictors 

of High Likelihood for pCR with Each of the Regimens. 

NSABP,$10,450. 

 

RTOG 0214, A Phase III Comparison Of Prophylactic Cranial 

Irradiation Versus Observation In Patients With Locally Advanced 

Non-Small Cell Lung Cancer. RTOG, $18,200. 

A Phase II Randomized Trial Of Surgery Followed By 

Chemoradiotherapy Plus C225 (Cetuximab) for Advanced 

Squamous Cell Carcinoma of the Head and Neck. RTOG, 

$18,900. 

RTOG 0232, A Phase III Study Comparing Combined External 

Beam Radiation And Transperineal Interstitial Permanent

Brachytherapy With Brachytherapy Alone for Selected Patients 

with Intermediate Risk Prostatic Carcinoma. RTOG, $20,700. 

 

GOG 218: A Phase III Trial of Carboplatin and Paclitaxel 

Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent 

Bevacizumab (RhuMab VEGF, NSC #704865, IND#7921) 

Followed by Placebo, versus Carboplatin and Paclitaxel Plus 

Concurrent and Extended Bevacizumab Women with Newly 

Diagnosed, Previously Untreated Suboptimal Advanced Stage 

Epithelial Ovarian and Peritoneal Primary Cancer. GOG, $49,368. 

 

Reaching Urban African-American Men with Prostate Cancer 

Screening Information. CDC - National Cancer Prevention & Control 

Program, $249,900. 

Human and Computer Mentors for Prostate Cancer Patients 

- CHESS Program. NCI subcontract through the University of 

Wisconsin, $111,559. 

NCCCP Pilot. SAIG-Fredericks/NIH, $1,457,633. 

 

CALGB 119901 Quality of Life of African-American Cancer 

Survivors. CALGB via DANA-FARBER, $1,000. 

ECOG PACCT-1: Program For e Assesment Of Clinical Cancer 

Tests: Trial Assigning Individualized Options for Treatment: e 

TAILORx Trial. ECOG, $21,000. 

ECOG E2603: A Double-blind, Randomized, Placebo-Controlled 

Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus 

Carboplatin, Paclitaxel and placebo in Patients with Unresectable 

Locally Advanced or Stage IV Melanoma. ECOG via CTSU, 

$15,400. 

NCCTG N0147: A Randomized Phase III Trial Of Oxaliplatin 

(OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or 

Without Cetuximab (C225) After Curative Resection For Patients 

With Stage III Colon Cancer. CALGB via Dana-Farber, 

$20,000. 

CALGB 70301: A Clinical Trial to Determine e Quality of Life, 

Employment and Informal Care Cost Analysis in Women Receiving 

Adjuvant Chemotherapy For Breast Care With 0-3 Positive Axillary 

Lymph Nodes. CALGB via Dana Farber, $4,400. 

 

 

City of Hartford Comprehensive Cancer Prevention and Control 

Plan. City of Hartford Department of Health and Human Services, 

$25,000. 

 

 

Evaluation of Multiple Biomarker Assay to Estimate Risk of 

Ovarian Cancer in Patients Presenting with a Pelvic Mass. Fujirebio 

Diagnostics, $66,500. 

 

A Randomized Phase III Trial Comparing Sequential erapy with 

TPF/Chemoradiation (ST) to Cisplatin-Based Chemoradiotherapy 

with Accelerated Concomitant Boost Radiotherapy (CRT) for 

Locally Advanced Squamous Cell Cancer of the Head and Neck. 

Dana Farber, $19,000. 

A Multicenter, Open-Label, Single-Arm, Two-Stage Phase II 

Study of the Efficacy and Safety of AVE0005 (VEGF Trap) 

Administered Intravenously Every 2 Weeks in Subjects with 

Platinum-, Taxane- and Erlotinib-Resistant Advanced Non-Small- 

Cell Lung Adenocarcinoma (ARD6123). Sanofi Aventis, $246,775. 

Alexion EXPLORE: EXamination of PNH, by Level Of CD59 

on REd and white blood cells, in bone marrow failure syndromes. 

Alexion Pharmaceuticals, $27,100. 

 

 

Trends in Renal Cancer Surgery: e Hartford Hospital Experience. 

Small Grant, $1,280. 

 

 

Prognostic Value of HER2 Status in High Risk Node Negative 

Breast Cancer. $3,200. 

Clinical Outcomes Following Brachytherapy for Prostate 

Carcinoma. $4,800. 

Clinical and Quality of Life Outcomes Following Diagnosis 

of Prostate Adenocarcinoma. Supported through Departmental 

($27,000) and Medical Staff funds ($10, 762). 

 

Retrospective Analysis of Breast Cancers Negative for Estrogen 

Receptor, Progesterone Receptor and HER-2/neu (Basal Like 

Cancers). $1,600. 

 

 

Retrospective Review of Adrenal Carcinoma. 

 

e Utility of Coronal CT Reformatting in Predicting Extent of 

Disease in Ovarian Cancer and Pelvic Mass Patients. 

 

Pilot Study on Mobile Mammography: Estimating Eligibility and 

Participation in a Senior Housing Setting. 

 

Meningioma: Risk Factors and Quality of Life (Hartford 

Hospital). 

Meningioma: Risk Factors and Quality of Life (Windham 


Environment, Gene, and Testicular Cancer Risk (Hartford 


Environment, Gene, and Testicular Cancer Risk (Windham 


Psychosocial Needs of Colorectal Cancer Patients and Partners in 

the First Year After Diagnosis. 

Psychosocial Needs Assessment of Colorectal Cancer Patients and 

Partners in the First Year After Diagnosis (Qualitative Research 

Phase). 

 

Prediction of Chemotherapy Tolerance in Elderly Patients with 

Non-Small Cell Lung via a Screening Functional Assessment: A 

Pilot Study.

NSABP B-34: A Clinical Trial Comparing Adjuvant Clodronate 

erapy vs. Placebo in Early Stage Breast Cancer Patients Receiving 

Systemic Chemotherapy and/or Tamoxifen or No erapy. NSABP, 

$15,000. 

A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin 

(LV) and Oxaliplatin with 5-FU Plus LV for the Treatment of 

Patients with Stages II and III Carcinoma of the Colon (C-07 

NSABP). 

NSABP-B-31: A Randomized Trial Comparing e Safety And 

Efficacy of Adriamycin And Cyclophosphamide Followed By 

Taxol (AC-T) To at Of Adriamycin And Cyclosphosphamide 

Followed By Taxol Plus Herceptin (AC-T+H) in Node-Positive 

Breast Cancer Patients Who Have Tumors at Overexpress 

HER2. 

A ‘Unified’ Trial to Compare Short Intensive Pre-operative Systemic 

Adrimycin/Cyclophosphamide erapy with Similar erapy 

Administered in Conventional Post-operative Fashion (B-18). 

A Clinical Trial to Compare Sequential Methotrexate, 5- 

Fluorouracil with Conventional CMF in Primary Breast Cancer 

Patients with Negative Nodes and Estrogen Receptor Negative 

Tumors (B-19). 

A Clinical Trial to Evaluate Natural History and Treatment of 

Patients with Non-Invasive Intraductal Adenocarcinoma. 

A Clinical Trial to Assess Tamoxifen in Patients with Primary 

Breast Cancer and Negative Axillary Nodes Whose Tumors are 

Positive for Estrogen Receptors (B-14). 

A Clinical Trial to Determine the Worth of Chemotherapy and 

Tamoxifen Over Tamoxifen Alone in the Management of Patients 

with Primary Invasive Breast Cancer, Negative Axillary Nodes and 

Estrogen Receptor Positive Tumors (B-20). 

A Clinical Trial to Determine the Worth of Tamoxifen and the 

Worth of Breast Radiation in the Management of Patients with 

Node-negative, Clinically Occult, Invasive Breast Cancer Treated 

by Lumpectomy (B-21). 

A Clinical Trial to Evaluate the Effect of Dose Intensification 

and Increased Cumulative Dose of Postoperative Adriamycin- 

Cyclophosphamide (AC) erapy on the Disease-Free Survival 

and Survival of Patients with Primary Breast Cancer and Positive 

Axillary Nodes (B-22). 

A Clinical Trial Comparing Short Intensive Adriamycin 

Cyclophosphamide +/- Tamoxifen with Conventional 

Cyclophosfamide Methotrexate in Node-negative Breast Cancer 

Patients with ER-negative Tumors (B-23). 

A Clinical Trial to Evaluate the Worth of Tamoxifen in Conjunction 

with Lumpectomy and Breast Irradiation for the Treatment of 

Noninvasive Intraductal Carcinoma (DCIS) of the Breast (B-24). 

A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin 

with or without Interferon Alfa-2a in Patients with Dukes’ B and C 

Carcinoma of the Colon (C-05). 

A Clinical Trial to Determine the Worth of Tamoxifen for 

Preventing Breast Cancer (NSABP P-1). 

A Clinical Trial to Evaluate the Effect of Dose Intensification 

and Increased Cumulative Dose of Postoperative Adriamycin- 

Cyclophosphamide (AC) erapy with G-CSF on the Disease-Free 

Survival and Survival of Patients with Primary Breast Cancer and 

Positive Axilary Nodes (B-25). 

A Randomized Trial Evaluating the Worth of Paclitaxel (Taxol) 

Following Doxorubicin (Adrimycin)/ Cyclophosphamide in Breast 

Cancer Patients with Positive Axillary Nodes (B-28). 

A Randomized Trial Comparing Preoperative Doxorubicin 

(Adriamycin) Cyclophosphamide (AC) to Preoperative AC 

Followed by Preoperative Docetaxel (Taxotere) and to Preoperative 

AC Followed by Postoperative Docetaxel in Patients with Operable 

Carcinoma of the Breast (B-27). 

A Trial to Evaluate the Worth of Tumor Biomarkers Obtained 

by FNA or Core Biopsy in Predicting Response to Preoperative 

Chemotherapy and Long-Term Outcome in Patients with Operable 

Breast Cancer Who are Participating in NSABP Protocol B-27. 

A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus 

Leucovorin (LV) with 5-Fluorouracil (5-FU) Plus LV in the 

Treatment of Patients with Stages II and III Carcinoma of the 

Colon (C-06). 

A Trial to Evaluate the Worth of Serum ErbB-2 Extracellular 

Domain and Serum ErbB-2 Antibodies in Predicting Response to 

Preoperative Chemotherapy and Long-Term Outcome in Patients 

with Operable Breast Cancer Who are Participating in NSABP 

Protocol B-27. 

A Clinical Trial to Evaluate the Benefit of Adding Octreotide 

(SMS 202-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and 

Chemotherapy in Patients with Axillary Node-negative, Estrogenreceptor-positive, 

Primary Invasive Cancer (B-29). 

NSABP B-30: A ree Arm Randomized Trial to Compare 

Adjuvant Adriamycin and Cycophosphamide Followed by Taxotere 

(AC-T); Adriamycin and Cyclophosphamide (ATC) in Breast 

Cancer Patients with Positive Axillary Lymph Nodes. 

STAR: Study of Tamoxifen and Raloxifene for the Prevention of 

Breast Cancer. NSABP, $75,000. 

Effects of Selective Estrogen Receptor Modulators on Cognitive 

Aging: Cognition in the Study of Tamoxifen and Raloxifene (Co- 

STAR). NSABP, $1,000. 

NSABP B-33: A Randomized, Placebo-Controlled, Double-Blind 

Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3 

NO-1 MO Postmenopausal Breast Cancer Patients Completing at 

Least Five Years of Tamoxifen erapy. NSABP, $1,000. 

NSABP B-35: A Clinical Trial Comparing Anastrozole with 

Tamoxifen in Postmenopausal Patients with Ductal Carcinoma In 

Situ (DCIS) Undergoing Lumpectomy with Radiation erapy. 

NSABP, $21,000. 

NSABP B-36: A Clinical Trial of Adjuvant erapy Comparing Six 

Cycles of 5-Flouroracil, Epirubicin and Cyclophosphamiode (FEC) 

to Four Cycles of Adriamycin and Cyclosphosphamine (AC), With 

or Without Celocoxib, in Patients with Node-Negative Breast 

Cancer. NSABP, $16,000. 

Breast Conservation Rates in Breast Cancer Surgery: Comparison

Based On Ethnicity, Race, and Insurance Status. 

NSABP P-3: Celecoxib Polyp Prevention Trial in Participants with 

Resected Stage I Colon Cancer. NSABP, $38,000. 

NSABP B-38: A phase III Adjuvant Trial Comparing ree 

Chemotherapy Regimens in Women with Node-Positive Breast 

Cancer: Docetaxel / Doxorubicin / Cyclophosphamide (TAC); 

Dose-Dense (DD) Doxorubicin / Cyclophosphamide Followed by 

DD Paclitaxel (DD AC>P); DD AC Followed by DD Paclitaxel 

Plus Gemcitabine (DD AC > PG). NSABP, $19,000. 

A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil 

(5-FU), Leucovorin, And Oxaliplatin (mFOLFOX6) Every Two 

Weeks With Bevacizumab To e Same Regimen Without 

Bevacizumab For e Treatment Of Patients With Resected Stages 

II And III Carcinoma. NSABP, $19,000. 

A Randomized Phase III Study of Conventional Whole Breast 

Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for 

Women With Stage 0,I or II Breast Cancer. NSABP/RTOG, 

$20,900. 

 

Compassionate Use Protocol DMS: A Prospective Study of 

Adjuvant Radiation erapy After Resection of Borderline and 

Malignant Phyllodes Tumors. 

 

GOG #182: A Phase III Randomized Trial of Paclitaxel and 

Carboplatin Versus Triplet or Sequential Doublet Combinations in 

Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma. 

GOG, $1,500. 

Phase III Randomized Trial of 12 Months vs 3 Months of Paclitaxel 

in Patients with Advanced Ovarian Cancer Who Attain a Clinically 

Defined Complete Response (CR) Following Platinum/Paclitaxelbased 

Chemotherapy (GOG 178). 

A Randomized Phase III Trial of IV Carboplatin (AUC6) and 

Paclitaxel 175 mg/m2 Q 21 days x 3 courses Plus Low Dose 

Paclitaxel 40 mg/m2/wk versus IV Carboplatin (AUC6) and 

Paclitaxel 175/mg/m2 Q 21 days x 3 courses Plus Observation in 

Patients with Early Stage Ovarian Carcinoma (GOG 175). 

GOG #199: Prospective Study of Risk-Reducing Salpingo- 

Oophorectomy and Longitudinal CA-125 Screening Among 

Women at Increased Genetic Risk of Ovarian Cancer. GOG, 

$20,000. 

GOG #212: A Randomized Phase III Trial of Maintenance 

Chemotherapy Comparing 12, Monthly Cycles of Single Agent 

Paclitaxel or Xyotaxa (Ct-2103 (Ind #70177)), Versus No 

Treatment Until Documented Relapse in Women With Advanced 

Ovarian or Primary Peritoneal Cancer who Achieve a Complete 

Clinical Response to Primary Platinum/Taxane Chemotherapy. 

GOG, $49,500. 

 

Grant Application for CDC CBCCEDP/WISEWOMAN Patient 

Compliance/Incentive Awards. 

 

Self-Determined Length and Patterns of Usage for the Internet- 

Based Information and Support Program CHESS (Comprehensive 

Health Enhancement Support System) “Living with Breast 

Cancer.” 

e Effects of Training and Follow-up Patients Contact on 

Utilization of the Internet-Based Information and Support Program 

CHESS (Comprehensive Health Enhancement Support System). 


Centers of Excellence in Cancer Communication: Component and 

Couple Analysis of Cancer Communication (CHESS Program). 

NCI subcontract through the University of Wisconsin - Madison, 

$101,362. 

Center of Excellence in Cancer Communications - Mentor 

Integration Project (CHESS Program). NCI subcontract through the 

University of Wisconsin, $101,362. 

Defining the Role of the Breast Cancer Resource Specialist (BCRS) 

and Measuring its Effect on Patients’ Satisfaction with Care, 

Understanding of Support Services, Self-Efficacy, and Quality of 

Life. 

Web-Based Support for Informal Caregivers in Cancer (CHESS 

- Comprehensive Health Enhancement Support System). N I H 

subcontract through the University of Wisconson-Madison, $137,747. 

 

Combined-Modality Treatment for Operable Pancreatic 

Adenocarcinoma. 

 

Multi-Center, Open-ended, Double-Blind, Placebo-controlled, 

Phase III Study of AE941 in Addition to Combined Modality 

Treatment Chemotherapy/ Radiotherapy for Locally Advanced 

Unresectable Non-Small-Cell Lung Cancer (AE-941). NCI/Cancer 

Treatment Evaluation Program, $40,750. 

Phase III Double-blinded Randomized Trial of 13-Cis Retinoic 

Acid (13-cRA) to Prevent Second Primary Tumors (SPTs) in Stage 

I Non-small Cell Lung Cancer (ECOG-91025). 

A Phase III Comparison of Fludarabine Phosphate vs Chlorambucil 

vs Fludarabine Phosphate + Chlorambucil in Previously Untreated 

B-Cell Chronic Lymphocytic Leukemia (C9011). 

A Phase II Study of Neoadjuvant Chemotherapy and Radiation 

erapy in the Management of High-risk, High-grade, Soft Tissue 

Sarcomas of the Extremities and Body Wall (ECOG R9514). 

Phase III Trial of CHOP versus CHOP and Chimeric Anti-CD20 

Monoclonal Antibody (IDEC-C2B8) in Older Patients with 

Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell 

Histology Non-Hodgkin’s Lymphoma (CALGB 9793). 

A Randomized Phase III Trial of Sequential Chemotherapy Using 

Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent 

Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 

21 Day Intervals in Women with Node Positive Stage II/IIIA Breast 

Cancer (C9741). 

A Phase III Randomized Double Blinded Study of Letrozole Versus 

Placebo in Women with Primary Breast Cancer Completing Five or 

More Years of Adjuvant Tamoxifen (CALGB Study #49805). 

Phase III Chemoprevention Trial of Selenium Supplementation in 

Persons with Resected Stage I Non-Small Lung Cancer (CALGB 

79803/E5597). CALGB, $1,500. 

CALGB #89904: A Randomized Phase II Study of Gemcitabine/

Cisplatin, Gemcitabine/Docetaxel, Gemcitabine/Irinotecan, or 

Fixed Dose Rate Infusion Gemcitabine in Patients with Metastatic 

Pancreatic Cancer. CALGB / Dana-Farber Cancer Institute, $1,500. 

A Phase III Study of Delayed versus Immediate Second-Line 

erapy with Docetaxel after Gemcitabine plus Carboplatin in 

Advanced Non-Small Cell Lung Cancer (Dana Farber #01-235). 

Dana Farber / Partners Cancer Care, $10,400. 

CALGB #99811: A Phase II Study of Neo-Adjuvant Paclitaxel, 

Estramustine and Carboplatin (TEC) Plus Androgen Ablation Prior 

to Radiation erapy in Patients with Poor Prognosis Localized 

Prostate Cancer. Dana Farber / Partners Cancer Care, $8,000. 

A Randomized, Double Blind, Placebo-Controlled Trial of 

Celecoxib (Celebrex) vs Placebo in Men with Prostate Cancer 

with Rising PSA Following Prostatectomy or Radiation erapy 

(DF#02-193). Dana Farber / Partners Cancer Care, $7,800. 

A Randomized, Multi-Center Phase III Trial of Irinotecan in 

Combination with ree Different Methods of Administration of 

Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5- 

FU (Day 1 & 8), and Oral Capecitabine (Day 1-14); with Celecoxib 

Versus Placebo as First-Line Treatment for Patients with Metastatic 

Colorectal Cancer. Dana Farber, $20,000. 

Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus 

Paclitaxel (4 vs 6 cycles) as Adjuvant erapy for Breast Cancer in 

Women with 0-3 Positive Axillary Lymph Nodes: A 2x2 Factorial 

Phase III Randomized Study (CALGB 40101). CALGB / Dana 

Farber Cancer Institute, $8,000. 

Feasibility of SH2 Domain Profiling as a Molecular Diagnostic Tool 

for Patients with Breast Cancer. 

GPC Protocol SAT3-03-01: A Multi-Center, Multi-National, 

Double-Blind, Randomized Phase III Study Of Satraplatin Plus 

Prednisone or Placebo Plus Prednisone In Patients With Hormone 

Refractory Prostate Cancer Previously Treated With One Cytotoxic 

Chemotherapy Regimen. Pharmanet, $66,176. 

A Phase II Randomized Double-blinded Efficacy and Safety Study of 

ree Doses of TAS-108, Administered Orally in Postmenopausal 

Patients with Locally Advanced or Locally Recurrent Inoperable or 

Progressive Metastatic Breast Carcinoma Following Standard First 

or Second Line Endocrine erapy. Quintiles, Inc., $138,113. 

A Phase III Trial Evaluating the Role of Ovarian Function 

Suppression and the Role of Exemestane as Adjuvant erapies for 

Premenopausal Women with Endocrine Responsive Breast Cancer 

(IBCSG 24002 SOFT). CTSU/IBCSG, $8,000. 

A Phase III, Randomized Study of Gemcitabine [fixed-dose rate 

infusion] and Oxaliplatin (NSC2666046) versus Gemcitabine 

[fixed-dose rate infusion] versus Gemcitabine [30-min infusion] 

in Pancreatic Carcinoma. ECOG- Dana Farber Cancer Institute, 

$8,000. 

Phase II, Randomized Study of Concomitant Chemoradiation 

Using Weekly Carboplatinum/Paclitaxel with (Arm A) Daily 

Subcutaneous Amifostine in Patients with Newly Diagnosed 

Locally Advanced Squamous Cell Cancer of the Head and Neck 

(DF #03-018). DFPCC Office, $5,850. 

Phase III Trial of Novel Epothilone Plus Capecitabine versus 

Capecitabine alone in Patients with Advanced Breast Cancer 

Previously Treated with or Resistant to an Anthracycline and 

who are Taxane Resistant. Bristol Myers Squibb via Dana Farber, 

$24,375. 

TRIUMPH: A Hemoglobin Stabilization and Transfusion 

Reduction Efficacy and Safety Clinical Investigation, Randomized, 

Multi-Center, Double-Blind, Placebo-Controlled, Using 

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients 

(C04-001). Alexion Pharmaceuticals, Inc., $40,910. 

S0124: Randomized Phase III Trial of Cisplatin and Irinotecan 

(NSC-616348) versus Cisplatin and Etoposide in Patients with 

Extensive Stage Small Cell Lung Cancer (E-SCLC). Lung Cancer 

Specimen Repository Protocol, Ancillary. SWOG via Dana Farber/ 

CALGB, $6,150. 

SHEPHERD: Safety In Hemolytic PNH Patients Treated with 

Eculizumab: A Multicenter Open-label Research Design Study 

(C04-002). Alexion Pharmaceuticals, Inc., $33,213. 

A Phase III Trial Of CHOP + Rituximab Vs CHOP + Iodine- 

131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) 

For Treatment Of Newly Diagnosed Follicular Non-Hodgkin’s 

Lymphomas. SWOG via Dana Farber/CALGB, $6,000. 

CD117 immunoreactivity as a prognostic indicator of treatment 

response of gastrointestinal stromal tumors (GISTs) with Iminitab 

(Gleevac). 

CALGB 80101: Phase III Intergroup Trial of Adjuvant 

Chemoradiation After Resection of Gastric or Gastroesophageal 

Adenocarcinoma. Dana Farber Cancer Institute, DF/PCC Office, 

$4,000. 

An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase 

2 Study of S-1 as 2nd Line erapy for Patients with Metastatic 

Pancreatic Cancer, Protocol Number TPU-S1201. TAIHO Pharma 

USA, Inc., $84,812. 

Protocol 2055-003: A Phase 2, Multi-Center, Randomized, Open- 

Label Study of Two Dose Levels of IMOxine (TM) (HYB2055 for 

injection) in Patients with Metastatic or Locally Recurrent Clear 

Cell Renal Carcinoma. Idera Pharmaceuticals, $70,638. 

A Phase III, Open-Label, Extension Study of Eculizumab in 

Patients with Transfusion Dependent, Hemolytic Paroxysmal 

Nocturnal Hemoglobinuria (PNH) Who Have Participated in the 

TRIUMPH (C04-001), SHEPHERD (C04-002) or X03-001 

Studies. Alexion Pharmaceuticals, Inc., $50,988. 

A Randomized, Phase III Trial Of Exemestane Versus Anastrozole 

In Postmenopausal Women With Receptor Positive Primary Breast 

Cancer (CALGB). NCIC/CALGB, $6,000. 

An Open-Label Phase 2 Trial of Talabostat and Gemcitabine In 

Patients with Stage IV Adenocarcinoma of the Pancreas (PTH- 

320). Point erapeutics, Inc., $60,488. 

 

Alekshun TJ, Lundbye J, Sokol L, Dailey ME. Use of bivalirudin to treat 

heparin-induced thrombocytopenia in a patient with idiopathic giant-cell 

myocarditis. Connecticut Medicine, 70, 69-71, 2006. 

Alexander G, Swartz H, Amundson S, Blakely W, Buddemeier B, Gallez 

B, Dainiak N, Goans R, Hayes R, Lowry P, Noska M, Okunieff P, Salner 

A, Schauer D, Trompier F, Turteltaub K, Voisin P, Wiley A, Wilkins

R. BiodosEPR-2006 Meeting: Acute dosimetry consensus committee 

recommendations on biodosimetry applications in events involving uses of 

radiation by terrorists and radiation accidents. Radiation Measurements, 42: 

972-996,2007. 

Brown AK, Madom L, Moore R, Granai CO, DiSilvestro P. e prognostic 

significance of lower uterine segment involvement in surgically staged 

endometrial cancer patients with negative nodes. Gynecologic Oncology, 105, 

55-58, 2007. 

Czito BG, Hong TJ, Cohen DP, Petros WP, Tyler DS, Pappas TN, Yu 

D, Lee CG, Lockhart AC, Morse MA, Fernando N, Hurwitz HI. A 

phase I study of eniluracil/5-FU in combination with radiation therapy for 

potentially resectable and/or unresectable cancer of the pancreas and distal 

biliary tract. Cancer Investigation, 24(1):9-17, 2006. 

Dainiak N, Carpini D, Bohan M, Werdmann M, Wilds E, Barlow A, 

Beck C, Cheng D, Daly N, Glazer P, Mas P, Nath R, Piontek G, Price K, 

Albanese J, Roberts K, Salner AL, Rockwell S. Development of a statewide 

hospital plan for radiologic emergencies. International Journal of Radiation 

Oncology, Biology, Physics, 65, 1, 16-24, 2006. 

Madom L, Brown AK, Lui F, Moore R, Granai CO, DiSilvestro P. Lower 

uterine segment involvement as a predictor for lymph node spread in 

endometrial carcinoma. Gynecologic Oncology, 107: 75-78, 2007. 

Servodidio, C. Working holiday shifts may be difficult, but Heather remains 

thankful. ONS Connect, Nov;22(11):15, 2007. 

Servodidio, C. Communicating with patients and coworkers is an essential 

job skill for oncology nurses. ONS Connect, Oct;22(10):17, 2007. 

Servodidio, C. Mentors and role models influence the past, present, and 

future for an oncology nurse. ONS Connect, Sep;22(9):15, 2007. 

Servodidio, C. When cancer strikes home: nurses share their personal 

experiences with cancer. ONS Connect, Aug;22(8):15, 2007. 

Servodidio, C. Relationships with patients have a deep impact on oncology 

nurses. ONS Connect, Jul;22(7):15, 2007. 

Servodidio, C. Values learned in childhood help nurses in their practice 

today. ONS Connect, Jun;22(6):15, 2007. 

Servodidio, C. Nursing school experiences helped shape nurses’ approach to 

patient education. ONS Connect, May;22(5):15, 2007. 

Servodidio, C. Patient and family experiences remind nurses why they love 

nursing. ONS Connect, Apr ;21(4):17, 2007. 

Servodidio, C. Nurse and patients alike will benefit from organization and 

coordination. C. ONS Connect, Mar ;21(3):17, 2007. 

Servodidio, C. Oncology nurses of today mentor the cancer caregivers of 

tomorrow. ONS Connect, Feb;21(2):1, 4-5, 2007. 

Servodidio, C. Members will share a “Year in the Life” of inpatient and 

outpatient oncology nursing. ONS Connect, Jan;21(1):1, 4-5, 2007. 

Servodidio, C. How do you care for a patient with a cancer you have never 

seen before? ONS News, Jun;21(6):1, 4-6, 2006. 

Servodidio, C. Oncology nurses of today mentor the cancer caregivers of 

tomorrow. ONS News, Feb;21(2):1, 4-5, 2006. 

 

 

Brown, AK, Madom, L, Granai, CO, DiSilvestro, P. e prognostic 

significance of lower uterine segment involvement in surgically staged 

endometrial cancer patients with negative nodes. Program in Women’s 

Oncology, Women and Infants’ Hospital, Providence, RI. Presented at the 

SGO 37th Annual Meeting on Women’s Cancer, March 2006. 

Brown, AK, Moore, RG, Miller, MC, Allard, WJ, Lu, K., Granai, CO, Bast, 

R. A novel multiple biomarker assay for the detection of ovarian carcinoma. 

Program in Womens’ Oncology, Providence, RI; Fujirebio Diagnostics 

Inc., Malvern, PA; MD Anderson Cancer Center, Houston, TX. Poster 

Discussion, Presented at the 2006 ASCO Annual Meeting, June 2006. 

Brown, AK, Skates, S, Sardesai, N, Verch, T, Glover, C, DiSilvestro, P, 

Granai, CO, Moore RG. Development of a multiple marker assay using 

novel serum tumor markers for the detection of ovarian carcinoma. Program 

in Womens’ Oncology, Providence, RI; Massachusetts General Hospital, 

Boston, MA; Fujirebio Diagnostics Inc., Malvern, PA. Presented at the SGO 

37th Annual Meeting on Women’s Cancer, March 2006. 

Brown, AK, Skates, S, Sardesai, N, Verch, T, Glover, C, DiSilvestro, P, 

Granai, CO, Moore, RG. Development of a multiple marker assay using 

novel serum tumor markers for the detection of ovarian carcinoma. Program 

in Womens’ Oncology, Providence, RI; Massachusetts General Hospital, 

Boston, MA; Fujirebio Diagnostics Inc., Malvern, PA. Presented at ISOBM 

2006, Pasadena, CA, September 2006. 

Clements A, Robison K, Brown AK, Miller MC, Allard WJ, Granai CO, 

Bast R, Lu K, Moore RG. Utility of a novel eerum tumor biomarker HE4 in 

patients with uterine cancer. Presented at the NEAGO Annual Meeting, June 

2007. 

Currie J, Boyd T, Brown AK, Sorosky J. Recurrent cervical cancer: e 

CORT procedure revisited. Presented at the NEAGO Annual Meeting, June 

2007. 

Flowers A, Kamradt, J. Sequential intra- Ommaya chemotherapy and 

systemic Tarceva prolong survival in a patient with brain and leptomeningeal 

metastases from lung adenocarcinoma. (Abstract P129) J Neuro- Oncology 8: 

345, 2006. 

Kibler K, Currie J, Sorosky J, Brown AK. Benign ovarian neoplasm 

presenting as hypertensive urgency, virilization, and endocrinopathy. 

Presented at the NEAGO Annual Meeting, June 2007. 

McNamara J, Granai CO, Brown AK, Sorosky J, Currie J. Management 

of port site recurrence of cervical cancer. Presented at the NEAGO Annual 

Meeting, June 2007. 

Moore R, Brown AK, Brard L, DiSilvestro P, Miller C, Allard J, Quddus 

M, Granai CO. Utility of a novel serum tumor marker HE4 versus CA- 

125 in patients with endometrial cancer. Program in Womens’ Oncology, 

Providence, RI; Fujirebio Diagnostics Inc., Malvern, PA. Presented at the 

SGO 37th Annual Meeting on Women’s Cancer, March 2006. 

Moore, RG, Brown, AK, Miller, MC, Allard, JW, Granai, CO, Robert Bast, 

R, Lu, K. Utility of a novel serum tumor biomarker HE4 in patients with 

uterine cancer. Program in Womens’ Oncology, Providence, RI; Fujirebio 

Diagnostics Inc., Malvern, PA; MD Anderson Cancer Center, Houston, 

TX. Presented at the 2006 ASCO Annual Meeting, June 2006. 

Platt L, O’Loughlin M, Currie J, Sorosky J, Brown AK. e utility of CT 

scan multiplanar reformatting in predicting the extent of disease in suspected 

ovarian cancer patients. Presented at the NEAGO Annual Meeting, June 2007. 

Salner A, Burke M, Ward D, & Staff I. Reaching urban African-American 

men with prostate cancer awareness information. NCI Cancer Health 

Disparities Summit. Bethesda, MD July 16-18, 2007. 

Salner A, Burke M, Ward D, & Staff I. Reaching urban African-American 

men with prostate cancer awareness information. 2007 CDC Cancer 

Conference in Atlanta, GA, August 13-14, 2007. 

Spring, M, Rosenberg, R, and Buckley, J. Predictive value of the standardized 

uptake value (SUV) in positron emission tomography in patients with 

carcinoma of the esophagus. Presented at Hartford Hospital, August 2006.

Evaluation of Osteoporosis Outreach and Education Initiative. 

Merck & Co., Inc, $100,365. 

 

A Randomized, Double-Blind, Active- and Placebo-Controlled, 

Parallel-Group, Multicenter Study to Evaluate the Efficacy 

and Safety of Multiple Doses of CG5503 Immediate-Release 

Formulation in the Treatment of Acute Pain From Total Hip 

Replacement Surgery Followed by a Voluntary Open-Label 

Extension. Johnson & Johnson PRD, $85,913. 

 

A Phase 3 Randomized, Double-Blind, Active-Controlled 

(Enoxaparin), Parallel Group, Multi-Center Study to Evaluate 

the Safety and Efficacy of Oral Apixaban in Subjects Undergoing 

Elective Total Knee Replacement Surgery. Bristol-Myers Squibb, 

$172,860. 

 

A Prospective, Randomized, Controlled, Multi-Center, Pivotal 

Human Clinical Trial to Evaluate the Safety and Effectiveness 

of GEM OS1 Compared to Autologous Bone Graft as a Bone 

Regeneration Device in Foot and Ankle Fusions. Biomimetic 

erapeutics, $168,825. 

 

 

Does Simultaneous Carpal Tunnel Release Improve Outcomes 

Following Distal Radius Open Reduction and Internal Fixation: A 

Retrospective Review. 

 

Osteoporosis Prevention and Management in Adult Primary Care. 

 

FDA-HDE (Humanitarian Device Exemption) Approved 

Ascension PIP Finger Joint #H010005. 

 

A Prospective Randomized Comparison Study of Modern Pilates 

and Spinal Segmental Stabilization Training on the Clinical 

Outcome of Individuals with Chronic Low Back Pain. 

 

 

Evaluation of Outcomes Following Lumbar Spine Fusion Surgery at 

Hartford Hospital: Phase I. Hartford Hospital Research Endowment 

Funds, $9,725; DuPuy, $12,500. 

 

Transfusion Trigger Trial for Functional Outcomes in 

Cardiovascular Patients Undergoing Surgical Hip Fracture Repair 

(FOCUS). University of Medicine & Dentistry of New Jersey,NHLBI, 

$700. 

Functional Status, Morbidity and Mortality in Cemented versus 

Uncemented Hemiarthroplasty: A Prospective Randomized Trial. 

Zimmer Corporation, $166,492. 

A Phase 2 Randomized, Double-Blinded (BMS-562247 and 

Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), 

Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor 

BMS-562247 in Subjects Undergoing Elective Total Knee 

Replacement Surgery. Bristol Myers Squibb, $64,170. 

A Randomized, Double-Blind, Placebo-Controlled Study to 

Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of 

CP-533,536 in Subjects With Closed Fracture of the Tibial Shaft 

(A3241002). Pfizer Inc., $133,813. 

An Open-Label, Randomized, Parallel-Group Study To Confirm 

e Safety and Efficacy of Procrit (Epoetin Alfa) Administered 

Perioperatively vs. e Standard of Care In Blood Conservation in 

Subjects Undergoing Major Elective Spinal Surgery. Ortho Biotech, 

Inc., $133,810. 

 

Humanitarian Use Device: OP-1 Implant. 

 

Global Orthopedic Registry (GLORY): Measuring and improving 

outcomes of total hip and knee arthroplasty. UMASS Medical- 

Center for Outcomes Research, $6,900.

William T. Pastuszak, MD, Chairman • Jaber Aslanzadeh, PhD • Margaret Assaad, 

MD • Fabiola Balarezo, MD • Richard Cartun, PhD • omas Ciesielski, MD • Joseph 

DiGiuseppe, MD • Mary Fiel-Gan, MD • Saverio Ligato, MD • Mark Ludwig, MD • 

Gregory Makowski, PhD • Srinivas Mandavilli, MD • Laila Mnayer, PhD • Richard Muller, 

MD • William Rezuke, MD • Andrew Ricci, MD • Peter Shen, MD • Bradford Sherburne, 

MD • Dean Uphoff, MD • Terry Voytek, MD • Rebecca Williams, MD 

 

e Department of Pathology and Laboratory Medicine 

(DPLM), through its biomedical and chemical research 

initiatives, seeks to improve the understanding of the 

mechanisms of human disease and acquire knowledge that 

will assist in clinical diagnosis and development of new 

therapies that will improve cellular, molecular and genetic 

disease manifestations. Research-based knowledge provides 

the fundamental basis for translating information into 

clinically useful diagnostic testing and treatment for patients 

served at Hartford Hospital. DPLM oversees state-of-theart 

equipment and technologies that support complex analysis 

of biochemical, infectious, molecular, and tissue markers of 

disease as evidenced by the Department’s current research 

projects. 

Several divisions of DPLM conduct independent research 

and development. e Division of Hematology conducts 

research in use of immunologic and molecular techniques in 

the diagnosis and classification of hematologic and lymphoid 

malignancies. e Division of Anatomic Pathology uses 

immunohistochemistry to investigate a variety of pathologic 

disorders. e Division of Microbiology has investigated the 

application of molecular diagnostics to infectious diseases. 

e addition of a Ph.D.-level staff member to the Department 

to direct Molecular Pathology opens new opportunities for 

research in a rapidly growing field of Pathology. 

 

 

Clinicopathological Evaluation of Esosinophilic Esophagitis 

 

Development of a Reference System for the Measurement of the 

Activity of Erythrocyte Choline Estrase “Eche” in Human Blood. 


 

Use of Laboratory Tests and a Neural Network for the Detection of 

Myocardial Ischemia in Patients with Acute Coronary Syndromes. 


 

e Comparison of Clinical Specificity between Two Urine 

Immunoassays for Tricyclic Antidepressants: Correlation to 

Clinical Presentation. 

Use of Cardiac Troponin T and the Natriuretic Peptides in Plasma 

for Monitoring of Left Ventricular Dysfunction in Patients with 

Sepsis. 

Correlation of Cytochrome P450 and Drug Transport Gene 

Polymorphisms in Statin-Induced Myopathies. Hartford Hospital 


 

Alarcon-Chaidez F, Ryan R, Wikel S, Dardick K, Lawler C, Foppa I, Tomas 

P, Cushman A, Hsieh A, Spielman A, Bouchard K.R., Dias F, Aslanzadeh 

J, Krause PJ. Confirmation of tick bite by detecting antibody to Ixodes 

Calreticulin Salivary Protein. Clin Vaccine Immunol 2006; 13:1217-1222. 

Ariyanayagam-Baksh SM, Baksh FK, Cartun RW, Sieber PR. Histoplasma 

phimosis: an uncommon presentation of a not uncommon pathogen. Am J 

Dermatopathol 2007; 29(3):300-2. 

Aslanzadeh J. Biochemical profile-based microbial identification systems. In 

Yi-We Tang (ed) Advanced Techniques in Diagnostic Microbiology. Springer 

Science + Business media LLC, Spring St., New York, NY, pp 84-116. 

Benn PA, Makowski GS, Egan JFX, Wright D. e reproducibility of risk 

figures in second trimester maternal serum screening for Down syndrome: a 

comparison of two laboratories. Clin Chem 2006; 52:2087-2094. 

Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, Nassar A, 

Mandavilli SR. Diagnostic utility of D2-40 and podoplanin in effusion cell 

blocks. Diagn Cytopathol 2007; 35(6):342-7. 

DiGiuseppe JA. Acute lymphoblastic leukemia: Diagnosis and detection 

of minimal residual disease following therapy. Clin Lab Med 2007; 27:533- 

549. 

DiGiuseppe JA. Flow cytometric immunophenotyping of plasmacytic 

neoplasms. Am J Clin Pathol 2007; 127:172-174. 

Finelli PF, Naik K, DiGiuseppe JA, Prasad A. Primary lymphoma of CNS, 

mycophenolate mofetil and lupus. Lupus 2006; 15:886-888. 

Glaser SL, Keegan THM, Clarke CA, Trinh M, Dorfman RF, Mann RB, 

DiGiuseppe JA, Ambinder RF. Exposure to childhood infections and risk 

of EBV-defined Hodgkin’s lymphoma in women. Int J Cancer 2005; 115: 

599-605. 

Keegan THM, Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe 

JA, Dorfman RF, Mann RB, Ambinder RF. Epstein-Barr virus as a marker 

of survival after Hodgkin’s lymphoma: a population-based study. J Clin Oncol 

2005; 23:7604-7613. 

Lee CJ, Whang JH, Lazova R, Ciesielski T, omson G, McCarthy, T, 

Persing JA. Growth factor expression with different wound treatments after 

laser resurfacing. Aesthetic Surgery Journal 2007; January/February 55-64. 

Liu JL, Fiel-Gan M, Mandavilli S, Vignati P, Ludwig M. PEComa, a not 

so rare tumor that can cause clinical and pathologic diagnostic confusion: a

case report. CT Med: e Journal of Ct State Med Society August 2007 71(7): 

399-401. 

Mnayer L, Khuri S., Merheby HA, Meroni G, Elsas L. A structure-function 

study of MID1 mutations associated with a mild ppitz phenotype. Molecular 

Genetics and Metabolism 2006; 87: 198-203. 

Quercia RA, Udeh E, Keating KP, Sherburne B, Goldman MC. 

Management of epoetin alpha use in the intensive care unit: a drug use 

evaluation. Formulary 41 2007; 442-449. 

Ricci Jr. A. Potential diagnostic utility of CDX-2 immunophenotyping in 

extra mammary Paget’s disease. Appl Immunohistochem Mol Morphol 2005; 

13(4):342-346. 

Ruaño G, Makowski GS, Windemuth A, Kocherla M, Weiss S, Goethe JW, 

Bower B, Wu AHB, ompson PD. High carrier prevalence of deficiency 

and null alleles of CYP2 genes in a major USA hospital: implications of 

personalized drug safety. Pers Med 2006; 3:131-137. 

Sebenik M, Ricci Jr. A, DiPasquale B, Mody K, Pytel P, Jee KJ, Khutila S, 

Scholes J. Undifferentiated intimal sarcoma of large systemic blood vessels: 

A report of 14 cases with immunohistochemical profile and review of the 

literature. Am J Surg Pathol 2005; 29(9)1184-93. 

Shao H, Davydova L, Mandich D, Cartun RW, Ligato S. S100A4 protein 

and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile 

duct. Am J Clin Pathol 2007; 127(3):374-9. 

Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska 

J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Cartun RW, 

Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, 

Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt 

SM, Garcia-Closas M. Variation in breast cancer hormone receptor and 

HER2 levels by etiologic factors: a population-based analysis. Int J Cancer 

2007;121(5):1079-85. 

Stetler-Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe 

JA, Marti G, Menozzi D, Oldaker TA, Orfao de Matos A, Rabellino 

E, Stone EC, Walker C. Clinical flow cytometric analysis of neoplastic 

hematolymphoid cells; Approved Guideline-Second Edition. CLSI document 

H43-A2, Clinical and Laboratory Standards Institute, 2007. 

Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker 

T, Shenkin M, Stone E, Wallace P. 2006 Bethesda International Consensus 

recommendations on the immunophenotyping analysis of hematolymphoid 

neoplasia by flow cytometry: Optimal reagents and reporting for the flow 

cytometric diagnosis of hematopoietic neoplasia. Cytometry Part B (Clinical 

Cytometry) 2007; 72B:S14-22. 

Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, 

Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, 

Zatonski W, Cartun RW, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek 

S, Kordek R, Garcia-Closas M. Differences in risk factors for breast cancer 

molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers 

Prev 2007;16(3):439-43. 

 

 

Aslanzadeh JH, Li J, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang 

YW. Performance of rapid tests for detection of respiratory syncytial virus 

and human metapneumovirus. Presented at the 23rd Annual Clinical Virology 

Symposium and Annual Meeting of the Pan-American Society for Clinical 

Virology, April 28-May 2, 2007, Clearwater, FL. 

Assaad M, Stevens D, Cartun R, Ricci Jr. A, Mandavilli S. Comparison 

of mammoglobin and gross cystic disease fluid protein – 15 as specific 

immunocytochemical markers of metastatic mammary carcinoma in effusion 

cytology specimens. Mod Pathol January 2006; 19 (Suppl) 53A. 

Cartun R. Applications of immunohistochemistry for infectious diseases 

diagnosis. Presented at e First Annual International Course on Applied 

Immunohistochemistry and Molecular Morphology, January 23-26, 2007, Duck 

Key, FL. 

Cartun R. Immunohistochemistry Forum. One-day forum sponsored 

by the National Society of Histotechnology and the Society for Applied 

Immunohistochemistry, Moderator and Speaker, National Society for 

Histotechnology Annual Meeting, October 30, 2007, Denver, CO. 

Cartun R. Timely topics in diagnostic immunohistochemistry. Presented 

at the National Society for Histotechnology Annual Meeting, October 29, 2007, 

Denver, CO. 

Clark MS, Fuller SG, DiGiuseppe JA. Clinical validation of two PCR-based 

assays for detection of the JAK2 V617F mutation in non-CML chronic 

myeloproliferative disorders. Mod Pathol 2006; 326A. 

Davydova L, Zhao H, Mandich D, Cartun R, Ligato S. Expression 

of S100A4-protein and mesothelin in dysplasia and carcinoma of the 

extrahepatic biliary tract. Am J Clin Pathol. 2005; 124:649-650. 

Elaba Z, Ricci Jr. A., Voytek T, Parikh N. Spitzoid melanoma in an 8-yearold 

Caucasian male. ASDP, Chicago, October 26-29, 2006. 

Elaba Z, Ricci Jr. A, Voytek T, Purikh N. Spitzoid melanoma in an 8-yearold 

Caucasian male. J Cutaneous Pathol 2007; 34(1):79A. 

Gupta R, Hasserjian RP, Rezuke WN, DiGiuseppe JA, Hunt JP. 

Percentage hematogones by flow cytometric analysis is lower in patients with 

myelodysplastic syndrome than in cytopenic patients without myelodysplastic 

syndrome. Mod Pathol 2006; 19:229A. 

He W, Marinescu L, Cartun RW, Stevens D, Ricci Jr. A. Where were basallike 

mammary duct carcinoma (BL-MDC) hiding prior to the year 2000? 

Mod Pathol; 2007 20:35A. 

Ligato S, Mandich D, Cartun RW. Diagnostic utility of the 

immunocytochemical expression of Glypican-3 oncofetal protein in fine 

needle aspiration biopsies of hepatic lesions in differentiating hepatocellular 

carcinoma from other primary and metastatic hepatic lesions. Mod Pathol 

2007; 30:75A. 

Ligato S, Zhao H, Mandich D, Cartun R. KOC (K Homology Domain 

Containing Protein Overexpressed in Cancer) and S100A4-protein 

immunoreactivity improves the diagnostic sensitivity of brush cytology 

for diagnosing pancreaticobiliary malignancies. Mod Pathol. Sep. 2006; 

19(supplement 3):45. 

Marinescu L, Cartun RW, Stevens D, Ricci Jr. A. CK5 is more sensitive 

than CK5/6 in identifying basal-like mammary duct carcinoma (BL-MDC) 

by immunohistochemistry (IHC). Mod Pathol 2007; 30:40A. 

Parab MS, Ahmad N, Fuller SG, DiGiuseppe JA. Changes in antigen 

density during remission induction in precursor beta-cell acute lymphoblastic 

leukemia detected by flow cytometric immunophenotyping. Mod Pathol 

2007; 20:353-4A. 

Tetreault J, Aslanzadeh J. Measures to control false negative and false 

positive blood cultures in a large tertiary care hospital. Presented at the 106th 

annual meeting of the American Society for Microbiology, May 21-25, 2007, 

Toronto, Canada. 

Wang W, Poulin M, Ricci Jr. A. Fluorescent in-situ hybridization assay for 

Ewing’s sarcoma/PNET on formal-fixed paraffin embedded tissue: A pilot 

study of genetically confirmed cases. Mod Pathol June 2006; 19 (Suppl) 19A. 

Xia L, Cartun R, Voytek T. Basaloid squamous cell carcinoma vs. small cell 

carcinoma: cytological features and utility of immunocytochemistry. Poster 

presented at the American Society of Cytopathology Annual Scientific Meeting, 

November 2006, Toronto, Canada. 

Zhao H, Mandich D, Cartun R, Ligato S. Expression of KOC (K Homology 

Domain Containing Protein Overexpressed in Cancer) in pancreatic FNAs 

for diagnosing invasive pancreatic malignancies. Cancer Cytopathology. 

Supplement Oct. 2006; 108:408. 

Zhao H, Mandich D, Cartun RW, Ligato S. Expression of p53 protein 

in ulcerative colitis indefinite for dysplasia may help to differentiate reactive 

atypia from early low-grade dysplasia: A clinical-pathologic correlation of 14 

cases. Mod Pathol. Sep. 2006; 19(supplement 3):74.

e mission of the Anxiety Disorders Center (ADC) 

at e Institute of Living is to provide evidence-based 

psychosocial treatment for anxiety-related problems, to 

conduct meaningful research on the nature and treatment 

of anxiety, and to provide education for students, staff, and 

the community. Areas of clinical emphasis include obsessivecompulsive 

disorder and obsessive-compulsive spectrum 

disorders, generalized anxiety disorder, panic disorder, social 

phobia, and post-traumatic stress disorder. 

 

e ADC has developed the nation’s largest and most 

comprehensive program of research on compulsive hoarding. 

In one study, Psychopathology of Compulsive Hoarding 

(sponsor: NIMH), we are interviewing large numbers of 

patients with compulsive hoarding, patients with obsessivecompulsive 

disorder, and participants without mental 

disorders in order to define the phenomenon of compulsive 

hoarding and differentiate it from obsessive-compulsive 

disorder. Another study, Neural Mechanisms of Compulsive 

Hoarding (sponsor: NIMH), uses functional magnetic 

resonance imaging to examine brain activity during a 

decision-making task in compulsive hoarding patients with 

and without major depressive disorder, obsessive-compulsive 

disorder patients, and individuals without mental disorders. 

In Neuropsychological Functioning in Compulsive Hoarding 

(sponsor: Hartford Hospital), we are examining brain-behavior 

relationships by assessing a variety of cognitive functions in 

individuals with and without compulsive hoarding. Finally, 

we recently completed Treatment of Compulsive Hoarding 

(sponsor: NIMH), the aim of which was to develop and 

test a cognitive-behavioral intervention for patients with 

compulsive hoarding. Results of that study (published in 

Behaviour Research and erapy) were highly promising, 

and we have submitted a proposal for further study to the 

National Institute of Mental Health. We also conducted 

An Internet Study of Compulsive Hoarding (unfunded), a 

web-based survey of individuals with compulsive hoarding as 

well as their family members. is is the largest study ever 

conducted on this topic; initial analyses have been published 

in Behaviour Research and erapy and Psychiatry Research, 

and more data analyses are underway. is year, Dr. Tolin 

published a popular book on the topic, Buried in Treasures: 

Help for Compulsive Acquiring, Saving, and Hoarding (Oxford 

University Press), which has received national attention on 

e Oprah Winfrey Show and e New York Times. 

 

We are currently midway through the study Stepped Care 

for Obsessive-Compulsive Disorder (sponsor: NIMH), the 

aim of which is to develop and test a variant of cognitivebehavioral 

therapy for OCD in which patients start with 

a largely self-directed treatment and move to progressively 

more intensive treatment as needed. is year we finished 

D-Cycloserine Augmentation of Behavior erapy for 

Obsessive-Compulsive Disorder (unfunded), a pilot study in 

which the N-Methyl D-Aspartate (NMDA) receptor agonist 

D-cycloserine was added to traditional cognitive-behavioral 

therapy. Results of that study (published in American Journal 

of Psychiatry) were promising and led to the development of a 

multi-site grant proposal to the National Institute of Mental 

Health. We are currently conducting a follow-up study, D- 

Cycloserine for OCD Treatment Nonresponders (sponsor: 

Hartford Hospital), in which cognitive-behavioral therapy 

plus open-label D-cycloserine are provided for patients who 

have failed to respond to cognitive-behavioral monotherapy. 

Additionally in the area of obsessive-compulsive spectrum 

disorders, this year Dr. Tolin published the cognitivebehavioral 

therapy manual Treating Trichotillomania: 

Cognitive Behavior erapy for Hair Pulling and Related 

Problems (Springer). 

 

Dr. Gretchen Diefenbach has developed several studies 

investigating anxiety-related concerns in older adults. In 

one study, Screening for GAD among Frail Elderly (sponsor: 

NIMH), we examined optimal ways to assess frail older 

individuals receiving home care services for generalized 

anxiety disorder and related concerns. Another study, e 

Nature and Impact of Anxiety Symptoms upon Psychosocial 

Functioning of Older Adults with Major Depressive 

Disorder (sponsor: Hartford Hospital), examined differences 

between older depressed patients with and without anxiety 

symptoms who were attending the Geriatric Day Program 

at the Institute of Living. Finally, the new study Cognitive 

Enhancing Effects of D-Cycloserine among Non-Demented 

Elderly (sponsor: Hartford Hospital) will examine whether 

D-cycloserine can affect cognitive processes such as learning, 

memory, and attention in older adults with age-appropriate 

cognitive function. e results of that study are expected to 

inform a trial of D-cycloserine augmentation of cognitivebehavioral 

therapy in older adults with generalized anxiety 

disorder. 

 

We recently completed the study Augmenting Exposure 

erapy with an NMDA Agonist: A Pilot Study (sponsor:

Hartford Hospital), in which we examined the effect of 

adding D-cycloserine to brief cognitive-behavioral therapy for 

adults with panic disorder. Results of that study (currently in 

preparation for submission) led to the development of a study, 

recently approved for funding, “Exposure, D-Cycloserine 

Enhancement, and Genetic Modulators in Panic Disorder” 

(sponsor: National Institute of Mental Health), in which we 

will conduct a larger version of the study and examine genetic 

factors associated with response to cognitive-behavioral 

therapy and D-cycloserine. 

 

We are in the preliminary stages of the study Virtual 

Reality Exposure erapy for Combat-Related PTSD in 

Iraq Veterans (sponsor: Hartford Hospital, with a generous 

equipment donation from the Hartford Hospital Auxiliary). 

Under the direction of Drs. Christina Gilliam and Melissa 

Norberg, this study will use cutting-edge virtual reality 

technology to simulate the sights and sounds of warfare for 

exposure-based treatment of veterans with posttraumatic 

stress disorder returning from Iraq and Afghanistan. 

 

 

 

Established in 1987, the Braceland Center for Mental Health 

and Aging conducts research and education to improve 

the health and well-being of older persons. In 2003, the 

Braceland Center became the home for Hartford Hospital’s 

Memory Disorders Center, a clinical, training and research 

specialty site. e Memory Disorders Center has brought 

to Northern Connecticut state of the art evaluation, diagnosis 

and treatment of cognitive disorders and dementing illnesses. 

It has established a wide referral base consisting of primary 

care physicians, internists, neurologists, psychiatrists, courts 

and attorneys. In addition, the Memory Disorders Center has 

brought the same standards of care to monolingual Spanish 

speaking patients through referral by Hartford Hospital and 

St. Francis outpatient medical clinics and well as community 

health centers. 

e Braceland Center and Memory Disorders Center works 

collaboratively with Adult Protective Services, REACT, 

CCCI and other local and state agencies. e Centers 

provide education and training to undergraduates, psychiatry 

and medical residents, social workers, occupational therapists 

and pharmacy fellows. e Memory Disorders Center staff 

has been active in educating the public through frequent and 

well attended speaking engagements including radio and 

television appearances. e Center also partners with the 

Alzheimer’s Association of Connecticut and has participated 

in and hosted their caregiver’s course. Patients and families 

seen through the Memory Disorders Center are provided 

information and referral to appropriate research projects at 

the Institute of Living, Hartford Hospital, Yale and other 

centers. 

Research underway at the Braceland Center emphasizes 

clinical applications wherever possible. e Center has 

developed a comprehensive database to facilitate research 

in the area of cognitive disorders, anxiety and depressive 

disorders. e Center, along with the Olin Center, has been 

a site in the multi-site Alzheimer’s Disease Neuroimaging 

Initiative. Other areas of study include cognitive training and 

remediation, anxiety disorders, late-life depression, decisional 

capacity, driving in late-life, and promotion of advance care 

planning for persons with cognitive loss. Research topics 

focusing on diversity include end of life and palliative care 

among racially diverse elders, and the impacts of racial/ 

ethical/religious diversity in geriatric psychiatry practitioners 

and patients. 

 

 

 

e mission of the Burlingame Center is to promote 

excellence in clinical care through research, consultation, 

professional education and medical information management. 

e Center developed and continues to manage the Institute’s 

research infrastructure (e.g., clinical research database, 

practice guidelines) and coordinates quality management/ 

performance improvement activities. 

Research is focused on four principal areas: 

psychopharmacology, patient outcomes, clinical practices, 

and pharmacogenomics. rough an alliance with Genomas, 

Inc. the Center is conducting two studies to demonstrate the 

utility of genotyping to improve drug selection and dosing. 

A full list of recent publications, presentations and grants is 

available at www.instituteofliving.com. 

e Center’s Outcome Assessment Program conducts 

long-term follow-up of discharged patients, an activity that 

supports staff education and outcomes research (e.g., changes 

in clinical, functional and vocational status over time, studies 

of the natural history of psychiatric disorders). 

e Center maintains the Clinical Evaluation and Monitoring 

System (CEMS) and uses it for quality management, program 

evaluation, and staff education. CEMS, the product of IOL 

research, also provides clinicians with “computerized decision 

support” to optimize the efficiency, effectiveness and safety of 

patient care. 

e Center, through its Office of Professional Education, 

coordinates the Institute’s continuing education programs, 

and for 2007 received the Connecticut State Medical 

Society’s Excellence in CME Award. Center staff collaborate 

with a number of other Connecticut institutions, including 

the Department of Mental Health and Addiction Services, 

the University of Connecticut School of Medicine and School 

of Pharmacy, and the Yale University School of Medicine. 

 

 

e Olin Neuropsychiatry Research Center (ONRC) is at 

the forefront of brain imaging research, applying quantitative

measures of brain structure and function to the study of 

neuropsychiatric disorders. Techniques include structural and 

functional MRI and diffusion tensor imaging. In addition, 

electrophysiologic measures, including event-related potential 

assessments and virtual reality methods, are important 

components of our research. 

e goal of the ONRC is to increase the understanding of the 

brain, behavior and genetics and the relationships between 

the three using neuro-imaging techniques. In particular, 

the ONRC’s mission is to conduct neuroscience research 

in severe psychiatric illnesses and to translate the results 

into new and effective treatments. We also strive to educate 

ourselves, train other researchers and disseminate information 

to the general public. In order to achieve our goals, we utilize 

a team approach that rewards individual creativity, initiative 

and excellence. 

e Center has published papers in many aspects of brain 

imaging including normal aging and a variety of brain 

disorders in both children and adults. Our focus includes 

schizophrenia, childhood conduct disorder, Alzheimer’s 

disease, manic-depressive illness, depression, PTSD, autism, 

as well as substance abuse. We have been awarded multiple 

peer-reviewed grants including six RO1 awards by the 

National Institute of Health (NIMH, NINDS, NIAAA and 

NIDA), totaling several million dollars. e Center’s faculty 

have obtained grants in support of research in genetics and 

neuroimaging of schizophrenia and bipolar disorder, alcohol 

and cocaine abuse, attention deficit hyperactivity disorder, 

autism spectrum disorders and behavioral effects of cocaine, 

nicotine, alcohol, marijuana and amphetamine use. We also 

train postdoctoral fellows and participate in educational 

activities with IOL residents, some of whom request research 

electives in the Olin Center. e ONRC currently houses 

three laboratories; e Cognition Behavior Brain and 

Allelic Variation lab (COBBRA), Clinical Neuroscience and 

Development lab (CND), and Virtual Reality (VR) Labs. 

 

e ONRC is housed in approximately 32,000 square feet 

of space in the newly renovated Whitehall building and first 

floor of the Butler building. Facilities include faculty and 

staff offices and specialized rooms for clinical interviews, 

examinations and consultations. All clinical interviews are 

recorded and archived on DVDs for future research use 

using a digital video system. ree digital video cameras 

are configured for use with PCs, each having a 60 gigabyte 

storage capacity. Each interview room is also equipped 

for neuropsychological testing. In addition, the Center 

is equipped with video conferencing rooms, a dedicated 

T1 line, cognitive assessment and rehabilitation facilities, 

electrophysiology laboratories, an image reading room, a 

state-of-the-art 3T Siemens MR scanner, MR control/ 

projection rooms, and two computer lab spaces for research 

staff. 

e ONRC owns a 3T Siemens Allegra MRI. Since the 

facility opened in December 2002, we have performed 

numerous research scans including structural MRI, fMRI, 

and diffusion tension imaging (DTI). We currently perform 

an average of 1000 research scans per year. e 3 Tesla 

Magnetom Allegra is a dedicated MR head scanner, offering 

multiple advantages as a research system. e magnet is 

capable of echo-planar imaging for the BOLD signal, DTI, 

and MR spectroscopy, all of which are valuable research tools. 

e short magnet bore and wide opening ensure optimal 

accessibility, and afford advantages for both patient comfort 

and visual stimulation in functional neuroimaging. e 3T 

system also includes equipment for online recording of pulse, 

respiration, and galvanic skin response. Recently, an MR-safe 

ASL video system was installed to monitor eye movements 

and pupilometry outside the scanner. e new NRC building 

houses a dedicated projector room capable of presenting 

various types of experimental stimuli including virtual 

reality simulations. 

e NRC is equipped with two complete electrophysiology 

systems for recording EEGs during the performance of 

cognitive tasks. ese systems comprise stimuli presentation 

computers, electrode caps, amplifiers, digital/analog boards 

and PCs for data recording. Each of the two systems are 

equipped with four head sizes of electrode caps. One system 

employs an SA bioelectric amplifier capable of amplifying 

electrical activity from 64 separate channels for recording. 

is amplifier is connected to a 16-bit A/D conversion using 

a custom program implemented on a Pentium II microcomputer 

running Solaris for Intel. is computer records 

EEG data and all stimulus and behavioral responses are 

coded for later analysis. We use a custom suite of software 

for precise presentation of multimodal stimuli, online 

monitoring of behavioral data (i.e., computation of d-prime, 

reaction time, accuracy) and high resolution EEG acquisition 

using custom programmed software on this system. A second, 

recently-acquired system is a 64-channel Neuroscan EEG 

suite, including dedicated PCs for stimulus presentation and 

another for recording EEG. e system is able to perform 

eye-tracking and pupilometry during EEG recording. 

Equipment for pre-pulse inhibition and quantitative eyemovement 

physiology was recently installed. 

 

e ONRC was recently awarded three large grants. Dr. 

Stevens obtained two grants, the first of which will examine 

impulsivity and its genetic underpinnings in adolescents with 

attention deficit hyperactivity disorder. e second grant, from 

the American Foundation for Suicide Prevention, will support 

a 2-year fMRI study of brain activity in depressed adolescents 

with histories of suicide attempts. Dr. Pearlson obtained a 

grant to support a study that will address how genetic and 

behavioral markers may be associated with a predisposition 

to schizophrenia and psychotic bipolar disorder. is is a 

five-site, 3000-subject study involving patients with these 

disorders and their unaffected family members. e study will 

involve genotyping, neuro imaging and collection of multiple 

behavioral, cognitive and physiologic measures.

e Neuronal Correlates of eory of Mind in Schizophrenia. 

NIMH, $164,000. 

 

Cocaine-Induced Place Preference in Virtual Reality Environments 

R21 DA020013-01. NIDA, $290,852. 

Neuroimaging of Mothers Overcoming and Managing Stress. 

Office of Juvenile Justice and Delinquency Program subcontract through 


 

Function BIRN (BioInformatics Research Network). NIH 

subcontract through Yale University, $126,075. 

Collaborative Research SEI: Independent Component Analysis of 

Complex-Valued Brain Imaging Data. NSF, $299,376. 

 

DNA Diagnostics for Minimizing Side-Effects of Antipsychotics. 

SBIR subcontract through Genomas, $150,000. 

 

Neurocognitive Changes Associated with Behavioral Treatment in 

Cocaine Abusers. NIDA, $2,647,970. 

 

Ventral Striatal Functional Deficits and Familial Alcoholism Risk. 

NIAAA subcontract through Yale, $466,956.00; Yale, $15,000. 

Schizophrenia Biomarkers: Memory, Genes and fMRI. NIMH, 

$1,493,033. 

Molecular Studies of Cognition and Chronic Alcoholism. NIAAA 

subcontract through the University of Pittsburgh, $134,843. 

 

Girls in Recovery from Life Stress (GIRLS) Study. Office of Juvenile 

Justice and Delinquency Program subcontract through the University of 

Connecticut, $49,500. 

fMRI of CBT and CM Cocaine Dependence. NIH subcontract 

through Yale University, $172,183. 

Reward, Impulsivity and Cocaine Addiction: fMRI Studies. NIDA 

subcontract through Yale University, $1,303,559. 

 

Neural Mechanisms of Compulsive Hoarding. NIMH, 

$1,062,000. 

Stepped Care for Obsessive-Compulsive Disorder. NIMH, 

$596,160. 

 

 

Modulation of Neuroimaging and Neurocognitive Correlates 

of Attention and Memory by Nicotine and Nicotinic Alpha-7 

Receptor Genotype Polymorphisms in Schizophrenia and Healthy 

Controls. Philip Morris USA, Inc., $86,400. 

 

Cognitive Remediation for Schizophrenia: Effects on Distal 

Outcome Measures and Relationship to Social-Skills Training. 

NARSAD, $51,130. 

 

 

Functional Magnetic Resonance Imaging Correlates of Decision- 

Making. Yale University, $50,000. 

Syntactic Development and Learning Processes in Autism Spectrum 

Disorders. University of Connecticut, $18,250. 

 

Prospective Memory in Schizophrenia. Trinity College, $938. 

 

 

A Randomized, Parallel Group, Multiple Dose, 6-Week Study to 

Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in 

Elderly Subjects with Psychosis. Pfizer, $47,362.25 

A Six-Week, Double-Blind, Multicenter, Placebo-Controlled 

Study Evaluating the Efficacy and Safety of Flexible Doses of 

Oral Ziprasidone in Outpatients with Bipolar I Depression. Pfizer, 

$77,071. 

A Multi-Center, Double-Blind, Randomized-Withdrawal, Parallel- 

Group, Placebo-Controlled Phase III Study of the Efficacy and 

Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as 

Monotherapy in the Maintenance Treatment of Patients with Major 

Depressive Disorder Following an Open-Label Stabilisation Period 

(Amethyst Study) d1448c0005. AstraZeneca, $198,000. 

A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension 

Trial Comparing the Safety and Efficacy of Asenapine with 

Olanzapine in Subjects who Completed Protocol A7501013 (Pfizer 

1014). Pfizer, $47,693. 

A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial 

Comparing the Efficacy and Safety of Asenapine with Olanzapine 

in Stable Subjects with Predominant, Persistent Negative Symptoms 

of Schizophrenia (Pfizer 1013). Pfizer, $86,125. 

A ree-Week, Double-Blind, Multicenter, Placebo-Controlled 

Study Evaluating the Efficacy and Safety of Add-on Oral 

Ziprasidone in Subjects with Acute Mania Treated with Lithium or 

Divalproex. Pfizer, Inc., $57,005. 

A Multicenter, Double-Blind, Randomized, Parallel-Group, 

Placebo-Controlled Phase III Study of the Efficacy and Safety of 

Quetiapine Fumarate Sustained Release (Seroquel SR?) as Mono- 

erapy in the Treatment of Adult Patients with Major Depressive 

Disorder (OPAL STUDY). AstraZeneca, $96,000. 

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 

16 Week Study of Aripiprazole Used as Dual erapy in the 

Treatment of Patients with Chronic Stable Schizophrenia or 

Schizoaffective Disorder Demonstrating An Inadequate Response 

to Quetiapine or Risperidone Monotherapy. Bristol-Myers Squibb, 

$71,950. 

 

 

Sleep Dependent Consolidation of Spatial Memory. Small Grant, 

$7,750. 

 

Long-term Psychological Adjustment in Patients with Implantable 

Cardioverter Defibrillators. New Investigator, $7,559.

White Matter Changes in Normal Aging: Impact on Everyday 

Functioning. Open Competition, $16,563. 

 

Neuropsychological Functioning in Compulsive Hoarding. Open 

Competition, $74,898. 

Virtual Reality Exposure Treatment for Combat-Related 

Posttraumatic Stress Disorder in Operation Iraqi Freedom and 

Operation Enduring Freedom Veterans. Open Competition, 

$73,894. 

 

Characterizing the Dyslexia Phenotype Using Genetics and MR 

Morphology. Small Grant, $9,722. 

 

Prospective Follow-up Study of the Effects of Locus-of-Control 

and Life Stressors on Long-Term Outcome of Treatment for Major 

Depressive Disorder. Small Grant, $9,723. 

 

 

fMRI of Virtual Reality Navigation. $2,000. 

Amphetamine and Memory in Virtual Reality. $3,000. 

 

fMRI of Brain Activation During Menstrual Migraine. $8,955. 

 

Brain Mechanisms of Interpersonal Judgement. $2,400. 

 

Neural Correlates of Trauma and Stress Treatment Change. 

$6,688. 

 

 

Inpatient Psychiatric Unit Medications and Falls Outcomes. 

 

Treatment of Late-Life Anxiety Among Home Health Care 

Recipients: A Feasibility Study. 

 

Assessment of ought Disorder in Adults: e Relationship of the 

Rorschach Perceptual inking Index, Other Rorschach Variables, 

and the Millon Clinical Multiaxial Inventory - III ought Disorder 

Index to Diagnoses in a Psychiatric Sample. 

 

Understanding Repetitive Behavior and Associated Experiences. 

Group Treatment for Compulsive Hoarding. 

 

Accuracy of a Mental Status Exam for Assessing Cognitive 

Dysfunction in Patients with Schizophrenia. 

 

Evaluation of Perceived Stigma Among Family Members of Persons 

with Severe Mental Illness. 

 

Functional Genomics of Behavioral Control. 

e Effect Pharmacotherapy on Trauma-Related Sleep Disturbance 

in Pediatric Populations. 

 

Anxiety Disorders Outcomes Protocol. 

An Internet Survey of Compulsive Hoarding. 

 

 

fMRI Investigation of PTSD-Related Cognitive Deficits and DNA 

Tissue Banking. National Center for PTSD/ VA, $48,293. 

 

Social Interactions in Developmental Disorders: Functional MRI 

Study. Departmental funds, $500. 

Implicit Mentalizing in Adults with Autistic Spectrum Disorders. 


Differential Diagnosis of Psychotic Patients. Donaghue Medical 

Research Foundation, $239,179. 

Neuronal Correlates of Implicit Social Interaction in Autism 

Spectrum Disorders: A Functional MRI Study. National Alliance for 

Autism Research, $118,968. 

 

Virtual Navigation in Individuals with Alzheimer’s Disease During 

fMRI. Hartford Hospital Research Endowment Funds, $49,950. 

Neuroimaging Cognition in Post-Traumatic Stress Disorder. 

Attention and Memory in Eating Disorder Populations. 

Fear Conditioning During Functional Magnetic Resonance 

Imaging. Departmental Funds, $400. 

 

Dying Experiences Among Racially Diverse Hospitalized Patients: 

Are ere Differences Between Older African Americans and 

Whites in End-Of-Life Treatment Outcomes? D e p a r t m e n t a l 

Funds, $10,593. 

 

A Controlled, Cross-sectional Comparison of Total Homocysteine 

Concentrations in Schizophrenic Outpatients Treated with 

Risperidone or Olanzapine. Jannsen Pharmaceutical, $30,000. 

A Controlled, Cross-Sectional Comparison of Total Homocysteine 

Concentrations in Schizophrenic Outpatients Treated With 

Risperidone or Olanzapine. Hartford Hospital Research Endowment 

Funds, $11,537. 

Tenex (guanfacine) Augmentation for the Remediation of Attention 

and Working Memory Deficits in Patients with Schizophrenia: 

A Pilot Study. Hartford Hospital Research Endowment Funds, 

$7,198.75 

A Prospective Comparison of Side Effects in Patients Treated with 

One or More Antipsychotics. 

 

Functional Mapping of the Neocortical Network in Schizophrenia: 

Executive-Function Impairments and Spontaneous Fluctuations in 

fMRI. Hartford Hospital Research Endowment Funds, $49,973. 

Semi-Blind Multi-Group ICA of fMRI. NIH, $1,000,000. 

Assessment of the State-Trial Specificity of Auditory Cortex fMRI 

Synchrony Maps in Schizophrenia and Bipolar Disorder. NARSAD, 

$60,000.

CRCNS: Collaborative Research: Spatiotemporal Fusion of fMRI, 

EEG, and Genetic Data Using Independent Component Analysis. 

NIH, $886,292. 

 

Comparison of Remediation Techniques on the WCST in 

Schizophrenia. Hartford Hospital Research Endowment Funds, 

$9,851. 

 

Feasibility Pilot Study of the Spanish and English Neuropsychological 

Assessment Scales (SENAS) in Puerto Ricans and Other Hispanics 

in the Greater Hartford Area. Hartford Hospital Research Endowment 

Funds, $9,988. 

 

Clinical Characteristics of OCD Spectrum Disorders: A 

Comparison of OCD and Trichotillomania. Hartford Hospital 

Research Endowment Funds, $9,329.25 

e Nature and Impact of Anxiety Symptoms upon Psychosocial 

Functioning of Older Adults with Major Depressive Disorder. 


Screening for GAD Among Frail Elderly. NIMH, $147,200. 

 

SSRIs in the Treatment of Major Depressive Disorder: Side Effects 

and Patient Choices of Treatment. Merck, $112,500. 

Information Dissemination as a Method of Improving Patient 

Outcome: A Demonstration Project and Study of the Outcomes of 

Patients with Major Depressive Disorder. Hartford Hospital Research 


Enhancing Short-Term Memory in Patients with Schizophrenia. 

Adjunctive Treatment with Bupropion in Major Depressive 

Disorder. GlaxoSmithKline, $60,700. 

Physiogenomic Analysis of Antipsychotic erapies and their 

Metabolic Side Effects. NIH subcontract through Genomas, 

$100,000. 

e Utility of Routine Cytochrome P450 Genotyping in the 

Selection of Type and Dosage of Antidepressant Medication. 

Psychiatric Treatment Practices and Patient Outcomes. 

 

Expectancy erapy and Medication for Smoking Cessation. 


 

Hemodynamic Assessment of Neurocognitive Remediation in 

Schizophrenia. NARSAD, $60,000.

Electrophysiological Assessment of Error Monitoring in Psychotic 

Illnesses. Hartford Hospital Research Endowment Funds, $50,000. 

fMRI Investigation of GAD and PTSD-Related Cognitive 

Deficits. 

ERP and fMRI of Emotion and Cognition in Psychopathy. 

Departmental Funds, $40,000.00; NIH, $1,192,320. 

Neurocognitive assessment of Callous Conduct Disordered Youth. 

Hartford Hospital Research Endowment Funds, $10,000.00; NIH, 

$1,564,000. 

Differentiating the Neural Systems Involved in Psychosis: Affective 

Disorder Versus Schizophrenia. Hartford Hospital Research 


Aberrant Functional Connectivity in Psychosis. NIMH, 

$1,564,000. 

 

Neurocognitive Remediation for Schizophrenia. Hartford Hospital 


FMRI Assessment of Treatment Response in the Schizophrenia 

Rehabilitation Program at the Institute of Living. Hartford Hospital 


Predictors of Treatment Response to Rehabilitation in 

Schizophrenia. NIH, $71,450. 

Neurocognitive Predictors of Response to Cognitive Remediation in 

Patients with Schizophrenia. NARSAD, $60,000. 

Virtual Reality Assessment of Psychosocial Status in Patients 

with Schizophrenia. Hartford Hospital Research Endowment Funds, 

$9,690. 

Facial Affect Recognition, Social Functioning, and Neurocognitive 

Deficits in Schizophrenia. 

Neurocognitive Remediation for Schizophrenia. NIH, $749,579. 

 

Intimacy - Sexuality Group erapy for Impaired and Distressed 

Professionals. 

 

Patterns of Verbal List Learning in Mild Traumatic Brain Injury: 

e Role of Effort and Motivation. 

 

Mild Traumatic Brain Injury Outcome Study. Hartford Hospital 


 

ABC: Aging, Brain Imaging, and Cognition. NIMH, $912,727. 

Sex Differences in Schizophrenia. NIMH, $776,448. 

Quantitative Neuroimaging in Psychosis. NIMH, 

$1,356,166. 

Computer-Based Driving Assessment in Early Alzheimer’s Disease. 


Marijuana and Driving: A Functional MRI Study. 

NIAAA, $1,198,370. 

Alcohol and Driving: A Functional MRI Study. NIH subcontract 

through Yale, $1,283,384. 

Human 31 - IH MRI and MRI Brain Studies of Nicotine. NIH 

subcontract through the University of Pittsburgh, $53,767. 

fMRI Studies of Healthy Volunteers at 3.0 Tesla. Departmental 

Funds, $2,000. 

Alcohol and Reward Mechanisms: Functional MRI Studies. 

Departmental Funds, $57,000. 

Amphetamine and Reward Mechanisms:fMRI Study. Yale 


Using fMRI to Differentiate Dementias. Departmental Funds,$200. 

Alzheimer’s Disease Neuroimaging Initiative - ADNI. Unv. Of 

California, San Diego, $292,959. 

Physiogenomic Arrays for Clinical Neuropsychiatry. NIH subcontract 

through Genomas, $100,931. 

 

Non-Compliance with Psychiatric Treatment. 

 

Diffusion Tensor Magnetic Resonance Imaging Correlates of 

Cognitive and Functional Outcome After Closed-Head Traumatic 

Brain Injury. Hartford Hospital Research Endowment Funds, 

$65,000. 

Response Inhibition in Attention-Deficit/Hyperactivity Disorder. 


Neuroimaging Cognition in Adolescent Behavior Disorders. 

NIMH, $798,709. 

Functional MRI Activation in Children to Monaural, Binaural and 

Dichotic Words. University of Connecticut, Storrs, $14,000. 

 

Intensive Behavior erapy for Medication Nonresponders with 

OCD. Hartford Hospital Research Endowment Funds, $49,972.30 

Cognitive-Behavioral Treatment of Pediatric Trichotillomania. 


Cognitive Processes in Anxiety Disorders. 

Two Treatments for Medication Nonresponders with OCD. 

Donaghue Medical Research Foundation, $172,999.97 

A Pilot Study of Conflict Monitoring in Obsessive-Compulsive 

Disorder: Relationship to Symptoms and Treatment Response. 


Cognitive Differences Between Generalized Anxiety Disorder 

and Obsessive-Compulsive Disorder. Hartford Hospital Research 


Dismantling the Neural Systems of Obsessive-Compulsive Disorder: 

A Symptom Provocation Study of Compulsive Hoarding. Hartford 


Treatment of Compulsive Hoarding. Boston University, $113,072. 

Long-Term Follow-Up of Cognitive-Behavioral erapy Patients 

with Anxiety Disorders. 

Multi-Site Study of CBT Treatment Failures. Obsessive-Compulsive 

Foundation, $750.

Augmenting Exposure 

erapy with an 

NMDA Agonist: A 

Pilot Study. Hartford 

Hospital Research 

Endowment Funds, 

$64,865. 

Cognitive-behavioral 

Bibliotherapy for 

the Treatment of 

Obsessive Compulsive 

Disorder in Children 

and Adolescents. 

P s y c h o p a t h o l o g y 

of Compulsive 

Hoarding. Smith 

College, $365,563. 

A Randomized, 

D o u b l e - B l i n d , 

Placebo-Controlled 

Trial of D-Cycloserine 

Augmentation of 

Behavior erapy for Obsessive-Compulsive Disorder. Departmental 

Funds, $245. 

 

Assessment of a Suicide Screening Program to Improve Detection of 

Post-Discharge Suicide Risk. Hartford Hospital Research Endowment 

Funds, $27,662. 

Extension of the Longitudinal Study of SSRIs in the Treatment of 

Depressive Disorder: Side Effects and Patient Choices of Treatment. 


 

Allen PD, Nelson HW, Gruman C, Cherry KE. Nursing home complaints: 

Who’s complaining and what’s gender got to do with it? Journal of 

Gerontological SocialWork, 47:89-106, 2006. 

Assaf M, Calhoun V, Kuzu C, Kraut M, Rivkin P, Hart J, Pearlson GD. 

Neural correlates of the object recall process in semantic memory. Psychiatry 

Research: Neuroimaging, 147:115-26, 2006. 

Assaf M, Rivkin P, Kraut M, Calhoun V, Hart J, Pearlson G. Schizophrenia 

and semantic memory. In Hart J and Kraut M. Neural Basis of Semantic 

Memory. Cambridge University Press, Cambridge, UK, 2007. 

Assaf M, Rivkin P, Kuzu C, Calhoun V, Kraut M, Groth K, Yassa M, Hart 

J, Pearlson GD. Abnormal object-recall and anterior cingulate overactivation 

correlate with formal thought disorder in schizophrenia. Biological Psychiatry, 

59:452-459, 2006. 

Astur RS, St Germain SA, Baker EK, Calhoun V, Pearlson GD, Constable 

RT. fMRI hippocampal activity during a virtual radial arm maze. Applied 

Psychophysiology and Biofeedback, 30:307-17, 2005. 

Astur RS, St. Germain SA, Tolin D, Ford J, Russell D, Stevens M. 

Hippocampus function predicts severity of post-traumatic stress disorder. 

Cyberpsychology & Behavior, 9:234-240, 2006. 

Baker EK, Kurtz MM, Astur RS. Virtual reality assessment of medication 

compliance in patients with schizophrenia. Cyberpsychology and Behavior, 9: 

224-229, 2006. 

Blair E, Gruman C. Falls in an inpatient geriatric psychiatric population. 

Journal of the American Psychiatric Nurses Association, 11:1-4, 2006. 

Bullock K, Blank K. e use of palliative care among racially diverse older 

hospitalized adults. e Gerontologist, 46 (Special Issue I), 595, 2006. 

Bullock K. Ahora le voy a cuidar mis nietos: Rural Latino grandparents 

raising grandchildren of substance abusing parents. Reprint in M. Delgado 

(ED.), Latinos and alcohol use/ab use revisited: Advances and challenges for 

prevention and treatment programs. New York, Haworth Press, pp. 107-130, 

2005. 

Bullock K. Get thee behind me: African-American grandparents raising 

grandchildren exposed to domestic violence. In RL Hampton, T Gullotta 

(Eds), Interpersonal Violence in the African American Community: Evidence- 

Based Prevention and Treatment Practices. New York, Springer, pp.149-163, 

2006. 

Bullock K. Grandfathers raising grandchildren: an exploration of African- 

American kinship networks. Journal of Health and Social Policy, 22:181-97, 

2007. 

Bullock K. Promoting advance care directives among African-Americans: A 

faith-based model. Journal of Palliative Medicine 9:183-195, 2006 

Bullock K. McGraw SA. A community capacity-enhancement approach to 

breast and cervical cancer screening among older women of color. Health & 

Social Work. 31:16-25, 2006. 

Calhoun VD, Adali T, Giuliani NR, Pekar JJ, Kiehl KA, Pearlson GD. 

Method for multimodal analysis of independent source differences in 

schizophrenia: Combining gray matter structural and auditory oddball 

functional data. Human Brain Mapping, 27:47-62, 2006. 

Calhoun VD, Adali T, Kiehl KA, Astur R, Pekar JJ, Pearlson GD. A 

method for multitask fMRI data fusion applied to schizophrenia. Human 

Brain Mapping, 27:598-610, 2006. 

Calhoun VD, Adali T. Unmixing fMRI with independent component 

analysis (Review). IEEE Engineering in Medicine and Biology Magazine, 25: 

79-90, 2006. 

Calhoun VD, Carvalho K, Astur R, Pearlson GD. Using virtual reality 

to study alcohol intoxication effects on the neural correlates of simulated 

driving. Applied Psychophysiology and Biofeedback, 30:285-306, 2005. 

Calhoun VD, Pearlson GD, Kiehl KA. Neuronal chronometry of target 

detection: Fusion of hemodynamic and event-related potential data. 

Neuroimage, 30:544-553, 2006. 

Carter AL, Wilber C, Sahl R. Motivational interviewing techniques and the 

harm-reduction model in a short-term substance-abuse group for adolescents 

with psychiatric problems. Connecticut Medicine, 69: 535-541, 2005. 

Carvalho KN, Pearlson GD, Astur RS, Calhoun VD. Simulated driving and 

brain imaging: Combining behavior, brain activity, and virtual reality. CNS 

Spectrums, 11:52-62, 2006. 

Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller 

SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling 

RA. Alterations in memory networks in mild cognitive impairment 

and Alzheimer’s disease: an independent component analysis. Journal of 

Neuroscience, 26:10222-31, 2006. 

Correa N, Adali T, Calhoun VD. Performance of blind source separation 

algorithms for fMRI analysis using a group ICA method. Magnetic Resonance 

Imaging, 2:684-94, 2007. 

Davidson K and Bullock K. Zelda Foster and her contributions to end-oflife 

care in social work. Journal of Social Work in End-of-Life Care, 3:69-82, 

2007. 

Diefenbach GJ and Goethe J. Clinical interventions for late-life anxious 

depression. Clinical Interventions in Aging, 1:41-50, 2006. 

Diefenbach GJ, Tolin DF, Crocetto JS, Maltby N, Hannan SE. Assessment 

of trichotillomania: A psychometric evaluation of hair pulling scales. Journal 

of Psychopathology and Behavioral Assessment. 27:169-178, 2005. 

Diefenbach GJ, Tolin DF, Hannan S, Maltby N, Crocetto J. Group 

treatment for trichotillomania: behavior therapy versus supportive therapy. 

Behavior erapy, 37: 353-63, 2006.

Diefenbach GJ. Culture-bound syndromes: Nervios. In Jackson Y (eds). e 

encyclopedia of multicultural psychology. Sage Publications, ousand Oaks, 

CA, pp. 141-42, 2006. 

Diefenbach, GJ. Integrating anxiety services into community care 

management. Anxiety Disorders: A Quarterly Report, Spring:7-9, 2006. 

Fogg-Waberski JH, Szarek BL, Knauft RF. Electroconvulsive therapy for 

treatment of refractory depression in a patient with cystic fibrosis. Journal of 

ECT, 22:72-73, 2006. 

Franklin ME, Tolin DF, Diefenbach GJ. Trichotillomania. In Hollander 

E, Stein DJ (eds). Clinical manual of impulse control disorders. American 

Psychiatric Press, Washington, DC, pp. 149-173, 2006. 

Franklin ME, Tolin DF. Treating trichotillomania: cognitive behavior therapy 

for hair pulling and related problems. Springer, New York, 2007. 

Garrity AG. Pearlson GD. McKiernan K. Lloyd D. Kiehl KA, Calhoun VD. 

Aberrant “default mode” functional connectivity in schizophrenia. American 

Journal of Psychiatry, 164:450-7, 2007. 

Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms 

associated with metabolic syndrome in psychiatric inpatients receiving 

antipsychotics. Journal of Clinical Psychiatry, 68:22-28, 2007. 

Goethe JW, Woolley SB, Cardoni AC, Woznicki B, Piez D. Selective 

serotonin reuptake inhibitor discontinuation: side effects and other factors 

that influence medication adherence. Journal of Clinical Psychopharmacology, 

27:451-58, 2007. 

Goethe JW. Antibiotics and mental disorder. Connecticut Medicine, 69: 

649, 2005. 

Goethe JW. Expanding the do no harm mandate. Invited article. 

Connecticut Medicine, 71:499-500, 2007. 

Goethe JW. Melman D. Mind and brain: together again. Invited article. 


Hannan SE, Tolin DF. Mindfulness and acceptance based behavior 

therapy for obsessive-compulsive disorder. In Orsillo SM, Roemer L (Eds.) 

Acceptance and Mindfulness-Based Approaches to Anxiety: Conceptualization and 

Treatment. New York, Springer, pp.271-299, 2005. 

Hejnar MP. Kiehl KA, Calhoun VD. Interparticipant correlations: a model 

free fMRI analysis technique. Human Brain Mapping, 28:860-7, 2007. 

Jiang H, van Zijl PC, Kim J, Pearlson GD, Mori S. DtiStudio: Resource 

program for diffusion tensor computation and fiber bundle tracking. 

Computer Methods & Programs in Biomedicine, 81:l06-116, 2006. 

Johnson MR, Morris NA, Astur RS, Calhoun VD, Mathalon DH, Kiehl 

KA, Pearlson GD. A functional magnetic resonance imaging study of 

working memory abnormalities in schizophrenia. Biological Psychiatry, 60: 

11-21, 2006. 

Kanaan RA, Kim JS, Kaufmann WE, Pearlson GD, Barker GJ, McGuire 

PK. Diffusion tensor imaging in schizophrenia. Biological Psychiatry, 58: 

921-929, 2005. 

Kiehl KA, Bates AT, Laurens KR Hare RD, Liddle PF. Brain potentials 

implicated temporal lobe abnormalities in criminal psychopaths. Journal of 

Abnormal Psychology, 115:443-453, 2006. 

Kiehl KA. A cognitive neuroscience perspective on psychopathy: Evidence 

for paralimbic system dysfunction. Psychiatry Research, 15:107-128, 2006. 

Krystal JH, D’souza DC, Gallinat J, Driesen N, Abi-Dargham A, Petrakis 

I, Heinz A, Pearlson G. e vulnerability to alcohol and substance abuse in 

individuals diagnosed with schizophrenia. Neurotoxicity Research,10:235-52, 

2006. 

Kurtz MM, Wexler BE. Differences in performance and learning 

proficiency on the Wisconsin Card Sorting Test in schizophrenia: Do they 

reflect distinct neurocognitive subtypes with distinct functional profiles? 

Schizophrenia Research, 81:167-171, 2006. 

Kurtz MM. Symptoms versus neurocognitive skills as correlates of everyday 

functioning in patients with severe mental illness: A review and synthesis. 

Expert Review of Neurotherapeutics, 6:47-56, 2006. 

Kurtz MM, Seltzer JC, Shagan DS, ime WR, Wexler BE. Computerassisted 

cognitive remediation in schizophrenia: what is the active ingredient? 

Schizophrenia Research, 89:251-60, 2007. 

Liddle PF, Laurems KR, Kiehl KA, Ngan ET. Abnormal function of the 

brain system supporting motivated attention in medicated patients with 

schizophrenia: An fMRI study. Psychological Medicine, 36:1097-1108, 2006. 

Lindberg M, Vergara C, Wild-Wesley R, Gruman C. Physicians-intraining 

attitudes toward caring for and working with patients with alcohol 

and drug abuse diagnoses. Southern Medical Journal 99:28-35, 2006. 

Lothstein L. Gender identity disorders: social-cultural, psychological and 

clinical perspectives. In Plante T. (Ed.), Abnormal psychology in the 21st 

century. Vol. III. Chapter 9. Greenwood, N.Y, pp 255-80, 2006. 

Lothstein L. Taking a social history: when is enough, enough?. Review 

of social history assessment. Arlene Bowers. Sage ousand Oaks, CA. 

PsychCRITIQUES:2007. 

Lothstein L. Murder in the psychiatrist’s cathedral. Review of homicide: a 

psychiatric perspective. 2nd Ed. Malmquist C. American Psychiatric Press. 

Washington D.C. 2006. PsychCRITIQUE, 2007. 

Lothstein L. e third way and beyond: criminal and social justice 

in England. Criminal and social justice. Dee Cook. Sage, London. 

PsychCRITIQUES, 2006. 

Lothstein, L. From ‘Hello Dolly’ to ‘Baby Look at You Now’: the new 

science of reprogenetics. Edited by Lori Knowles and Gregory Kaebnick. 

Baltimore Md. e Johns Hopkins Press. PsychCRITIQUES: 2007. 

Lothstein, L. Treating gambling additions: don’t bet on “one size fits all” 

model. Review of treating gambling problems. William McGown & William 

Howatt. John Wiley & Sons Hoboken NJ. PsychCRITIQUES:2007. 

Lyketsos CG, Colenda CC, Beck C, Blank K, Doraiswamy MP, Kalunian 

DA, Yaffe K. Position statement of the American Association for Geriatric 

Psychiatry regarding principles of care for patients with dementia resulting 

from Alzheimer Disease. American Journal of Geriatric Psychiatry, 14:561- 

572, 2006 

Maltby N, Tolin DF. A brief motivational intervention for treatmentrefusing 

OCD patients. Cognitive Behaviour erapy, 34:176-84, 2005. 

Mandelbaum DE, Stevens M, Rosenberg E, Wiznitzer M, Steinschneider 

M, Filipek P, Rapin I. Comparison of sensory/motor performance in 

school-age children with autism, developmental language disorder or low 

IQ. Developmental Medicine and Child Neurology, 48:33-39, 2006. 

Manning KJ. Gordon B. Pearlson GD. Schretlen DJ. e relationship of 

recency discrimination to explicit memory and executive functioning. Journal 

of the International Neuropsychological Society, 13:710-5, 2007. 

Martel AL. Child and Adolescent Psychiatry Training in the 21st Century. 

Connecticut Medicine, 69: 547-551, 2005. 

McKiernan KA, D’Angelo B, Kaufman JN, Binder JR. Interrupting the 

“stream of consciousness”: An fMRI investigation. Neuroimage, 29:1185- 

1191, 2006. 

Most SB, Chun MM, Johnson MR, Kiehl KA. Attentional modulation of 

the amygdala varies with personality. Neuroimage, 31:934-44, 2006. 

Nace EP, Tinsley JA. Patients with substance abuse problems: effective 

identification, diagnosis, and treatment. WW. Norton & Company, NY, 

2007. 

Niego SH, Kofman MD, Weiss JJ, Geliebter A. Binge eating in the bariatric 

surgery population: a review of the literature. International Journal of Eating 

Disorders, 40: 349-59, 2007. 

Norberg MM, Wetterneck CT, Woods DW, Conelea C. Examination 

of the mediating role of psychological acceptance in relationships between 

cognitions and the severity of chronic hairpulling. Behavior Modification, 31: 

367-81, 2007. 

Offsay J. Treatment of alcohol-related problems in the elderly. Annals of

Long-Term Care, 7:39-44, 2007. 

Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety disorders: a 

meta-analytic review. Clinical Psychology Review, 27:572-581, 2007. 

Olatunji BO, Deacon BJ, Abramowitz JS, Tolin DF. Dimensionality of 

somatic complaints:factor structure and psychometric properties of the Self- 

Rating Anxiety Scale. Journal of Anxiety Disorders, 20: 543-61, 2006. 

Olatunji BO, Lohr JM, Sawchuk CN, Tolin DF. Multimodal assessment of 

disgust in contamination-related obsessive-compulsive disorder. Behaviour 

Research and erapy, 45:263-76, 2007. 

Olatunji BO, Williams NL, Tolin DF, Sawchuk CN, Abramowitz JS, 

Lohr JM, Elwood L. e Disgust Scale: item analysis, factor structure, and 

suggestions for refinement. Psychological Assessment, 19:281-97, 2007. 

Pearlson GD. Calhoun VD. Structural and functional magnetic resonance 

imaging in psychiatric disorders. Canadian Journal of Psychiatry - Revue 

Canadienne de Psychiatrie, 52:158-66, 2007. 

Rosario-Campos MC, Miguel EC, Quatrano PC, Ferrao Y, Findley D, 

Scahill L, King R, Woody S, Tolin DF, Hollander E, Kano Y, Goodman 

WK, Leckman JF. e Dimensional Yale-Brown Obsessive Compulsive 

Scale (DY-BOCS): An instrument for assessing obsessive-compulsive 

symptom dimensions. Molecular Psychiatry, 11:495-504, 2006. 

Ruaño G, Blair CL, Bower B, Windemuth A, Kocherla M, Aleman 

Y, Pearlson G, Goethe JW, Schwartz HI. Somatic complications of 

psychotropic medications in a patient with multiple CYP2 drug metabolism 

deficiencies. Connecticut Medicine, 71:197-200, 2007. 

Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocheria M, 

Windemuth A, de Leon J. Physiogenomic comparison of weight profiles 

of olanzapine- and risperidone-treated patients. Molecular Psychiatry,12: 

474–82, 2007. 

Ruaño G, Makowski G, Windemuth A, Kocherla M. Weiss S, Goethe JW, 

Bower B, WU AHB, ompson PD. High carrier prevalence of deficient 

and null alleles of CYP2 genes in a major USA hospital: Implications for 

personalized drug safety. Personalized Medicine, 3:131-137, 2006. 

Ruaño GR, Zollner S, Goethe JW. Drug induced metabolic 

syndrome (DIMS) in psychiatry: A diagnostic need uniquely suited to 

pharmacogenomics. In Wong SHY, Linder MW, Valdes R Jr. (Eds.) 

Pharmacogenomics and Proteomics: Enabling the Practice of Personalized 

Medicine. AACC Press, Washington, DC, pp: 277-282, 2006. 

Sahl RA. Golden excellence. Editorial. Connecticut Medicine, 69:517, 2005. 

Sahl RA. Guest Editor. Commemorative special edition 50th anniversary of 

the division of child and adolescent services at Hartford Hospital’s Institute 

of Living. Connecticut Medicine, 69, 2005. 

Schlaepfer TE, Lancaster E, Heidbreder R, Strain EC, Kosel M, Fisch HU, 

Pearlson GD. Decreased frontal white-matter volume in chronic substance 

abuse. International Journal of Neuropsychopharmacology, 9:147-153, 2006. 

Schretlen DJ, Buffington AL, Meyer SM, Pearlson GD. e use of wordreading 

to estimate “premorbid” ability in cognitive domains other than 

intelligence. Journal of the International Neuropsychological Society, 11:784- 

787, 2005. 

Schretlen DJ, Cascella NG, Meyer SM, Kingery LR, Testa SM, Munro 

CA, Pulver AE, Rivkin P, Rao VA, Diaz-Asper CM, Dickerson FB, Yolken 

RH, Pearlson GD. Neuropsychological functioning in bipolar disorder and 

schizophrenia. Biological Psychiatry, 62:179-86, 2007. 

Schretlen DJ, Inscore AB, Jinnah HA, Rao V, Gordon B, Pearlson GD. 

Serum uric acid and cognitive function in community-dwelling older adults. 

Neuropsychology, 21:136-40, 2007. 

Schwartz HI. Death Row Syndrome and Demoralization: Psychiatric 

Means to Social Policy Ends. Journal of the American Academy of Psychiatry 

and the Law, 33: 153-155, 2005 

Seltzer J, Kurtz M, ime W. e Schizophrenia Rehabilitation Program 

at the Institute of Living: Combining neurocognitive, motivational and 

vocational rehabilitation. e Behavior erapist, 29:30-35, 2006. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stanley MA, Veazey C, Hopko D, Diefenbach GJ, Kunik ME. Anxiety 

and depression in chronic obstructive pulmonary disease (COPD): A new 

intervention and case report. Cognitive and Behavioral Practice, 12:424-436, 

2005. 

Stevens MC, Calhoun VD, Kiehl, KA. fMRI in an oddball task: Effects of 

target-to-target interval. Psychophysiology, 42:636-642, 2005.

Stevens MC, Kiehl KA, Pearlson G, Calhoun VD. Functional neural circuits 

for mental timekeeping. Human Brain Mapping, 28:394-408, 2007. 

Stevens MC, Kiehl KA, Pearlson GD, Calhoun VD. Functional neural 

networks underlying response inhibition in adolescents and adults. 

Behavioural Brain Research, 181:12-22, 2007. 

Stevens MC, Laurens KR, Liddle PF, Kiehl KA. e hemodynamics of 

oddball processing during single-tone and two-tone target detection tasks. 

International Journal of Psychophysiology, 60:292-303, 2006. 

Stevens MC. Functional neuroimaging in child and adolescent psychiatry. 


Tolin D, Hannan S, Maltby N, Diefenbach GJ, Worhunsky P, Brady RE. 

A randomized controlled trial of self-directed versus therapist-directed 

cognitive-behavioral therapy for obsessive-compulsive disorder patients with 

prior medication trials. Behavior erapy, 38:179-91, 2007. 

Tolin DF, Abramowitz JS, Diefenbach GJ. Defining “response” in clinical 

trials for OCD: A signal detection analysis of the Yale-Brown Obsessive- 

Compulsive Scale. Journal of Clinical Psychiatry, 66:1549-1557, 2005. 

Tolin DF, Breslau N. Sex differences in risk of PTSD. PTSD Research 

Quarterly, 18:1-7, 2007. 

Tolin DF, Diefenbach GJ, Maltby N, Hannan SE. Stepped care for 

obsessive-compulsive disorder: A pilot study. Cognitive and Behavioral 

Practice, 12:403-414, 2005. 

Tolin DF, Foa EB. Sex differences in trauma and posttraumatic stress 

disorder: a quantitative review of 25 years of research. Psychological Bulletin, 

132:959-92, 2006. 

Tolin DF, Frost RO, Steketee G. Buried in treasures: help for compulsive 

acquiring, saving and hoarding. Oxford University Press, New York, 2007. 

Tolin DF, Frost RO, Steketee G. An open trial of cognitive-behavioral 

therapy for compulsive hoarding. Behaviour Research and erapy, 45:1461- 

70, 2007. 

Tolin DF, Hannan S, Maltby N, Diefenbach GJ, Worhunsky P, Brady RE. 

A randomized controlled trial of self-directed versus therapist-directed CBT 

for OCD patients with prior medication trials. Behavior erapy, 38: 179- 

91,2007. 

Tolin DF, Hannan SE. e role of the therapist in behavior therapy. In 

Abramowitz JS, Houts AC (Eds.). Handbook Of Obsessive-Compulsive 

Spectrum Disorders. New York, Springer, pp.317-332, 2005. 

Tolin DF, Hannan SE. What’s in a name? e distinction between selfdirected 

and self-conducted treatment. In Abramowitz JS, Houts AC (Eds.) 

Handbook of Obsessive-Compulsive Spectrum Disorders. New York, Springer, 

pp.347-352, 2005. 

Tolin DF, Koby D, Monteiro M. Disseminating cognitive-behavioral 

therapy for OCD. [Review of the book Understanding and Treating 

Obsessive-Compulsive Disorder: A Cognitive-Behavioral Approach]. 

PsycCritiques-Contemporary Psychology: APA Review of Books, 2006. 

Tolin DF, Steketee G. General issues in psychological treatment for OCD. 

In Antony MM, Purdon C, Summerfeldt LJ (Eds.). Psychological treatment 

of OCD: beyond the basics. American Psychological Association, Washington, 

DC, pp.31-59, 2007. 

Tolin DF, Woods CM, Abramowitz JS. Disgust sensitivity and obsessivecompulsive 

symptoms in a non-clinical sample. Journal of Behavior erapy 

& Experimental Psychiatry, 37:30-40-2006. 

Tolin DF, Worhunsky P, Brady RE, Maltby N. e relationship between 

obsessive beliefs and thought control strategies in a clinical sample. Cognitive 

erapy and Research, 31:307-18, 2007. 

Tolin DF, Worhunsky P, Maltby N. Are “obsessive” beliefs specific to 

OCD?: a comparison across anxiety disorders. Behaviour Research and 

erapy, 44:469-80, 2006. 

 

Abraham AC, Meunier SA, Olatunji BO. Disgust sensitivity and information 

processing biases in bulimia. Presented at the annual meeting of the Association 

for Behavioral and Cognitive erapies, Washington, DC, November 2005. 

Assaf M, Johnson MR, Schultz R, Hendler T, Sahl R, Calhoun V, Pearlson 

G. Neural correlates of implicit mentalizing in autism spectrum disorders: 

functional MRI study. Presented at the International Meeting for Autism 

Research, Seattle, WA, 2007. 

Assaf M, Johnson MR, Schultz R, Sahl R, Calhoun V, Hendler T, Pearlson 

G. Abnormal brain activation during implicit mentalization in autism 

spectrum disorders. Symposium presentation at the annual meeting of the Society 

of Biological Psychiatry, San Diego, CA, 2007. 

Assaf M. Autism spectrum disorders: current state of brain research. Presented 

at the Breakfast series, Grace Webb School, Hartford, CT, April 2007. 

Assaf M. inking about others: the mentalization neural network and its 

role in autism spectrum disorders. Presented at the Tel Aviv Human Brain 

Mapping Meeting, Tel Aviv, Israel, 2007 

Baker E K, Kurtz MM, Astur RS. Virtual-reality assessment of medication 

compliance in patients with schizophrenia. International Workshop on Virtual 

Rehabilitation, Avalon, CA, .October 2005. 

Baker EK, Kurtz MM, Astur RS. Virtual-reality assessment of medication 

self-management in patients with schizophrenia. Presented at the Society for 

Neuroscience, Washington, DC, October 2005. 

Benjamin S, Bentman A, Beresin E, Kay J, Kaye D, Martel A, Mohl P. e 

rituals of psychiatric residency training: rites of passage, carriers of culture. 

Presented at the annual meeting of the American Association of Directors of 

Psychiatric/Residency Training, San Juan, PR, March 2007. 

Blank K, Szarek BL, Goethe JW. Metabolic abnormalities in patients with 

major depressive disorder. Presented at the annual meeting of the American 

Psychiatric Association, San Diego, CA, May 2007. 

Blank K, Szarek BL, Goethe JW. e influence of dementia on the 

treatment of depression in geriatric inpatients. Presented at the annual meeting 

of the American Psychiatric Association, Toronto, Canada, May 2006. 

Blank K. Advances in Memory Disorders and Dementia. Presented to 

Hartford Hospital Women’s Physicians Organization, Hartford, CT, April 

2007. 

Blank K. Everything you ever wanted to know about Alheimer’s disease 

and related disorders: but were afraid (or forgot) to ask. H.H.Focus on Health 

Luncheon, Hartford, CT, November 2006. 

Blank K. Overview of dementia. Caregivers’ Course, Alzheimer’s Association, 

Connecticut Chapter, Caregivers’ Course, 2007. 

Blank K. e importance of early diagnosis and treatment of memory 

disorders: dementia and cognitive disorders. UConn Medical Residents 

rotation in Geriatrics, 2007. 

Blank K. e importance of early diagnosis and treatment of memory 

disorders. Multiple presentations in the community including at West Hartford 

Town Hall, Rocky Hill Nurse’s Association, Beth Israel Synagogue, 2005-2006. 

Bochicchio MJ, Kurtz MM. Neurocognition, affect recognition and social 

skills performance in outpatients with schizophrenia. Presented at the 

International Neuropsychological Society, Boston, MA, February 2006. 

Brady RE, Diefenbach GJ, Tolin DF, Hannan SE, Crocetto JS. What 

works in CBT for trichotillomania: Patients’ self-report of efficacy. Presented 

at the annual meeting of the Association for Behavioral and Cognitive erapies, 

Washington, DC, November 2005. 

Brady RE, Tolin DF. Ongoing group therapy for OCD: a preliminary study 

of effectiveness and cost. Presented at the annual meeting of the Association of 

Behavioral and Cognitive erapies, Chicago, IL, November 2006.

Brady RE, Tolin DF. What do hoarders hoard? Possessions and 

maladaptive beliefs. Presented at the annual meeting of the Association of 

Behavioral and Cognitive erapies, Chicago, IL, November 2006. 

Bullock K, Blank K. Dying experience among racially diverse 

hospitalized older adult patients. Presented at the European Association 

for Palliative Care, Venice, Italy, May 2006. 

Bullock K, Blank K. Factors that influence the completion of advance 

directives: a racially diverse population of older adults. Presented at the 

10th Congress of the European Association for Palliative Care, Budapest, 

Hungary, June 2007. 

Bullock K, Blank K. e use of palliative care among racially diverse 

older hospitalized older adults. Presented at the annual scientific meeting 

of the Gerontological Society of America. Dallas, TX. November 2006. 

. 

Bullock K, Hickey E, LaRocca C, Spear H. Mental health treatment 

in an ethnically diverse population of urban elders: overcoming 

barriers. Presented at the annual meeting of the American Association of 

Geriatric Psychiatry, New Orleans, LA, March 2007. 

Bullock K, Johnson JW. Intergenerational service learning with 

community-dwelling older adults and middle school youth. e 

Council on Social Work Education, Chicago, IL, February 2006. 

Bullock K, McGraw SL, Costa L, Smith K, Cohen D, Gift H. 

Promoting cancer screening among older Latina and African- 

American women. Presented at the annual meeting of the Gerontological 

Society of America, November 2005. 

Bullock K, Robison J, Hickey E. Overcoming barriers: Behavioral 

health intervention in a diverse population of older adults. e Council 

on Social Work Education, Chicago, IL, February 2006. 

Bullock K, Robison J, Hickey E. Social support and mental health 

services among three ethnic groups of elders in urban community 

housing. Gerontological Society of America, Orlando FL, November 

2005. 

Bullock K. Cultural proficiency in end-of-life care. Presented at 

the New Jersey Health Decisions Statewide Educational Training for 

Practitioners, Union, NJ, May 2006. 

Bullock K. Diversity/minority issues. Presented at the Gero-Ed 

Forum/AGE-SW rountable Session, Council on Social Work Education 

Annual Program meeting, Chicago, IL, February 2006. 

Bullock K. Grandparents raising grandchildren in urban communities. 

Presented at the Caritas Conference, In Praise of Grandparents, Saint 

Joseph College, West Hartford CT, May 2006. 

Bullock K. Individuals in crisis: e aftermath of hurricane Katrina. 

Presented at the Institute of Living Grand Rounds, Hartford CT, May 

2006. 

Bullock K. e aftermath of hurricane Katrina: A reflection of 

the black experience. Presented at the Millikin University Student 

Education Forum, Decatur, IL, February 2006. 

Burke A, Connors M, Jones D, Melman D, Rahim S, Yotova M. 

Cultural influence on formulation, diagnosis, and treatment of a 

Bangladeshi immigrant. Institute of Living Grand Rounds, Hartford, 

CT, March 2006. 

Caley C. Essential fatty acids and treatment response. Presented at the 

annual meeting of NAMI– CT, Wallingford, CT, October 2005. 

Caley CF. Atypical antipsychotics in schizophrenia: evaluating 

adherence and relapse. Presented at the Annual Meeting of the College 

of Psychiatric and Neurologic Pharmacists, Colorado Springs, CO, April 

2007. 

Caley CF. Medication management for bipolar disorder: advantages 

and disadvantages. Presented at the Depression and Bipolar Support 

Alliance, Hartford, CT, December 2006. 

Caley CF. More than the baby blues: identification and management 

of postpartum depression. Presented at the annual meeting and

exposition of the American Pharmacy Association, Atlanta, GA, March 2007. 

Caley CF. Treatment outcomes in schizophrenia: current issues and 

emerging options. Symposium chair, 10th Annual Meeting of the College of 

Psychiatric and Neurologic Pharmacists, Colorado Springs, CO, April 2007. 

Caley CF. Treatment resistant depression. Presented at the 10th Annual 

Northeastern Psychiatric Pharmacotherapy Symposium, Northampton, MA, 


Cardoni A, Woolley SB, Piez D, Goethe JW. Treatment-resistant 

depression: Changes in symptoms and functioning in a clinical sample. 

Presented at the annual meeting of the American Psychiatric Association, Toronto, 

Canada, May 2006. 

Cardoni AA, Woolley SB, Goethe JW. LOCF (last observation carried 

forward) and distortion of findings in a psychotropic drug clinical study. 

Presented at the annual meeting of the American Psychiatric Association, San 

Diego, CA, May 2007. 

Cardoni AA, Woolley SB, Piez DA, Goethe JW. Bupropion augmentation 

versus usual care in the treatment of patients with treatment-resistant 

depression. Presented at the annual meeting of the American Psychiatric 

Association, Toronto, Canada, May 2006. 


versus usual care in treatment of patients with treatment-resistant depression. 

Presented at the annual meeting of the U.S. Psychiatric & Mental Health 

Congress, New Orleans LA, November 2006. 


versus usual care in the treatment of patients with treatment-resistant 

depression. Presented at the 10th Annual Meeting of the College of Psychiatric 

and Neurologic Pharmacists, Colorado Springs, CO, April 2007. 

Cardoni AA. Antipsychotics in OCD. Psychopharmacology/Neuroscience 

Rounds, e Institute of Living, Hartford, CT, November 2005. 

Cardoni AA. Bipolar update. Presented to the Department of Psychiatry, 

Institute of Living, Hartford, CT, September 2006. 

Cardoni AA. Anticonvulsants in the treatment of anxiety disorders. Presented 

at Psychopharmacology/Neuroscience Rounds, e Institute of Living, Hartford, 

CT, October 2005. 

Carter A. e legacy of substance abuse: Fetal alcohol syndrome and fetal 

alcohol effects in the classroom. Institute of Living Breakfast Series for school 

personnel, Hartford, CT, April 2006. 

DeTore NR, D’Olio CM, Pasupuleti RV, Tolin DF, Diefenbach GJ, 

Cahill SP, Piacentini JC, Rozeman M, Franklin ME. Is there a relationship 

between pediatric trichotillomania and history of interpersonal violence? 

Presented at the annual meeting of the Association of Behavioral and Cognitive 

erapies, Chicago, IL, November 2006. 

Diefenbach GJ, Disch WB, Robison JT, Baez E. Characteristics of 

generalized anxiety disorder among ethnic minority adults living in urban 

senior housing. Presented at the annual meeting of the Association for Behavioral 

and Cognitive erapies, Washington, DC, November 2005. 

Diefenbach GJ, Tolin DF, Meunier SA, Worhunsky P. Emotion regulation 

and trichotillomania: A comparison of clinical and nonclinical hair pulling. 

Presented at the annual meeting of the Association for Behavioral and Cognitive 

erapies, Washington, DC, November 2005. 

Diefenbach GJ, Tolin DF, Worhunsky P. Interpersonal processes in 

generalized anxiety disorder. Presented at the annual meeting of the Association 

for Behavioral and Cognitive erapies, Washington, DC, November 2005. 

Diefenbach GJ. CBT for generalized anxiety disorder: A Case Study. 

Presented to Psychiatry Resident Rounds, Institute of Living, Hartford, CT, 

June 2006. 

Diefenbach GJ. Comorbidity of anxiety and eating disorders. Presented to the 

Connecticut College Eating Disorder Task Force, Hartford, CT, December 2005. 

Diefenbach, GJ. CBT for generalized anxiety disorder: a case study. Presented 

at Psychiatry Resident Rounds, Institute of Living, Hartford, CT, November, 

2006. 

Fabricant L, Frost RO, Steketee G, Tolin DF. Hoarding with and without 

depression. Presented at the World Congress of Behavioral and Cognitive 

erapies, Barcelona, Spain, July 2007. 

Franklin ME, Roth Ledley DA, Cardona D, Anderson E, Hajcak G. CBT 

for pediatric trichotillomania: A randomized controlled trial. Presented to 

the Annual Meeting of the Association for Behavioral and Cognitive erapies, 


Frost RO, Steketee G, Kyrios M, Tolin DF, Brown TA. Diagnostic issues 

in compulsive hoarding. Presented at the annual meeting of the European 

Association of Behavioral and Cognitive erapies, Paris, France, May 2006. 

Frost RO, Steketee G, Kyrios M, Tolin DF, Brown TA. Vulnerability for 

compulsive hoarding. Presented at the annual meeting of the Association for 

Behavioral and Cognitive erapies, Washington, DC, November 2005. 

Frost RO, Steketee G, Tolin DF, Brown TA. Comorbidity and diagnostic 

issues in compulsive hoarding. Presented to the annual meeting of the Anxiety 

Disorders Association of America, Atlanta, GA, March 2006. 

Goethe JD Blank K, Szarek BL. Metabolic risk factors in geriatric inpatients 

with major depressive disorder. Presented at the annual meeting of the American 

Psychiatric Association, San Diego, CA, 2007. 

Goethe JW, Szarek BL, Caley CF. Metabolic abnormalities in psychiatric 

inpatients. Presented at the annual meeting of the American Psychiatric 

Association, San Diego, CA, May 2007. 

Goethe JW, Szarek BL, Woolley SB, Caley CF. Metabolic syndrome 

in psychiatric inpatients. Presented at the annual meeting of the American 


Goethe JW, Woolley SB, Piez DA. Hopelessness and suicidality three 

months post-hospital discharge. Presented at the annual meeting of the 

American Psychiatric Association, Toronto, Canada, May 2006 

Gugger JJ, Caley CF, Goethe JW, Szarek BL, Ehret MJ, Woolley SB. e 

pharmacogenomics of antidepressant tolerance. Presented at the annual 

meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado 

Springs, CO. April 2007. 

Gugger JJ, Caley CF. Clozapine treatment in a patient with a persistently low 

neutrophil count. Presented at the annual meeting of the College of Psychiatric 

and Neurologic Pharmacists, Colorado Springs, CO, April 2007. 

Ham LS, Norberg MM. Understanding social anxiety and problem drinking: 

an examination of the role of alcohol expectancies related to positive social 

effects. Presented at the annual meeting of the Anxiety Disorders Association of 

America, Toronto, Ontario, Canada, March 2007. 

Karabelnik L, Hanna N. Medication for ED kids: New findings. Institute of 

Living Breakfast Series for school personnel, Hartford, CT, May 2006. 

Kellett K, Robison J, Haber L. Burden and well-being in aging families 

of people with severe mental illness. Presented at the annual meeting of the 

Gerontological Society of America, Orlando, FL, November 2005. 

Kurtz MM, Wexler BE, Stevens MC, Kiehl KA. Abnormal hemodynamics 

during a verbal working memory task in patients with schizophrenia. 

Presented at the annual meeting of the Biological Psychiatry Society, Toronto, 


Kurtz MM. Cognitive remediation at Cedarcrest Hospital. Presented at 

Cedarcrest Hospital (DMHAS), Newington, CT, September 2006. 

Kurtz MM. Cognitive remediation for schizophrenia: What is the active 

ingredient? Presented at the Cognitive Remediation Experts Workshop, London, 

United Kingdom, September 2006. 

Kurtz, M.M. Neurocognitive remediation for schizophrenia: Current status 

and future prospects. Current Issues in Neuroscience Lecture Series. Trinity 

College. Hartford, CT. October 2006. 

Lothstein L. Competency and standards for psychology: A review of 

treatments that don’t work and the role of evidence based and relationally 

based therapies. Psychology Rounds. IOL/HH September 2007. 

Lothstein L. Al-Quaida terrorist and mental illness: A case report. Institute 

of Living Psychology Rounds, 2006.

Lothstein L. e IOL Psychology Department reaches 70: Perspectives on 

psychology at the IOL. Institute of Living Psychology Rounds, 2006. 

Lothstein, L. Childhood sexuality: When to worry? Breakfast Series, Grace 

Webb School. 2006 

Maltby N, Tolin DF, Kiehl KA. Compulsive hoarding: Is there evidence of 

dysfunctional error processing? Presented at the annual meeting of the Society of 

Biological Psychiatry, Toronto, Canada, May 2006. 

Maltby N, Worhunsky P, Book GA, Kiehl KA, Tolin DF. Putting 

neurobiological models of OCD to the test: An fMRI study of specificity 

and response to treatment. Presented at the annual meeting of the Association of 


Maltby N, Worhunsky P, Kiehl KA, Tolin DF. Dismantling the neural 

systems of obsessive-compulsive disorder: A symptom provocation fMRI 

study of compulsive hoarding. Presented at the annual meeting of the Anxiety 

Disorders Association of America, Atlanta, GA, March 2006. 

Maltby NM. Treating school refusal. Grand Rounds, New York Medical 

College, Valhalla, NY, December 2005. 

Marsh ND, Reilly A, Marcinczyk S. I wish God would take me: suicide risk 

assessment in the elderly. Presented at the 3rd annual NASW/CT Fall specialty 

conference, Cromwell, CT, November 2006. 

McCloskey HW. Suicide assessment. Presented at the annual conference of 

the New England Chapter of American Psychiatric Nurses’ Association, Nashua, 

NH, March 2007. 

McKiernan KA. Examining the structure and function of the human 

brain with fMRI. Guest Lecturer, Trinity College Undergraduate Course in 

Neuroanatomy, Hartford, CT, November 2005 

McKiernan KA. e human brain: Structure and function and what can 

we learn from magnetic resonance imaging. Presented as part of the PGY-2 

Psychiatry Residents’ Lecture Series, Institute of Living, Hartford, CT, June 

2006 

Meunier SA, Abraham AC, Olatunji BO. Disgust sensitivity as a predictor 

of eating disorder symptoms in a college sample. Poster presented at the 39th 

annual meeting of the Association for Behavioral and Cognitive erapies, 


Meunier SA, Diefenbach GJ, Tolin DF, Worhunsky P. Impulsivity across 

the obsessive-compulsive spectrum. Presented at the annual meeting of the 

Association for Behavioral and Cognitive erapies, Washington, DC, November 

2005. 

Meunier SA, Lohr JM, Cisler JM. State and trait disgust reactivity and 

symptoms of anxiety. Presented at the annual meeting of the Association for 


Meunier SA, Lohr JM, Olatunji BO. Expectancy and covariation biases 

in blood-injury-injection phobia. Presented at the annual meeting of the 


2005. 

Meunier SA, Tolin DF, Diefenbach GJ, Brady RE. Severity and course 

of hair pulling symptoms across the lifespan. Presented at the annual meeting 

of the Association for Behavioral and Cognitive erapies, Washington, DC, 

November 2005. 

Meunier SA, Tolin DF, Franklin ME, Diefenbach GJ, Anderson E. A 

descriptive study of pediatric trichotillomania. Presented at the annual 

meeting of the Association for Behavioral and Cognitive erapies, Washington, 

DC, November 2005. 

Meunier SA, Tolin DF, Franklin ME. Affective and sensory correlates 

of hair pulling in a pediatric sample. Presented at the annual meeting of the 


2005. 

Meunier SA, Tolin DF, Frost RO, Steketee G, Brady RE, Brown TA. 

ADHD symptoms in compulsive hoarders. Presented at the annual meeting 

of the Association of Behavioral and Cognitive erapies, Chicago, IL, November 

2006. 

Meunier SA, Tolin DF, Frost RO, Steketee G, Brady RE. Prevalence of 

hoarding symptoms across the anxiety disorders. Presented at the annual 

meeting of the Anxiety Disorders Association of America, Atlanta, GA, March 

2006. 

Meunier SA, Tolin DF, Frost RO, Steketee G, Brady, RE. ADHD 

symptoms in compulsive hoarders. Presented at the annual meeting of the 


2006. 

Moncrieff DW, Stevens MC, Kiehl KA. Regional differences in fMRI 

activation during a divided attention task using single syllable words. Poster 

presented at the annual meeting of the Organization for Human Brain Mapping, 

Florence, Italy, June 2006. 

Namerow L. Attachment disturbance and its clinical implications. Presented 

at the 3rd annual NASW/CT Fall specialty conference, Cromwell, CT, November 

2006. 

Norberg MM, Diefenbach GJ, Abramowitz JS, Tolin DF. Quality of life 

following CBT for obsessive-compulsive disorder. Presented at the annual 

meeting of the Anxiety Disorders Association of America, Toronto, Ontario, 

Canada, March 2007. 

Norberg MM, Diefenbach GJ, Abramowitz JS, Tolin DF. Quality of life 

impairment in the anxiety disorders: Single disorder versus comorbid anxiety 

and mood disorders. Presented at the annual meeting of the Anxiety Disorders 

Association of America, Toronto, Ontario, Canada, March 2007. 

Norberg MM, Wetterneck CT, Levine JC, Sullivan J, Kerr K, Klausen 

E. e Milwaukee psychotherapy expectancy questionnaire (M-PEQ): 

Reliability analyses. Presented at the Annual Meeting of the Association of 


Offsay J. Addiction in the elderly. Presented at an educational meeting 

sponsored by the Connecticut Association for Home Care, Inc., Wallingford, CT, 

January 2006. 

Offsay J. Opiates in the elderly: Use, misuse, and abuse. Presented at the 

annual meeting of the American Association of Geriatric Psychiatry, San Juan, 

Puerto Rico, March 2006. 

Olatunji BO, Deacon BJ, Abramowitz JS, Tolin DF. Dimensionality of 

somatic complaints: Factor structure and psychometric properties of the 

Self-Rating Anxiety Scale. Presented at the annual meeting of the Association for 


Olatunji BO, Meunier SA, Connolly KM, Lohr JM. Expectancy bias and 

behavioral avoidance of disgust in spider phobia. Presented at the annual 

meeting of the Association for Behavioral and Cognitive erapies, Washington, 

DC, November 2005. 

Pearlson GD, Deckel AW, Calhoun VD, Assaf M, Groth K, Stevens M, 

Meda SA, Gelernter J. An alpha7 nicotinic cholinergic receptor (CHRNA7) 

polymorphism discriminates figural memory abilities and related brain 

structural and functional MRI patterns in healthy adults. Poster presented at 

the annual meeting of ACNP, 2006. 

Ranga J. Self mutilating behavior in adolescents. Institute of Living Breakfast 

Series for school personnel, Hartford, CT, March 2006. 

Renaud S, Frost RO, Tolin DF, Steketee G. Measured by quantity: 

Reliability and validity of two measures of clutter. Presented at the annual 

meeting of the Association of Behavioral and Cognitive erapies, Chicago, IL, 


Rosenthal MA, Stevens MC, Kelley EA, Dunn M, Rapin I., Fein DA. 

Predictors of school-age language outcome in ASD. Poster presented at the 5th 

International Meeting for Autism Research, Montreal, Canada., May 2006. 

Ruaño G, Goethe JW, Windemuth A, Rahim US. CYP genotyping in 

patients treated for depression. Presented at the annual meeting of the American 


Schwartz HI. From the Hartford Retreat for the Insane to e Institute 

of Living: A model for developments in American psychiatry. Annual 

Combined Meeting of the Beaumont Medical Society (Yale University School of

Medicine), the Hartford Medical Society and the Massey History of Medicine 

Society (University of Connecticut School of Medicine), Hartford, CT, 2005 

Schwartz HI. e future of the end-of-life: Reflections on the right to die 

post-Schiavo. e Annual Lecture on the Humanities in Surgery honoring H. 

David Crombie, MD, Grand Rounds, Department of Surgery, Hartford Hospital, 

Hartford, CT, 2005 

Schwartz, HI. e future of the end-of-life: reflections on the right to die 

post-Schiavo. Keynote speaker, Connecticut Coalition to Improve End-of-Life 

Care, Middletown, CT, September 2007. 

Seltzer J, Kurtz MM. Neurocognitive rehabilitation in schizophrenia. 

Workshop presented at Westborough State Hospital, Westborough, MA, January 

2007. 

Seltzer JC, Kurtz MM. Cognitive remediation in psychiatry. Workshop 

presented to Mental and Addictions Program, Vancouver Island Health Authority, 

Victoria, British Columbia, Canada, March 2006. 

Shagan DS, Kurtz MM. Bridging assessment and treatment planning in 

cognitive remediation. Presented at the Cognitive Remediation in Psychiatry 

Conference, New York, NY, June 2006. 

Steketee G, Frost RO, Tolin DF, Brown TA. Is compulsive hoarding 

a subtype of OCD? Presented at the annual meeting of the Association for 


Stevens MC, Kiehl KA, Pearlson G, Calhoun VD. Functional neural 

circuits for mental timekeeping. Poster presented at the annual meeting of the 

Organization for Human Brain Mapping, Florence, Italy, June 2006. 

Stevens MC. Adolescent and adult differences in the function of response 

inhibition neural networks. Invited presentation to the Psychology Department, 

University of Louisville, Louisville, KY. August 2006. 

Stevens MC. Attention-deficit/hyperactivity disorder: Current questions 

and emerging understandings from neuroimaging research. Invited 

presentation at the 2006 annual conference of Connecticut Association of Private 

Special Education Facilities. Rocky Hill, CT, March 2006. 

Stevens MC. Attention-deficit/hyperactivity disorder: Child and adolescent 

research at the IOL. Invited presentation to Hartford Hospital Board of 

Directors. Hartford, CT. September 2006. 

Stevens MC. Attention-deficit/hyperactivity disorder: Response inhibition 

neural network function in ADHD and healthy adolescents. Invited 

presentation to the Psychology Department, University of Connecticut, Storrs, 

CT, October 2006. 

Stevens MC. Brain changes in cocaine dependence. Presentation at 

Psychopharmacology and Neuroscience Rounds at the Institute of Living, 

Hartford, CT, February 2006. 

Stevens MC. Neurobiology of impulsivity. Presentation at Psychopharmacology 

and Neuroscience Rounds at the Institute of Living, Hartford, CT, January 

2006. 

Stevens MC. Neuroimaging research in adolescent ADHD: New findings 

and emerging understanding. Presentation to the Williams School, New 

London, CT, January 2006. 

Stevens MC. Neuroimaging research in adolescent ADHD: New findings 

and emerging understanding. Presentation to the Connecticut ADHD Task 

Force, Hamden, CT, November 2005. 

Szarek BL, Goethe JW, Fogg-Waberski JH. Predictors of referral for ECT. 

Presented at the annual meeting of the American Psychiatric Association, Toronto, 


Szarek BL, Goethe JW, Wooley SB. Indicators of treatment refractory 

illness and risk of suicide. Presented at the annual meeting of the American 


ime WR, Kurtz MM. Neurocognitive function and rehabilitation in 

persons with schizophrenia. Presented to River Valley Services, Middletown, 

CT, February 2006. 

Tinsley JA. Pharmacotherapy of addictions. Grand Rounds, University of 

Nevada, Reno, NV; April 2007. 

Tolin DF, Brady RE, Fitch K. Does prior treatment history predict outcome 

of exposure and response prevention for OCD? Presented at the annual 



Tolin DF, Frost RO, Steketee G, Brown TA, Gibson A, Renaud S, Brady 

RE. Cognitive-behavioral therapy for compulsive hoarding: results from a 

multi-center open trial. Presented at the annual meeting of the Association of 


Tolin DF, Pearlson GD, Krystal JH, Davis M, Meunier SA, Brady RE, 

Simon NM, Pollack MH, Otto MW. A controlled trial of D-cycloserine with 

brief CBT for panic disorder. Presented at the annual meeting of the World 

Congress of Behavioral and Cognitive erapies, Barcelona, Spain, July 2007. 

Tolin DF, Pearlson GD, Krystal JH, Davis M, Meunier SA, Carlson S, 

Brady RE, Simon NM, Pollack MH, Smits JA, Otto MW. A controlled 

trial of D-cycloserine with brief CBT for panic disorder. Presented at the 

annual meeting of the Association of Behavioral and Cognitive erapies, Chicago, 

IL, November 2006. 

Tolin DF. [Discussant] Experimental approaches to disgust in anxiety 

and related disorders. Presented at the annual meeting of the Association for 


Tolin DF. Cognitive-behavioral therapy for anxiety disorders. Guest lecture, 

Quinnipiac University Nursing Program, Hartford, CT, November, 2005. 

Tolin DF. Compulsive hoarding. Invited address to the Bloomfield Senior 

Service Team, Bloomfield, CT, December 2005. 

Tolin DF. Compulsive hoarding. Invited address to the Connecticut Local 

Administrators of Social Services, Berlin, CT, January 2006. 

Tolin DF. e use of atypical antipsychotics for obsessive-compulsive 

disorder. Discussant, Psychopharmacology and Neuroscience Rounds, the Institute 

of Living, Hartford, CT, November 2005. 

Tolin DF. Buried in treasures: the psychology of compulsive hoarding. 

Invited workshop for the National Association of Professional Organizers, 

Washington, DC Metro Chapter, March 2007. 

Tolin DF. Buried in treasures: e psychology of compulsive hoarding. 

Workshop, Department of Social Work, West Haven VA Medical Center, New 

Haven, CT, April 2007. 


Grand Rounds, Institute of Living, April, 2007. 


Invited workshop for the National Association of Professional Organizers, 

Connecticut Chapter, May 2007. 


Invited workshop for the National Study Group on Chronic Disorganization, 

Philadelphia, September 2007. 

Tolin DF. Compulsive hoarding. Invited address to the UCLA Sloan Center on 

Everyday Lives of Families, Los Angeles, CA, October 2005. 

Tolin DF. Fear factor: Anxiety and impairment. Invited address to Berkshire 

Guardian Insurance, Pittsfield, MA, April 2006. 

Tolin DF. Fear factor: Anxiety and impairment. Invited address to the New 

England Chapter of the International Association of Rehabilitation Professionals, 

May, 2006. 

Tolin DF. Motivational interviewing. Invited workshop for the National Study 

Group on Chronic Disorganization, Philadelphia, September 2007. 

Tolin DF. Obsessive-compulsive disorder in children and adolescents. 

Invited address, Grace Webb School, Hartford, CT, February 2007. 

Tolin DF. Obsessive-compulsive disorder in children and adolescents. 

Invited address to ARCHES, North Grosvenordale, CT, April 2007. 

Tolin DF. OCD and related disorders. Community lecture series, Hartford 

Hospital, Wethersfield, CT, March 2007.

Tolin DF. OCD and related disorders. Community lecture series, Hartford 

Hospital, West Hartford, CT, April 2007. 

Tolin DF. OCD and related disorders. Invited address, Capitol Region Mental 

Health, Hartford, CT, February 2007. 

Washburn CF., Jr. Directed “A problem of pain.” A presentation of 

somatoform pain disorder. Presented at the annual meeting of the Connecticut 

Osteopathic Association, Mystic, CT, May 2006. 

Washburn, C.F. (Chair) e use of botanically based psychotherapeutic 

agents. Presented at the annual meeting of the Connecticut Osteopathic Medical 

Society, Mystic, CT, June 2007. 

Webb SA, Diefenbach G, Novy DM, Kunik M, Rhoades HM, Stanley MA. 

Utility of GAD-Q-IV to identify late-life GAD in a referred primary care 

sample. Presented at the annual meeting of the Association for Behavioral and 

Cognitive erapies, Washington, DC, November 2005. 

Wetterneck CT, Norberg MM, Adams TG, Wilcox K, Riemann BC. 

e expanded cognitive self-consciousness scale: reliability and validity in 

a clinical sample of obsessive compulsive disorder. Presented at the annual 



Wetterneck CT, Norberg MM, Adams TG, Wilcox K, Tiffany SM, 

Riemann BC. Do subtypes of OCD differ in the magnitude of obsessional 

beliefs and appraisal of intrusions? A pilot study. Presented at the annual 


2006. 

Wetterneck CT, Norberg MM, Hynan M. e Milwaukee psychotherapy 

expectations questionnaire: reliability and validity in non-clinical and clinical 

samples. Presented at the annual convention of the Association for Behavioral and 

Cognitive erapies, Chicago, IL, November 2006. 

 

Wetterneck CT, Norberg MM, Phillips K, Klausen E, Levine JC, LaVigne 

JC. e relationship between psychotherapy expectations, therapeutic 

alliance, and treatment variables: results from a training clinic sample. 

Presented at the annual meeting of the Association of Behavioral and Cognitive 

erapies, Chicago, IL, November 2006. 

Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese 

H, Cannistraro P, Pitman RK, Rauch SL, Jenike MA. A randomized, 

double-blind, placebo-controlled medication trial with D-cycloserine for 

individuals with obsessive-compulsive disorder currently receiving behavior 

therapy: a work in progress. Presented at the Annual Meeting of the Association 

of Behavioral and Cognitive erapies, Chicago, November 2006. 

Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese H, 

Cannistraro P, Jenike MA, Pitman RK, Rauch SL. A randomized, doubleblind, 

placebo-controlled medication trial with D-cycloserine for individuals 

with obsessive-compulsive disorder currently receiving behavior therapy: a 

work in progress. Presented at the World Congress of Behavioral and Cognitive 

erapies, Barcelona, Spain, July 2007. 

Woody SR, Corcoran K, Tolin DF. Patients with more severe OCD show 

impaired disgust recognition. Presented at the annual meeting of the Society for 

Research in Psychopathology, San Diego, CA, October 2006. 

Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T. Severe 

headaches and the risk of subsequent suicidal thoughts or behaviors. 

Presented at the annual meeting of the American Psychiatric Association, San 

Diego, CA, 2007. 

Woolley SB, Goethe JW, May AM, Piez DA. Distinguishing patients who 

attempt suicide from patients with ideation only. Presented at the annual 

meeting of the American Psychiatric Association, Toronto, Canada, May 2006. 

Woolley SB, Pavel S, Goethe JW. Locus-of-control and outcome of 

treatment for MDD. Poster presented at the annual meeting of the American 

Psychiatric Association, Toronto, CA, May 2006.

A Phase II Evaluation of the Safety and Efficacy of the ENOVUS 

AAA Endograft in the Treatment of Abdominal Aortic Aneurysms 

(G020269). TriVascular, Inc., $60,800. 

e EXACT Study - Emboshield(R) and Xact(R) Post Approval 

Carotid Stent Trial. Abbott Vascular Devices, $22,000. 

e Pivotal Study Positive Impact of Endovascular Options 

for Treating Aneurysms Early. e Cleveland Ohio Foundation, 

$138,000. 

Stenting and Angioplasty with Protection in Patients at High-Risk 

for Endarterectomy - SAPPHIRE WW - Protocol Number P06- 

3603. Cordis Corporation, a Johnson and Johnson Company, $47,200. 

 

e Bard® Recovery® Filter Study (EVEREST) for Patients who 

are Candidates for an Optional (retrievable) Inferior Vena Cava 

filter who Undergo Placement of the Bard® Recovery® Filter. Bard 

Peripheral Vascular, INC., $54,163. 

 

 

Analysis of CT Perfusion and Salvageable Penumbra as a Function 

of Time in Acute Stroke. New Investigator, $10,000. 

 

 

Standardized Uptake Value in PET as a Pedictor of Survival in 

Esophageal Cancer. 

Partial Breast Radiation erapy-A Paradigm Shift. 

 

Use of 18F-FDG PET/CT for Diagnosis of Osteomyelitis of the 

Foot. 

Retrospective Analysis of the Utility of MRI for Evaluation of Acute 

Abdominal Pain in Pregnant Patients. 

 

Trends in the Utilization of Radiologic Studies at Hartford 

Hospital. 

 

Prospective Analysis of MRI for Evaluation of Acute Abdominal 

Pain in Pregnant Patients. 

 

 

A Single Center Clinical Evaluation of Carotid Stenting for the 

Treatment of Obstructive Carotid Artery Disease. 

An Investigation of the Talent Endoluminal Spring Stent-Graft 

System for the Treatment of Sub-Renal Abdominal Aortic 

Aneurysms in Patients Who Are Candidates for Standard Surgical 

Intervention. Medtronic Vascular, $72,000. 



Aneurysms in Patients Who Are Not Candidates for Standard 

Surgical Intervention. Medtronic Vascular, $50,000. 

A Randomized, Multicenter Study for Use of the HEMOBAHN 

Endovascular Prosthesis to Percutaneous Transluminal Angioplasty 

(PTA) in the Treatment of Superficial Femoral Artery Obstructive 

Disease. W.L. Gore & Associates, Inc. - Medical Products Division, 

$32,500. 

An Investigation of the TALENT LPS A Low Profile Endoluminal 

Stent-Graft System for the Treatment of Sub-renal Abdominal 

Aortic Aneurysms in Patients who are Candidates for Standard 

Surgical Intervention (LOW RISK). Medtronic Vascular, $10,000. 

An Investigation of the TALENT Endoluminal Spring Stent-Graft 

System for the Treatment of the Sub-Renal Abdominal Aortic 

Aneurysms in Patients Who Are Candidates for Standard Surgical 

Intervention (Low Risk Stock Device Study). M e d t r o n i c 

Vascular, $20,000. 



Aneurysms in Patients Who are Not Candidates for Standard 

Surgical Intervention - Emergency Protocol. M e d t r o n i c 

Vascular $40,000. 

Evaluation of the Enhanced TALENT LPS Stent Graft System for 

the Treatment of Abdominal Aortic Aneurysm. Medtronic Vascular, 

$50,000. 

Emergency Use of the Talent Endoluminal Spring Stent-Graft 

System in High Surgical Risk Patients with oracic Aortic 

Aneurysms. Medtronic Vascular, $80,000. 

Treatment IDE for use of the GORE TAG oracic Endoprosthesis 

in Subjects with Descending oracic Aortic Aneurysms Requiring 

Surgical Repair. W.L. Gore & Associates, $10,220. 

Carotid Artery Stenting With Emboli Protection Surveillance - 

Post Marketing Study. CORDIS Johnson & Johnson, $24,650. 

 

MRI Evaluation of the Contralateral Breast in Women with a 

Recent Diagnosis of Breast Cancer/ACRIN 6667. American College

of Radiology Imaging Network, $170,000. 

Prospective Analysis of Breast MRI Outcomes in a Large Hospital 

Population. Connecticut Breast Health Initiative, $49,939. 

 

Humanitarian Use Device: Neuroform Microdelivery Stent. 

 

MRI Image and Clinical Application Development Protocol. 

 

Contrast Enhanced Multi-Detector Computed Tomography 

(MDCT) as a Noninvasive Modality for the Evaluation of Active 

Lower Gastrointestinal Bleeding: Initial Prospective Assessment 

of Contrast Enhanced MDCT Verses Technetium 99m Tagged 

Red Blood Cell Scanner at Large Community Hospital. Berlex 

Laboratories, Inc., $99,769. 

 

Comparison of Contrast Enhanced Computed Tomography 

(CECT) with Same Day 18F-Fluorodeoxyglucose Positron 

Emission Tomography/Computed Tomography (FDG PET/CT) 

in Hodgkin and Non-Hodgkin Lymphoma Patients: Effect on 

Staging. 

Incidental Non-cardiac Findings Seen Prospectively on Cardiac CT 

Angiogram (CTA). 

 

 

Khachi G., Skirgaudas M., et al. e clinical applications of peripheral nerve 

imaging in the upper extremity. J Hand Surg (Am), 32 (10): 1600-4, 2007. 

 

Hansen AA and Rosenberg RJ. Gastrointestinal stromal tumor detected on 

Tc-99m Red Blood Cell Scintigraphy. Clin Nucl Med, 32(3):221-3, 2007. 

Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, 

Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, 

Schnall MD, ACRIN Trial 6667 Investigators Group. MRI evaluation of 

the contralateral breast in women with recently diagnosed breast cancer. New 

England Journal of Medicine, 356(13):1295-303, 2007. 

Zhu Q, Cronin E, Currier A, Vine H, Huang M, Chen N, and Xu C. 

Benign vs malignant breast masses: Optical differentiation with US-guided 

optical imaging reconstruction. Radiology, 237:57-66, 2005. 

Zink S, O’Loughlin M, Stein B. Incidental non-cardiac findings 

prospectively seen on cardiac CT angiography. Presented at the RSNA, Dec 

1, 2006.

e Department of Surgery continues to participate in clinical 

and scientific research and has contributed significantly to the 

surgical body of knowledge. Members of the department 

have presented their findings at several prestigious forums 

and have published in a variety of refereed journals. 

e Department continues to encourage its members to be 

involved in academic as well as clinical endeavors. It seeks to 

engage its staff in a variety of experiences that contribute to 

the growth of the department, the reputation of the institution 

as well as the enhancement of the individuals themselves. e 

faculty of the department continues to be actively involved 

in the education process within the institution and the 

community and continues to encourage the residents and 

fellows to pursue research activities. 

e Department is identifying ways to access data for 

the purpose of trending and quality improvement. e 

Department’s own database (ORBIT) has been redesigned to 

facilitate the integration of specific data from other databases 

such as SIS. In addition, the Division of Colorectal Surgery 

had created a database for ileoanal pouch procedures in order 

to compare those patients who have undergone a laparoscopic 

approach with those patients who have undergone a more 

traditional open technique. is division is also collaborating 

with UCONN (Storrs) on a project entitled “Psychosocial 

Needs Assessment of Patients with Colorectal Cancer and 

Partners” with the goal of addressing the area of patient and 

family support systems. 

 

 

 

Training Organ Procurement Organization Coordinators to Use an 

Esophageal Doppler Monitor for Donor Management to Improve 

Organs Transplanted per Donor (OTPD). HRSA, $94,253. 

 

 

Allergan Corporation Style 410 Silicone-Filled Breast Implant 

Continued Access Reconstruction/Revision Expansion (CARE) 

Clinical Study. Inamed, $8,300. 

 

A Randomized, Double-Blind, Placebo-Controlled, Phase-2b 

Study to Assess the Safety and Efficacy Effects of ART-123 on 

Subjects with Sepsis and Disseminated Intravascular Coagulation. 

Artisan Pharma Inc., $96,000. 

 

A Randomized, Prospective Study Comparing Needle Stick Injuries 

with Hand versus SuturTek Device Closure of Abdominal Fascia. 

SuturTek Inc., $27,000. 

 

 

e Role of Experience in Laparoscopic Hartmann Closures. 

Support for statistical analysis provided through Hartford Hospital Small 

Grant. 

 

 

Advanced Laparoscopic Training Course. $17,500. 

 

 

To Determine the Outcome of Patients Having Surgery for 

Antibiotics Associated Colitis. 

 

e Efficacy and Durability of Super-Selective Embolization (SSE) 

in the Treatment of Lower Gastrointestinal Bleeding (LGIB). 

Safety, Feasibility and Long-term Outcomes of Laparoscopic Ileal- 

Pouch-Anal Anastomosis. A Single Institution Case-Matched 

Experience. 

 

Analysis of Long and Short-Term Outcome after EVAR - Is it 

Superior to Open Repair? 

A Comparison of CT Venography to Duplex Ultrasonography in 

the Diagnosis of DVT. 

 

Intraoperative and Preoperative Parameters at Predict Abdominal 

Compartment Syndrome After Repair of Ruptured Abdominal 

Aortic Aneurysm. 

 

Surgery Clinical Outcomes. 

 

Application of a Web-Based Teaching Module for Instruction and 

Standardization of Post-Pyloric Feeding Tube Insertion. 

 

Cryoablation of Irresectable Lung Tumors. 

Indeterminate for Dysplasia, What Next? 

Differences Between Male and Females in the Operative Findings 

and Outcome of Laparoscopic Cholecystectomy. 

 

Hand-Assisted Laparoscopic Transduodenal Resection: Initial

Experience. 

Laparoscopic Gastric Resection: Technique and Outcomes in 25 

Patients. 

Safety and Long-term Efficacy of Angiographic Embolization 

for Upper Gastrointestinal Hemorrhage: A Single Institution 

Experience. 

 

ymoglobulin: Now or Later? 

Assessment of Changes in Renal Function in Living Kidney Donors 

Post-Nephrectomy in the First Year After Donation. 

 

Enterra erapy Humanitarian Device Exemption. 

 

Lithium Induced Hyperparathyroidism: A Basis for Parathyroid 

Adenoma versus Four Gland Hyperplasia. 

 

 

Histocompatability Determination for Highly Sensitized Patients. 

Serologic Testing. Diagnostic Access LLC, $4,000. 

 

TAG: A Clinical Study Comparing Use of the oracic 

EXCLUDER Endoprosthesis to Open Surgical Repair in the 

Primary Treatment of Descending oracic Aortic Aneurysms. 

W.L. Gore & Associates, Inc., $78,750. 

VALOR: Evaluation of the Medtronic AVE oracic Stent Graft 

System for the Treatment of oracic Aortic Aneurysms. Medtronic 

AVE, $52,000. 

 

McGhan Medical Corporation Silicone-Filled Breast Implant 

Adjunct Clinical Study. 

 

A Randomized, Open-Label, Comparative Evaluation of 

Conversion from Calcineurin Inhibitor Treatment to Sirolimus 

Treatment versus Continued Calcineurin Inhibitor Treatment 

in Liver Allograft Recipients Undergoing Maintenance erapy. 

Wyeth Pharmaceuticals, $213,147. 

 

Does Simulation Training Improve Nursing and Resident’s Clinical 

Performance? 

 

Impact of Donor Hyperglycemia on Ischemia/Reperfusion Injury in 

Transplanted Renal and Liver Grafts. 

 



 

Outcomes of Patients Undergoing Lower Limb Amputations. 

 

Intimal Hyperplasia in Arteriovenous Fistulas. Roche, $18,162. 

e Impact of an Expedited Allocation System and Pulsatile 

Preservation Upon the Transplantation of Kidneys from Expanded 

Criteria Donors. 

Retrospective Study of Liver Transplant Recipient’s Pre-Procedure 

MELD Scores and Post-surgical Outcomes 

Oral Infection and Inflammation in Transplant Patients. NIH 

subcontract through the University of Connecticut Health Center, 

$25,000. 

An Open Label Randomized, Multicenter Study to Evaluate the 

Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in 

Recipients of Primary Renal Allografts Maintained Long-Term 

on Mycophenolate Mofetil; MMF (CellCept) and Sirolimus 

(Rapamune). Roche Hoffman - La Roche, $430,709. 

Transplant Clinical Outcomes. 

 

Characterizing Symptomatic Pleural Effusions in Post-Cardiotomy 

Patients: Does Total Protein Play a Significant Role? 

 

Breathing Pattern and Predicting Power of Breathing in Patients 

with Respiratory Failure. Respironics, Inc, $18,875. 

Evaluation of Sublingual Capnometry in Critically Ill Surgical 

Patients Subjected to a Resuscitation Protocol (SLT). Tyco 

Healthcare/Nelcor, $66,250. 

 

Long-term Outcome of Pancreatic Debridement and Abdominal 

Wall Reconstruction for Necrotic Pancreatitis. 

 

Role of Intravenous Chromium in Reducing Insulin Requirements 

in Critically Ill Patients. 

 

Evaluation of long-term outcomes amongst living donor kidney 

transplant recipients from donors older than 50 years: Are they 

comparable to recipients of kidneys from donors less than 50 years 

of age? 

Does the Use of CMV Immunoglobulin Confer Any Additional 

Protection Along with Antiviral Prophylaxis for Prevention of 

CMV Infection in High Risk Liver Transplant Recipients? 

Is Valacyclovir Effective Antiviral Prophylaxis Against 

Cytomegalovirus (CMV) Infection in CMV Positive Recipients of 

CMV Negative Kidneys in Renal Transplantation? 

Does CMV Immunoglobulin Confer Any Additional Advantage in 

Preventing CMV Seroconversion in D+/R- Recipients of Cardiac 

Transplantation, Compared to Anti-Viral Prophylaxis Alone? 

 



 

Study 98-1 Carpentier-Edwards PERIMOUNT Plus Pericardial 

Bioprosthesis, Model 6900P. Edwards LifeSciences, LLC, $110,250. 

Multi-Center, Non-Randomized Study Involving Patients 

Receiving the Edwards MC3 Tricuspid Annuloplasty System, 

Model 4900. Edwards Lifesciences, LLC, $90,000.

Allan, B, Rader, C, Babigian, A. Giant lipomas of the upper extremity. 

Canadian Journal of Plastic Surgery 2007; 15(3):141-144. 

Antonetti, M, Kirton, O, Bui,D, Ademi, A, Staff, I, Hudson-Civetta, J, Lilly, 

R. e effects of pre-operative rofecoxib, metoclopramide, dexamethasone, 

and ondansetron on post-operative pain and nausea in patients undergoing 

elective laparoscopic cholecystectomy. J of Surg Endoscopy 2007. 

Cheema, M, Kirton, O, Lukose, B, Gallagher, J. Ligation of subclavian 

artery after blunt trauma presenting as massive hemothorax. Journal of 

Trauma injury, Infection, and Critical Care, 2006, Vol. 61 No. 6. 

Diaz, J, Campbell, B, Moursi, M, Boneti, C, Kokoska, E, Jackson, R, Smith, 

S. Delayed manifestation of abdominal aortic stenosis in a child presenting 

ten years after blunt abdominal trauma. Journal of Vascular Surgery, 2006; 44: 

1104-1106. 

Folcik, M, Kirton, O, Ivy, M. A two-tiered quality management program: 

Morbidity and mortality conference data applied to resident education. 

Connecticut Medicine, 2007: 7(8):417-424. 

Khan, Manickaratnam S, Brown M, Tray K, Ranga K. Recurrent 

Immunotactoid Glomerulopathy in a Renal Transplant Recipient: National 

Kidney Foundation—2006. 

Kirton, O, Folcik, M, Calabrese, R, Ivy, M, Keating, K, Mah, J, Pepe, J, 

Dobkin, E, et al: Mid Level Practitioner (MLP) work force analysis at a 

University affiliated teaching hospital. Arch Surg. 2007; 336-341. 

Koloska, E, Bird, T, Robbins, J, Smith, S, Corsi, J, Campbell, B. Racial 

disparities in the management of pediatric appendicitis, Journal of Surgical 

Research, 2007: 137; 83-88. 

Manickarartnam S, Hyder, Lally A, Brown M, Charpentier K, Hull D, 

Ranga K. Gitelman’s Syndrome: From Donor to Recipient. National 

Kidney Foundation—2006. 

Nicksa, G, Dring, R, Cohen, J, Johnson, K, Sardella, W, Vignati, P. 

Anastomotic leaks: what is the best diagnostic imaging study? Dis Colon 

Rectum 2007; 50:97-203. 

Park, B, Danes, S, Drezner, AD, Gallagher, J, Allmendinger, P, Lowe, 

R, Windels, M, Foster, J, Hallisey, M. Endovascular abdominal aortic 

aneurysm repair at Hartford Hospital: A six-year experience. Connecticut 

Medicine, 2006, Vol. 70 (6), 357-362. 

Park, B, Mavanur, A, Drezner, AD, Gallagher, J, Menzoian, J. e clinical 

impact of chronic renal insufficiency on endovascular repair, Vascular Surgery, 

2007, Vol. 40, No. 6. 

Rader, C, Isakoff, M, Balaraiso, F, Pingpank, J, Bourque, M. Peritoneal 

mesothelioma in a pediatric patient: a case report and review of the literature. 

Connecticut Board. 

Ranga K, Manickaratnam S, McNab J, Lally A, Brown M, Charpentier 

K, Hoffman D, Israel J, Polio and Hull D. Massive Proteinuria Following 

the Use of Rapamycin in a Liver Transplant Recipient. National Kidney 

Foundation—2006. 

Smith-Slatus,C, Bourque, M, Salazar, J. Clostridium septicum infections in 

childred: a case report and review of the literature. Pediatrics, March 2006 

(on-line). 

Takata, M, Rader, C, Kirton, O. Laparoscopic marsupialization of a giant 

non-parasitic splenic cyst: A case report and review of treatment options. 

Surgical Rounds, May, 2007 18-23. 

Vignati, P. Anastomotic leaks: What is the best diagnostic imaging study? 

DCR 2007:50:97-203. 

Vignati, P. PEComa, a not so rare tumor that can cause clinical and 

pathological diagnostic confusion: A case report. CT Medicine, Vol. 71: 

August, 2007, pp 399-401. 

 

 

Adibe O. Post-operative antibiotic therapy for children with perforated 

appedicitis: Long course of intravenous antibiotics versus early conversion to 

an oral regimen. Poster Presentation at the 17th Annual Meeting of the Society of 

Black Academic Surgeons (April, 2007) in Chicago, IL. 

Aiello, F. e influence of gender on clinical outcomes and durability of 

repair following carotid angioplasty with stenting and carotid endarterectomy. 

Paper presentation at the 35th Annual Symposiumon Vascular Surgery of the 

Society for Clinical Vascular Surgery (March, 2007) in Orlando FL. 

Ayers, A. e role of experience in the performance of laparoscopic 

Hartmann closures. Paper presentation at the International Society of e 

University of Colon and Rectal Surgeons in Istambul, Turkey (June 2006). 

Fernandez, Madadi S, Palmeri, Charpentier K, Lally A, Brown M, 

Hull D, Hoffman, Israel J, Polio, Ranga K. Cytomegalovirus (CMV) 

immunoglobulin does not confer any additional protection along with newer 

antiviral prophylaxis for the prevention of CMV infection in high risk liver 

transplant recipients. Liver Transplant Society in Milan, Italy, 2006. 

Gross E and Aiello F. Incidence of return visits to the emergency department 

following appendectomies within the global period: An analysis of incidence 

and cost-effectiveness of post-appendectomy emergency department visits. 

Paper presentation at NESS (September, 2007) in Burlington, VT. 

Hull D, Florence, Distant, Christensen, Johnson, Kauffman. Deceased 

renal donor discard rates: Analysis of multiple factors with emphasis on 

renal biopsies. Poster and Abstract presented at the UNOS Management Forum, 

April 2007. 

Hull D, Kauffman, Christiansen, Johnson, Florence. Influence of kidney 

biopsies and pump preservation on deceased donor discard rates. Poster and 

Abstract presented at the UNOS Management Forum, April 2007. 

Hull D, Lipkowitz, Brown M, Lally A, Savaria. Donor kidney pumping 

from OPO/transplant center perspective. Poster and Abstract presented at the 

UNOS Management Forum, April 2007. 

Hull D. Kidney donor biopsy: Standardizing technique using a wedge 

biopsy. Abstract and Poster at the World Transplant Congress, 2006. 

Jhagroo R, Gowda N, Vigneault C, Bhimidi C, Brown M, Lally A, Hull 

D, Ranga K. Rhabdomyolysis as a complication of ehrlichiosis in a renal 

transplant recipient. National Kidney Foundation, Spring, 2007. 

Mah, J, Bingham, K, Dobkin, E, Malchiodi, L, Russell, A, Donohue, S, Ivy, 

M, Kirton, O. Error identification after institution of sepsis guidelines in a 

surgical ICU using manikin-based simulation. Crit Care Med. 2006 34(12 

suppl) A119. 

Mah, J, Kirton, O, Ivy, M, Keating, K, Dobkin, E, Staff, I. Utility of 

sublingual capnometry as a predictor of multi-system organ failure in 

critically ill surgical patients. J Trauma, 2006; 61(6):1562. 

Manickaratnam S, Balarezo F, Drouin E, Lally A, Brown M, Charpentier K, 

Hull D, Ranga K. Histologic features on renal biopsy parallel clinical criteria 

for expanded criteria donors (ECD) in renal transplantation. Abstract and 

Poster at the American and World Transplant Congress in Boston, 2006. 

Mavanur A. Compressive orthotics: A new paradigm in operative correction 

of pectus carinatum in children. Poster presentation at NESS (New England 

Surgical Society), October 2006. 

Mavanur A. Staple line reinforcement reduces post-operative pancreatic 

stump leak after distal pancreatectomy. Poster presentation at NESS (New 

England Surgical Society), October 2006. 

Phillip, Alias, Ranga K. Multifactorial etiology of anemia in renal transplant 

recipients. Poster presented at the ACP Meeting, Connecticut Chapter, October 

2007. 

Poultsides, G. Angiographic embolization for gastroduodenal hemorrhage: 

Safety, efficacy, and predictors of outcome. Paper presentation at NESS 

(September, 2007) In Burlington, VT.

Poultsides, G. Hand Assisted Laparoscopic Transduodenal Resection. Paper 

presentation at SAGES (April, 2007) in Las Vegas, NV. 

Reines L and Fitzgerald H. Hand-Assisted Laparoscopic Colectomy: Is 

ere an Advantage Over Open Resections? Paper presentation at NESS 

(September, 2007) in Burlington, VT. 

See S, Jhagroo R, Anca, Vigneault C, Brown M, Lally A, Hull D, Ranga K. 

Positive Recurrent IgA Nephropathy Post Transplantation. National Kidney 

Foundation, Spring 2007. 

Underhill, D, Humphrey, C, Kirton, O, Boden, W, McKay, R, Mennett, 

R. Improving process and outcomes in very high-risk patients undergoing 

CABG surgery: prospective use of EuroScore to enhance pre-operative 

clinical decisions making and improve outcomes. American Heart Association 

annual meeting, Dallas, TX, November 13-15, 2005. 

Zar T, See S, Balarezo F, Ghuman N, Gonzalez, McHugh, Brown M, 

Lally A, Hull D, Ranga K. Early and Aggressive Recurrence of Idiopathic 

Membranous Nephropathy in a Renal Transplant Recipient. National Kidney 

Foundation, Spring 2007.

As an academic clinical department, research is integral 

to Traumatology and Emergency Medicine at Hartford 

Hospital. e mission of the department includes a strong 

emphasis on research in order to improve our clinical, 

operational, and educational endeavors. All divisions within 

the department participate in research. ese include the 

LIFE STAR Critical Care Helicopter Service, the Emergency 

Department, the Trauma Program, the Center for Wound 

Healing and Hyperbaric Medicine, Rehabilitation, and 

Bioterrorism Preparedness. 

 

e LIFE STAR Critical Care Helicopter Service has 

a long history of quality research. Recent projects have 

included studies regarding the documentation of medications 

administered by critical care transport teams, a comparison 

of pre-hospital trauma analgesia by air and ground EMS 

providers, and an evaluation of helicopter transport utilization 

by prospective application of consensus criteria. Other studies 

include an examination of crew weight and fitness policies, an 

evaluation of cardiac arrest management by the air medical 

team, an investigation into the effectiveness of a read and 

respond checklist in assuring safety behavior and compliance, 

and the use of bispectral analysis to assess sedation in patients 

requiring sedation and transported by helicopter. 

 

e Emergency Medicine Division (ED) has conducted 

numerous projects relating to diagnosis and treatment of 

medical emergencies. For instance, the ED cooperates with 

the Stroke Center at Hartford Hospital to enroll patients for 

the FAST, IMS 3, ICTuS, and NEST-2 clinical trials. One 

study has been completed regarding the use of the i-STAT 

device to obtain PT and INR values in the ED to potentially 

shorten the time to thrombolytic therapy in stroke patients. 

Another investigated the use of D-Dimer in low risk patients 

to rule out pulmonary emboli. An additional project looked 

at the prevalence of thrombocytopenia and antiheparin 

antibodies in adult ED patients. An industry sponsored study 

collected blood samples from patients with abdominal pain 

to test for biomarkers that could lead to the development of 

a blood test to aid in diagnosis. Another study concerned 

the use of the Airtraq? airway device in emergency airway 

management. An ongoing project is studying intimate partner 

violence in patients with acute overdose. Research regarding 

ED operations includes a study of overcrowding and another 

about patients who left without being seen. Educational 

research has looked at the utilization of simulated clinical 

case scenarios in medical student education for chest pain 

evaluation, diagnosis, and management. 

 

Research by the Trauma Program continues with an 

investigation of a hemostatic agent to control bleeding 

in severe liver injury. A study of current practices in the 

management of liver injuries was completed and data were 

collected for a multi-center evaluation of patient outcomes 

after pancreato-duodenal injuries. e TELOS (Trauma 

end-of-life optimum support) project has completed a 

best practice model and will soon begin implementing and 

testing the model at Hartford Hospital as well as in three 

centers across the nation. Educational research in trauma 

has explored the use of simulation to teach ED personnel 

the initial management of patients with blunt injuries and an 

evaluation of orientation to the trauma team. Data continue 

to be collected to assess the Advanced Trauma Operative 

Management (ATOM) course. 

 

 

 

e Toxicology Division has had two projects dealing 

with cyanide poisoning. One was the CRISIS-1 study that 

examined the role of cyanide in smoke inhalation and the other 

is investigating cyanmethemoglobin as an alternate laboratory 

test for the diagnosis of cyanide toxicity. In collaboration 

with Bioterrorism Preparedness, the Toxicology Division has 

been working on a project to identify normative distributions 

of plasma and erythrocyte cholinesterase activity based on 

demographic and clinical data for use as a rule-out screen for 

significant nerve agent toxicity. Two other funded studies 

are a multi-center retrospective review of the clinical efficacy 

of DigiFab in digoxin-poisoned patients and a retrospective 

comparison of safety and efficacy between the oral and the 

intravenous form of N-acetylcysteine. An examination 

into the relationship between CPK and aminotransferase 

elevations in rhabdomyolysis has been completed. 

 

 

 

Research in the Center for Wound Healing and Hyperbaric 

Medicine has been involved in several research studies 

examining the treatment use of hyperbaric oxygen. One 

involved patients with Wagner III diabetic foot ulcers and

sought to determine if a positive response to an oxygen 

challenge could predict response to treatment with hyperbaric 

oxygen. ree other studies reported on the Center’s initial 

experiences of using hyperbaric oxygen to treat severe 

soft-tissue infections, crush injuries, and delayed radiation 

tissue injury of soft tissue and bone. Recently, the Center 

was approved to participate in the Radionecrosis Research 

Registry sponsored by the American College of Hyperbaric 

Medicine to document and analyze outcomes related to 

the treatment of radionecrosis with hyperbaric oxygen. e 

Center is also conducting a study to characterize the clinical 

features and outcomes of calciphylaxis in patients requiring 

chronic dialysis therapy. 

 

e Rehabilitation division is currently involved in two 

clinical trials. One study evaluated the safety, tolerability, 

and activity of oral Fampridine-SR in subjects with chronic, 

incomplete spinal cord injury. It was a funded, open label 

extension of a double-blind, placebo-controlled, parallel 

group study. Another project is designed to assess the 

efficacy and safety of HP184 at 100, 200 and 400 mg doses 

administered orally once a day for twenty-four weeks to adult 

subjects with chronic spinal cord injury. is funded study 

is a phase II double-blind, placebo controlled multi-center 

investigation. 

While research spans all divisions in the department, the goal 

of all of our research efforts is to ultimately improve patient 

care. To achieve this goal, the department has a strong focus on 

research, scholarship, and mentoring of young professionals. 

Our goal for the future is to participate in practice-oriented 

translational research. We intend to engage in, and test 

activities that will bring about effective dissemination and 

use of evidence-based guidelines, new technologies, and new 

ways to educate health care professionals. We look forward 

to a partnership of clinicians, translational researchers, 

educators, and policy makers to move forward with this 

research agenda. 

 

 

 

Retrospective Comparison of Safety and Efficacy Between the Oral 

and the Intravenous Form of N-acetylcysteine. Rocky Mountain 

Poison and Drug Center, $2,200. 

 

 

Interventional Management of Stroke: A Phase III, Randomized, 

Multi-Center Clinical Trial to Examine Whether a Combined 

IV and IA Approach to Recanalization is Superior to Standard IV 

rt-PA (Activase) Alone. NIH subcontract through the University of 

Cincinati, $33,221. 

 

Multicenter Retrospective Review of the Clinical Efficacy and Safety 

of DigiFab in Digoxin Poisoned Patients. DHHA, $4,375. 

 

 

QuikClot versus Packing For Hemostasis after Grade V Liver Injury 

in Swine. Z-Medica, $224,000. 

 

CRISIS-1: Cyanide’s Role In Smoke Inhalation Study. EMD 


 

Sample Collection for Abdominal Pain Substudy with Focus 

on Acute Pancreatitis, Acute Cholecystitis, and Ischemic Bowel 

Disease. Biosite Incorporated, $46,750. 

 

 

Cyanmethemoglobin: An Alternative Laboratory Test for the 

Diagnosis of Cyanide Toxicity. $2,460. 

 

 

Pentoxifylline vs. Steroids in Acute Alcoholic Hepatitis: A 

Retrospective Study. 

 

Clusters of Snowblower Injuries to the Hand: Epidemiology, 

Patterns of Injury, and Strategies for Prevention. 

 

Reliability of Emergency Department Patients’ Contact 

Information. 

 

Bispectral Analysis of Air Transport Patients. 

Prevalence of Intimate Partner Violence in Acute Overdose 

Patients. 

 

Overcrowding in the Emergency Department. Statistical analysis 

supported through Hartford Hospital small grant. 

i-STAT PT INR Correlation Study. 

 

Effectiveness of a Read-and-Respond Checklist in Assuring Safety 

Behavior Compliance at a Rotor Wing Air Medical Program. 

A Comparison of Pre-Hospital Trauma Analgesia by Air and 

Ground EMS Providers. 

Evaluation of Cardiac Arrest Management by a Helicopter Air 

Medical Team. 

Evaluation of Helicopter Air Medical Transport Utilization by 

Prospective Application of Consensus Criteria. 

Effect of Line-Oriented Flight Training on Team Behaviors and 

Beliefs at a Helicopter Air Medical Program. 

Evaluation of a Modified Sign-Out Procedure on Hospital 

Documentation of Medications Administered by Critical Care 

Transport Teams. 

 

Is the Use of D-Dimers in a Low Risk Population Cost Effective and 

Safe in Ruling Out PE? Statistical analysis supported through Hartford 

Hospital small grant.

Evaluation of Outcomes After Pancreato-Duodenal Injuries In New 

England Hospitals. 

 

History Taking in Emergency Department Patients Presenting with 

Acute Chest Pain. 

 

Relationship between CPK and Aminotransferase Elevations in 

Rhabdomyolysis Patients. 

 

Airtraq Airway Device in Emergency Airway Management. 

 

Case Review: Successful Multi-Organ Donation from a Donor with 

Idiopathic rombocytopenia Purpura. 

 

Outcomes of Patients with Diabetic Foot Ulcers Treated with 

Hyperbaric Oxygen erapy. 

e Role of Hyperbaric Oxygen erapy in the Treatment of Severe 

Soft-Tissue Infections. 

Crush Injuries and Hyperbaric Oxygen erapy: Initial Experience at 

a Level 1 Trauma Center with a Multiplace Hyperbaric Chamber. 

Radionecrosis Research Registry. 

 

Variations in Usage of Emergency Medicine. 

 

Patients who leave without being seen at the Hartford Hospital 

Emergency Department. Statistical analysis supported through 

Hartford Hospital small grant. 

 

Evaluation Of Trauma Orientation. 

 

e Utilization of Simulation Medicine Clinical Case Scenarios in 

Medical Student Education for Chest Pain Evaluation, Diagnosis, 

and Management. 

 

 

Injury Patterns of Less an Lethal Munitions. 

 

e Development of Lower Extremity Compartment Syndrome 

Following Fractures of the Tibia and Fibula. 

Evaluation of the Trauma Simulation Education Course. 

 

Can Trauma Patients with Airway Compromise be Managed with 

an Airway Protocol Guiding Emergency Medicine Providers? 

Statistical analysis supported through Hartford Hospital small grant. 

 

Do Attending ED Physicians and ED Nurses Agree on ED 

Resident Evaluation? 

 

Quantification of Environmental Pesticide Exposure in Golf Course 

Workers. 

 

Can Family History be used as a Predictor for Appendicitis? 

 

Utility of Nasogastric Tube Placement in Hemodynamically Stable 

Patients Presenting to the Emergency Department with Clinically 

Isolated Lower Gastrointestinal Bleeding. 

 

Does Early Implementation of a Modified Constraint Induced 

Movement erapy Program During Inpatient Acute Rehabilitation, 

Minimize Development of Learned Non Use Behavior in Subjects 

with Hemiplegia? Hartford Hospital Research Endowment Funds, 

$50,000. 

 

Flight Team Management of Cardiac Patients. 

Rest Patterns Prior to Night Shift Work in Rotor Wing Flight 


Body Temperature Preservation in Patients Transported by Air 


Rest Patterns of 24-Hour Shift Workers in Rotor Wing Flight 


Compliance with Safety Behavior in Rotor Wing Air Medical 

Transport. 

Evaluation of a Process Improvement Plan for Managing Cardiac 

Chest Pain. 

Flight nurse administration of analgesic and amnestic medications to 

patients receiving neuromuscular blocking agents. 

Evaluation of Trauma Analgesia in Patients Transported by Air 


Actual work time totals for air medical crew members. 

 

e Utility of Arterial Blood Gases in the Diagnosis of Pulmonary 

Embolism in Today’s Diagnostic Era. 

 

Incidence of Post-Lumbar Puncture Headache Among Adult 

Patients in an Urban Teaching Emergency Department. Connecticut 

College of Emergency Medicine, $2,000. 

 

Do Nurses Have a Role in the Evaluation of EM Residents? 

A Comparison of EM Resident Evaluation by Teaching and Non- 

Teaching Attendings. 

 

American College of Surgeons Advance Trauma Life Support 

Course (ATLS). 

Current Practices in Management of Liver and Spleen Injuries. 

Role of Ultrasound in Pre-Hospital Aeromedical Evacuation and 

Triage. Hartford Hospital Research Endowment Funds, $10,128.

Advanced Trauma Operative Management (ATOM) Course. 

Bioterrorism Surveillance and Response Preparedness and Training. 

University of Connecticut, $50,000. 

Evaluation of the Advanced Trauma Operative Management 

(ATOM) Course. 

Multi-Center Trial of the Advanced Trauma Operative Management 

(ATOM) Course. 

Survey of Health Care Professionals Regarding Attitudes and 

Beliefs for End-of-Life Care in Trauma. 

Development, Implementation, and Testing of a Best Practice Model 

for End-of-Life Care in Trauma. Aetna Foundation, $295,000. 

 

FESS-UP: Focused Epigastric Sonography Of e Stomach In e 

Unreliable Poisoned Patient. 

 

rombocytopenia and antiheparin antibodies in adult ED patients. 

Glaxo Smith Kline, $9,800. 

 

Resident Physician Knowledge of Allowed Pharmaceutical 

Representative Activity and Limitations of at Activity Within 

eir Teaching Institution. 

 

Emergency Procedures for Emergency Medicine Residents. 

 

Effect of Sternal Intraosseous Access on CVL Usage in Air Medical 

Setting. 

 

Comparative Pharmacokinetic Study of Intranasal Naloxone Versus 

Intravenous Naloxone. Hartford Hospital Research Endowment 

Funds, $6,981. 

Assessment of Inter-Institutional Reproducibility of Automated 

Plasma Cholinesterase Assays in Connecticut: Can We Reliably 

Communicate in the Event of Chemical Terrrorism? 

Normative Distributions of Plasma and Erythrocyte Cholinesterase 

Activity in a Tertiary Care Emergency Department, Based on 

Demographic and Clinical Data, for Use as a Rule-Out Screen for 

Significant Nerve Agent Toxicity. HRSA,$60,250. 

 

Defibrillator Availability On Rotor Wing Air Medical Transports. 

Crew Weight and Fitness Policies in Rotor Wing Air Medical 


 

Management of the Difficult Airway (CME - Educational 

Course). 

 

Geriatric Trauma: A Comparison of Bone Fracture Healing Rates. 


Prevention of Complicated Alcohol Withdrawal Syndrome in 

the Hospitalized Trauma Patient: A Comparison of Intravenous 

Benzodiazepine vs. Ethyl Alcohol erapies. Hartford Hospital 


e Role of Hyperglycemia in the Development of Contrast- 

Induced Nephropathy During Cardiac Catheterization Procedures. 


Acute Pancreatitis at Hartford Hospital: Incidence and Outcomes. 


Development of a Stress-Sensitive Assay Using Discarded Human 

Red Blood Cells. 

Minimally Invasive Treatment of the Abdominal Compartment 

Syndrome: Initial Experience. 

Chart review of the treatment of delayed radiation tissue injury of 

soft tissue and bone with hyperbaric oxygen therapy. 

 

Intranasal Midazolam in the Initial Management of Seizing 

Patients in the Pre-Hospital Treatment of Seizing Patients. 


Procedure Under-Documentation in the Emergency Department: 

Are Residents Guilty? Is there an easy Solution? Connecticut College 

of Emergency Physicians, $2,000. 

Utilization of Transfer Criteria to a Liver Transplant Center 

Following an Acetaminophen Overdose. 

Survey of Medical Toxicology Fellowships Progress in Adherence to 

Core Competencies Evaluation. 

Determination of Urinary Kinetics of Acetaminophen Volunteer 

Study. Hartford Hospital Research Endowment Funds, 

$11,335; UCSF, $2,170. 

Evaluation of Core Competencies Assessment by Emergency 

Medicine Residencies. 

 

Flight Nurse Training of Surgical Skills. 

Prehospital Blood Administration vs Crystalloids in Resuscitation. 

e Effect of the Combination of Surgical Gloves over Nomex 

Gloves on Dexterity and Accuracy of Commonly Performed Air 

Medical Tasks. 

 

Open Label Extension of Double-Blind, Placebo-Controlled, 

Paralleled Group Study to Evaluate Safety, Tolerability, and Activity 

of Oral Fampridine-SR in Subjects with Chronic, Incomplete 

Spinal Cord Injury SCI-F300 EXT. Acorda erapeutics, Inc., 

$66,125. 

A Phase II, Double-blind, Placebo-controlled, Multicenter study 

to assess the efficacy and safety of HP184 at 100, 200 and 400 MG 

doses administered orally once daily for twenty-four weeks in adult 

subjects with chronic spinal cord injury. Aventis Pharmaceuticals, Inc., 

$88,075. 

 

Comparison of Spectrophotometric and Automated Cerebrospinal 

Fluid Bilirubin in the Detection of Xanthochromia After 

Subarachnoid Hemorrhage. Hartford Hospital Research Endowment 

Funds, $8,925. 

Factors Affecting Early Unscheduled Revisit at the Emergency 

Department.

Aschkenasy MT, Drescher MJ, Ratzan RM. Physician reporting of 

medically impaired drivers. J Emerg Med. 2006;30:1, 29-39. 

Bowen JD, Kamin R, Leverenz JB, Fishel MA, McCormick WC, Kukull 

WA, Larson EB. Interrater reliability and accuracy in identifying ischemic 

strokes using computed tomography scans in people with dementia. J Am 

Geriatr Soc. 2005;53(10):1743-1747. 

Burns KJ, Robinson KJ, Lowe E. Evaluation of responses of an air medical 

helicopter program during a comprehensive emergency response drill. Air 

Med J. 2007;26(3):139-143. 

Chau B, Dufel S. Gastric volvulus. Emerg Med J. 2007;24:446-447. 

Ciraulo DL, Barie PS, Briggs SM, Bjerke HS, Born CT, Capella J, Cancio 

L, Denis A, DiGiacomo JC, Gross RI, Hammond JS, Holcomb JB, Jenkins 

D, Knuth TE, Letarte PB, Lynn M, O’Neill PA, Salomone JP, Shatz 

DV. An update on the surgeons’ scope and depth of practice to all hazards 

emergency response. J Trauma. 2006;60:1267-1274. 

Drescher MJ, Elstein Y. Prophylactic COX 2 inhibitor: An end to the Yom 

Kippur headache. Headache. 2006;46:1487-91. 

Drescher MJ, Aharonson L, Peleg J, Liebman J. A study of the workforce in 

emergency medicine in Israel. J Emerg Med. 2007;33:433-437. 

Dufel S, Martino M. Simple cellulitis or a more serious infection? Journal of 

Family Practice. 2006;55(5):396-400. 

Frakes MA, Van Voorhis S. Effectiveness of a challenge-and-respond 

checklist in ensuring safety behavior compliance by medical team members at 

a rotor-wing air medical program. Air Med J. 2007;26(5):248-51. 

Frakes MA, Neher SW. Defibrillator availability on rotor-wing critical care 

transports. Air Med J. 2007;26(3):144-6. 

Frakes MA, Kelly JG. A survey of adherence to community-generated safety 

guidelines in rotor-wing air medical programs. Air Med J. 2007;26(2):100- 

3. 

Frakes MA, Kelly JG. Sleep debt and outside employment patterns in 

helicopter air medical staff working 24-hour shifts. Air Med J. 2007;26(1): 

45-9, 2007. 

Frakes MA, Lord WR. Sedative use in patients receiving neuromuscular 

blocking agents from a helicopter flight team. Air Med J. 2006;25(4):173-5. 

Frakes MA, Evans T. An overview of Medicare reimbursement regulations 

for advanced practice nurses. Nursing Economics. 2006;24(2):59-65, 55. 

[reprint in Dermatol Nurs. 2006;18(6):555-60] 

Frakes MA, Lord WR, Kociszewski C, Wedel SK. Efficacy of fentanyl 

analgesia for trauma in critical care transport. American Journal of Emergency 

Medicine. 2006;24(3):286-9. 

Frakes MA, Kelly JG. Off-duty preparation for overnight work in rotor wing 

air medical programs. 2005; Air Med J. 24(5):215-7. 

Gabram SG, Espat NJ, Jacobs LM, Macleod JB. Academic careers in 

surgery: the many paths from which to choose. Journal of Surgical Education. 

2007;64(1):27-35. 

Gross RI. Optimizing trauma care in special populations: Morbidly obese. 

PanAm J Trauma. 2005;2(1):46-54. 

Gross RI, Eversgerd JL. Transthoracic lung herniation due to blunt trauma. 

J Trauma. 2006;60:1149. 

Gutman M, Drescher MJ. e role of emergency medicine in the military. 

Israeli Journal of Emergency Medicine. 2006;6(4):32-35. 

Jacobs LM, Burns KJ, Luk SS, Marshall WT. Follow-up survey of 

participants attending the Advanced Trauma Operative Management 

(ATOM) Course. J Trauma. 2005;58:1140-1143. 

Jacobs LM, Jacobs BB, Burns KJ. A plan to improve end-of-life care for 

trauma victims and their families. J Trauma Nursing. 2005;12:73-76. 

Jacobs LM, Burns KJ. Terrorism preparedness: Web-based resource 

management and the TOPOFF 3 exercise. J Trauma. 2006;60:566-572. 

Jacobs LM, Burns KJ, Luk SS. Advanced Trauma Operative Management 

Course: Site and instructor selection and evaluation. J Am Coll Surg. 

2006;203:772-779. 

Kaplan LJ, Frankel HL, Hojman H, Portereiko J, Rabinovici R. What price 

for general surgery? J Trauma. 2005;59:391-394. 

Kuntz J, Cheesman J, Powers, R. Acute thrombotic disorders. Am J Emerg 

Med. 2006; 24:460-467. 

Lynes MA, Kang YJ, Sensi SL, Perdrizet GA, Hightower LE. Heavy metal 

ions in normal physiology, toxic stress, and cytoprotection. Ann NY Acad Sci. 

2007;1113:159-172. 

McKay CA. Can the laboratory help me? Toxicology laboratory testing in 

the possibly poisoned pediatric patient. Clin Ped Emerg Med. 2005;6:116- 

122 (DOI: 10.1016/j.cpem.2005.04.004). 

Mittal MK, Florin T, Perrone J, Delgado JH, Osterhoudt KC. Toxicity from 

the use of niacin to beat urine drug screening. Ann Emerg Med. 2007;50: 

587-590. 

Murray SB, Bates DW, Spear J, Ufber JW, Shapiro NS. Charlson index is 

associated with one-year mortality in emergency department patients with 

suspected infection. Acad Emerg Med. 2006;13(5):530-6. 

Perdrizet GA, Giles DL, Dring R, Agarwal SK, Khwaja K, Gao YZ, 

Geary M, Cowell VL, Berman M, Brautigam RT. Major hepatic trauma: 

Warm ischemic tolerance of the liver after hemorrhagic shock. J Surg Res. 

2006;136;70-77. 

Portereiko JV, Perez MM, Hojman H, Frankel HL, Rabinovici R. Acute 

upper airway obstruction by an over-inflated Combitube esophageal 

obturator balloon. J Trauma. 2006;60:426-427. 

Ratzan RM. Rabies in Israel 2006: An update and review. Israeli J Emerg 

Med. 2006; 6(3):16-25. 

Robinson KJ, Blomstrom S. Skin and soft tissue infections. Emergency 

Medicine Reports. 2006; 27(12):1-14. 

Rotondo MF, Esposito TJ, Reilly PM, Jacobs LM. e position of the 

Eastern Association for the Surgery of Trauma on the future of trauma 

surgery. J Trauma. 2005;59(1):77-79. 

Sanchez M, Smally AJ, Grant RJ, Jacobs LM. Effects of a fast-track area on 

emergency department performance. J Emerg Med. 2006;31(1):117-120. 

Scalora MA, Gross RI, Burns KJ. Management of blunt hepatic trauma at a 

Connecticut level I trauma center. Conn Med. 2007;71:529-532. 

Soli C, Smally AJ. Vocal cord dysfunction: An uncommon cause of stridor. 

J Emerg Med. 2005;28(1):31-33. 

Smally AJ. Images in emergency medicine. Burns and acute atrial fibrillation 

precipitated by electrical shock. Ann Emerg Med. 2005;46(4):383, 392. 

Smally AJ. Clinical controversies: rombolysis in stroke, 2005. Israeli 

Journal of Emergency Medicine. 2005;5(1):29-30. 

Smally AJ. e esophageal-tracheal double lumen airway: Rescue for the 

difficult airway. J Am Assoc Nurse Anesth. 2007;75(2): 129-134. 

Smally AJ, Souzzi JC. Images in emergency medicine: Deep sulcus sign. Ann 

Emerg Med. 2007;49(5):717,725. 

Tokarsky G, Drescher M. Bilateral popliteal artery thrombosis from 

traumatic knee dislocation. Israeli Journal of Emergency Medicine. 2006: 6(2): 

37-40. 

Vena J, Dufel S, Paige T. Acute olanzapine-induced akathisia and dystonia in 

a patient discontinued from fluoxetine. J Emerg Med. 2006;30(3):311-317. 

Zeller J, Murray SB, Fisher J. Spontaneous globe subluxation in a patient 

with hyperemesis gravidarum: a case report and review of the literature. J

Emerg Med. 2007;32(3):285-287. 

 

 

Adamcewicz M, McKay C, McDonagh J, McCombe R. Impact of RBC 

cholinesterase determination on decision-making for low normal plasma 

cholinesterase measurements. New England Regional Society of Academic 

Emergency Medicine, Worcester, MA. April 2007. 

Adamcewicz M, McKay CA, McDonagh JC. Impact of RBC cholinesterase 

determination on decision-making for low normal plasma cholinesterase 

measurements. Clin Tox. 2006;44(5):630. Abstract 13 – North American 

Congress of Clinical Toxicology, San Francisco CA, October 2006. 

Adra S, Miller M, Shapter C, Perdrizet G. Treatment of delayed radiation 

tissue injuries with hyperbaric oxygen therapy. Connecticut Chapter American 

College of Surgeons, Meriden, CT, November 2006. 

Adra S, Shahmodammadi K, Miller M, Shapter C, Perdrizet G. Treatment 

of delayed radiation tissue injuries with HBO2T. Undersea and Hyperbaric 

Medicine Society Northeast Chapter, Hartford, CT, November 2006. 

Adra S, Shahmodammadi K, Shapter C, Portereiko J, Perdrizet G. Taser 

trauma: What every clinician needs to know. Connecticut Chapter American 


Anderson C, Corbet L, Magliato B, Tray K, Babigian A, Perdrizet G. 

Nephrogenic fibrosing dermopathy: Lower extremity wound response to 

adjunctive hyperbaric oxygen therapy. Connecticut Chapter, American College 

of Surgeons, Meriden, CT, November 2005. 

Bolton L, Robinson K, Drescher M, Burns K. Factors that correlate with 

patients leaving an emergency department without being seen. American 

College of Emergency Physicians, New Orleans, LA, October 2006. 

Bolton L, Robinson K, Drescher M, Burns K. Factors that correlate with 

patients leaving an emergency department without being seen. Connecticut 

College of Emergency Physicians, Rocky Hill, CT, November 2006. Best Poster 

presentation. 

Brautigam RT, Schott E, Fernandez F. Simulation education for the 

management of blunt head trauma. 65th Annual American Association for the 

Surgery of Trauma meeting, New Orleans, LA, September 2006. 

Delgado D, Delgado J. Educating nurses about domestic violence 

intervention: Trends among magnet hospitals. National Conference on Health 

and Domestic Violence, San Francisco, CA, 2007. 

Delgado J, O’Sullivan D, Rosner G, McKay C. Population-based estimate of 

the prevalence of carbon monoxide poisoning: A capture-recapture analysis 

of three statewide databases. New England Regional Society for Academic 

Emergency Medicine Conference, Shrewsbury, MA, April 2007. 

Drescher MJ, Dziedzic M, Robinson K, Smally AJ. A predictable weekly 

pattern in admitted patients awaiting beds in the ED and correlation with 

elective admissions. American College of Emergency Physicians Research Forum, 

New Orleans, LA, October 2006. 

Drescher MJ, Rockwell D, Spence A, Staff I, Smally AJ. Point of care testing 

for coagulation studies in an emergency department stroke protocol: A time 

saving innovation. American College of Emergency Physicians Research Forum, 

Seattle, WA, October 2007. 

Dziedzic M, Suozzi J, Nowicki T. Comparison of the Airtraq Optical 

Laryngoscope to direct laryngoscopy in a manikin model for easy and 

difficult intubations. American College of Emergency Physicians, Seattle, WA, 

October 2007. 

Fernandez FB, Cortes V, Brautigam RT, Perdrizet GA. Minimally invasive 

treatment of the abdominal compartment syndrome: initial experience. New 

England Surgical Society, September 2006. 

Frakes M, Kelly J, Kociszewski C, Wedel S. Actual worked hours for 

critical care transport professionals. Air Medical Transport Conference, 

Phoenix, AZ, September 2006. 

Frakes M, Lord W, Kociszewski C, Wedel S. Factors associated with 

trauma oligoanalgesia by critical care transport teams. Air Medical Transport 

Conference, Phoenix, AZ, September 2006. 

Frakes M, O’Donnell S, Sahjian M. Need for defibrillation during cardiac 

arrest management by rotor wing critical care transport teams. Air Medical 

Transport Conference, Phoenix, AZ, September 2006. 

Frakes M, Sahjian M, O’Donnell S. Resuscitation from cardiac arrest in 

patients managed by rotor wing critical care transport teams. Air Medical 

Transport Conference, Phoenix, AZ, September 2006. 

Frakes M, Van Voorhis S. Effectiveness of a checklist in verifying operational 

safety behaviors at a rotor wing air medical program. Air Medical Transport 

Conference, Phoenix, AZ, September 2006. 

Frakes MA, Delgado J. BIS-Monitor consciousness measurement in 

patients with neuromuscular blockade and empirical sedation by a critical 

care transport team. Crit Care Med. 2007;35(12 supp):A245. 

Frakes MA, Lord WR, Verrengia S, Gaeta S, Robinson KJ, McQuay J, 

Harman AL. Transfer of medication administration information from 

critical care transport teams to trauma teams. Acad Emerg Med. 2007;14: 

S142-S143. Air Med J. 2007;26:232. 

Frakes MA, Lord WR, Verrengia S, Gaeta S, Robinson KJ, McQuay J, 

Harman AL. Transfer of medication administration information from 

critical care transport teams to trauma teams. New England Society of 

Academic Emergency Medicine Annual Conference. Worcester MA, April 2007. 

Society of Academic Emergency Medicine Annual Conference. Chicago, May 2007; 

Air Medical Transport Conference. Tampa, FL, September 2007. 

Frakes MA, McQuay J, Harman AL, Lord WR. Factors associated with 

incomplete trauma resuscitation documentation. Society of Trauma Nurses 

Annual Conference. Las Vegas, March 2007. 

Frakes MA, McQuay J, Harman AL, Lord WR. Pain and pain 

documentation in trauma resuscitation. Society of Trauma Nurses Annual 

Conference. Las Vegas, March 2007. 

Johnson-Arbor K, Goldstein R, McKay C, Wu A, Smith A. e TCA 

“tox screen”: Where should we draw the line? Clin Tox. 2006;44(5):736. 

Abstract 229 – North American Congress of Clinical Toxicology, San Francisco 

CA, October 2006. 

Johnson-Arbor K, Goldstein R, McKayC, Wu A, Smith A. e TCA “tox 

screen”: Where should we draw the line? New England Regional Society for 

Academic Emergency Medicine, Shrewsbury, MA, April 2007. 

Johnson-Arbor K, McKay CA. Prolonged increases in troponin T after 

carbon monoxide poisoning. Undersea and Hyperbaric Medical Society 

Northeast Chapter, October 2005. 

Johnson-Arbor K. Hyperbaric oxygen therapy for endoscopy-induced air 

embolism: Case report and literature review. Undersea and Hyperbaric Medical 

Society Northeast Chapter, Hartford, CT, November 2006. 

Kim N, Abbensetts JMK, Perdrizet G. Pelvic crush injuries: Use of 

adjunctive hyperbaric oxygen. Connecticut Chapter, American College of 

Surgeons, Meriden, CT, November 2005. 

Lantos D, Perdrizet G. Congestive heart failure and HBO2T: Brain-type 

atrial natriuretic peptide monitoring. Undersea and Hyperbaric Medicine 


Laska E, Johnson-Arbor K, McKay C. A 34-month review of pediatric 

escitalopram ingestions. Clin Tox. 2006;44(5):666. Abstract 85 – North 

American Congress of Clinical Toxicology, San Francisco CA, October 2006. 

Laska E, Johnson-Arbor K, Sangalli B, McKay C. Pediatric Escitalopram 

ingestions: A 34-month review of exposures reported to a poison center. New 

England Regional Society for Academic Emergency Medicine , Shrewsbury, MA, 

April 2007. 

Magge S, Voytovich A, Taylor S, Fuller R, Kozol R. A prospective 

evaluation of the utility of CT Scans in patients with abdominal pain in 

the emergency department. Connecticut Chapter of the American College of 

Surgeons, Meriden, CT, November 2005. 1st Prize in General Surgery.

Magliato B, Perdrizet G, Shapter C. Implementation of an electronic 

medical record in a wound care and hyperbaric medical center. Undersea and 

Hyperbaric Medicine Society Northeast Chapter, Hartford, CT, November 2006. 

Marcelynas J, Down P. e efficacy of a sternal intraosseous infusion device 

in an aeromedical program. Air Medical Transport Conference, Phoenix AZ, 


Marcelynas J, Robinson K, Duquette L, Flight volume and revenue effects 

of a “Flying Standby” autolaunch policy. Air Medical Transport Conference, 

Phoenix AZ, September 2006. 

McKay C, McDonagh J, Adamcewicz M, Kristie V. Normative distributions 

of plasma cholinesterase activity in a tertiary care emergency department: 

utility as a rule-out screen for significant nerve agent toxicity. New England 

Regional Society for Academic Emergency Medicine, Shrewsbury, MA, April 

2007. 

McKay CA, McDonagh JC, Adamcewicz M, Kristie V. Normative 

distribution of plasma cholinesterase activity in a tertiary care emergency 

department, for use as a rule-out screen for significant nerve agent toxicity. 

Clin Tox. 2006;44(5):632-3. Abstract 17 – North American Congress of Clinical 

Toxicology, San Francisco CA, October 2006. 

McKay CA, Wu AHB, Smith A, Vena J, Kristie V, Butcher C, Zibiuk J. 

Assessment of a statewide laboratory network for cholinesterase screening: 

Can we communicate in the event of chemical terrorism? Connecticut College 

of Emergency Physicians Annual Meeting and Scientific Symposium, Rocky Hill, 

CT. November 2005. 

McKinney C, Bolton L, Robinson K, Burns K. Characterization of patients 

who leave an emergency department without being seen. American College of 

Emergency Physicians Research Forum, Seattle, WA, October 2007. 

Montminy J, Conley J, Perdrizet G. Characterization of blood glucose 

in diabetic patients treated with hyperbaric oxygen. Connecticut Chapter, 

American College of Surgeons, Meriden, CT, November 2005. 

Myer E, Anderson C, Fernando F, Perdrizet G. Repair of severe hypospadias: 

use of adjunctive hyperbaric oxygen therapy. Connecticut Chapter, American 


O’Brien JA, Jacobs LM. Cost of hospitalizations for acute injuries resulting 

from motorcycle accidents pre- and post-repeal of the universal helmet law in 

Florida. ISPOR 11th Annual International Meeting, May 2006. 

O’Brien JA, Jacobs LM. Occupational injuries: use and cost of emergency 

department for treatment of accidental hypodermic needle punctures. 

ISPOR 9th Annual European Congress, Copenhagen, Denmark. October 2006. 

Oprisiu C, Rutland R, Shapter C, Brautigam R, Perdrizet G. Crush injuries 

and HBO2T: experience at a level I trauma center. Connecticut Chapter 


Oprisiu C, Rutland R, Shapter C, Brautigam R, Perdrizet G. Crush injuries 

and HBO2T: experience at a level I trauma center. Undersea and Hyperbaric 

Medicine Society Northeast Chapter, Hartford, CT, November 2006. 

Perdrizet G, Worth W, Moher J, Solomon B, Anderson C, Shapter C. 

Clinical outcomes in patients with severe diabetic foot wounds treated with 

or without hyperbaric oxygen. Wound Repair and Regeneration. 2007;15(2): 

165-A60. Abstract 57 - Symposium on Advanced Wound Care and Wound 

Healing Society, Phoenix, AZ. February 2007. 

Perdrizet G, Worth W, Moher J, Solomon B, Anderson C, Shapter C. 

Vascular assessment in chronic wound care: effect of HBO2T on forecasting 

patient outcomes. Wound Repair and Regeneration. 2007;15(2):165-A60. 

Abstract 58 - Symposium on Advanced Wound Care and Wound Healing Society, 

Phoenix, AZ. February 2007. 

Perdrizet GA, Cabigas B, Worth P, Moher J, Anderson C, Shapter C. 

Vascular assessment in chronic wound care: effect of HBO2T on forecasting 

patient outcomes. New England Surgical Society, Burlington, VT, September 

2007. 

Perdrizet GA, Cabigas B, Worth P, Moher J, Anderson C, Shapter C. 

Clinical outcomes in patients with severe diabetic foot ulcers treated with or 

without hyperbaric oxygen therapy. New England Surgical Society, Burlington, 

VT, September 2007. Best poster presentation. 

Perdrizet GA, Duong L, Rewinski M, McKone H, Hightower L. Assay 

for in vivo stress tolerance: Clinical implications for trauma –critical care. 

Academic Surgical Congress, Phoenix, AZ, February 2007. 

Perdrizet GA. CNS oxygen toxicity: Unrecognized risk factors. 40th Annual 

UHMS Scientific Meeting, Undersea and Hyperbaric Medical Society, Maui, HI, 

June 2007. 

Perdrizet GA. Clinical outcomes in patients with severe diabetic foot wounds 

treated with or without hyperbaric oxygen. 17th Annual Wound Healing 

Society Meeting and Exhibition, Tampa, FL, April 28-May 1, 2007. 

Perdrizet GA. Clinical outcomes in patients with severe diabetic foot wounds 

treated with or without hyperbaric oxygen. 40th Annual UHMS Scientific 

Meeting, Undersea and Hyperbaric Medical Society, Maui, HI, June 2007. 

Perdrizet GA. CNS oxygen toxicity: Potential risk factors. 17th Annual 

Wound Healing Society Meeting and Exhibition, Tampa, FL, April 28-May 

1, 2007. 

Perdrizet GA. CNS toxicity associated with the use of a multiplace hyperbaric 

chamber: Lessons learned. Undersea and Hyperbaric Medicine Society Northeast 

Chapter, Hartford, CT, November 2006. 

Perdrizet GA. Congestive heart failure and HBO2T: Brain-type atrial 

natriuretic peptide monitoring. 40th Annual UHMS Scientific Meeting, 

Undersea and Hyperbaric Medical Society, Maui, HI, June 2007. 

Perdrizet GA. Does hyperbaric oxygen therapy cause hypoglycemia in 

diabetic patients? A review of 119 diabetic patients treated in a multiplace 

chamber. 40th Annual UHMS Scientific Meeting, Undersea and Hyperbaric 

Medical Society, Maui, HI, June 2007. 

Perdrizet GA. Hypospadias repair: e use of perioperative hyperbaric 

oxygen therapy. 40th Annual UHMS Scientific Meeting, Undersea and 

Hyperbaric Medical Society, Maui, HI, June 2007. 

Perdrizet GA. Off label use of HBO2T. Undersea and Hyperbaric Medicine 


Perdrizet GA. Severe soft tissue infections: use of emergent HBO2 therapy. 

40th Annual UHMS Scientific Meeting, Undersea and Hyperbaric Medical 

Society, Maui, HI, June 2007. 

Perdrizet GA. Traumatic amputation in a Jehovah’s Witness: options for 

enhancing oxygen delivery. 40th Annual UHMS Scientific Meeting, Undersea 

and Hyperbaric Medical Society, Maui, HI, June 2007. 

Perdrizet GA. Vascular assessment in chronic wound care: effect of HBO2T 

on forecasting patient outcomes. Undersea and Hyperbaric Medicine Society 

Northeast Chapter Hartford, CT, November 2006. 

Perdrizet GA. Vascular assessment in chronic wound care: effect of HBO2T 

forecasting patient outcomes. 17th Annual Wound Healing Society Meeting 

and Exhibition, Tampa, FL, April 28-May 1, 2007. 

Perdrizet GA. Worth P, Moher J. Clinical outcomes in patients with 

severe diabetic foot wounds treated with or without HBO2T. Undersea and 

Hyperbaric Medicine Society Northeast Chapter, Hartford, CT, November 2006. 

Perez A, Vena J, Wu AHB, Smith A, O’Sullivan D, McKay CA. An 

evaluation of a urinary acetaminophen point-of-care test (POCT). 

Connecticut College of Emergency Physicians Scientific Symposium, Rocky Hill, 

CT, November 2005. 

Perez A, Vena J, Wu AHB, Smith A, O’Sullivan D, McKay CA. Carapeutics 

non-toxic ingestion. Connecticut College of Emergency Physicians Annual 

Meeting and Scientific Symposium, Rocky Hill, CT, November 2005. 

Qureshi I, Gasho K, Fan L, Perdrizet G. Does HBO2T cause hypoglycemia 

in diabetic patients? A review of 119 diabetic patients treated in a multiplace 

chamber. Wound Repair and Regeneration. 2007;15(2):165-A60. Abstract 

115 - Symposium on Advanced Wound Care and Wound Healing Society, 

Phoenix, AZ. February 2007. 

Qureshi I, Gasho K, Fan L, Perdrizet G. Does HBO2T cause hypoglycemia 

in diabetic patients? A review of 163 diabetic patients treated in a multiplace 

chamber. Connecticut Chapter American College of Surgeons, Meriden, CT,


Qureshi I, Gasho K, Perdrizet G. Does HBO2T cause hypoglycemia in 

diabetic patients? Undersea and Hyperbaric Medicine Society Northeast Chapter, 

Hartford, CT, November 2006. 

Qureshi I, Perdrizet G. Vascular surgical wound complications: role for 

hyperbaric oxygen therapy. Connecticut Chapter American College of Surgeons, 

Meriden, CT, November 2006. 

Qureshi I, Perdrizet G. Wound complications following surgical 

revascularization of the lower extremity: Role for HBO2T. Wound Repair 

and Regeneration. 2007;15(2):165-A60. Abstract 125 - Symposium on Advanced 

Wound Care and Wound Healing Society, Phoenix, AZ. February 2007. 

Qureshi I, Perdrizet, G. Wound complications following surgical 

revascularization of the lower extremity: Role for hyperbaric oxygen therapy. 

Undersea and Hyperbaric Medicine Society Northeast Chapter, Hartford, CT, 


Rader C, Perdrizet G, Piorkowski R. Complication of pyriform sinus tumor. 

Connecticut Chapter American College of Surgeons, Meriden, CT, November 

2006. 

Robinson K, Marcelynas J, Phillips E. Line oriented flight training . Air 

Medical Transport Conference, Phoenix, AZ, September 2006. 

Rutland R, Oprisiu C, Shapter C, Keating K, Abbensetts JMK, Perdrizet 

G. Traumatic amputation in a Jehovah’s Witness: Options for O2 delivery. 

Connecticut Chapter American College of Surgeons, Meriden, CT, November 

2006. 

Rutland R, Oprisiu C, Shapter C, Keating K, Abbensetts JMK, Perdrizet 

G. Traumatic amputation in a Jehovah’s Witness: Options for O2 delivery. 

Undersea and Hyperbaric Medicine Society Northeast Chapter, Hartford, CT, 


 

Shahmohammadi K, Adra S, Shapter C, Luk S, Perdrizet G. e role of 

HBO2T in treatment of severe soft tissue infections. Connecticut Chapter 


Shahmohammadi K, Miller M, Shapter C, Perdrizet G. e role of HBO2T 

in treatment of severe soft tissue infections. Undersea and Hyperbaric Medicine 


Sherry T, McDonagh J, Johnson-Arbor K, McKay C. Clenbuteroladulterated 

cocaine: A case series. Clin Tox 2006;44(5):739. Abstract 236 

– North American Congress of Clinical Toxicology, San Francisco CA, October 

2006. 

Sherry T, McDonagh J, Johnson-Arbor K, McKay C. Clenbuteroladulterated 

cocaine: A case series. New England Regional Society for Academic 

Emergency Medicine, Shrewsbury, MA, April 2007.

. 

 

Robotic-Assisted Laparoscopic Bladder Diverticulectomy. 

 

 

Hartford Hospital Nephrectomy Research Database. 

Database supported by Hartford Hospital Small Grant. 

 

 

Dinlenc C.Z., Berman A., and Wagner J.R. Quality of life outcomes after 

robot assisted laparoscopic radical prostatectomy: 3 year follow-up. J. Urol., 

173 (4), 25A, 7, 2005. 

Irwin B.H. and Wagner J.R. Cystoscopic treatment of ureteral obstruction 

following robotic-assisted laparoscopic radical prostatectomy. J. Urol., 177 

(4), V356, 119, 2007. 

Irwin B.H. and Wagner J.R. Robotic ureterocalycostomy. American 

Urological Association Northeastern & New England Section Joint Annual 

Meeting, Southampton, Bermuda, 2005. 

Irwin B.H. and Wagner J.R. Cystoscopic treatment of ureteral obstruction 

following robotic-assisted laparoscopic radical prostatectomy. American 

Urological Association New England Section Annual Meeting, Providence, RI, 

2006. 

Myer E.G. and Wagner J.R. Robotic-assisted laparoscopic bladder 

diverticulectomy. American Urological Association New England Section 

Annual Meeting, Providence, RI, 2006. 

Nagler M.M., Gerber E.W., Homel P., Wagner J.R., Norton J., Lebovitch 

S., and Phillips J.L. Digital rectal examination is barrier to population-based 

prostate cancer screening. Urology, 65 (6): 1137-1140, 2005. 

Schimpf M.O., Morgenstern J.H., Tulikangas P.K., and Wagner J.R. 

Vesicovaginal fistula repair without intentional cystotomy using the 

laparoscopic robotic approach: a case report. JSLS, Jul-Sep;11(3):378-80, 

2007. 

Shichman S.J. and Wagner J.R. Hand-assisted laparoscopic nephrectomy. In 

Gill (Ed). Textbook of Laparoscopic Urology, 2006. 

Shichman S.J. and Wagner J.R. Minimally invasive hand-assisted 

nephrectomy for the treatment of renal cancer. In Moore and Bishoff (Eds.) 

Minimally Invasive Uro-Oncologic Surgery, 2005. 

Shichman S.J. and Wagner J.R. Hand-assisted laparoscopic nephrectomy. 

In Moore, Bishoff, Loening, Domocimo (Eds). Minimally Invasive Urologic 

Surgery, 2005. 

Wagner J.R. and Dinlenc C.Z. Laparoscopic radical prostatectomy editorial 

comment. In Cummings (Ed.) Management of Prostate Cancer: Advances and 

Controversies, 138-141, 2005. 

Warner J. Robotic radical prostatectomy: e Hartford Hospital experience. 

Presented at the University of Connecticut School of Medicine, Farmington, CT, 

2006.

Joel Sorosky, MD • Lynn Deasy, RN • John Greene, MD 

Women’s Health Services Collaborative Management Team 

Women’s Health has recently grown. New staff members: Janice Hartnett, MD, Lawrence Engmann, 

MD, Amy Brown, MD, Adam Steinberg, MD, Amy Johnson, MD, and Debra Hein, CNM. Recent promotions: 

Lynn Deasy, RN,Nursing Director; Megan Ruppenicker, RN, Nurse Manager of Labor & Delivery; Elizabeth Brinkley, 

RN and Nancy Scanlon, RN, managers of Postpartum and Ambulatory Services, respectively. Dr. Gary Nobert retired from 

private practice and is assisting in Women’s Ambulatory Services. Dr. Tracy Brennan was the first recipient of the Palermino 

Professorship. Drs. Kerrie Henry and Mina Rasoulpour provide part-time mentorship in the clinic. 

 

Amy Brown, MD has joined the division and has 

added minimally invasive gynecologic oncology 

surgery to the division’s services. e division is now 

seeing patients in the new 85 Seymour Street facility 

and the Helen and Harry Gray Cancer Center. A 

multi-disciplinary tumor board was initiated and 

meets on a regular basis. Hartford Hospital and the 

Hospital of Central Connecticut became a primary 

Gynecologic Oncology Group site. e division 

continues with its plans for continued growth to keep 

pace with increased patient volumes. It is recruiting 

new department members and has submitted an 

application for a fellowship program. 

 

Adam Steinberg, MD recently joined the division. 

Patient volume continues to increase, staff has 

increased and the division now occupies a more 

spacious Medical Office Building suite. e division 

is growing its fellowship program with plans for a 

second fellow position in 2008. 

 

e first trimester screening program for the early 

detection of birth defects continues to grow. e 

division continues to see increased patient volume. 

An additional sonographer has been hired and the 

division is recruiting a fourth physician member. e 

University of Connecticut Program’s first year fellow 

now spends 5 months at Hartford Hospital. 

 

 

Dr. Amy Johnson recently joined the division. e 

division established a partnership with Community 

Health Services (CHS). e partnership is actively 

recruiting three new physician members, two at 

CHS and one for the division. e division plans to 

establish additional offices at 85 Seymour Street. 

 

 

 

is division continues under the private practice 

model. Dr. August Olivar joined the University of 

Connecticut’s Center for Advanced Reproductive 

Services. His offices remain on the Hartford campus. 

Dr. Lawrence Engmann has joined this practice. 

 

Debra Hein, CNM, joined Women’s Helath as 

the Director of the new nurse midwifery program. 

Lucinda Canty, CNM, transferred from Women’s 

Ambulatory Services, and the program is recruiting 

two additional midwives for outpatient Ob/Gyn, 

Labor & Delivery triage and to assist with cesarean 

sections. 

Women’s Health continues to have the largest 

number of physicians listed in Hartford 

Magazine as “Best Doctors” in the area.

GOG 220: Pelvic Mass Study to Develop Serum Proteomic Profiles 

(Signatures) for Epithelial Ovarian Cancer Diagnosis and Prognosis. 

GOG, $8,712. 

 

Breastfeeding Education and Support Trial for Obese Women: 

Early Dyad Dynamics (BESTOW:EDD). CDC subcontract through 


 

 

e Role Of e Provider In Racial And Ethnic Disparities In 

Prenatal Care. CT Health Foundation, $5,000. 

 

Breastfeeding Education and Support Trial for Obese Women 

(BESTOW). Donaghue Foundation subcontract through the University 

of Connecticut, $20,590. 

 

 

ChemoFx Registry: An Observational, Longitudinal, Multicenter 

Study Examining Outcomes Associated with the Use of 

the ChemoFx Assay in Solid Tumor Malignancies. Precision 

erapeutics, $30,031. 

 

A Prospective, Single-Arm, Post Market Clinical Study to Evaluate 

a Mid-Urethral Vaginal Tape Procedure with a Pre-Pubic Delivery 

Approach for the Treatment of Stress Urinary Incontinence (SUI). 

Boston Scientific Corporation, $49,688. 

 

 

Is Isolated Rectocele Repair Associated with Post-Operative 

Voiding Dysfunction. Statistical analysis supported through Hartford 

Hospital Small Grant. 

 

Late-Pregnancy Fears of Labor and Delivery in Nulliparous 

Pregnant Women: A Survey. New Investigator, $8,840. 

Is ere a Relationship Between Glomerular Filtration Rate and 

Detrusor Overactivity in Women? Statistical analysis supported 


Using Color, Clarity and Smell to Predict Urinary Tract Infections 

in Community-Dwelling Women. Statistical analysis supported 


 

Antepartum Depression Inventory: A Comparative Analysis 

of Performance With e Beck Depression Inventory. New 

Investigator, $9,966. 

 

A Comparison of Hormonal erapy Tapering Regimens for 

Mediating Hot Flashes. Open Competition, $56,623. 

Association of Adolescent and Early Adult Pregnancy with Future 

Development of Postmenopausal Osteoporosis. Statistical analysis 

support through Hartford Hospital Small Grant. 

 

 

Factors Influencing a ird-Year Medical Student’s Decision to 

Choose Obstetrics and Gynecology Versus Another Specialty Prior 

to Beginning Clinical Rotations. Statistical analysis supported through 


 

 

Docosahexaenoic Acid in Pregnancy: Postpartum Depression. 

 

Trends in Blood Transfusion at Hartford Hospital. 

Effect of Mode of Delivery of 23-28 Week Infants on Infant 

Morbidity and Mortality. 

Trends in Mode of Delivery for Clinic Versus Private Patients From 

1988-2005. 

Pregnancy Outcomes of Women Who Report Antepartum 

Depression. 

Infant Neuronal Maturity and Tobacco Use in Pregnancy: Is ere 

An Association? 

Trends in Down Syndrome Screening. 

 

A Comparison of Antenatal Betamethasone vs Dexamethasone 

in Reducing Neonatal Complications of Prematurity. Statistical 


Short-term Outcomes of Neonatal Congenital Heart Disease. 

 

Resident Education Research. 

 

A Prospective Cohort Study Comparing the Discontinuation 

Rates Between Levonorgestrel-Releasing Intrauterine Systems and 

Etonogestrel Subdermal Single-Rod Contraceptive Implants in a 

Residency Clinic Population. 

An Institutional Review of Management Outcomes for High Grade 

Cervical Dysplasia in Adolescent Women. 

 

Correlation of Functional and Anesthetic Bladder Capacity with 

Urinary Frequency in Women with Interstitial Cystitis. Statistical 


 

Are Mondays and Fridays the Busiest Days for Nursing Phone 

Triage in a Urogynecology Office Practice? 

Sexual Activity and Function in Women with Pelvic Floor Disorders. 


 

Is an ECC Always Necessary During the Colposcopic Evaluation of 

an Abnormal Pap Smear? 

 

Women’s Health Clinical Outcomes Protocol. 

 

Screening for Fetal Aneuploidy: A Patient Survey. 

Outcomes of Triplet Gestations Based on Chorionicity.

Prolift’s Effect on Post-Operative Hematocrit. Statistical analysis 

supported through Hartford Hospital Small Grant. 

 

Recent Trends in VBAC at Hartford Hospital. 

 

 

A Survey of Women Undergoing First Trimester Screening. 

Neonatal Outcomes at 23-24 weeks at a Single Institution. 

Pregnancy Outcome following Induction of Labor for Macrosomia. 

Trends in Chorionic Villus Sampling Since Institution of First 

Trimester Screening at Hartford Hospital. 

Pregnancy Outcome following Hospital Admission for a Short 

Cervix in the Second Trimester. 

 

e Impact of Multiple Gestations on Prematurity. 

Pregnancy Outcomes After Prenatal Exposure to Antidepressants. 

Trends in Preterm Birth at Hartfford Hospital. 

e Use of a Depression Screening Scale to Improve the Detection 

of Postpartum Depression in Women Receiving Care in an 

Urban Ambulatory Healthcare Setting. Hartford Hospital Research 


 

Pregnancy Outcomes of Eccentric Placental Cord Insertion. 

Risk of Cesarean Delivery with Twin Gestation. 

 

Oral Health and its Implications During Pregnancy. 

 

Transcatheter Arterial Embolization of Uterine Fibroids. 

Cigarette Smoking and Effects on Infant/Child Health. CT 

Department of Public Health subcontract through the University of 

Connecticut Health Center, $37,025. 

 

e Glucose Screen in Pregnancy-Association of Low Values of 

Perinatal Outcome. 

 

Extent of Urogynecology Experience of Obstetrics and Gynecology 

Residents in the United States. Statistical analysis supported through 


e Tension Free Vaginal Tape Procedure In Women With 

Intrinsic Sphincter Deficiency and No Urethral Hypermobility. 

Porcine-Derived Small Intestine Submucosa Graft-Augmented 

Rectocele Repair - A Randomized Trial. 

Does Intra-Operative Cystotomy at the Time of TVT Affect 

Success Rates? Statistical analysis supported through Hartford Hospital 

Small Grant. 

Risk Factors for Women with Stress Urinary Incontinence due to 

Intrinsic Sphincter Deficiency. 

Outcomes of Vaginal Prolapse Surgery on Urinary Continence. 


 

Development of a Prenatal Nutrition Guide for Puerto Rican 

Women 

Food Insecurity, Meal Skipping, Nutrient Intakes and Pregnancy 

Outcomes Among Low-Income Latinas. 

 

e Relationship Between Anterior Vaginal Wall Prolapse and 

Voiding Dysfunction in Female Urogynecology Patients. Statistical 


 

Is Menopause the Same Cross-Culturally? Wyeth Pharmaceuticals, 

$4,000. 

Incidence of HPV in an Inner City Population without Dysplasia. 


Is Breast Arterial Calcification (BAC) Found on Routine 

Mammography Associated with an Increased Risk of Cardiovascular 

Disease? Statistical analysis supported through Hartford Hospital Small 

Grant. 

An International Randomized, Double-Blind, Placebo-Controlled, 

Multicenter, 6-Month Study of the Efficacy and Safety of 

Valaciclovir 1g QD vs. Placebo for the Suppression of HSV-2 

Genital Herpes in Newly Infected Immunocompetent Subjects. 

GlaxoSmithKline, $29,261. 

Relative Importance of Gender in Patients’ Selection of Obstetrics 

and Gynecology Provider. Statistical analysis supported through 


A Comparison of Skin Closure Techniques after Primary Cesarean 

Delivery. Statistical analysis supported through Hartford Hospital Small 

Grant. 

Yale Pink and Blue Study. 

A Retrospective Analysis of Cervical Polyps. Statistical analysis 

supported through Hartford Hospital Small Grant. 

 

GOG # 210: A Molecular Staging Study of Endometrial Carcinoma. 

GOG, $10,560. 

 

Patient-Centered Techniques to Enhance Outcomes for Abdominal 

Hysterectomy. Hartford Hospital Research Endowment Funds, 

$10,000. 

 

Analysis of Anti-Incontinence Medication Trials. 

A Comparison of Connective Tissue Remodeling in the Pelvic 

Floor of Pre and Postmenopausal Women. NIH subcontract through 

the University of Pittsburgh, $4,820. 

Evaluation of Women with Overactive Bladder Symptoms. 

Statistical analysis supported through Hartford Hospital Small Grant.

Ahmed A. De Geest K. Van Natta T. Sorosky J. Metastatic choriocarcinoma 

to the lung coexistent with a viable pregnancy. International Journal of 

Gynaecology & Obstetrics. 94(1):56-7, 2006 Jul. 

Bobrowski R, Greene J and Sorosky J. Bioterrorism and obstetrics: e 

exposed pregnant patient, Chapter 12. In: McIsaac JH (Ed.) Hospital 

Preparation for Bioterror (A Medical and Biomedical Systems Approach), pp. 

177-181, Elsevier, 2006. 

Borgida AF, Alkass R, Feldman DM, Ingardia CJ. Trends in the rate 

of maternal blood transfusion. Society for Maternal Fetal Medicine, San 

Francisco, February 2007. 

Carbone J, Schnatz PF, Werden J. Stump the professor: Post partum patient 

with acute chest pain. Presented at the annual ACOG District I meeting in New 

Port RI, September 2007. 

Dornelas EA, Magnavita J, Beazoglou T, Fischer EH, Oncken C, Lando 

H, Greene, J, Barbagallo J, Stepnowski, R, Gregonis E. Efficacy and costeffectiveness 

of a clinic-based counseling intervention tested in an ethnically 

diverse sample of pregnant smokers. Patient Education and Counseling. 2006 

64: 342-349. 

Egan JFX, Borgida AF. Ultrasound evaluation of multiple gestations. In 

Ultrasonography in Obstetrics and Gynecology, 5th Edition; Callen P, Editor. 

W B Saunders, 2007. 

Feldman DM, Carbone J, Belden L, Borgida AF, Herson V. Betamethasone 

vs dexamethasone for the prevention of morbidity in very-low-birth weight 

neonates. Am J Obstet Gynecol. 2007 Sep;197(3):284.e1-4. 

Feldman DM, Carbone J, Belden L, Borgida AF, Ingardia CJ. 

Betamethasone vs. dexamethasone for preventing morbidity in very low birth 

weight neonates. Society for Maternal Fetal Medicine, San Francisco, February 

2007. 

Fracasso PM. Blessing JA. Molpus KL. Adler LM. Sorosky JI. Rose PG. 

Phase II study of oxaliplatin as second-line chemotherapy in endometrial 

carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 

103(2):523-6, 2006 Nov. 

Gingras D. , Ruppenicker M. Team Performance Plus Training-Enhancing the 

Voice of Nursing in WHS- Oct 2007. 

Guile M, Schnatz PF, O’Sullivan DM. Relative importance of gender in 

patients’ selection of obstetrics and gynecology provider. Conn Med- Oct. 

2007;1(6):325-32. 

Harris G, Horowitz BJ, Borgida AF. Evaluation of Gabapentin in the 

treatment of generalized vulvodynia, unprovoked. Journal of Reproductive 

Medicine 2007 Feb;52:103-6. 

Ingardia CJ, Morosky C, Borgida AF, Feldman DM. Low glucose screen 

values and low birth weight. ACOG 55th Annual Clinical Meeting, San Diego, 

CA. May 2007. 

Johnson T, Schnatz PF, Johnson AM, and Sorosky JI. Update on cervical 

cancer screening. Hospital Physician Oct. 2007;43(5):15-24. 

Johnson AM, Schnatz PF, O’Sullivan DM. Gender preferences in clinic 

versus private patients: Does it influence a student’s perception of ObGyn? 

Presented March 8th 2007 at the APGO / CREOG Annual Meeting in Salt Lake 

City, Utah. 

LaSala CA, Schimpf MO. Occurrence of postoperative hematomas after 

prolapse repair using a mesh augmentation system. Obstetrics and Gynecology, 

Feb 2007, 109(Pt 2):569-72. 

LaSala CA, Schimpf MO, Udoh E, O’Sullivan D, Tulikangas P. Outcome 

of tension-free vaginal tape (TVT) procedure when complicated by intraoperative 

cystotomy. Am J Ob Gyn Dec. 2006,195(6):1857-61. 

Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, 

Miller DS, Eaton LA. Fiorica JV. Gynecologic Oncology Group. Clinical 

results and quality of life analysis for the MVAC combination (methotrexate, 

vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A 

Gynecologic Oncology Group study. Gynecologic Oncology. 100(3):537-43, 

2006 Mar. 

Mayr NA, Yuh WT, Taoka T, Wang JZ, Wu DH, Montebello JF, Meeks 

SL, Paulino AC, Magnotta VA, Adli M, Sorosky JI, Knopp MV, Buatti JM. 

Serial therapy-induced changes in tumor shape in cervical cancer and their 

impact on assessing tumor volume and treatment response. American Journal 

of Roentgenology. 187(1):65-72, 2006 Jul. 

Nieves L, Egan JFX, Benn PA, Kaminsky L, Fang V, Borgida AF. Trends 

in twin zygosity in the US by maternal race from 1990 to 2001. Society for 

Maternal Fetal Medicine, San Francisco, February 2007. 

O’Sullivan DM, Abrantes J, Romegialli A, Marakovits K, Cunningham 

D, and Schnatz PF. A pilot study: Does pregnancy increase the risk of 

osteoporosis? Presented at the 18th Annual Meeting of the North American 

Menopause Society (NAMS), Dallas, TX, October 3-6, 2007. 

O’Sullivan, D.M., Serra, J., and Schnatz, P.F. Knowledge of menopause in 

postmenopausal hispanic women. Presented at the 16th Annual Meeting of the 

North American Menopause Society (NAMS), San Diego, CA, September 28- 

October 1, 2005. 

Schimpf MO, Feldman DM, O’Sullivan DM, LaSala CA. Resident 

education and training in urogynecology and pelvic reconstructive surgery: A 

survey. Int Urogyn Jnl. On-Line 2006; 18(6): 613-7, 2007. 

Schimpf MO, Murdza M, O’Sullivan DM, Tulikangas PK, LaSala CA. 

Does smelly, cloudy urine call for antibiotics? Presented at the American 

Urogynecology Society Oct 2006, Palm Springs, CA; Society of Urologic Nurses and 

Associates, Colorado Springs, CA, March 2007; HH Evidence-Based 11th Annual 

Conference “e Essence of Nursing” (third place poster winner). 

Schimpf MO, Murdza M, O’Sullivan DM, Tulikangas PK, LaSala CA. 

Does smelly, cloudy urine call for antibiotics? International Urogynecology 

Journal, 2007;18:1357-61. 

Schimpf MO, Strohbehn K. Urinary retention and bilateral adnexal masses 

(Stump the Professors). American Urogynecology Society Oct 2006, Palm 

Springs, CA. 

Schimpf MO, Morgenstern J, Tulikangas PK, Wagner J. “Robotic-assisted 

laparoscopic vesicovaginal repair” (video). Presented at American Urogynecology 

Society Oct 2006, Palm Springs, CA. 

Schimpf MO, Morgenstern J, Tulikangas PK, Wagner J. Vesicovaginal 

fistula repair without intentional cystotomy using the laparoscopic robotic 

approach: A case report. Journal of the Society of Laparoendoscopic Surgeons, 

July-Sept 2007, 11(3):378-80. 

Schimpf MO, O’Sullivan DM, LaSala C, Tulikangas PK. e relationship 

between anterior vaginal wall prolapse and voiding dysfunction in female 

urogynecology patients. International Urogynecology Journal, Aug 2007, 18: 

721-5. 

Schnatz PF. Hormonal therapy: Does it increase or decrease cardiovascular 

risk? Obstet Gynecol Surv. Oct, 2006 61(10):673-81. 

Schnatz PF. ObGyn scholars: Running an effective student interest group. 

Presented at the annual APGO Faculty Development Seminar; Educational 

Resources: Yours, Mine and (H) Ours. Amelia Island, Fl. January 9th, 2007. 

Schnatz PF. Preparing the next generation of menopause providers. Presented 

October 4th, 2007 at the NAMS 8th Annual Meeting in Dallas, Texas. 

Schnatz, P.F., Banever, A.E., Greene, J.F., and O’Sullivan, D.M. Pilot study 

of menopause symptoms in a clinic population. Menopause. 12(5):623-9, 

2005 Sep-Oct. 

Schnatz PF, Guile M, O’Sullivan DM. Relative importance of gender in 

patients’ selection of obstetrics and gynecology provider (Letter to the Editor 

– reply). Conn Med- Oct. 2007; 71(9):563. 

Schnatz, P.F., Guile, M., O’Sullivan, D.M., and Sorosky, J.I. Clinical

significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 

107(3):701-8, 2006. 

Schnatz PF, Gunn C, and O’Sullivan DM. How do we encourage the next 

generation of menopause providers? Menopause Oct. 2006; 13(6):1013. 

Schnatz PF, Johnson T. Cervical cancer screening: Clinical review quiz. 

Hospital Physician Oct. 2007; 43(5):42,49. 

Schnatz PF, Johnson AM, and O’Sullivan DM. Qualities and attributes 

desired in menopause clinicians. Maturitas 2007; 56(2):184-9. 

Schnatz PF, Johnson AM, and Sorosky JI. Excelling in all phases of your 

academic career. Presented at the annual APGO Faculty Development Seminar; 

Educational Resources: Yours, Mine and (H) Ours. Amelia Island, Fl. January 

9th, 2007. 

Schnatz PF, Kubica L, Murphy J, and O’Sullivan DM. e risk of 

cardiovascular disease in women with a history of low birth weight. Presented 

October 5th, 2007 at the NAMS 18th Annual Meeting in Dallas, Texas. 

Schnatz PF, Murphy J, Schmidt V, and Kubica L. Patients’ choice: 

Comparing criteria for selecting an obstetrician-gynecologist based upon 

image, gender, and professional attributes. Presented March 8th 2007 at the 

APGO / CREOG Annual Meeting in Salt Lake City, Utah. 

Schnatz PF, Rotter MA, Hadley S, Currier AA, and O’Sullivan DM. 

Hormonal therapy is associated with a lower prevalence of breast arterial 

calcification on mammography. Maturitas 2007; 57(2):154-160. 

Schnatz PF and Schnatz JD. Dyslipidemia in menopause: Mechanisms and 

management. Obstet Gynecol Surv. Oct, 2006 61(9):608-13. 

Schnatz, P.F., Serra, J., O’Sullivan, D.M., and Sorosky, J.I. Menopausal 

symptoms in Hispanic women and the role of socioeconomic factors. 

Obstetrical & Gynecological Survey 61(3):187-93, 2006. 

 

Steinberg AC, DeLisa BM, Schimpf MO, LaSala CA. e effect of 

anterior compartment mesh augmentation on urinary continence. Society for 

Gynecologic Surgeons, Orlando, FL, April 2007. 

Tulikangas, P. Female urinary tract and gynecologic infections. Requisites in 

Obstetrics and Gynecology: General Gynecology. 

Tulikangas P. Pathophysiology of incontinence and pelvic organ prolapse. In: 

Urogynecology for Primary Care, pp. 34-39, Springer, London, 2007. 

Tulikangas PK, Ayers A, O’Sullivan DM. A meta-analysis comparing trials 

of antimuscarinic medications funded by industry or not. BJU International 

2006, 9 8(2):377-80. 

Tulikangas PK and Schimpf MO. Genital and urinary tract infections. In 

Sokol and Sokol (eds). General Gynecology: e Requisites in Obstetrics and 

Gynecology, 2007. 

Tulikangas PK, Schimpf MO, Sorosky J “Laparoscopic Ovarian 

Transposition” (video). Society for Gynecologic Surgeons, Orlando, FL, April 

2007. 

Werden J, Schnatz PF, Mandavilli S, Allen G, Greene JF, Sorosky JI. 

Prevalence of the human papillomavirus in an inner city indigent population 

with previously normal pap tests. Presented at the annual ACOG District I 

meeting in Newport RI, September 2007.

Examining Behavioral Risk Factors, Chronic Disease and Health 

Related Poly-syndromes in Hartford. CT DPH subcontract through 

e City of Hartford, $80,000. 

 

2006 Census of the Homeless of Hartford. City of Hartford 

subcontract through the Community Renewal Team, $1,500. 

 

 

Detection of Triamcinolone Acetonide in Human Intraocular 

Fluids. Small Grant, $9,900. 

 

 

Magnet Status Hospitals and Domestic Violence Nursing 

Education. 

 

Methods of Education for Patients Undergoing Tonsillectomy. 

 

2006 APIC MRSA Prevalence Study. 

 

Dental Pressure During Intubation - Pilot Study. 

Power Quality in the Operating Room - Pilot Study. 

 

A Multi-Center Survey of Anesthesiologists Attitudes and 

Abilities in Difficult Airway Management Using Simulation-Based 

Performance Evaluation? 

 

Pilot-Testing of a Tool Titled: Confidence Assessment in the 

Management of Simulated Patient “Cardiac Arrest” Situations. 

 

 

Factors Associated with Hypothermia on NICU Admission in Very 

Low Birth Weight Infants. 

 

Ethical Force Program’s Organizational Toolkit for Patient- 

Centered Communication. 

 

Evaluation of Systems Based Practice Changes on Patient Care 

Near Misses on the Medical Teaching Service at the University of 

Connecticut. 

 

 

Surgical Cooling Garment Phase III. Hartford Hospital Research 


Electronic Esophageal Stethoscope. 

e Brain Temperature Tunnel in the Neuro-ICU. 

e Brain Temperature Tunnel During General Anesthesia. 

Brain Temperature Tunnel- Surface Probe Study. 

 

Minimum Training for Successful Cricothyroidotomy: e Effect 

of an Adverse Environment. 

High Fidelity Simulation: Assessment of its Role in Resident 

Education. 

 

Perioperative Prophylactic Beta-Blockade. 

 

An Assessment of the Homeless of Hartford, 2002. Hartford Health 

Dept, $33,750. 

Evaluating the Hartford Continuum of Care’s “Increased Demands 

for Shelter Care” Project. Hartford Foundation for Public Giving & 

City of Htfd., $18,500. 

A Brief Assessment of the Homeless of Hartford, 2004. City of 

Hartford, $1,200. 

2005 Census of the Homeless of Hartford. CRT, $1,700. 

 

Reiki: What are its effects for Patients During Hemodialysis? 


 

Bispectral Index Monitoring in the Neurosurgical Patient. Hartford 


 

e use of Computer Program in Diabetes Meal Planning for 

efficiency of dietitian time and accuracy of macronutrient distribution 

within a patient’s meal plan. 

 

Extending Pastoral Care and Reducing Anxiety Among Family 

Members of Patients Receiving Palliative and Hospice Care (on 

Unit CB4). 

 

e Effect of Tendo-Achilles Lengthening on Function and Ulcer 

Healing and Recurrence in Persons with Diabetes.

Prostate Cancer Practice Patterns and Health-related Quality of 

Life. 

Comparison of Treatment Efficacy for Prostate Cancer. 

 

Exploration of the Effect of Nausea, Self-efficacy, and Health 

Care Relationships on Medication Adherence in AIDS Patients. 

Donaghue Medical Research Foundation, $4,300. 

 

Care for the Underserved: Community-Based Clinical Dental 

Education Program. UCHC-Columbia University, $137,962. 

Dental Pipeline: California Initiative Endowment (CALE). 

Columbia University, $487,592. 

 

Increasing Fruit and Vegetable Intake in Patients with Early State 

Head and Neck Cancer. 

 

Genetic Epidemiology of Breast Carcinoma In Situ. 

 

e Clinical Utility of Head-Up Tile Test (HUTT) for Patients 

with Syncope While Driving. 

 

Screening, Outreach, and Safety for Abused Prenatal Patients 

(SOS: Domestic Violence). Donaghue Medical Research Foundation, 

$6,240. 

 

A Controlled Study of Antidepressant Treatment in Postpartum 

Depression. 

e Role of GABA and Neurosteroids in Postpartum Depression. 

Impact of Estrogen (17-Beta Estradiol) Administration on 

Cognition, Brain Activation and Cytokine Production in Healthy 

Peri and Postmenopausal Women. 

e Impact of Fluoxetine Treatment on GABA and Neurosteroid 

Levels in Women with Premenstrual Dysphoric Disorder. 

 

Assessment of the Prevalence of Anemia, and its Correlates and 

Predictors, Among Low Income Two Year Olds in Hartford, CT. 

 

Options/Opciones Project. NIMH, $96,804. 

Changing Antiretroviral erapy (ART)Adherence Behavior. NIH 

subcontract through the University of Connecticut, Storrs, $274,973. 

A Brief Intervention to Improve Diabetes Control. NIH subcontract 

through the University of Connecticut, Storrs, $11,188. 

 

Surveillance of Connecticut for Organisms Causing Neonatal 

Sepsis. 

 

Unexplained Deaths Related to Bioterrorism. 

 

Does Adopting a Universal Jaundice Screening Program Using 

a Transcutaneous Device Reduce the Proportion of Infants 

Readmitted with Severe Hyperbilirubenemia? 

 

Glutathione-S-Transferase Polymorphisms, Race, and Survival 

from Cancer. 

 

Testosterone Effects on Bone Frailty in Men with Osteoporosis. 

 

Can DHA-functional Food in Pregnancy Enhance Infant 

Neurobehavioral Development? 

 

Cellular Cooperativity in Osteo-Metastatic Disease. 

 

Feasibilty Study of Gender Differences in Psychosocial Determinants 

of Recovery Following MI. UCHC Center for Interdisciplinary 

Research on Women’s Health, $2,400. 

Predicting and Understanding Positive Life Changes in Young 

Adult Cancer Survivors: Types, Trajectories, Predictors, and 

Relations with Adjustment. Lance Armstrong Foundation, $500. 

 

Exclusive Breastfeeding Peer Counseling Intervention at Hartford 

Hospital : A Randomized Trial. CDC, $11,432. 

 

Magnetic Resonance Spectroscopy Studies of Statin-Induced 

Myopathy. Hartford Hospital Research Endowment Funds, $11,824. 

 

Case Control Study of Ovarian Cancer Hormonal Etiology. 

Hartford Hospital Case Control Study of Pancreas Cancer Etiology 

Factors. 

Windham Hospital Case Control Study of Pancreas Cancer 

Etiology Factors. 

 

National Quality of Life Study (Study of Cancer Survivors). 

 

Prognostic Value of Intra-Chromosomal Genomic Instability in 

Colon Cancer. 

 

Phase 2, Multi-Center, Randomized, Double-Blind, Placebo- 

Controlled, 3 Arm, 12-Month Study to Evaluate the Effects of GPI 

1485 on Erectile Function in Patients Undergoing Bilateral Nerve- 

Sparing Radical Retropubic Prostatectomy for Prostatic Carcinoma. 

Gillford Pharmaceuticals, $2,500. 

Influence of Patient Size and Prostate Weight on Operative and Peri- 

Operative Outcomes for Robot-assisted Radical Prostatectomy. 

 

An expressive arts intervention to promote psychosocial health in 

adults with type 2 diabetes. 

 

Atypical Antipsychotic Medications: Outcomes and Costs. Yale

University,$8,960. 

Ethyl Eicosapentaenoic Acid (eEPA) for Symptoms of the 

Schizophrenia Prodrome. 

Glycine for Symptoms of the Schizophrenia Prodrome. 

Longitudinal Follow-Up of Patients Undergoing Evaluation for the 

Schizophrenia Prodrome. Yale University, $11,382. 

Brain Structure and Function in Schizophrenia: Neuroanatomical 

and Neurophysiological Predictors of Clinical Outcome in 

Prodromal Schizophrenia. 

Effects of Aripiprazole in Patients Meeting Criteria for the 

Schizophrenia Prodrome. Yale University, $20,694. 

 

A Two-Center, Double-Blind, Parallel Comparison of Fluoxetine, 

Calcium, and Placebo for the Treatment of Moderate to Severe 

Premenstrual Syndrome (PMS). 

Treating PMS: Research vs Clinical Reality. 

 

Hartford Hospital Epidemiologic Study of Uterus Cancer. 

Windham Hospital Epidemiologic Study of Uterus Cancer. 

 

 

e Role of Epstein-Barr Virus in the Etiology of Hodgkin’s 

Disease. 

 

 

Chhabra J., Champagne A., Rojano R. Hartford Health Survey 2006. Report 

submitted to the Health and Human Services Department at City of Hartford, 

Aug., 2006. 

McLaughlin T., Maljanian R., Kornblum R., Clark P., Simpson J. and 

McCormack K. Evaluating the availability and use of asthma action plans for 

school-based asthma care: A case study in Hartford, Connecticut. Journal of 

School Health, 76(6): 325-328, 2006.

Research Program 

Laurine Bow, Ph.D. 

Vice President 

Grants & Contracts 

Tammy Weirs, Manager 

Grants Administrator 

Corey Glider 

Administrative Associate 

Linda Thompson 

 

Administrative Associate 

Chris Harvey 

Human Research 

Protection Program 

Cherie Bilbie, M.S. 

Director 

Clinical Research Center 

Liz Roper, M.H.S. 

Director 

Database Design Group 

Jeff Mather, M.S. 

Director 

Statistical Analysis & 

Proposal Design 

Jyoti Chhabra, Ph.D. 

David O'Sullivan, M.S. 

Iliene Staff, Ph.D. 

Preclinical Facility 

Liz Pelletier, Director 

IRB Administrators 

Rebecca Fordyce-Bercick 

Susan Hughes 

IRB Coordinators 

Dottie Bearse 

Indrani Cooma-Ramberan 

Research Coordinators 

Arben Ademi 

Martha Ahlquist 

Cherie Bilbie 

Jennifer Blum 

Alison Champagne 

Jill Cloutier 

Lynne Fox 

Brenda Foxen 

A. Lynne Hosig 

Christina Phillips 

Marilyn Siwy 

Cara Statz, Ph.D. 

Lee Sullivan 

Sandra Trifiro 

Ellen Volponi 

Pharmacy Technician 

Candice Johnson 

Research Assistants 

Jamie Fish-Fuhrman 

Margarita Garcia 

Adam Grimaldi 

Coordinator, CRC 

Study Center 

Mary Maibaum 

Business Systems 

Analysts 

Gil Fortunato, M.B.A. 

Juan Gonzalez 

Joe Tortora 

Steve Wilcox 

Grant Writer 

Tara McLaughlin, Ph.D. 

Veterinarian 

Teri Digiulio, V.M.D. 

Veterinary Technologists

Hartford Hospital 

Research Program 

80 Seymour St. 

Hartford, CT 06102

Hartford Hospital Research Program

Create successful ePaper yourself

Delete template?

Save as template?